CN101346357A - 氨基二氢噻嗪衍生物 - Google Patents
氨基二氢噻嗪衍生物 Download PDFInfo
- Publication number
- CN101346357A CN101346357A CNA2006800488108A CN200680048810A CN101346357A CN 101346357 A CN101346357 A CN 101346357A CN A2006800488108 A CNA2006800488108 A CN A2006800488108A CN 200680048810 A CN200680048810 A CN 200680048810A CN 101346357 A CN101346357 A CN 101346357A
- Authority
- CN
- China
- Prior art keywords
- substituent
- compound
- group
- alkyl group
- low alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/18—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
- C07D279/06—1,3-Thiazines; Hydrogenated 1,3-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
- C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
以式(I)所示的化合物或其药学上可接受的盐或它们的溶剂合物作为有效成分的BACE1抑制剂(式中,环A为可具有取代基的碳环式基团或可具有取代基的杂环式基团;E为低级亚烷基等;X为S、O或NR1;R1为氢或低级烷基;R2a、R2b、R3a、R3b、R4a和R4b各自独立表示氢、卤素、羟基等;n和m各自独立为0~3的整数,n+m为1~3;R5为氢、可具有取代基的低级烷基等)。
Description
技术领域
本发明涉及具有淀粉状β蛋白(amyloid βprotein)产生抑制作用、作为由淀粉状β蛋白的产生、分泌和/或沉积所诱发的疾病的治疗药有用的化合物。
背景技术
在阿尔茨海默病患者的脑内广泛确认到被称作淀粉状β蛋白的含有约40个氨基酸的肽蓄积在神经细胞外形成的不溶性斑点(老年斑)。认为该老年斑通过杀灭神经细胞而引发阿尔茨海默病,作为阿尔茨海默病治疗药,正在研究淀粉状β蛋白的分解促进剂、淀粉状β疫苗等。
分泌酶是在细胞内切断被称作淀粉状β蛋白前体(APP)的蛋白而生成淀粉状β蛋白的酶。掌管生成淀粉状β蛋白的N末端的酶称作BACE1(β位点APP裂解酶1,β分泌酶),认为通过抑制该酶来抑制淀粉状β蛋白生成,能够成为阿尔茨海默病治疗药。
专利文献1中记载了结构与本发明化合物类似的化合物,并揭示其具有NO合成酶抑制活性、对痴呆有效。
专利文献2~4、非专利文献1和非专利文献2中记载了结构与本发明化合物类似的化合物,但记载各自作为升压药、吗啡样镇痛剂或镇静剂等、药物中间体、镇痛剂是有用的。
作为BACE-1抑制剂,已知专利文献5~13等,但均具有不同于本发明化合物的骨架。
[专利文献1]国际公开第96/014842号小册子
[专利文献2]美国专利第3235551号说明书
[专利文献3]美国专利3227713号说明书
[专利文献4]日本特开平9-067355号公报
[专利文献5]国际公开第01/187293号小册子
[专利文献6]国际公开第04/014843号小册子
[专利文献7]日本特开2004-149429号公报
[专利文献8]国际公开第02/96897号小册子
[专利文献9]国际公开第04/043916号小册子
[专利文献10]国际公开第2005/058311号小册子
[专利文献11]国际公开第2005/097767号小册子
[专利文献12]国际公开第2006/041404号小册子
[专利文献13]国际公开第2006/041405号小册子
[非专利文献1]Journal ofHeterocyclic Chemistry,14卷,717页~723页(1977年)
[非专利文献2]Journal of Organic Chemistry,33卷,8号,3126页~3132页(1968年)
发明内容
发明所要解决的课题
提供具有淀粉状β蛋白产生抑制作用、特别是BACE1抑制作用,作为由淀粉状β蛋白的产生、分泌或沉积所诱发的疾病的治疗药有用的化合物。
解决课题的方法
本发明提供以下(a)~(x):
(a)BACE1抑制剂,其以式(I)所示的化合物或其药学上可接受的盐或它们的溶剂合物作为有效成分,
[化学式1]
(式中,环A为可具有取代基的碳环式基团或可具有取代基的杂环式基团;
[化学式2]
Alk1为低级亚烷基或低级亚烯基;
R0为氢、低级烷基或酰基;
X为S、O或NR1;
R1为氢或低级烷基;
R2a和R2b各自独立表示氢、羟基、可具有取代基的低级烷基、可具有取代基的低级烯基、可具有取代基的氨基、可具有取代基的脒基、可具有取代基的酰基、可具有取代基的氨基甲酰基、可具有取代基的氨基甲酰基羰基、可具有取代基的低级烷基磺酰基、可具有取代基的芳基磺酰基、可具有取代基的碳环式基团或可具有取代基的杂环式基团;
R3a、R3b、R4a和R4b各自独立表示氢、卤素、羟基、可具有取代基的低级烷基、可具有取代基的低级烯基、可具有取代基的酰基、羧基、可具有取代基的低级烷氧基羰基、可具有取代基的氨基、可具有取代基的氨基甲酰基、可具有取代基的碳环式基团或可具有取代基的杂环式基团;
n和m各自独立表示0~3的整数,且n+m为1~3;
各R3a、各R3b、各R4a、各R4b可以不同;
R5表示氢、可具有取代基的低级烷基、可具有取代基的低级烯基、可具有取代基的低级炔基、可具有取代基的碳环式基团或可具有取代基的杂环式基团;
[化学式3]
(R5a和R5b各自独立表示氢或低级烷基;s为1~4的整数;各R5a、各R5b可以不同)。
其中,n+m为2、R5为氢、且环A为未取代的苯基的化合物除外)。(a1)BACE1抑制剂,其以式(I)所示的化合物或其药学上可接受的盐或它们的溶剂合物作为有效成分,
[化学式4]
(式中,环A为可具有取代基的碳环式基团或可具有取代基的杂环式基团;
[化学式5]
Alk1为低级亚烷基;
R0为氢、低级烷基或酰基;
X为S、O或NR1;
R1为氢或低级烷基;
R2a和R2b各自独立表示氢、羟基、可具有取代基的低级烷基、可具有取代基的低级烯基、可具有取代基的氨基、可具有取代基的脒基、可具有取代基的酰基、可具有取代基的氨基甲酰基、可具有取代基的低级烷基磺酰基、可具有取代基的芳基磺酰基、可具有取代基的碳环式基团或可具有取代基的杂环式基团;
R3a、R3b、R4a和R4b各自独立表示氢、卤素、羟基、可具有取代基的低级烷基、可具有取代基的低级烯基、可具有取代基的酰基、羧基、可具有取代基的低级烷氧基羰基、可具有取代基的氨基、可具有取代基的氨基甲酰基、可具有取代基的碳环式基团或可具有取代基的杂环式基团;
n和m各自独立表示0~3的整数,且n+m为1~3;
各R3a、各R3b、各R4a、各R4b可以不同;
R5表示氢、可具有取代基的低级烷基、可具有取代基的低级烯基、可具有取代基的低级炔基、可具有取代基的碳环式基团或可具有取代基的杂环式基团;
[化学式6]
(R5a和R5b各自独立表示氢或低级烷基;s为1~4的整数;各R5a、各R5b可以不同);
其中,n+m为2、R5为氢、且环A为未取代的苯基的化合物除外)。
(b)(a)的BACE1抑制剂,其中X为S。
(c)(a)的BACE1抑制剂,其中n为2、m为0。
(d)(a)的BACE1抑制剂,其中E为单键。
(e)式(I)所示的化合物或其药学上可接受的盐或它们的溶剂合物,
[化学式7]
(式中,各记号与(a)同义。其中,以下化合物除外:
i)n+m为2、R5为氢、环A为未取代的苯基的化合物;
ii)n为2、m为0、R2a为氢、R2b为氢或乙酰基、R5为甲基、环A为苯基或4-甲氧基苯基的化合物;
iii)n为2、m为0、R2a为氢、R2b为氢或乙酰基、R5为乙基、环A为3,4-二甲氧基苯基的化合物;
iv)n为2、m为0、R2a为氢、R2b为氢或乙酰基、R5和环A为苯基的化合物;
v)n为2、m为0、R2a和R2b为氢、R5和环A一起形成:
[化学式8]
的化合物(式中,Me为甲基,各记号定义同上);
vi)n+m为2、R5为氢、环A为只被选自羟基、卤素、低级烷基、低级烷氧基、硝基、氨基、低级烷基羰基氨基、巯基、低级烷硫基和氨基甲酰基的1~2个取代基取代的苯基、未取代的苯基或未取代的萘基的化合物)。
(f)(e)的化合物或其药学上可接受的盐或它们的溶剂合物,其中X为S。
(g)(e)或(f)的化合物或其药学上可接受的盐或它们的溶剂合物,其中n为2、m为0。
(h)(e)~(g)中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中R5为可具有取代基的低级烷基、可具有取代基的低级烯基、可具有取代基的低级炔基、可具有取代基的碳环式基团或可具有取代基的杂环式基团。
(i)(e)~(h)中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中R2a为氢,R2b为氢、可具有取代基的低级烷基、可具有取代基的酰基、可具有取代基的低级烷基磺酰基、可具有取代基的脒基。
(j)(e)~(h)中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中NR2aR2b为:
[化学式9]
R6、R7和R8各自独立表示氢、低级烷基或酰基;
Y为可具有取代基的低级亚烷基、可具有取代基的低级亚烯基或可具有取代基的低级亚炔基;
Z为O或S。
(k)(e)~(j)中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中环A为被取代的苯基。
(l)(e)~(j)中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中环A为:
[化学式10]
(R9、R10和R11为氢或G,G为卤素、羟基、氰基、硝基、巯基、可具有取代基的低级烷基、可具有取代基的低级烷氧基、可具有取代基的低级烯基、可具有取代基的低级炔基、可具有取代基的酰基、可具有取代基的酰氧基、羧基、可具有取代基的低级烷氧基羰基、可具有取代基的低级烷氧基羰基氧基、可具有取代基的芳氧基羰基氧基、可具有取代基的氨基、可具有取代基的氨基甲酰基、可具有取代基的氨基甲酰氧基、可具有取代基的低级烷硫基、可具有取代基的芳硫基、可具有取代基的低级烷基磺酰基、可具有取代基的芳基磺酰基、可具有取代基的低级烷基亚硫酰基、可具有取代基的芳基亚硫酰基、可具有取代基的低级烷基磺酰氧基、可具有取代基的芳基磺酰氧基、可具有取代基的碳环式基团、可具有取代基的碳环氧基、可具有取代基的杂环式基团或可具有取代基的杂环氧基,各G可以不同)。(m)(l)的化合物或其药学上可接受的盐或它们的溶剂合物,其中G为:
[化学式11]
Q1、Q2和Q3各自独立表示单键、可具有取代基的低级亚烷基或可具有取代基的低级亚烯基;
Q4为可具有取代基的低级亚烷基或可具有取代基的低级亚烯基;
W1和W2各自独立表示O或S;
W3为O、S或NR12;
R12为氢、低级烷基、羟基低级烷基、低级烷氧基低级烷基、低级烷氧基羰基低级烷基、碳环低级烷基或酰基;
R14为氢或低级烷基;
环B为可具有取代基的碳环式基团或可具有取代基的杂环式基团;
Alk2为可具有取代基的低级烷基;
p为1或2;
存在多个W1、多个W3、多个R12时,可以各自独立不同,(xii)中氧原子相对于取代基R14可以是顺式或反式的关系。
(n)(m)的化合物或其药学上可接受的盐或它们的溶剂合物,其中环B为可被选自卤素、羟基、可具有取代基的低级烷基、可具有取代基的低级烷氧基、可具有取代基的酰基、可具有取代基的氨基、氰基、可具有取代基的氨基甲酰基、可具有取代基的碳环式基团、可具有取代基的碳环氧基或可具有取代基的杂环式基团的一个以上基团分别取代的芳基或杂芳基。
(o)(m)的化合物或其药学上可接受的盐或它们的溶剂合物,其中G为:
[化学式12]
(式中,各记号定义同上)。
(p)(e)~(o)中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中R5为C1~C3的烷基。
(q)(e)~(o)中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中R5为甲基。
(r)(e)~(q)中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中R3a和R3b各自独立表示氢、卤素、羟基、可具有取代基的低级烷基、可具有取代基的低级烷氧基或可具有取代基的芳基。
(s)(e)~(q)中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中R3a和R3b全部为氢。
(t)药物组合物,其特征在于:以(e)~(s)中任一项的化合物或其药学上可接受的盐或它们的溶剂合物作为有效成分。
(u)BACE1抑制剂,其特征在于:以(e)~(s)中任一项的化合物或其药学上可接受的盐或它们的溶剂合物作为有效成分。
(v)(a)~(d)或(u)的BACE1抑制剂,该抑制剂为淀粉状β蛋白产生抑制剂。
(w)(a)~(d)、(u)或(v)中任一项的BACE1抑制剂,该抑制剂为由淀粉状β蛋白的产生、分泌和/或沉积所诱发的疾病的治疗药。
(x)(a)~(d)、(u)或(v)的BACE1抑制剂,该抑制剂为阿尔茨海默病治疗药。
本发明还提供以下(y)~(ab):
(y)由淀粉状β蛋白的产生、分泌或沉积所诱发的疾病的治疗方法,其特征在于:给予上述(a)的式(I)所示的化合物或其药学上可接受的盐或它们的溶剂合物。
(z)上述(a)的式(I)所示的化合物或其药学上可接受的盐或它们的溶剂合物在制造用于治疗由淀粉状β蛋白的产生、分泌或沉积所诱发的疾病的药物中的应用。
(aa)阿尔茨海默病的治疗方法,其特征在于:给予上述(a)的式(I)所示的化合物或其药学上可接受的盐或它们的溶剂合物。
(ab)上述(a)的式(I)所示的化合物或其药学上可接受的盐或它们的溶剂合物在制备用于治疗阿尔茨海默病的药物中的应用。
发明效果
本发明的化合物作为由淀粉状β蛋白的产生、分泌或沉积所诱发的疾病(阿尔茨海默病等)的治疗药是有用的。
实施发明的最佳方式
本说明书中,“卤素”包含氟、氯、溴和碘。
“卤代低级烷基”、“卤代低级烷氧基”、“卤代酰基”、“卤代低级烷硫基”和“卤代低级烷氧基羰基”的卤素部分与上述“卤素”相同。
“低级烷基”包含碳原子数为1~15、优选碳原子数为1~10、更优选碳原子数为1~6、进一步优选碳原子数为1~3的直链或支链状的烷基,其例子有:甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、异戊基、新戊基、己基、异己基、正庚基、异庚基、正辛基、异辛基、正壬基和正癸基等。
“碳环低级烷基”、“低级烷氧基”、“卤代低级烷基”、“卤代低级烷氧基”、“卤代低级烷硫基”、“羟基低级烷基”、“低级烷氧基羰基”、“卤代低级烷氧基羰基”、“低级烷氧基羰基低级烷基”、“低级烷氧基羰基氧基”、“低级烷基氨基”、“低级烷基羰基氨基”、“低级烷氧基羰基氨基”、“低级烷氧基低级烷基”、“低级烷基氨基甲酰基”、“羟基低级烷基氨基甲酰基”、“氨基低级烷基”、“羟基亚氨基低级烷基”、“低级烷氧基亚氨基低级烷基”、“低级烷硫基”、“低级烷基磺酰基”、“低级烷基氨磺酰基”、“低级烷基亚硫酰基”、“低级烷基磺酰氧基”、“低级烷氧基羰基低级炔基”、“低级烷硫基低级烷基”、“芳基低级烷基”、“芳基低级烷基氨基”、“芳基低级烷氧基羰基”、“芳基低级烷基氨基甲酰基”、“杂环低级烷基氨基”和“杂环低级烷基氨基甲酰基”的低级烷基部分也与上述“低级烷基”相同。
作为环A的取代基的“可具有取代基的低级烷基”的例子有:可被选自取代基组α、羟基亚氨基和低级烷氧基亚氨基的一个以上基团取代的低级烷基;上述(i)、(ii)、(iv)、(vi)、(viii)、(x)所示的基团(各Q1为可具有取代基的低级亚烷基);(iii)、(v)、(vii)、(ix)(各Q2为可具有取代基的低级亚烷基)、(xii)所示的基团。
除此以外的情况下,“可具有取代基的低级烷基”可以被选自取代基组α的一个以上基团取代。
其中,取代基组α包含:卤素、羟基、低级烷氧基、羟基低级烷氧基、低级烷氧基低级烷氧基、酰基、酰氧基、羧基、低级烷氧基羰基、氨基、酰基氨基、低级烷基氨基、低级烷硫基、氨基甲酰基、低级烷基氨基甲酰基、羟基低级烷基氨基甲酰基、氨磺酰基、低级烷基氨磺酰基、低级烷基亚硫酰基、氰基、硝基、芳基和杂环式基团。
特别是作为Alk2中的“可具有取代基的低级烷基”的取代基,优选卤素、羟基、低级烷氧基、低级烷氧基低级烷氧基、低级烷氧基羰基、氨基、酰基氨基、低级烷基氨基和/或低级烷硫基等。
作为环A的取代基的“可具有取代基的低级烷氧基”的例子有:可被选自上述取代基组α的一个以上基团取代的低级烷氧基和上述(iii)(Q1为可具有取代基的低级亚烷基,Q2为单键,W2为O)、(v)(Q1为可具有取代基的低级亚烷基,Q2为单键,W3为O)、(vi)(Q1为单键,Q2为可具有取代基的低级亚烷基,W2为O)或(xi)(Q4为可具有取代基的低级亚烷基,W2为O)所示的基团。
除此以外的情况下,作为“可具有取代基的低级烷氧基”以及“可具有取代基的低级烷氧基羰基”、“可具有取代基的低级烷氧基羰基氧基”、“可具有取代基的低级烷基磺酰基”、“可具有取代基的低级烷基亚硫酰基”、“可具有取代基的低级烷基磺酰氧基”和“可具有取代基的低级烷硫基”的取代基,可以列举出:选自上述取代基组α的一个以上的基团。
“低级烯基”包含在任意位置上具有一个以上双键的碳原子数为2~15、优选碳原子数为2~10、更优选碳原子数为2~6、进一步优选碳原子数为2~4的直链或支链状烯基。具体包含:乙烯基、烯丙基、丙烯基、异丙烯基、丁烯基、异丁烯基、异戊二烯基、丁二烯基、戊烯基、异戊烯基、戊二烯基、己烯基、异己烯基、己二烯基、庚烯基、辛烯基、壬烯基、癸烯基、十一碳烯基、十二碳烯基、十三碳烯基、十四碳烯基、十五碳烯基等。
“低级炔基”包含在任意位置上具有一个以上三键的碳原子数为2~10、优选碳原子数为2~8、进一步优选碳原子数为3~6的直链或支链状炔基。具体包含:乙炔基、丙炔基、丁炔基、戊炔基、己炔基、庚炔基、辛炔基、壬炔基、癸炔基等。上述炔基可以进一步在任意位置上具有双键。
“低级烷氧基羰基低级炔基”的低级炔基部分也与上述“低级炔基”相同。
作为环A的取代基的「可具有取代基的低级烯基”的例子有:可被选自取代基组α的一个以上基团取代的低级烯基;上述(i)、(ii)、(iv)、(vi)、(viii)或(x)(Q1为可具有取代基的低级亚烯基)所示的基团;(iii)、(v)、(vii)或(ix)(Q2为可具有取代基的低级亚烯基)所示的基团。
除此以外的情况下,作为“可具有取代基的低级烯基”和“可具有取代基的低级炔基”的取代基,可以列举出:选自上述取代基组α的一个以上的基团。
作为环A的取代基的“可具有取代基的氨基”的例子有:可被选自低级烷基、酰基、羟基、低级烷氧基、低级烷氧基羰基、碳环式基团和杂环式基团的一个以上基团取代的氨基和上述(ii)(Q1为单键)、(iv)(Q1为单键)、(v)(Q2为单键,W3为NR12)、(ix)(Q2为单键)、(xiii)或(xiv)所示的基团。
作为环A的取代基的“可具有取代基的氨基甲酰基”的例子有:可被选自低级烷基、酰基、羟基、低级烷氧基、低级烷氧基羰基、碳环式基团和杂环式基团的一个以上基团取代的氨基甲酰基和上述(i)、(viii)(各Q1为单键)或(xv)所示的基团。
除此以外的情况下,作为“可具有取代基的氨基”、“可具有取代基的脒基”、“可具有取代基的氨基甲酰基”、“可具有取代基的氨基甲酰基羰基”和“可具有取代基的氨基甲酰氧基”的取代基,可以列举出:选自低级烷基、酰基、羟基、低级烷氧基、低级烷氧基羰基、碳环式基团和杂环式基团等的1~2个的基团。
“酰基”包含碳原子数为1~10的脂肪族酰基、碳环羰基和杂环羰基。具体例示:甲酰基、乙酰基、丙酰基、丁酰基、异丁酰基、戊酰基、叔戊酰基、己酰基、丙烯酰基、丙酰基、甲基丙烯酰基、巴豆酰基、苯甲酰基、环己甲酰基、吡啶羰基、呋喃羰基、噻吩羰基、苯并噻唑羰基、哌嗪羰基、哌啶羰基、硫代吗啉基等。
“卤代酰基”、“酰基氨基”和“酰氧基”的酰基部分也与上述相同。
“可具有取代基的酰基”和“可具有取代基的酰氧基”的取代基的例子有:选自取代基组α的一个以上的基团。另外,碳环羰基和杂环羰基的环部分可以被选自低级烷基、取代基组α和被选自取代基组α的一个以上基团取代的低级烷基的一个以上基团取代。
“碳环式基团”包含环烷基、环烯基、芳基和非芳族缩合碳环式基团等。
“环烷基”是指碳原子数为3~10、优选碳原子数为3~8、更优选碳原子数为4~8的碳环式基团,例如包含环丙基、环丁基、环戊基、环己基、环庚基、环辛基、环壬基和环癸基等。
“环烯基”包含在上述环烷基的环中的任意位置上具有一个以上双键的环烯基,具体列举出:环丙烯基、环丁烯基、环戊烯基、环己烯基、环庚烯基、环辛烯基和环己二烯基等。
“芳基”包含苯基、萘基、蒽基和菲基等,特别优选苯基。
“非芳族缩合碳环式基团”包含选自上述“环烷基”、“环烯基”和“芳基”的两个以上环状基团缩合的基团,具体列举出:茚满基、茚基、四氢萘基和芴基等。
“碳环氧基”、“碳环低级烷基”和“碳环低级烷基”的碳环部分也与“碳环式基团”相同。
“芳基低级烷基”、“芳氧基”、“芳氧基羰基”、“芳氧基羰基氧基”、“芳基低级烷氧基羰基”、“芳硫基”、“芳基氨基”、“芳基低级烷基氨基”、“芳基磺酰基”、“芳基磺酰氧基”、“芳基亚硫酰基”、“芳基氨磺酰基”、“芳基氨基甲酰基”和“芳基低级烷基氨基甲酰基”的芳基部分也与上述“芳基”相同。
“杂环式基团”包含环内具有一个以上任意选自O、S和N的杂原子的杂环式基团,具体包含:吡咯基、咪唑基、吡唑基、吡啶基、哒嗪基、嘧啶基、吡嗪基、三唑基、三嗪基、四唑基、异噁唑基、噁唑基、噁二唑基、异噻唑基、噻唑基、噻二唑基、呋喃基和噻吩基等5~6元杂芳基;吲哚基、异吲哚基、吲唑基、indolidinyl、吲哚啉基、异吲哚啉基、喹啉基、异喹啉基、噌啉基、酞嗪基、喹唑啉基、萘啶基(naphthridinyl)、喹喔啉基、嘌呤基、蝶啶基、苯并吡喃基、苯并咪唑基、苯并三唑基、苯并异噁唑基、苯并噁唑基、苯并噁二唑基、苯并异噻唑基、苯并噻唑基、苯并噻二唑基、苯并呋喃基、异苯并呋喃基、苯并噻吩基、苯并三唑基、咪唑并吡啶基、吡唑并吡啶基、三唑并吡啶基、咪唑并噻唑基、吡嗪并哒嗪基、喹唑啉基、喹啉基、异喹啉基、萘啶基(naphthyridinyl)、二氢苯并呋喃基、四氢喹啉基、四氢异喹啉基、二氢苯并噁嗪、四氢苯并噻吩基等二环的缩合杂环式基团;咔唑基、吖啶基、呫吨基、吩噻嗪基、啡噁噻基、吩噁嗪基、二苯并呋喃基、咪唑并喹啉基等三环的缩合杂环式基团;二噁烷基、硫杂丙环基(thiiranyl)、环氧乙烷基、oxathioranyl、azethidinyl、thianyl、噻唑烷、吡咯烷基,、吡咯啉基、咪唑烷基、咪唑啉基、吡唑烷基、吡唑啉基、哌啶基、哌嗪基、吗啉基(morpholinyl)、吗啉(morpholino)、硫代吗啉基(thiomorpholinyl)、硫代吗啉(thiomorpholino)、二氢吡啶基、二氢苯并咪唑基、四氢吡啶基、四氢呋喃基、四氢吡喃基、四氢噻唑基、四氢异噻唑基、二氢噁嗪基(dihydroxadinyl)、氮杂环庚烷基(hexahydroazepinyl)、tetrahydroazepyinyl等非芳族杂环式基团。优选为5~6元的杂芳基或非芳族杂环式基团。
“杂环氧基”、“杂环硫基”、“杂环羰基”、“杂环氨基”、“杂环羰基氨基”、“杂环氨磺酰基”、“杂环磺酰基”、“杂环氨基甲酰基”、“杂环氧基羰基”、“杂环低级烷基氨基”和“杂环低级烷基氨基甲酰基”的杂环部分也与上述“杂环式基团”相同。
作为环A的“可具有取代基的碳环式基团”和“可具有取代基的杂环式基团”的取代基,可以被选自下述基团的一种以上基团取代,可以列举出:
取代基组α(优选卤素、羟基、酰基、酰氧基、羧基、低级烷氧基羰基、氨基甲酰基、氨基、低级烷基氨基、低级烷硫基等);
可被选自取代基组α的一个以上基团取代的低级烷基(其中,取代基优选卤素、羟基、低级烷氧基、低级烷氧基羰基等);
被选自取代基组α的一个以上基团取代的氨基低级烷基(其中取代基为酰基、低级烷基和/或低级烷氧基等);
羟基亚氨基低级烷基、低级烷氧基亚氨基低级烷基;
可被选自取代基组α的一个以上基团取代的低级烯基(取代基优选低级烷氧基羰基、卤素和/或卤代低级烷氧基羰基等);
可被选自取代基组α的一个以上基团取代的低级炔基(取代基优选低级烷氧基羰基等);
可被选自取代基组α的一个以上基团取代的低级烷氧基(取代基优选低级烷基氨基甲酰基和/或羟基低级烷基氨基甲酰基等);
可被选自取代基组α的一个以上基团取代的低级烷硫基;
被选自取代基组α的一个以上基团取代的低级烷基氨基;
可被选自取代基组α的一个以上基团取代的低级烷基磺酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基低级烷氧基羰基;
被选自取代基组α的一个以上基团取代的酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的环烷基;
可被选自取代基组α的一个以上基团取代的低级烷基亚硫酰基;
氨磺酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环式基团;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳氧基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环氧基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳硫基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环硫基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基氨基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环氨基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基低级烷基氨基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环低级烷基氨基;
可被选自取代基组α的一个以上基团取代的低级烷基氨磺酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基氨磺酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环氨磺酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基磺酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环磺酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基氨基甲酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环氨基甲酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基低级烷基氨基甲酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环低级烷基氨基甲酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳氧基羰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环氧基羰基;
可被卤素取代的低级亚烷基二氧基;氧基(oxo);叠氮基;
[化学式13]
(Q1、Q2和Q3各自独立表示单键、可具有取代基的低级亚烷基或可具有取代基的低级亚烯基;
Q4为可具有取代基的低级亚烷基或可具有取代基的低级亚烯基;
W1和W2各自独立表示O或S;
W3为O、S或NR12;
R12为氢、低级烷基、羟基低级烷基、低级烷氧基低级烷基、低级烷氧基羰基低级烷基、碳环低级烷基或酰基;
R14为氢或低级烷基;
环B为可具有取代基的碳环式基团或可具有取代基的杂环式基团;
Alk2为可具有取代基的低级烷基)所示的基团等。
存在多个W1、多个W3、多个R12等时,可以各自独立不同。
在(xii)中,氧原子相对于取代基R14可以是顺式或反式的关系。
“被取代的苯基”的取代基也同上,优选为被选自取代基组α和(i)~(xv)所示基团的1~2个基团取代的苯基。
作为环B中的“可具有取代基的碳环式基团”或“可具有取代基的杂环式基团”的取代基,可以被选自下述基团的一种以上基团取代,可以列举如:
取代基组α(优选卤素、羟基、低级烷氧基、羧基、低级烷氧基羰基、酰基、氨基、低级烷基氨基、酰基氨基、氨基甲酰基、低级烷基氨基甲酰基、氰基、硝基等);
可被选自取代基组α的一个以上基团取代的低级烷基(其中取代基优选卤素、羟基、低级烷氧基等);
被选自取代基组α的一个以上基团取代的氨基低级烷基、羟基亚氨基低级烷基、低级烷氧基亚氨基低级烷基;
可被选自取代基组α的一个以上基团取代的低级烯基;
可被选自取代基组α的一个以上基团取代的低级炔基;
可被选自取代基组α的一个以上基团取代的低级烷氧基(取代基优选卤素、羟基等);
可被选自取代基组α的一个以上基团取代的低级烷硫基(取代基优选卤素);
可被选自取代基组α的一个以上基团取代的低级烷基氨基(取代基优选氨基);
可被选自取代基组α的一个以上基团取代的低级烷基磺酰基;
可被选自取代基组α和低级烷基的一个以上基团取代的芳基低级烷氧基羰基;
可被选自取代基组α的一个以上基团取代的酰基(取代基优选卤素);
可被选自取代基组α的一个以上基团取代的低级烷基磺酰基;
氨磺酰基;
可被选自取代基组α的一个以上基团取代的低级烷基氨磺酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的环烷基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环式基团(取代基优选卤素、低级烷基等);
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳氧基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环氧基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳硫基(取代基优选卤素、羟基、低级烷氧基、酰基等);
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环硫基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基氨基(取代基优选卤素、羟基、低级烷氧基、酰基等);
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环氨基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基低级烷基氨基(取代基优选卤素、羟基、低级烷氧基、酰基等);
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环低级烷基氨基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基氨磺酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环氨磺酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基磺酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环磺酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基氨基甲酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环氨基甲酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳基低级烷基氨基甲酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环低级烷基氨基甲酰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的芳氧基羰基;
可被选自取代基组α、叠氮基和低级烷基的一个以上基团取代的杂环氧基羰基;
可被卤素取代的低级亚烷基二氧基;氧基等。
除上述情况外,作为“可具有取代基的碳环式基团”、“可具有取代基的杂环式基团”、“可具有取代基的碳环氧基”、“可具有取代基的芳基磺酰基”、“可具有取代基的芳氧基羰基氧基”、“可具有取代基的杂环氧基”、“可具有取代基的芳基亚硫酰基”、“可具有取代基的芳基磺酰氧基”、“可具有取代基的芳硫基”的取代基,可以列举出:可被选自低级烷基和取代基组α的一个以上基团取代的基团。
“杂芳基”包含上述“杂环式基团”中的芳族环式基团。
“可具有取代基的5~6元杂芳基”的取代基与上述环B中的“可具有取代基的杂环式基团”的取代基相同。优选为选自低级烷基和取代基组α的一种以上的基团。
“低级亚烷基”包含碳原子数为1~10、优选碳原子数为1~6、更优选碳原子数为1~3的直链状或支链状的二价碳链。具体有亚甲基、二亚甲基、三亚甲基、四亚甲基、甲基三亚甲基等。
“低级亚烷基二氧基”的低级亚烷基部分也与上述“低级亚烷基”相同。
“低级亚烯基”包含在任意位置上具有双键的直链或支链状的碳原子数为2~10、优选碳原子数为2~6、更优选碳原子数为2~4的二价碳链。具体有亚乙烯基、亚丙烯基、亚丁烯基、亚丁二烯基、甲基亚丙烯基、亚戊烯基和亚己烯基等。
“低级亚炔基”包含在任意位置上具有三键且可以进一步具有双键的直链或支链状的碳原子数为2~10、更优选碳原子数为2~6、更优选碳原子数为2~4的二价碳链。具体可以列举出:亚乙炔基、亚丙炔基、亚丁炔基、亚戊炔基和亚己炔基等。
作为“可具有取代基的低级亚烷基”、“可具有取代基的低级亚烯基”、“可具有取代基的低级亚炔基”的取代基,可以列举出取代基组α,优选为卤素、羟基等。
“各R3a、各R3b、各R4a、各R4b可以不同”意思是指:当n为2或3时,两个或三个R3a各自可以不同,两个或三个R3b各自可以不同。同样当m为2或3时,两个或三个R4a各自可以不同,两个或三个R4b各自可以不同。
[化学式14]
[化学式15]
(各记号定义同上)
优选为R5a、R5b全部为氢的基团。
本说明书中,“溶剂合物”包含例如与有机溶剂的溶剂合物、水合物等。形成水合物时,可以和任意数目的水分子配位。
化合物(I)包含药学上可接受的盐。可以列举如:与碱金属(锂、钠或钾等)、碱土金属(镁或钙等)、氨、有机碱和氨基酸的盐;或者与无机酸(盐酸、硫酸、硝酸、氢溴酸、磷酸或氢碘酸等)和有机酸(乙酸、三氟乙酸、枸橼酸、乳酸、酒石酸、草酸、马来酸、富马酸、扁桃酸、戊二酸、苹果酸、苯甲酸、邻苯二甲酸、苯磺酸、对甲苯磺酸、甲磺酸或乙磺酸等)的盐。特别优选盐酸、磷酸、酒石酸或甲磺酸等。上述盐可以按照通常进行的方法来形成。
另外,化合物(I)并不限于特定的异构体,包括所有可能的异构体(酮-烯醇异构体、亚胺-烯胺异构体、非对映异构体、光学异构体和旋转异构体等)或外消旋体。例如R2a为氢的化合物(I)包含以下互变异构体。
[化学式16]
本发明的化合物(I)例如可以按照非专利文献1所记载的方法或下述方法进行制备。
氨基二氢噻嗪环的合成A法
[化学式17]
(式中,R2b和R2c中至少一个为氢;R3c和R3d各自独立表示氢、卤素、羟基、可具有取代基的低级烷基、可具有取代基的低级烯基、可具有取代基的酰基、羧基、可具有取代基的低级烷氧基羰基、可具有取代基的氨基、可具有取代基的氨基甲酰基、可具有取代基的碳环式基团或可具有取代基的杂环式基团;其他各记号定义同上)
步骤一
在-100℃~50℃、优选-80℃~0℃下,向乙醚、四氢呋喃等溶剂或乙醚-四氢呋喃等混合溶剂中加入市售或利用公知方法可以制备的化合物a和氯化乙烯基镁、溴化乙烯基镁、溴化丙烯基镁等具有对应于目标化合物的取代基的格利雅试剂,使之反应0.2小时~24小时、优选0.5小时~5小时,可以得到化合物b。
步骤二
在甲苯等溶剂的存在或非存在下,向乙酸、三氟乙酸、氯化氢、硫酸等酸或它们的混合物中加入硫脲或N-甲基硫脲、N,N’-二甲基硫脲等具有对应于目标化合物的取代基的取代硫脲,使其与化合物b在-20℃~100℃、优选0℃~50℃下反应0.5小时~120小时、优选1小时~72小时,可以得到化合物c。
步骤三
在甲苯等溶剂的存在或非存在下,向化合物c中加入三氟乙酸、甲磺酸、三氟甲磺酸等酸或它们的混合物,在-20℃~100℃、优选0℃~50℃下反应0.5~120小时、优选1小时~72小时,当R2b为氢时可以得到(I-2),当R2c为氢时可以得到(I-1)。
氨基二氢噻嗪环的合成B法
[化学式18]
(式中,L为卤素或磺酰氧基等离去基团,其他记号定义同上)
步骤一
在甲苯、氯仿、四氢呋喃等溶剂中,在水和盐酸、硫酸等酸的存在下,使市售或利用公知方法可以制备的化合物d与硫氰酸钠、硫氰酸铵等硫氰酸盐在0℃~150℃、优选20℃~100℃下反应0.5小时~24小时、优选1小时~12小时,可以得到化合物e。
步骤二
在磷酸二氢钠等缓冲剂的存在或非存在下,向四氢呋喃、甲醇、乙醇、水等溶剂中或乙醇-水等混合溶剂中加入硼氢化钠等还原剂,使与化合物e在-80℃~50℃、优选-20℃~20℃下反应0.1小时~24小时、优选0.5小时~12小时,可以得到化合物f。
步骤三
在甲苯、二氯甲烷等溶剂的存在或非存在下,使化合物f与亚硫酰氯、氯氧化磷、四溴化碳-三苯基膦等卤化剂在-80℃~50℃、优选-20℃~20℃下反应0.1小时~24小时、优选0.5小时~12小时,或者在甲苯、二氯甲烷等溶剂中,在三乙胺等碱的存在下使甲磺酰氯、对甲苯磺酰氯等磺化剂与化合物f在-80℃~50℃、优选-20℃~20℃下反应0.1小时~24小时、优选0.5小时~12小时,可以得到化合物g。
步骤四
在甲醇、乙醇、水等溶剂中或甲醇-水等混合溶剂中,使氨或甲胺等伯胺与化合物g在-20℃~80℃、优选0℃~40℃下反应0.5小时~48小时、优选1小时~24小时,可以得到化合物(I-3)。
氨基二氢噻嗪环的合成C法
[化学式19]
(式中,R为氢或羧基的保护基,其他记号定义同上)
步骤一
使市售或利用公知方法可以制备的化合物h与氢化锂铝、氢化二异丙基铝等还原剂在四氢呋喃、二乙醚等溶剂中在-80℃~150℃、优选25℃~100℃下反应0.1小时~24小时、优选0.5小时~12小时,可以得到化合物i。
步骤二
在甲苯、氯仿、四氢呋喃等溶剂中,在二异丙基乙胺、三乙胺、吡啶、氢氧化钠等碱的存在下或非存在下,使4-甲氧基苄基异硫氰酸酯、叔丁基异硫氰酸酯等对应于目标化合物的异硫氰酸酯或N,N-二甲基硫代氨基甲酰氯、N,N-二乙基硫代氨基甲酰氯等对应于目标化合物的硫代氨基甲酰卤与化合物i在0℃~150℃、优选20℃~100℃下反应0.5小时~120小时、优选1小时~72小时,可以得到化合物j。
步骤三
在乙腈、甲苯、二氯甲烷等溶剂中,使化合物j与亚硫酰氯、氯氧化磷、四溴化碳-三苯基膦等卤化剂在-80℃~50℃、优选-20℃~20℃下反应0.1小时~24小时、优选0.5小时~12小时,或者在甲苯、二氯甲烷等溶剂中,在三乙胺等碱的存在下使甲磺酰氯、对甲苯磺酰氯等磺化剂与化合物j在-80℃~50℃、优选-20℃~20℃下反应0.1小时~24小时、优选0.5小时~12小时。使二异丙基乙胺、碳酸钾、碳酸氢钠、氢化钠、氢氧化钠等碱与所得卤化物或磺酰基化合物在0℃~150℃、优选20℃~100℃下反应0.5小时~120小时、优选1小时~72小时,可以得到化合物(I-4)。
氨基二氢噻嗪环的合成D法
氨基噻唑啉环的合成A法
氨基四氢噻唑环的合成A法
[化学式20]
(式中,L为卤素或磺酰氧基等离去基团,m为1~3的整数,其他记号定义同上)
步骤一
在二甲基甲酰胺、四氢呋喃等溶剂中加入叠氮化钠等叠氮化剂,使与市售或利用公知方法可以制备的化合物k在0℃~200℃、优选40℃~150℃下反应0.5小时~24小时、优选1小时~12小时,可以得到化合物1。
步骤二
使化合物1和氢化锂铝、氢化二异丁基铝等还原剂在四氢呋喃、二乙醚等溶剂中在-80℃~150℃、优选25℃~100℃下反应0.1小时~24小时、优选0.5小时~12小时,可以得到化合物m。
步骤三
在甲苯、氯仿、四氢呋喃等溶剂中,使甲基异硫氰酸酯、乙基异硫氰酸酯等对应于目标化合物的异硫氰酸酯或N,N-二甲基硫代氨基甲酰氯、N,N-二乙基硫代氨基甲酰氯等对应于目标化合物的硫代氨基甲酰卤与化合物m在0℃~150℃、优选20℃~100℃下反应0.5小时~120小时、优选1小时~72小时,可以得到化合物n。
步骤四
使化合物n与亚硫酰氯、氯氧化磷、四溴化碳-三苯基膦等卤化剂在乙腈、甲苯、二氯甲烷等溶剂中在-80℃~50℃、优选-20℃~20℃下反应0.1小时~24小时、优选0.5小时~12小时,或者在甲苯、二氯甲烷等溶剂中,在二异丙基乙胺、三乙胺等碱的存在下使甲磺酰氯、对甲苯磺酰氯等磺酰化剂与化合物n在-80℃~50℃、优选-20℃~20℃下反应0.1小时~24小时、优选0.5小时~12小时。使碳酸钾、碳酸氢钠、氢化钠、氢氧化钠等碱与所得卤化物或磺酸酯衍生物在0℃~150℃、优选20℃~100℃下反应0.5小时~120小时、优选1小时~72小时,可以得到化合物(I-5)。
氨基二氢噻嗪环的合成E法
氨基噻唑啉环的合成B法
氨基四氢噻唑环的合成B法
[化学式21]
(式中,R2b和R2c中的至少一个为氢,n为1~3的整数,其他记号定义同上)
步骤一
在乙醇、甲醇、四氢呋喃、甲苯等溶剂中,使硫脲或N-甲基硫脲、N,N-二甲基硫脲、N,N’-二甲基硫脲等对应于目标化合物的取代硫脲与市售或利用公知方法可以制备的化合物o在-20℃~200℃、优选0℃~150℃下反应0.5小时~200小时、优选1小时~120小时,可以得到化合物p。
步骤二
在-100℃~50℃、优选-80℃~30℃下,向醚、四氢呋喃等溶剂中或它们的混合溶剂中加入化合物p和甲基氯化镁、乙基溴化镁、苄基溴化镁等对应于目标化合物的格利雅试剂,使之反应0.2小时~24小时、优选0.5小时~5小时,可以得到化合物q。
步骤三
在甲苯等溶剂的存在或非存在下,加入三氟乙酸、甲磺酸、三氟甲磺酸等酸或它们的混合物,使与化合物q在-20℃~100℃、优选0℃~50℃下反应0.5小时~200小时、优选1小时~150小时,可以得到化合物(I-6)(R2c=H)或化合物(I-7)(R2b=H)。
氨基二氢噻嗪环的合成F法
[化学式22]
(式中,各记号定义同上)
步骤一
使氯化铵和利用公知方法可以制备的化合物r在乙酸等溶剂中在0℃~200℃、优选10℃~100℃下反应0.1小时~100小时、优选0.5小时~24小时,可以得到化合物s。
步骤二
使化合物s与氢化锂铝、氢化二异丁基铝等还原剂在四氢呋喃、二乙醚等溶剂中在-80℃~150℃、优选0℃~100℃下反应0.1小时~24小时、优选0.5小时~12小时,可以得到化合物t。
步骤三
在甲苯、氯仿、四氢呋喃等溶剂中,在二异丙基乙胺、三乙胺、吡啶、氢氧化钠等碱的存在或非存在下,使4-甲氧基苄基异硫氰酸酯、叔丁基异硫氰酸酯等对应于目标化合物的异硫氰酸酯或N,N-二甲基硫代氨基甲酰氯、N,N-二乙基硫代氨基甲酰氯等对应于目标化合物的氨基甲酰卤与化合物t在0℃~150℃、优选20℃~100℃下反应0.5小时~120小时、优选1小时~72小时,可以得到化合物u。
步骤四
使化合物u和亚硫酰氯、氯氧化磷、四溴化碳-三苯基膦等卤化剂在乙腈、甲苯、二氯甲烷等溶剂中在-80℃~50℃、优选-20℃~20℃下反应0.1小时~24小时、优选0.5小时~12小时,或者在甲苯、二氯甲烷等溶剂中,在三乙胺等碱的存在下,使甲磺酰氯、对甲苯磺酰氯等磺酰化剂和化合物u在-80℃~50℃、优选-20℃~20℃下反应0.1小时~24小时、优选0.5小时~12小时。使二异丙基乙胺、碳酸钾、碳酸氢钠、氢化钠、氢氧化钠等碱与所得卤化物或磺酸酯衍生物在0℃~150℃、优选20℃~100℃下反应0.5小时~120小时、优选1小时~72小时,可以得到化合物(I-8)。
氨基二氢噁嗪环的合成A法
氨基四氢氧氮杂环的合成A法
[化学式23]
(式中,各记号定义同上)
步骤一
使甲基碘、二乙基硫酸、苄基溴等烷基化剂与氨基二氢噻嗪环的合成D法的步骤三(m至n)得到的化合物n在甲醇、乙醇、二甲基甲酰胺、四氢呋喃等溶剂中,在二异丙基乙胺、三乙胺、吡啶、氢氧化钠等碱的存在或非存在下,在0℃~200℃、优选40℃~150℃下反应0.1小时~48小时、优选0.5小时~24小时,可以得到化合物v。
步骤二
使氧化银、氧化汞、二氧化锰等金属氧化物和化合物v在二甲基甲酰胺、四氢呋喃、二氯甲烷等溶剂中,在二异丙基乙胺、三乙胺、吡啶、氢氧化钠等碱的存在或非存在下,在0℃~200℃、优选10℃~150℃下反应1小时~120小时、优选0.5小时~100小时,可以得到化合物(I-9)。
氨基二氢噁嗪环的合成B法
氨基噁唑啉环的合成
[化学式24]
(式中,R15为可具有取代基的低级烷基(叔丁基、苄基等);R16为氢或低级烷基;n为1~3的整数;其他记号定义同上)
步骤一
在甲苯、叔丁醇、四氢呋喃等溶剂中,在二异丙基乙胺、三乙胺、吡啶等碱的存在下,使叠氮化磷酸二苯酯等叠氮化剂与市售或利用公知方法可以制备的化合物w在0℃~200℃、优选40℃~150℃下反应1小时~48小时、优选0.5小时~24小时,可以得到化合物x。
步骤二
使叔丁醇、3,4-二甲氧基苄醇、4-甲氧基苄醇等醇与化合物x在甲苯、二甲苯、二甲基甲酰胺、四氢呋喃等溶剂中,在0℃~300℃、优选50℃~200℃下反应1小时~800小时、优选5小时~500小时,可以得到化合物y。
步骤三
在水、甲苯、二氯甲烷、甲醇、1,4-二噁烷、乙酸、乙酸乙酯等溶剂的存在或非存在下,在盐酸、硫酸、氢溴酸、三氟乙酸等酸的存在下,使化合物y在0℃~200℃、优选25℃~150℃下反应0.1小时~48小时、优选0.5小时~24小时,可以得到化合物z。
步骤四
在甲苯、氯仿、四氢呋喃等溶剂中,在二异丙基乙胺、三乙胺、吡啶等碱的存在下,使甲基异硫氰酸酯、乙基异硫氰酸酯等对应于目标化合物的异硫氰酸酯或N,N-二甲基硫代氨基甲酰氯、N,N-二乙基硫代氨基甲酰氯等对应于目标化合物的硫代氨基甲酰卤与化合物z在0℃~150℃、优选20℃~100℃下反应0.5小时~120小时、优选1小时~72小时,可以得到化合物aa。
步骤五
在甲醇、乙醇、二甲基甲酰胺、四氢呋喃等溶剂中,在二异丙基乙胺、三乙胺、吡啶、氢氧化钠等碱的存在或非存在下,使甲基碘、二乙基硫酸、苄基溴等烷基化剂与化合物aa在0℃~200℃、优选40℃~150℃下反应1小时~48小时、优选0.5小时~24小时,可以得到化合物ab。
步骤六
使氧化银、氧化汞、二氧化锰等金属氧化物与化合物ab在二甲基甲酰胺、四氢呋喃、二氯甲烷等溶剂中,在二异丙基乙胺、三乙胺、吡啶、氢氧化钠等碱的存在下,在0℃~200℃、优选10℃~150℃下反应1小时~120小时、优选0.5小时~100小时,可以得到化合物(I-10)。
氨基四氢嘧啶环的合成
[化学式25]
(式中,各记号定义同上)
步骤一
向二甲基甲酰胺、甲醇等溶剂中加入利用公知方法可以制备的化合物ac和叠氮化钠、叠氮化锂等叠氮化剂,使之在20℃~150℃、优选50℃~100℃下反应0.5小时~120小时、优选1小时~72小时,可以得到化合物ad。
步骤二
在氮气环境下,将氢化锂铝悬浮在四氢呋喃或二乙醚等溶剂中,在-80℃~20℃、优选-30℃~0℃下加入将化合物ad溶解在四氢呋喃或二乙基醚等溶剂中的溶液,反应1分钟~10小时、优选10分钟~1小时,或者在乙醇、异丙醇、正丁醇等溶剂中在10℃~110℃、优选50℃~80℃下加入拉尼镍,使之与化合物ad反应1分钟~10小时、优选10分钟~1小时,可以得到化合物ae。
步骤三
在四氢呋喃、二氯甲烷等溶剂中,在乙酸、丙酸等酸的存在下,使化合物ae与氰化硼氢化钠、三乙酰氧基硼氢化钠等还原剂在-50℃~100℃、优选0℃~50℃下反应0.1小时~48小时、优选0.5小时~24小时,或者在四氢呋喃、二甲基甲酰胺等溶剂中,在1-乙基-3-(3-二甲氨基丙基)碳二亚胺-N-羟基苯并三唑、羰基二咪唑等脱水缩合剂存在下,以及三乙胺、碳酸钾等碱的存在下或非存在下,使化合物ae与甲酸、乙酸等羧酸在-50℃~100℃、优选0℃~50℃下反应0.1小时~48小时、优选0.5小时~16小时,可以得到酰胺衍生物。接着,在氮气环境下,将氢化锂铝悬浮在四氢呋喃或二乙醚等溶剂中,在-50℃~60℃、优选0℃~50℃下加入将上述酰胺衍生物溶解在四氢呋喃或二乙醚等溶剂中的溶液,反应1分钟~48小时、优选10分钟~10小时,可以得到化合物af。
步骤四
使化合物ae或af与3,5-二甲基吡唑-1-羧基脒或S-甲基硫脲等在乙腈、四氢呋喃、二甲基甲酰胺等溶剂中,在0℃~150℃、优选20℃~100℃下反应0.5小时~120小时、优选1小时~24小时,可以得到化合物ag。
步骤五
在甲苯等溶剂的存在或非存在下,向化合物ag(R2b和R2c中的至少一个为氢)中加入三氟乙酸、甲磺酸、三氟甲磺酸等酸或它们的混合物,在-20℃~100℃、优选0℃~50℃下反应0.5~120小时、优选1小时~72小时,当R2b为氢时可以得到(I-2);当R2c为氢时可以得到(I-1)。其中,当R2a、R2b、R2c具有在叔丁氧基羰基等的酸性条件下容易分解的结构时,化合物(I-1)、(I-2)中的R2a、R2b、R2c有时会转化为氢。
氨基噻唑啉环的合成C法
[化学式26]
(式中,Hal为卤素,其他各记号定义同上)
步骤一
在甲苯、氯仿、四氢呋喃等溶剂中或氯仿-水等混合溶剂中,在碘、溴、氯等卤素和硫氰酸钠、硫氰酸铵等硫氰酸盐以及根据需要在四丁基溴化铵等相转移催化剂的存在下,使市售或利用公知方法可以制备的化合物ah在0℃~150℃、优选20℃~100℃下反应0.5小时~48小时、优选1小时~24小时,可以得到化合物ai。
步骤二
向甲苯、氯仿、四氢呋喃等溶剂中加入化合物ai、和氨或甲胺、二乙胺等具有对应于目标化合物的取代基的胺,使之在0℃~150℃、优选20℃~100℃下反应0.5小时~48小时、优选1小时~24小时,可以得到化合物(I-11)。
酰基氨基衍生物-1
[化学式27]
(式中,R17为可具有取代基的低级烷基、可具有取代基的烃环或可具有取代基的杂环式基团等,其他记号定义同上)
在四氢呋喃、二氯甲烷等溶剂的存在或非存在下,在吡啶、三乙胺等碱的存在或非存在下,使R2b为氢的化合物(I-12)与苯甲酰氯、2-糠酰氯、乙酸酐等具有对应于目标化合物的取代基的酰化剂在-80℃~100℃、优选-20℃~40℃下反应0.1小时~24小时、优选1小时~12小时,或者使化合物(I-12)与氨基酸、羟基乙酸等具有对应于目标化合物的取代基的羧酸在二甲基甲酰胺、四氢呋喃、二氯甲烷等溶剂中,在二环己基碳二亚胺、羰基二咪唑等脱水缩合剂的存在下,在-80℃~100℃、优选-20℃~40℃下反应0.1小时~24小时、优选1小时~12小时,可以得到化合物(I-13)和/或(I-14)(R2a为氢时)。
胍基衍生物
[化学式28]
(式中,各记号定义同上)
在乙腈、四氢呋喃、二甲基甲酰胺等溶剂中,在三乙胺、碳酸氢钠等碱的存在或非存在下,使R2b为氢的化合物(I-12)与3,5-二甲基吡唑-1-羧基脒或S-甲基异硫脲等在0℃~150℃、优选20℃~100℃下反应0.5小时~120小时、优选1小时~24小时,可以得到化合物(I-15)。
氨基甲酰基衍生物
[化学式29]
(式中,CONR18R19为可具有取代基的氨基甲酰基,其他记号定义同上)
在二甲基甲酰胺、四氢呋喃、二氯甲烷等溶剂中,在二环己基碳二亚胺、羰基二咪唑、二环己基碳二亚胺-N-羟基苯并三唑等脱水缩合剂的存在下,使具有羧基的化合物(I-16)作为环A的取代基与具有对应于目标化合物的取代基的伯胺或仲胺(苯胺、2-氨基吡啶、二甲胺等)在-80℃~100℃、优选-20℃~40℃下反应0.1小时~24小时、优选1小时~12小时,可以得到化合物(I-17)。
酰基氨基衍生物-2
[化学式30]
(式中,NHR20为可具有取代基的氨基;NR20COR21为可具有取代基的酰基氨基、可具有取代基的脲基、氧上具有取代基的羧基氨基;其他各记号定义同上)
使环A中具有可具有取代基的氨基的化合物(I-18)与具有对应于目标化合物的取代基的酰氯类、酸酐、氯碳酸酯类、异氰酸酯类等反应剂(苯甲酰氯、2-糠酰氯、乙酸酐、氯碳酸苄酯、二碳酸二叔丁酯、苯基异氰酸酯等)在四氢呋喃、二氯甲烷等溶剂的存在或非存在下,在吡啶、三乙胺等碱的存在或非存在下,在-80℃~100℃、优选-20℃~40℃下反应0.1小时~24小时、优选1小时~12小时,或者使化合物(I-18)与苯甲酸、2-吡啶碳酸等具有对应于目标化合物的取代基的羧酸在二甲基甲酰胺、四氢呋喃、二氯甲烷等溶剂中,在二环己基碳二亚胺、羰基二咪唑、二环己基碳二亚胺-N-羟基苯并三唑等脱水缩合剂的存在下,在-80℃~100℃、优选-20℃~40℃下反应0.1小时~24小时、优选1小时~12小时,可以得到化合物(I-19)。
烷基氨基衍生物
[化学式31]
(式中,NHR20为可具有取代基的氨基,R22为低级烷基)
在二氯甲烷,四氢呋喃等溶剂中,在乙酸等酸的存在下或非存在下,使环A中具有氨基的化合物(I-18)与苯甲醛、吡啶-2-甲醛等具有对应于目标化合物的取代基的醛和氰基三氢硼酸钠、三乙酰氧基硼氢化钠等还原剂在-80℃~100℃、优选0℃~40℃下反应0.5小时~150小时、优选1小时~24小时,可以得到化合物(I-20)。
取代烷氧基衍生物
[化学式32]
(式中,R23为可具有取代基的低级烷基、可具有取代基的碳环式基团或可具有取代基的杂环式基团等,其他记号定义同上)
在二甲基甲酰胺、四氢呋喃等溶剂中,在碳酸钾、氢氧化钠、氢化钠等碱的存在下,使具有羟基的化合物(I-21)作为A环的取代基与苄基氯、甲基碘等具有对应于目标化合物的取代基的烷基化剂在-80℃~100℃、优选0℃~40℃下反应0.5小时~150小时、优选1小时~24小时,或者使化合物(I-18)与2-氨基乙醇等醇类在二甲基甲酰胺、四氢呋喃等溶剂中、在三苯基膦-偶氮二羧酸二乙酯等Mitsunobu反应试剂的存在下,在-80℃~100℃、优选0℃~40℃下反应0.5小时~72小时、优选1小时~24小时,可以得到化合物(I-22)。
通过钯偶联反应导入取代基
[化学式33]
(式中,Hal为卤素;G为可具有取代基的低级烯基、可具有取代基的低级炔基、可具有取代基的低级烷氧基羰基、可具有取代基的碳环式基团或可具有取代基的杂环式基团等;其他记号定义同上)
在四氢呋喃、二甲基甲酰胺、1,2-二甲氧基乙烷、甲醇等溶剂中,在三乙胺、碳酸钠等碱、乙酸钯、氯化钯等钯催化剂和三苯基膦等配位子的存在下,使具有卤素的化合物(I-23)作为环A的取代基与具有对应于目标化合物的取代基的化合物(苯乙烯、丙炔醇、芳基硼酸、一氧化碳等)在微波的照射下或非照射下在-80℃~150℃、优选0℃~100℃下反应0.5小时~72小时、优选1小时~24小时,可以得到化合物(I-24)。
肟衍生物
[化学式34]
(式中,R24为氢或可具有取代基的低级烷基等;R25为氢、可具有取代基的低级烷基、可具有取代基的低级烯基或可具有取代基的碳环式基团或可具有取代基的杂环式基团等;其他记号定义同上)
在甲醇或乙醇等溶剂中,在乙酸钾等添加剂的存在或非存在下,使具有酰基的化合物(I-25)作为环A的取代基与具有对应于目标化合物的取代基的羟胺类(羟胺、甲氧基胺、邻苄基羟胺等)或其盐在-80℃~100℃、优选0℃~40℃下反应0.5小时~150小时、优选1小时~72小时,可以得到化合物(I-26)。
在上述所有步骤中,当具有成为反应障碍的取代基(例如羟基、巯基、氨基、甲酰基、羰基、羧基等)时,可以按照有机合成中的保护基(Protective Groups in Organic Synthesis)Theodora W Green(John Wiley&Sons)等中记载的方法预先进行保护,在希望的阶段除去该保护基。
本发明的化合物(I)中,特别优选X为S、E为单键或亚甲基的以下化合物。
1)式(I’)所示的化合物:
[化学式35]
(式中,t为0或1;其他各记号与上述(a)同义,其中以下化合物除外。
i)n+m为2、R5为氢、环A为未取代的苯基的化合物;
ii)n为2、m为0、R2a为氢、R2b为氢或乙酰基、R5为甲基、环A为苯基或4-甲氧基苯基的化合物;
iii)n为2、m为0、R2a为氢、R2b为氢或乙酰基、R5为乙基、环A为3,4-二甲氧基苯基的化合物;
iv)n为2、m为0、R2a为氢、R2b为氢或乙酰基、R5和环A为苯基的化合物;
v)n为2、m为0、R2a和R2b为氢、R5和环A一起形成:
[化学式36]
vi)n+m为1或2、R5为氢、环A为只被选自羟基、卤素、低级烷基、低级烷氧基、硝基、氨基、低级烷基羰基氨基、巯基、低级烷硫基、氨基甲酰基、低级烷基氨基、低级烷基氨基甲酰基和低级烷氧基羰基的1~2个取代基取代的苯基、未取代的苯基或未取代的萘基的化合物)。
另外,式(I’)中优选以下化合物。
2)n为1、m为0的化合物(以下该化合物由nm-1表示);
3)n为2、m为0的化合物(以下该化合物由nm-2表示);
4)n为3、m为0的化合物(以下该化合物由nm-3表示);
5)R2a为氢,R2b为氢、可具有取代基的低级烷基、可具有取代基的酰基、可具有取代基的低级烷基磺酰基、可具有取代基的脒基的化合物(以下该化合物由R2-1表示);
6)R2a为氢,R2b为氢、可具有取代基的低级烷基或可具有取代基的酰基的化合物(以下该化合物由R2-2表示);
7)NR2aR2b为:
[化学式37]
(各记号定义同上);R6、R7和R8各自独立表示氢、低级烷基或酰基;Y为可具有取代基的低级亚烷基、可具有取代基的低级亚烯基或可具有取代基的低级亚炔基;Z为O或S的化合物(以下该化合物由R2-3表示);
8)NR2aR2b为NH2的化合物(以下该化合物由R2-4表示);
9)环A为取代的苯基或取代的吡啶基的化合物(以下该化合物由A-1表示);
10)环A为:
[化学式38]
(R9、R10和R11为氢或G;
G为卤素、羟基、氰基、硝基、巯基、可具有取代基的低级烷基、可具有取代基的低级烷氧基、可具有取代基的低级烯基、可具有取代基的低级炔基、可具有取代基的酰基、可具有取代基的酰氧基、羧基、可具有取代基的低级烷氧基羰基、可具有取代基的低级烷氧基羰基氧基、可具有取代基的芳氧基羰基氧基、可具有取代基的氨基、可具有取代基的氨基甲酰基、可具有取代基的氨基甲酰氧基、可具有取代基的低级烷硫基、可具有取代基的芳硫基、可具有取代基的低级烷基磺酰基、可具有取代基的芳基磺酰基、可具有取代基的低级烷基亚硫酰基、可具有取代基的芳基亚硫酰基、可具有取代基的低级烷基磺酰氧基、可具有取代基的芳基磺酰氧基、可具有取代基的氨磺酰基、可具有取代基的碳环式基团、可具有取代基的碳环氧基、可具有取代基的杂环式基团或可具有取代基的杂环氧基;各G可以不同)(以下由A-2表示);
11)环A为:
[化学式39]
(R9和R10各自独立表示氢、卤素、羟基、可具有取代基的低级烷基、氰基、硝基、可具有取代基的低级烷氧基、可具有取代基的酰基、可具有取代基的氨基、可具有取代基的氨基甲酰基、可具有取代基的氨基甲酰氧基、可具有取代基的低级烷基磺酰基、可具有取代基的芳基磺酰基、可具有取代基的低级烷基磺酰氧基、可具有取代基的芳基磺酰氧基、可具有取代基的碳环式基团、可具有取代基的碳环氧基、可具有取代基的杂环式基团或可具有取代基的杂环氧基;G与上述10同义)的化合物(以下该化合物由A-3表示);
12)环A为:
[化学式40]
(R9和R10与11)同义,G与上述10)同义)的化合物(以下该化合物由A-4表示);
13)环A、R9和R10为11)所定义的基团、G为可具有取代基的氨基的化合物(以下该化合物由A-5表示);
14)环A、R9和R10为11)定义的基团、G为可具有取代基的芳基羰基氨基或可具有取代基的杂环羰基氨基的化合物;
15)环A、R9和R10为-11)所定义的基团、G为可具有取代基的杂环羰基氨基的化合物(以下该化合物由A-6表示);
16)环A为11)所定义的基团、G为:
[化学式41]
(Q1、Q2和Q3各自独立表示单键、可具有取代基的低级亚烷基或可具有取代基的低级亚烯基;
Q4为可具有取代基的低级亚烷基或可具有取代基的低级亚烯基;
W1和W2各自独立表示O或S;
W3为O、S或NR12;
R12为氢、低级烷基、羟基低级烷基、低级烷氧基低级烷基、低级烷氧基羰基低级烷基、碳环低级烷基或酰基;
R14为氢或低级烷基;
环B为可具有取代基的碳环式基团或可具有取代基的杂环式基团;
Alk2为可具有取代基的低级烷基)、R9和R10与11)同义的化合物(以下该化合物由A-7表示);
17)环A、R9和R10为11)所定义的基团、G为16)所定义的基团、环B为可被选自卤素、羟基、可具有取代基的低级烷基、可具有取代基的低级烷氧基、可具有取代基的酰基、可具有取代基的氨基、氰基、可具有取代基的氨基甲酰基、可具有取代基的碳环式基团、可具有取代基的碳环氧基或可具有取代基的杂环式基团的一个以上基团分别取代的芳基或杂芳基、其他记号与16)同义的化合物(以下该化合物由A-8表示);
18)环A、R9和R10为11)所定义的基团、G为:
[化学式42]
(式中,各记号与16)同义)的化合物(以下该化合物由A-9表示);
19)环A为:
[化学式43]
G为16)所定义的基团,环B为可具有取代基的芳基或可具有取代基的杂芳基,R9和R10的其中之一为氢;且另一个为氢、卤素、可具有取代基的低级烷基、氰基、硝基、可具有取代基的低级烷氧基、可具有取代基的氨基、可具有取代基的氨基甲酰基、可具有取代基的低级烷基磺酰基、可具有取代基的碳环式基团或可具有取代基的杂环式基团的化合物(以下该化合物由A-10表示);
20)环A为:
[化学式44]
G为18)所定义的基团、其他记号与19)同义的化合物(以下该化合物由A-11表示);
21)环A为:
[化学式45]
G为16)所定义的基团、环B为分别可以具有取代基的苯基、5~6元杂芳基、苯并噻二唑基或苯并噻吩基、R9和R10与19)同义的化合物(以下该化合物由A-12表示);
22)环A为:
[化学式46]
G为18)所定义的基团、环B与21)同义、R9和R10与19)同义的化合物(以下该化合物由A-13表示);
23)环A为:
[化学式47]
(式中,R9为氢、卤素、可具有取代基的低级烷基、氰基、硝基、可具有取代基的低级烷氧基、可具有取代基的氨基、可具有取代基的氨基甲酰基、可具有取代基的低级烷基磺酰基、可具有取代基的碳环式基团或可具有取代基的杂环式基团;环B与21)同义;R12为氢或低级烷基)的化合物(以下该化合物由A-14表示);
24)R5为氢或C1~C3烷基的化合物(以下该化合物由R5-1表示);
25)R5为C1~C3烷基的化合物(以下该化合物由R5-2表示);
26)R5为甲基的化合物(以下该化合物由R5-3表示);
27)R3a和R3b各自独立表示氢、卤素、羟基、可具有取代基的低级烷基、可具有取代基的低级烷氧基或可具有取代基的芳基的化合物(以下该化合物由R3-1表示);
28)R3a为氢、卤素、羟基、可具有取代基的低级烷基、可具有取代基的低级烷氧基或可具有取代基的芳基,R3b为氢,当n为2时1个R3a为氢,当n为3时1~2个R2a为氢的化合物(以下该化合物由R3-2表示);
29)R3a和R3b全部为氢的化合物(以下该化合物由R3-3表示);
式(I’)中,n、m、R2a、R2b、环A、R5、R3a和R3b的组合(nm、R2、A、R5、R3)为以下组合的化合物。
(nm、R2、A、R5、R3)=
(nm-1,R2-1,A-1,R5-1,R3-1),(nm-1,R2-1,A-1,R5-1,R3-2),(nm-1,R2-1,A-1,R5-2,R3-1),(nm-1,R2-1,A-1,R5-2,R3-2),(nm-1,R2-1,A-1,R5-3,R3-1),(nm-1,R2-1,A-1,R5-3,R3-2),(nm-1,R2-1,A-2,R5-1,R3-1),(nm-1,R2-1,A-2,R5-1,R3-2),(nm-1,R2-1,A-2,R5-2,R3-1),(nm-1,R2-1,A-2,R5-2,R3-2),(nm-1,R2-1,A-2,R5-3,R3-1),(nm-1,R2-1,A-2,R5-3,R3-2),(nm-1,R2-1,A-3,R5-1,R3-1),(nm-1,R2-1,A-3,R5-1,R3-2),(nm-1,R2-1,A-3,R5-2,R3-1),(nm-1,R2-1,A-3,R5-2,R3-2),(nm-1,R2-1,A-3,R5-3,R3-1),(nm-1,R2-1,A-3,R5-3,R3-2),(nm-1,R2-1,A-4,R5-1,R3-1),(nm-1,R2-1,A-4,R5-1,R3-2),(nm-1,R2-1,A-4,R5-2,R3-1),(nm-1,R2-1,A-4,R5-2,R3-2),(nm-1,R2-1,A-4,R5-3,R3-1),(nm-1,R2-1,A-4,R5-3,R3-2),(nm-1,R2-1,A-5,R5-1,R3-1),(nm-1,R2-1,A-5,R5-1,R3-2),(nm-1,R2-1,A-5,R5-2,R3-1),(nm-1,R2-1,A-5,R5-2,R3-2),(nm-1,R2-1,A-5,R5-3,R3-1),(nm-1,R2-1,A-5,R5-3,R3-2),(nm-1,R2-1,A-6,R5-1,R3-1),(nm-1,R2-1,A-6,R5-1,R3-2),(nm-1,R2-1,A-6,R5-2,R3-1),(nm-1,R2-1,A-6,R5-2,R3-2),(nm-1,R2-1,A-6,R5-3,R3-1),(nm-1,R2-1,A-6,R5-3,R3-2),(nm-1,R2-1,A-7,R5-1,R3-1),(nm-1,R2-1,A-7,R5-1,R3-2),(nm-1,R2-1,A-7,R5-2,R3-1),(nm-1,R2-1,A-7,R5-2,R3-2),(nm-1,R2-1,A-7,R5-3,R3-1),(nm-1,R2-1,A-7,R5-3,R3-2),(nm-1,R2-1,A-8,R5-1,R3-1),(nm-1,R2-1,A-8,R5-1,R3-2),(nm-1,R2-1,A-8,R5-2,R3-1),(nm-1,R2-1,A-8,R5-2,R3-2),(nm-1,R2-1,A-8,R5-3,R3-1),(nm-1,R2-1,A-8,R5-3,R3-2),(nm-1,R2-1,A-9,R5-1,R3-1),(nm-1,R2-1,A-9,R5-1,R3-2),(nm-1,R2-1,A-9,R5-2,R3-1),(nm-1,R2-1,A-9,R5-2,R3-2),(nm-1,R2-1,A-9,R5-3,R3-1),(nm-1,R2-1,A-9,R5-3,R3-2),(nm-1,R2-1,A-10,R5-1,R3-1),(nm-1,R2-1,A-10,R5-1,R3-2),(nm-1,R2-1,A-10,R5-2,R3-1),(nm-1,R2-1,A-10,R5-2,R3-2),(nm-1,R2-1,A-10,R5-3,R3-1),(nm-1,R2-1,A-10,R5-3,R3-2),(nm-1,R2-1,A-11,R5-1,R3-1),(nm-1,R2-1,A-11,R5-1,R3-2),(nm-1,R2-1,A-11,R5-2,R3-1),(nm-1,R2-1,A-11,R5-2,R3-2),(nm-1,R2-1,A-11,R5-3,R3-1),(nm-1,R2-1,A-11,R5-3,R3-2),(nm-1,R2-1,A-12,R5-1,R3-1),(nm-1,R2-1,A-12,R5-1,R3-2),(nm-1,R2-1,A-12,R5-2,R3-1),(nm-1,R2-1,A-12,R5-2,R3-2),(nm-1,R2-1,A-12,R5-3,R3-1),(nm-1,R2-1,A-12,R5-3,R3-2),(nm-1,R2-1,A-13,R5-1,R3-1),(nm-1,R2-1,A-13,R5-1,R3-2),(nm-1,R2-1,A-13,R5-2,R3-1),(nm-1,R2-1,A-13,R5-2,R3-2),(nm-1,R2-1,A-13,R5-3,R3-1),(nm-1,R2-1,A-13,R5-3,R3-2),(nm-1,R2-1,A-14,R5-1,R3-1),(nm-1,R2-1,A-14,R5-1,R3-2),(nm-1,R2-1,A-14,R5-2,R3-1),(nm-1,R2-1,A-14,R5-2,R3-2),(nm-1,R2-1,A-14,R5-3,R3-1),(nm-1,R2-1,A-14,R5-3,R3-2),(nm-1,R2-2,A-1,R5-1,R3-1),(nm-1,R2-2,A-1,R5-1,R3-2),(nm-1,R2-2,A-1,R5-2,R3-1),(nm-1,R2-2,A-1,R5-2,R3-2),(nm-1,R2-2,A-1,R5-3,R3-1),(nm-1,R2-2,A-1,R5-3,R3-2),(nm-1,R2-2,A-2,R5-1,R3-1),(nm-1,R2-2,A-2,R5-1,R3-2),(nm-1,R2-2,A-2,R5-2,R3-1),(nm-1,R2-2,A-2,R5-2,R3-2),(nm-1,R2-2,A-2,R5-3,R3-1),(nm-1,R2-2,A-2,R5-3,R3-2),(nm-1,R2-2,A-3,R5-1,R3-1),(nm-1,R2-2,A-3,R5-1,R3-2),(nm-1,R2-2,A-3,R5-2,R3-1),(nm-1,R2-2,A-3,R5-2,R3-2),(nm-1,R2-2,A-3,R5-3,R3-1),(nm-1,R2-2,A-3,R5-3,R3-2),(nm-1,R2-2,A-4,R5-1,R3-1),(nm-1,R2-2,A-4,R5-1,R3-2),(nm-1,R2-2,A-4,R5-2,R3-1),(nm-1,R2-2,A-4,R5-2,R3-2),(nm-1,R2-2,A-4,R5-3,R3-1),(nm-1,R2-2,A-4,R5-3,R3-2),(nm-1,R2-2,A-5,R5-1,R3-1),(nm-1,R2-2,A-5,R5-1,R3-2),(nm-1,R2-2,A-5,R5-2,R3-1),(nm-1,R2-2,A-5,R5-2,R3-2),(nm-1,R2-2,A-5,R5-3,R3-1),(nm-1,R2-2,A-5,R5-3,R3-2),(nm-1,R2-2,A-6,R5-1,R3-1),(nm-1,R2-2,A-6,R5-1,R3-2),(nm-1,R2-2,A-6,R5-2,R3-1),(nm-1,R2-2,A-6,R5-2,R3-2),(nm-1,R2-2,A-6,R5-3,R3-1),(nm-1,R2-2,A-6,R5-3,R3-2),(nm-1,R2-2,A-7,R5-1,R3-1),(nm-1,R2-2,A-7,R5-1,R3-2),(nm-1,R2-2,A-7,R5-2,R3-1),(nm-1,R2-2,A-7,R5-2,R3-2),(nm-1,R2-2,A-7,R5-3,R3-1),(nm-1,R2-2,A-7,R5-3,R3-2),(nm-1,R2-2,A-8,R5-1,R3-1),(nm-1,R2-2,A-8,R5-1,R3-2),(nm-1,R2-2,A-8,R5-2,R3-1),(nm-1,R2-2,A-8,R5-2,R3-2),(nm-1,R2-2,A-8,R5-3,R3-1),(nm-1,R2-2,A-8,R5-3,R3-2),(nm-1,R2-2,A-9,R5-1,R3-1),(nm-1,R2-2,A-9,R5-1,R3-2),(nm-1,R2-2,A-9,R5-2,R3-1),(nm-1,R2-2,A-9,R5-2,R3-2),(nm-1,R2-2,A-9,R5-3,R3-1),(nm-1,R2-2,A-9,R5-3,R3-2),(nm-1,R2-2,A-10,R5-1,R3-1),(nm-1,R2-2,A-10,R5-1,R3-2),(nm-1,R2-2,A-10,R5-2,R3-1),(nm-1,R2-2,A-10,R5-2,R3-2),(nm-1,R2-2,A-10,R5-3,R3-1),(nm-1,R2-2,A-10,R5-3,R3-2),(nm-1,R2-2,A-11,R5-1,R3-1),(nm-1,R2-2,A-11,R5-1,R3-2),(nm-1,R2-2,A-11,R5-2,R3-1),(nm-1,R2-2,A-11,R5-2,R3-2),(nm-1,R2-2,A-11,R5-3,R3-1),(nm-1,R2-2,A-11,R5-3,R3-2),(nm-1,R2-2,A-12,R5-1,R3-1),(nm-1,R2-2,A-12,R5-1,R3-2),(nm-1,R2-2,A-12,R5-2,R3-1),(nm-1,R2-2,A-12,R5-2,R3-2),(nm-1,R2-2,A-12,R5-3,R3-1),(nm-1,R2-2,A-12,R5-3,R3-2),(nm-1,R2-2,A-13,R5-1,R3-1),(nm-1,R2-2,A-13,R5-1,R3-2),(nm-1,R2-2,A-13,R5-2,R3-1),(nm-1,R2-2,A-13,R5-2,R3-2),(nm-1,R2-2,A-13,R5-3,R3-1),(nm-1,R2-2,A-13,R5-3,R3-2),(nm-1,R2-2,A-14,R5-1,R3-1),(nm-1,R2-2,A-14,R5-1,R3-2),(nm-1,R2-2,A-14,R5-2,R3-1),(nm-1,R2-2,A-14,R5-2,R3-2),(nm-1,R2-2,A-14,R5-3,R3-1),(nm-1,R2-2,A-14,R5-3,R3-2),(nm-1,R2-3,A-1,R5-1,R3-1),(nm-1,R2-3,A-1,R5-1,R3-2),(nm-1,R2-3,A-1,R5-2,R3-1),(nm-1,R2-3,A-1,R5-2,R3-2),(nm-1,R2-3,A-1,R5-3,R3-1),(nm-1,R2-3,A-1,R5-3,R3-2),(nm-1,R2-3,A-2,R5-1,R3-1),(nm-1,R2-3,A-2,R5-1,R3-2),(nm-1,R2-3,A-2,R5-2,R3-1),(nm-1,R2-3,A-2,R5-2,R3-2),(nm-1,R2-3,A-2,R5-3,R3-1),(nm-1,R2-3,A-2,R5-3,R3-2),(nm-1,R2-3,A-3,R5-1,R3-1),(nm-1,R2-3,A-3,R5-1,R3-2),(nm-1,R2-3,A-3,R5-2,R3-1),(nm-1,R2-3,A-3,R5-2,R3-2),(nm-1,R2-3,A-3,R5-3,R3-1),(nm-1,R2-3,A-3,R5-3,R3-2),(nm-1,R2-3,A-4,R5-1,R3-1),(nm-1,R2-3,A-4,R5-1,R3-2),(nm-1,R2-3,A-4,R5-2,R3-1),(nm-1,R2-3,A-4,R5-2,R3-2),(nm-1,R2-3,A-4,R5-3,R3-1),(nm-1,R2-3,A-4,R5-3,R3-2),(nm-1,R2-3,A-5,R5-1,R3-1),(nm-1,R2-3,A-5,R5-1,R3-2),(nm-1,R2-3,A-5,R5-2,R3-1),(nm-1,R2-3,A-5,R5-2,R3-2),(nm-1,R2-3,A-5,R5-3,R3-1),(nm-1,R2-3,A-5,R5-3,R3-2),(nm-1,R2-3,A-6,R5-1,R3-1),(nm-1,R2-3,A-6,R5-1,R3-2),(nm-1,R2-3,A-6,R5-2,R3-1),(nm-1,R2-3,A-6,R5-2,R3-2),(nm-1,R2-3,A-6,R5-3,R3-1),(nm-1,R2-3,A-6,R5-3,R3-2),(nm-1,R2-3,A-7,R5-1,R3-1),(nm-1,R2-3,A-7,R5-1,R3-2),(nm-1,R2-3,A-7,R5-2,R3-1),(nm-1,R2-3,A-7,R5-2,R3-2),(nm-1,R2-3,A-7,R5-3,R3-1),(nm-1,R2-3,A-7,R5-3,R3-2),(nm-1,R2-3,A-8,R5-1,R3-1),(nm-1,R2-3,A-8,R5-1,R3-2),(nm-1,R2-3,A-8,R5-2,R3-1),(nm-1,R2-3,A-8,R5-2,R3-2),(nm-1,R2-3,A-8,R5-3,R3-1),(nm-1,R2-3,A-8,R5-3,R3-2),(nm-1,R2-3,A-9,R5-1,R3-1),(nm-1,R2-3,A-9,R5-1,R3-2),(nm-1,R2-3,A-9,R5-2,R3-1),(nm-1,R2-3,A-9,R5-2,R3-2),(nm-1,R2-3,A-9,R5-3,R3-1),(nm-1,R2-3,A-9,R5-3,R3-2),(nm-1,R2-3,A-10,R5-1,R3-1),(nm-1,R2-3,A-10,R5-1,R3-2),(nm-1,R2-3,A-10,R5-2,R3-1),(nm-1,R2-3,A-10,R5-2,R3-2),(nm-1,R2-3,A-10,R5-3,R3-1),(nm-1,R2-3,A-10,R5-3,R3-2),(nm-1,R2-3,A-11,R5-1,R3-1),(nm-1,R2-3,A-11,R5-1,R3-2),(nm-1,R2-3,A-11,R5-2,R3-1),(nm-1,R2-3,A-11,R5-2,R3-2),(nm-1,R2-3,A-11,R5-3,R3-1),(nm-1,R2-3,A-11,R5-3,R3-2),(nm-1,R2-3,A-12,R5-1,R3-1),(nm-1,R2-3,A-12,R5-1,R3-2),(nm-1,R2-3,A-12,R5-2,R3-1),(nm-1,R2-3,A-12,R5-2,R3-2),(nm-1,R2-3,A-12,R5-3,R3-1),(nm-1,R2-3,A-12,R5-3,R3-2),(nm-1,R2-3,A-13,R5-1,R3-1),(nm-1,R2-3,A-13,R5-1,R3-2),(nm-1,R2-3,A-13,R5-2,R3-1),(nm-1,R2-3,A-13,R5-2,R3-2),(nm-1,R2-3,A-13,R5-3,R3-1),(nm-1,R2-3,A-13,R5-3,R3-2),(nm-1,R2-3,A-14,R5-1,R3-1),(nm-1,R2-3,A-14,R5-1,R3-2),(nm-1,R2-3,A-14,R5-2,R3-1),(nm-1,R2-3,A-14,R5-2,R3-2),(nm-1,R2-3,A-14,R5-3,R3-1),(nm-1,R2-3,A-14,R5-3,R3-2),(nm-1,R2-4,A-1,R5-1,R3-1),(nm-1,R2-4,A-1,R5-1,R3-2),(nm-1,R2-4,A-1,R5-2,R3-1),(nm-1,R2-4,A-1,R5-2,R3-2),(nm-1,R2-4,A-1,R5-3,R3-1),(nm-1,R2-4,A-1,R5-3,R3-2),(nm-1,R2-4,A-2,R5-1,R3-1),(nm-1,R2-4,A-2,R5-1,R3-2),(nm-1,R2-4,A-2,R5-2,R3-1),(nm-1,R2-4,A-2,R5-2,R3-2),(nm-1,R2-4,A-2,R5-3,R3-1),(nm-1,R2-4,A-2,R5-3,R3-2),(nm-1,R2-4,A-3,R5-1,R3-1),(nm-1,R2-4,A-3,R5-1,R3-2),(nm-1,R2-4,A-3,R5-2,R3-1),(nm-1,R2-4,A-3,R5-2,R3-2),(nm-1,R2-4,A-3,R5-3,R3-1),(nm-1,R2-4,A-3,R5-3,R3-2),(nm-1,R2-4,A-4,R5-1,R3-1),(nm-1,R2-4,A-4,R5-1,R3-2),(nm-1,R2-4,A-4,R5-2,R3-1),(nm-1,R2-4,A-4,R5-2,R3-2),(nm-1,R2-4,A-4,R5-3,R3-1),(nm-1,R2-4,A-4,R5-3,R3-2),(nm-1,R2-4,A-5,R5-1,R3-1),(nm-1,R2-4,A-5,R5-1,R3-2),(nm-1,R2-4,A-5,R5-2,R3-1),(nm-1,R2-4,A-5,R5-2,R3-2),(nm-1,R2-4,A-5,R5-3,R3-1),(nm-1,R2-4,A-5,R5-3,R3-2),(nm-1,R2-4,A-6,R5-1,R3-1),(nm-1,R2-4,A-6,R5-1,R3-2),(nm-1,R2-4,A-6,R5-2,R3-1),(nm-1,R2-4,A-6,R5-2,R3-2),(nm-1,R2-4,A-6,R5-3,R3-1),(nm-1,R2-4,A-6,R5-3,R3-2),(nm-1,R2-4,A-7,R5-1,R3-1),(nm-1,R2-4,A-7,R5-1,R3-2),(nm-1,R2-4,A-7,R5-2,R3-1),(nm-1,R2-4,A-7,R5-2,R3-2),(nm-1,R2-4,A-7,R5-3,R3-1),(nm-1,R2-4,A-7,R5-3,R3-2),(nm-1,R2-4,A-8,R5-1,R3-1),(nm-1,R2-4,A-8,R5-1,R3-2),(nm-1,R2-4,A-8,R5-2,R3-1),(nm-1,R2-4,A-8,R5-2,R3-2),(nm-1,R2-4,A-8,R5-3,R3-1),(nm-1,R2-4,A-8,R5-3,R3-2),(nm-1,R2-4,A-9,R5-1,R3-1),(nm-1,R2-4,A-9,R5-1,R3-2),(nm-1,R2-4,A-9,R5-2,R3-1),(nm-1,R2-4,A-9,R5-2,R3-2),(nm-1,R2-4,A-9,R5-3,R3-1),(nm-1,R2-4,A-9,R5-3,R3-2),(nm-1,R2-4,A-10,R5-1,R3-1),(nm-1,R2-4,A-10,R5-1,R3-2),(nm-1,R2-4,A-10,R5-2,R3-1),(nm-1,R2-4,A-10,R5-2,R3-2),(nm-1,R2-4,A-10,R5-3,R3-1),(nm-1,R2-4,A-10,R5-3,R3-2),(nm-1,R2-4,A-11,R5-1,R3-1),(nm-1,R2-4,A-11,R5-1,R3-2),(nm-1,R2-4,A-11,R5-2,R3-1),(nm-1,R2-4,A-11,R5-2,R3-2),(nm-1,R2-4,A-11,R5-3,R3-1),(nm-1,R2-4,A-11,R5-3,R3-2),(nm-1,R2-4,A-12,R5-1,R3-1),(nm-1,R2-4,A-12,R5-1,R3-2),(nm-1,R2-4,A-12,R5-2,R3-1),(nm-1,R2-4,A-12,R5-2,R3-2),(nm-1,R2-4,A-12,R5-3,R3-1),(nm-1,R2-4,A-12,R5-3,R3-2),(nm-1,R2-4,A-13,R5-1,R3-1),(nm-1,R2-4,A-13,R5-1,R3-2),(nm-1,R2-4,A-13,R5-2,R3-1),(nm-1,R2-4,A-13,R5-2,R3-2),(nm-1,R2-4,A-13,R5-3,R3-1),(nm-1,R2-4,A-13,R5-3,R3-2),(nm-1,R2-4,A-14,R5-1,R3-1),(nm-1,R2-4,A-14,R5-1,R3-2),(nm-1,R2-4,A-14,R5-2,R3-1),(nm-1,R2-4,A-14,R5-2,R3-2),(nm-1,R2-4,A-14,R5-3,R3-1),(nm-1,R2-4,A-14,R5-3,R3-2),(nm-2,R2-1,A-1,R5-1,R3-1),(nm-2,R2-1,A-1,R5-1,R3-2),(nm-2,R2-1,A-1,R5-2,R3-1),(nm-2,R2-1,A-1,R5-2,R3-2),(nm-2,R2-1,A-1,R5-3,R3-1),(nm-2,R2-1,A-1,R5-3,R3-2),(nm-2,R2-1,A-2,R5-1,R3-1),(nm-2,R2-1,A-2,R5-1,R3-2),(nm-2,R2-1,A-2,R5-2,R3-1),(nm-2,R2-1,A-2,R5-2,R3-2),(nm-2,R2-1,A-2,R5-3,R3-1),(nm-2,R2-1,A-2,R5-3,R3-2),(nm-2,R2-1,A-3,R5-1,R3-1),(nm-2,R2-1,A-3,R5-1,R3-2),(nm-2,R2-1,A-3,R5-2,R3-1),(nm-2,R2-1,A-3,R5-2,R3-2),(nm-2,R2-1,A-3,R5-3,R3-1),(nm-2,R2-1,A-3,R5-3,R3-2),(nm-2,R2-1,A-4,R5-1,R3-1),(nm-2,R2-1,A-4,R5-1,R3-2),(nm-2,R2-1,A-4,R5-2,R3-1),(nm-2,R2-1,A-4,R5-2,R3-2),(nm-2,R2-1,A-4,R5-3,R3-1),(nm-2,R2-1,A-4,R5-3,R3-2),(nm-2,R2-1,A-5,R5-1,R3-1),(nm-2,R2-1,A-5,R5-1,R3-2),(nm-2,R2-1,A-5,R5-2,R3-1),(nm-2,R2-1,A-5,R5-2,R3-2),(nm-2,R2-1,A-5,R5-3,R3-1),(nm-2,R2-1,A-5,R5-3,R3-2),(nm-2,R2-1,A-6,R5-1,R3-1),(nm-2,R2-1,A-6,R5-1,R3-2),(nm-2,R2-1,A-6,R5-2,R3-1),(nm-2,R2-1,A-6,R5-2,R3-2),(nm-2,R2-1,A-6,R5-3,R3-1),(nm-2,R2-1,A-6,R5-3,R3-2),(nm-2,R2-1,A-7,R5-1,R3-1),(nm-2,R2-1,A-7,R5-1,R3-2),(nm-2,R2-1,A-7,R5-2,R3-1),(nm-2,R2-1,A-7,R5-2,R3-2),(nm-2,R2-1,A-7,R5-3,R3-1),(nm-2,R2-1,A-7,R5-3,R3-2),(nm-2,R2-1,A-8,R5-1,R3-1),(nm-2,R2-1,A-8,R5-1,R3-2),(nm-2,R2-1,A-8,R5-2,R3-1),(nm-2,R2-1,A-8,R5-2,R3-2),(nm-2,R2-1,A-8,R5-3,R3-1),(nm-2,R2-1,A-8,R5-3,R3-2),(nm-2,R2-1,A-9,R5-1,R3-1),(nm-2,R2-1,A-9,R5-1,R3-2),(nm-2,R2-1,A-9,R5-2,R3-1),(nm-2,R2-1,A-9,R5-2,R3-2),(nm-2,R2-1,A-9,R5-3,R3-1),(nm-2,R2-1,A-9,R5-3,R3-2),(nm-2,R2-1,A-10,R5-1,R3-1),(nm-2,R2-1,A-10,R5-1,R3-2),(nm-2,R2-1,A-10,R5-2,R3-1),(nm-2,R2-1,A-10,R5-2,R3-2),(nm-2,R2-1,A-10,R5-3,R3-1),(nm-2,R2-1,A-10,R5-3,R3-2),(nm-2,R2-1,A-11,R5-1,R3-1),(nm-2,R2-1,A-11,R5-1,R3-2),(nm-2,R2-1,A-11,R5-2,R3-1),(nm-2,R2-1,A-11,R5-2,R3-2),(nm-2,R2-1,A-11,R5-3,R3-1),(nm-2,R2-1,A-11,R5-3,R3-2),(nm-2,R2-1,A-12,R5-1,R3-1),(nm-2,R2-1,A-12,R5-1,R3-2),(nm-2,R2-1,A-12,R5-2,R3-1),(nm-2,R2-1,A-12,R5-2,R3-2),(nm-2,R2-1,A-12,R5-3,R3-1),(nm-2,R2-1,A-12,R5-3,R3-2),(nm-2,R2-1,A-13,R5-1,R3-1),(nm-2,R2-1,A-13,R5-1,R3-2),(nm-2,R2-1,A-13,R5-2,R3-1),(nm-2,R2-1,A-13,R5-2,R3-2),(nm-2,R2-1,A-13,R5-3,R3-1),(nm-2,R2-1,A-13,R5-3,R3-2),(nm-2,R2-1,A-14,R5-1,R3-1),(nm-2,R2-1,A-14,R5-1,R3-2),(nm-2,R2-1,A-14,R5-2,R3-1),(nm-2,R2-1,A-14,R5-2,R3-2),(nm-2,R2-1,A-14,R5-3,R3-1),(nm-2,R2-1,A-14,R5-3,R3-2),(nm-2,R2-2,A-1,R5-1,R3-1),(nm-2,R2-2,A-1,R5-1,R3-2),(nm-2,R2-2,A-1,R5-2,R3-1),(nm-2,R2-2,A-1,R5-2,R3-2),(nm-2,R2-2,A-1,R5-3,R3-1),(nm-2,R2-2,A-1,R5-3,R3-2),(nm-2,R2-2,A-2,R5-1,R3-1),(nm-2,R2-2,A-2,R5-1,R3-2),(nm-2,R2-2,A-2,R5-2,R3-1),(nm-2,R2-2,A-2,R5-2,R3-2),(nm-2,R2-2,A-2,R5-3,R3-1),(nm-2,R2-2,A-2,R5-3,R3-2),(nm-2,R2-2,A-3,R5-1,R3-1),(nm-2,R2-2,A-3,R5-1,R3-2),(nm-2,R2-2,A-3,R5-2,R3-1),(nm-2,R2-2,A-3,R5-2,R3-2),(nm-2,R2-2,A-3,R5-3,R3-1),(nm-2,R2-2,A-3,R5-3,R3-2),(nm-2,R2-2,A-4,R5-1,R3-1),(nm-2,R2-2,A-4,R5-1,R3-2),(nm-2,R2-2,A-4,R5-2,R3-1),(nm-2,R2-2,A-4,R5-2,R3-2),(nm-2,R2-2,A-4,R5-3,R3-1),(nm-2,R2-2,A-4,R5-3,R3-2),(nm-2,R2-2,A-5,R5-1,R3-1),(nm-2,R2-2,A-5,R5-1,R3-2),(nm-2,R2-2,A-5,R5-2,R3-1),(nm-2,R2-2,A-5,R5-2,R3-2),(nm-2,R2-2,A-5,R5-3,R3-1),(nm-2,R2-2,A-5,R5-3,R3-2),(nm-2,R2-2,A-6,R5-1,R3-1),(nm-2,R2-2,A-6,R5-1,R3-2),(nm-2,R2-2,A-6,R5-2,R3-1),(nm-2,R2-2,A-6,R5-2,R3-2),(nm-2,R2-2,A-6,R5-3,R3-1),(nm-2,R2-2,A-6,R5-3,R3-2),(nm-2,R2-2,A-7,R5-1,R3-1),(nm-2,R2-2,A-7,R5-1,R3-2),(nm-2,R2-2,A-7,R5-2,R3-1),(nm-2,R2-2,A-7,R5-2,R3-2),(nm-2,R2-2,A-7,R5-3,R3-1),(nm-2,R2-2,A-7,R5-3,R3-2),(nm-2,R2-2,A-8,R5-1,R3-1),(nm-2,R2-2,A-8,R5-1,R3-2),(nm-2,R2-2,A-8,R5-2,R3-1),(nm-2,R2-2,A-8,R5-2,R3-2),(nm-2,R2-2,A-8,R5-3,R3-1),(nm-2,R2-2,A-8,R5-3,R3-2),(nm-2,R2-2,A-9,R5-1,R3-1),(nm-2,R2-2,A-9,R5-1,R3-2),(nm-2,R2-2,A-9,R5-2,R3-1),(nm-2,R2-2,A-9,R5-2,R3-2),(nm-2,R2-2,A-9,R5-3,R3-1),(nm-2,R2-2,A-9,R5-3,R3-2),(nm-2,R2-2,A-10,R5-1,R3-1),(nm-2,R2-2,A-10,R5-1,R3-2),(nm-2,R2-2,A-10,R5-2,R3-1),(nm-2,R2-2,A-10,R5-2,R3-2),(nm-2,R2-2,A-10,R5-3,R3-1),(nm-2,R2-2,A-10,R5-3,R3-2),(nm-2,R2-2,A-11,R5-1,R3-1),(nm-2,R2-2,A-11,R5-1,R3-2),(nm-2,R2-2,A-11,R5-2,R3-1),(nm-2,R2-2,A-11,R5-2,R3-2),(nm-2,R2-2,A-11,R5-3,R3-1),(nm-2,R2-2,A-11,R5-3,R3-2),(nm-2,R2-2,A-12,R5-1,R3-1),(nm-2,R2-2,A-12,R5-1,R3-2),(nm-2,R2-2,A-12,R5-2,R3-1),(nm-2,R2-2,A-12,R5-2,R3-2),(nm-2,R2-2,A-12,R5-3,R3-1),(nm-2,R2-2,A-12,R5-3,R3-2),(nm-2,R2-2,A-13,R5-1,R3-1),(nm-2,R2-2,A-13,R5-1,R3-2),(nm-2,R2-2,A-13,R5-2,R3-1),(nm-2,R2-2,A-13,R5-2,R3-2),(nm-2,R2-2,A-13,R5-3,R3-1),(nm-2,R2-2,A-13,R5-3,R3-2),(nm-2,R2-2,A-14,R5-1,R3-1),(nm-2,R2-2,A-14,R5-1,R3-2),(nm-2,R2-2,A-14,R5-2,R3-1),(nm-2,R2-2,A-14,R5-2,R3-2),(nm-2,R2-2,A-14,R5-3,R3-1),(nm-2,R2-2,A-14,R5-3,R3-2),(nm-2,R2-3,A-1,R5-1,R3-1),(nm-2,R2-3,A-1,R5-1,R3-2),(nm-2,R2-3,A-1,R5-2,R3-1),(nm-2,R2-3,A-1,R5-2,R3-2),(nm-2,R2-3,A-1,R5-3,R3-1),(nm-2,R2-3,A-1,R5-3,R3-2),(nm-2,R2-3,A-2,R5-1,R3-1),(nm-2,R2-3,A-2,R5-1,R3-2),(nm-2,R2-3,A-2,R5-2,R3-1),(nm-2,R2-3,A-2,R5-2,R3-2),(nm-2,R2-3,A-2,R5-3,R3-1),(nm-2,R2-3,A-2,R5-3,R3-2),(nm-2,R2-3,A-3,R5-1,R3-1),(nm-2,R2-3,A-3,R5-1,R3-2),(nm-2,R2-3,A-3,R5-2,R3-1),(nm-2,R2-3,A-3,R5-2,R3-2),(nm-2,R2-3,A-3,R5-3,R3-1),(nm-2,R2-3,A-3,R5-3,R3-2),(nm-2,R2-3,A-4,R5-1,R3-1),(nm-2,R2-3,A-4,R5-1,R3-2),(nm-2,R2-3,A-4,R5-2,R3-1),(nm-2,R2-3,A-4,R5-2,R3-2),(nm-2,R2-3,A-4,R5-3,R3-1),(nm-2,R2-3,A-4,R5-3,R3-2),(nm-2,R2-3,A-5,R5-1,R3-1),(nm-2,R2-3,A-5,R5-1,R3-2),(nm-2,R2-3,A-5,R5-2,R3-1),(nm-2,R2-3,A-5,R5-2,R3-2),(nm-2,R2-3,A-5,R5-3,R3-1),(nm-2,R2-3,A-5,R5-3,R3-2),(nm-2,R2-3,A-6,R5-1,R3-1),(nm-2,R2-3,A-6,R5-1,R3-2),(nm-2,R2-3,A-6,R5-2,R3-1),(nm-2,R2-3,A-6,R5-2,R3-2),(nm-2,R2-3,A-6,R5-3,R3-1),(nm-2,R2-3,A-6,R5-3,R3-2),(nm-2,R2-3,A-7,R5-1,R3-1),(nm-2,R2-3,A-7,R5-1,R3-2),(nm-2,R2-3,A-7,R5-2,R3-1),(nm-2,R2-3,A-7,R5-2,R3-2),(nm-2,R2-3,A-7,R5-3,R3-1),(nm-2,R2-3,A-7,R5-3,R3-2),(nm-2,R2-3,A-8,R5-1,R3-1),(nm-2,R2-3,A-8,R5-1,R3-2),(nm-2,R2-3,A-8,R5-2,R3-1),(nm-2,R2-3,A-8,R5-2,R3-2),(nm-2,R2-3,A-8,R5-3,R3-1),(nm-2,R2-3,A-8,R5-3,R3-2),(nm-2,R2-3,A-9,R5-1,R3-1),(nm-2,R2-3,A-9,R5-1,R3-2),(nm-2,R2-3,A-9,R5-2,R3-1),(nm-2,R2-3,A-9,R5-2,R3-2),(nm-2,R2-3,A-9,R5-3,R3-1),(nm-2,R2-3,A-9,R5-3,R3-2),(nm-2,R2-3,A-10,R5-1,R3-1),(nm-2,R2-3,A-10,R5-1,R3-2),(nm-2,R2-3,A-10,R5-2,R3-1),(nm-2,R2-3,A-10,R5-2,R3-2),(nm-2,R2-3,A-10,R5-3,R3-1),(nm-2,R2-3,A-10,R5-3,R3-2),(nm-2,R2-3,A-11,R5-1,R3-1),(nm-2,R2-3,A-11,R5-1,R3-2),(nm-2,R2-3,A-11,R5-2,R3-1),(nm-2,R2-3,A-11,R5-2,R3-2),(nm-2,R2-3,A-11,R5-3,R3-1),(nm-2,R2-3,A-11,R5-3,R3-2),(nm-2,R2-3,A-12,R5-1,R3-1),(nm-2,R2-3,A-12,R5-1,R3-2),(nm-2,R2-3,A-12,R5-2,R3-1),(nm-2,R2-3,A-12,R5-2,R3-2),(nm-2,R2-3,A-12,R5-3,R3-1),(nm-2,R2-3,A-12,R5-3,R3-2),(nm-2,R2-3,A-13,R5-1,R3-1),(nm-2,R2-3,A-13,R5-1,R3-2),(nm-2,R2-3,A-13,R5-2,R3-1),(nm-2,R2-3,A-13,R5-2,R3-2),(nm-2,R2-3,A-13,R5-3,R3-1),(nm-2,R2-3,A-13,R5-3,R3-2),(nm-2,R2-3,A-14,R5-1,R3-1),(nm-2,R2-3,A-14,R5-1,R3-2),(nm-2,R2-3,A-14,R5-2,R3-1),(nm-2,R2-3,A-14,R5-2,R3-2),(nm-2,R2-3,A-14,R5-3,R3-1),(nm-2,R2-3,A-14,R5-3,R3-2),(nm-2,R2-4,A-1,R5-1,R3-1),(nm-2,R2-4,A-1,R5-1,R3-2),(nm-2,R2-4,A-1,R5-2,R3-1),(nm-2,R2-4,A-1,R5-2,R3-2),(nm-2,R2-4,A-1,R5-3,R3-1),(nm-2,R2-4,A-1,R5-3,R3-2),(nm-2,R2-4,A-2,R5-1,R3-1),(nm-2,R2-4,A-2,R5-1,R3-2),(nm-2,R2-4,A-2,R5-2,R3-1),(nm-2,R2-4,A-2,R5-2,R3-2),(nm-2,R2-4,A-2,R5-3,R3-1),(nm-2,R2-4,A-2,R5-3,R3-2),(nm-2,R2-4,A-3,R5-1,R3-1),(nm-2,R2-4,A-3,R5-1,R3-2),(nm-2,R2-4,A-3,R5-2,R3-1),(nm-2,R2-4,A-3,R5-2,R3-2),(nm-2,R2-4,A-3,R5-3,R3-1),(nm-2,R2-4,A-3,R5-3,R3-2),(nm-2,R2-4,A-4,R5-1,R3-1),(nm-2,R2-4,A-4,R5-1,R3-2),(nm-2,R2-4,A-4,R5-2,R3-1),(nm-2,R2-4,A-4,R5-2,R3-2),(nm-2,R2-4,A-4,R5-3,R3-1),(nm-2,R2-4,A-4,R5-3,R3-2),(nm-2,R2-4,A-5,R5-1,R3-1),(nm-2,R2-4,A-5,R5-1,R3-2),(nm-2,R2-4,A-5,R5-2,R3-1),(nm-2,R2-4,A-5,R5-2,R3-2),(nm-2,R2-4,A-5,R5-3,R3-1),(nm-2,R2-4,A-5,R5-3,R3-2),(nm-2,R2-4,A-6,R5-1,R3-1),(nm-2,R2-4,A-6,R5-1,R3-2),(nm-2,R2-4,A-6,R5-2,R3-1),(nm-2,R2-4,A-6,R5-2,R3-2),(nm-2,R2-4,A-6,R5-3,R3-1),(nm-2,R2-4,A-6,R5-3,R3-2),(nm-2,R2-4,A-7,R5-1,R3-1),(nm-2,R2-4,A-7,R5-1,R3-2),(nm-2,R2-4,A-7,R5-2,R3-1),(nm-2,R2-4,A-7,R5-2,R3-2),(nm-2,R2-4,A-7,R5-3,R3-1),(nm-2,R2-4,A-7,R5-3,R3-2),(nm-2,R2-4,A-8,R5-1,R3-1),(nm-2,R2-4,A-8,R5-1,R3-2),(nm-2,R2-4,A-8,R5-2,R3-1),(nm-2,R2-4,A-8,R5-2,R3-2),(nm-2,R2-4,A-8,R5-3,R3-1),(nm-2,R2-4,A-8,R5-3,R3-2),(nm-2,R2-4,A-9,R5-1,R3-1),(nm-2,R2-4,A-9,R5-1,R3-2),(nm-2,R2-4,A-9,R5-2,R3-1),(nm-2,R2-4,A-9,R5-2,R3-2),(nm-2,R2-4,A-9,R5-3,R3-1),(nm-2,R2-4,A-9,R5-3,R3-2),(nm-2,R2-4,A-10,R5-1,R3-1),(nm-2,R2-4,A-10,R5-1,R3-2),(nm-2,R2-4,A-10,R5-2,R3-1),(nm-2,R2-4,A-10,R5-2,R3-2),(nm-2,R2-4,A-10,R5-3,R3-1),(nm-2,R2-4,A-10,R5-3,R3-2),(nm-2,R2-4,A-11,R5-1,R3-1),(nm-2,R2-4,A-11,R5-1,R3-2),(nm-2,R2-4,A-11,R5-2,R3-1),(nm-2,R2-4,A-11,R5-2,R3-2),(nm-2,R2-4,A-11,R5-3,R3-1),(nm-2,R2-4,A-11,R5-3,R3-2),(nm-2,R2-4,A-12,R5-1,R3-1),(nm-2,R2-4,A-12,R5-1,R3-2),(nm-2,R2-4,A-12,R5-2,R3-1),(nm-2,R2-4,A-12,R5-2,R3-2),(nm-2,R2-4,A-12,R5-3,R3-1),(nm-2,R2-4,A-12,R5-3,R3-2),(nm-2,R2-4,A-13,R5-1,R3-1),(nm-2,R2-4,A-13,R5-1,R3-2),(nm-2,R2-4,A-13,R5-2,R3-1),(nm-2,R2-4,A-13,R5-2,R3-2),(nm-2,R2-4,A-13,R5-3,R3-1),(nm-2,R2-4,A-13,R5-3,R3-2),(nm-2,R2-4,A-14,R5-1,R3-1),(nm-2,R2-4,A-14,R5-1,R3-2),(nm-2,R2-4,A-14,R5-2,R3-1),(nm-2,R2-4,A-14,R5-2,R3-2),(nm-2,R2-4,A-14,R5-3,R3-1),(nm-2,R2-4,A-14,R5-3,R3-2),(nm-3,R2-1,A-1,R5-1,R3-1),(nm-3,R2-1,A-1,R5-1,R3-2),(nm-3,R2-1,A-1,R5-2,R3-1),(nm-3,R2-1,A-1,R5-2,R3-2),(nm-3,R2-1,A-1,R5-3,R3-1),(nm-3,R2-1,A-1,R5-3,R3-2),(nm-3,R2-1,A-2,R5-1,R3-1),(nm-3,R2-1,A-2,R5-1,R3-2),(nm-3,R2-1,A-2,R5-2,R3-1),(nm-3,R2-1,A-2,R5-2,R3-2),(nm-3,R2-1,A-2,R5-3,R3-1),(nm-3,R2-1,A-2,R5-3,R3-2),(nm-3,R2-1,A-3,R5-1,R3-1),(nm-3,R2-1,A-3,R5-1,R3-2),(nm-3,R2-1,A-3,R5-2,R3-1),(nm-3,R2-1,A-3,R5-2,R3-2),(nm-3,R2-1,A-3,R5-3,R3-1),(nm-3,R2-1,A-3,R5-3,R3-2),(nm-3,R2-1,A-4,R5-1,R3-1),(nm-3,R2-1,A-4,R5-1,R3-2),(nm-3,R2-1,A-4,R5-2,R3-1),(nm-3,R2-1,A-4,R5-2,R3-2),(nm-3,R2-1,A-4,R5-3,R3-1),(nm-3,R2-1,A-4,R5-3,R3-2),(nm-3,R2-1,A-5,R5-1,R3-1),(nm-3,R2-1,A-5,R5-1,R3-2),(nm-3,R2-1,A-5,R5-2,R3-1),(nm-3,R2-1,A-5,R5-2,R3-2),(nm-3,R2-1,A-5,R5-3,R3-1),(nm-3,R2-1,A-5,R5-3,R3-2),(nm-3,R2-1,A-6,R5-1,R3-1),(nm-3,R2-1,A-6,R5-1,R3-2),(nm-3,R2-1,A-6,R5-2,R3-1),(nm-3,R2-1,A-6,R5-2,R3-2),(nm-3,R2-1,A-6,R5-3,R3-1),(nm-3,R2-1,A-6,R5-3,R3-2),(nm-3,R2-1,A-7,R5-1,R3-1),(nm-3,R2-1,A-7,R5-1,R3-2),(nm-3,R2-1,A-7,R5-2,R3-1),(nm-3,R2-1,A-7,R5-2,R3-2),(nm-3,R2-1,A-7,R5-3,R3-1),(nm-3,R2-1,A-7,R5-3,R3-2),(nm-3,R2-1,A-8,R5-1,R3-1),(nm-3,R2-1,A-8,R5-1,R3-2),(nm-3,R2-1,A-8,R5-2,R3-1),(nm-3,R2-1,A-8,R5-2,R3-2),(nm-3,R2-1,A-8,R5-3,R3-1),(nm-3,R2-1,A-8,R5-3,R3-2),(nm-3,R2-1,A-9,R5-1,R3-1),(nm-3,R2-1,A-9,R5-1,R3-2),(nm-3,R2-1,A-9,R5-2,R3-1),(nm-3,R2-1,A-9,R5-2,R3-2),(nm-3,R2-1,A-9,R5-3,R3-1),(nm-3,R2-1,A-9,R5-3,R3-2),(nm-3,R2-1,A-10,R5-1,R3-1),(nm-3,R2-1,A-10,R5-1,R3-2),(nm-3,R2-1,A-10,R5-2,R3-1),(nm-3,R2-1,A-10,R5-2,R3-2),(nm-3,R2-1,A-10,R5-3,R3-1),(nm-3,R2-1,A-10,R5-3,R3-2),(nm-3,R2-1,A-11,R5-1,R3-1),(nm-3,R2-1,A-11,R5-1,R3-2),(nm-3,R2-1,A-11,R5-2,R3-1),(nm-3,R2-1,A-11,R5-2,R3-2),(nm-3,R2-1,A-11,R5-3,R3-1),(nm-3,R2-1,A-11,R5-3,R3-2),(nm-3,R2-1,A-12,R5-1,R3-1),(nm-3,R2-1,A-12,R5-1,R3-2),(nm-3,R2-1,A-12,R5-2,R3-1),(nm-3,R2-1,A-12,R5-2,R3-2),(nm-3,R2-1,A-12,R5-3,R3-1),(nm-3,R2-1,A-12,R5-3,R3-2),(nm-3,R2-1,A-13,R5-1,R3-1),(nm-3,R2-1,A-13,R5-1,R3-2),(nm-3,R2-1,A-13,R5-2,R3-1),(nm-3,R2-1,A-13,R5-2,R3-2),(nm-3,R2-1,A-13,R5-3,R3-1),(nm-3,R2-1,A-13,R5-3,R3-2),(nm-3,R2-1,A-14,R5-1,R3-1),(nm-3,R2-1,A-14,R5-1,R3-2),(nm-3,R2-1,A-14,R5-2,R3-1),(nm-3,R2-1,A-14,R5-2,R3-2),(nm-3,R2-1,A-14,R5-3,R3-1),(nm-3,R2-1,A-14,R5-3,R3-2),(nm-3,R2-2,A-1,R5-1,R3-1),(nm-3,R2-2,A-1,R5-1,R3-2),(nm-3,R2-2,A-1,R5-2,R3-1),(nm-3,R2-2,A-1,R5-2,R3-2),(nm-3,R2-2,A-1,R5-3,R3-1),(nm-3,R2-2,A-1,R5-3,R3-2),(nm-3,R2-2,A-2,R5-1,R3-1),(nm-3,R2-2,A-2,R5-1,R3-2),(nm-3,R2-2,A-2,R5-2,R3-1),(nm-3,R2-2,A-2,R5-2,R3-2),(nm-3,R2-2,A-2,R5-3,R3-1),(nm-3,R2-2,A-2,R5-3,R3-2),(nm-3,R2-2,A-3,R5-1,R3-1),(nm-3,R2-2,A-3,R5-1,R3-2),(nm-3,R2-2,A-3,R5-2,R3-1),(nm-3,R2-2,A-3,R5-2,R3-2),(nm-3,R2-2,A-3,R5-3,R3-1),(nm-3,R2-2,A-3,R5-3,R3-2),(nm-3,R2-2,A-4,R5-1,R3-1),(nm-3,R2-2,A-4,R5-1,R3-2),(nm-3,R2-2,A-4,R5-2,R3-1),(nm-3,R2-2,A-4,R5-2,R3-2),(nm-3,R2-2,A-4,R5-3,R3-1),(nm-3,R2-2,A-4,R5-3,R3-2),(nm-3,R2-2,A-5,R5-1,R3-1),(nm-3,R2-2,A-5,R5-1,R3-2),(nm-3,R2-2,A-5,R5-2,R3-1),(nm-3,R2-2,A-5,R5-2,R3-2),(nm-3,R2-2,A-5,R5-3,R3-1),(nm-3,R2-2,A-5,R5-3,R3-2),(nm-3,R2-2,A-6,R5-1,R3-1),(nm-3,R2-2,A-6,R5-1,R3-2),(nm-3,R2-2,A-6,R5-2,R3-1),(nm-3,R2-2,A-6,R5-2,R3-2),(nm-3,R2-2,A-6,R5-3,R3-1),(nm-3,R2-2,A-6,R5-3,R3-2),(nm-3,R2-2,A-7,R5-1,R3-1),(nm-3,R2-2,A-7,R5-1,R3-2),(nm-3,R2-2,A-7,R5-2,R3-1),(nm-3,R2-2,A-7,R5-2,R3-2),(nm-3,R2-2,A-7,R5-3,R3-1),(nm-3,R2-2,A-7,R5-3,R3-2),(nm-3,R2-2,A-8,R5-1,R3-1),(nm-3,R2-2,A-8,R5-1,R3-2),(nm-3,R2-2,A-8,R5-2,R3-1),(nm-3,R2-2,A-8,R5-2,R3-2),(nm-3,R2-2,A-8,R5-3,R3-1),(nm-3,R2-2,A-8,R5-3,R3-2),(nm-3,R2-2,A-9,R5-1,R3-1),(nm-3,R2-2,A-9,R5-1,R3-2),(nm-3,R2-2,A-9,R5-2,R3-1),(nm-3,R2-2,A-9,R5-2,R3-2),(nm-3,R2-2,A-9,R5-3,R3-1),(nm-3,R2-2,A-9,R5-3,R3-2),(nm-3,R2-2,A-10,R5-1,R3-1),(nm-3,R2-2,A-10,R5-1,R3-2),(nm-3,R2-2,A-10,R5-2,R3-1),(nm-3,R2-2,A-10,R5-2,R3-2),(nm-3,R2-2,A-10,R5-3,R3-1),(nm-3,R2-2,A-10,R5-3,R3-2),(nm-3,R2-2,A-11,R5-1,R3-1),(nm-3,R2-2,A-11,R5-1,R3-2),(nm-3,R2-2,A-11,R5-2,R3-1),(nm-3,R2-2,A-11,R5-2,R3-2),(nm-3,R2-2,A-11,R5-3,R3-1),(nm-3,R2-2,A-11,R5-3,R3-2),(nm-3,R2-2,A-12,R5-1,R3-1),(nm-3,R2-2,A-12,R5-1,R3-2),(nm-3,R2-2,A-12,R5-2,R3-1),(nm-3,R2-2,A-12,R5-2,R3-2),(nm-3,R2-2,A-12,R5-3,R3-1),(nm-3,R2-2,A-12,R5-3,R3-2),(nm-3,R2-2,A-13,R5-1,R3-1),(nm-3,R2-2,A-13,R5-1,R3-2),(nm-3,R2-2,A-13,R5-2,R3-1),(nm-3,R2-2,A-13,R5-2,R3-2),(nm-3,R2-2,A-13,R5-3,R3-1),(nm-3,R2-2,A-13,R5-3,R3-2),(nm-3,R2-2,A-14,R5-1,R3-1),(nm-3,R2-2,A-14,R5-1,R3-2),(nm-3,R2-2,A-14,R5-2,R3-1),(nm-3,R2-2,A-14,R5-2,R3-2),(nm-3,R2-2,A-14,R5-3,R3-1),(nm-3,R2-2,A-14,R5-3,R3-2),(nm-3,R2-3,A-1,R5-1,R3-1),(nm-3,R2-3,A-1,R5-1,R3-2),(nm-3,R2-3,A-1,R5-2,R3-1),(nm-3,R2-3,A-1,R5-2,R3-2),(nm-3,R2-3,A-1,R5-3,R3-1),(nm-3,R2-3,A-1,R5-3,R3-2),(nm-3,R2-3,A-2,R5-1,R3-1),(nm-3,R2-3,A-2,R5-1,R3-2),(nm-3,R2-3,A-2,R5-2,R3-1),(nm-3,R2-3,A-2,R5-2,R3-2),(nm-3,R2-3,A-2,R5-3,R3-1),(nm-3,R2-3,A-2,R5-3,R3-2),(nm-3,R2-3,A-3,R5-1,R3-1),(nm-3,R2-3,A-3,R5-1,R3-2),(nm-3,R2-3,A-3,R5-2,R3-1),(nm-3,R2-3,A-3,R5-2,R3-2),(nm-3,R2-3,A-3,R5-3,R3-1),(nm-3,R2-3,A-3,R5-3,R3-2),(nm-3,R2-3,A-4,R5-1,R3-1),(nm-3,R2-3,A-4,R5-1,R3-2),(nm-3,R2-3,A-4,R5-2,R3-1),(nm-3,R2-3,A-4,R5-2,R3-2),(nm-3,R2-3,A-4,R5-3,R3-1),(nm-3,R2-3,A-4,R5-3,R3-2),(nm-3,R2-3,A-5,R5-1,R3-1),(nm-3,R2-3,A-5,R5-1,R3-2),(nm-3,R2-3,A-5,R5-2,R3-1),(nm-3,R2-3,A-5,R5-2,R3-2),(nm-3,R2-3,A-5,R5-3,R3-1),(nm-3,R2-3,A-5,R5-3,R3-2),(nm-3,R2-3,A-6,R5-1,R3-1),(nm-3,R2-3,A-6,R5-1,R3-2),(nm-3,R2-3,A-6,R5-2,R3-1),(nm-3,R2-3,A-6,R5-2,R3-2),(nm-3,R2-3,A-6,R5-3,R3-1),(nm-3,R2-3,A-6,R5-3,R3-2),(nm-3,R2-3,A-7,R5-1,R3-1),(nm-3,R2-3,A-7,R5-1,R3-2),(nm-3,R2-3,A-7,R5-2,R3-1),(nm-3,R2-3,A-7,R5-2,R3-2),(nm-3,R2-3,A-7,R5-3,R3-1),(nm-3,R2-3,A-7,R5-3,R3-2),(nm-3,R2-3,A-8,R5-1,R3-1),(nm-3,R2-3,A-8,R5-1,R3-2),(nm-3,R2-3,A-8,R5-2,R3-1),(nm-3,R2-3,A-8,R5-2,R3-2),(nm-3,R2-3,A-8,R5-3,R3-1),(nm-3,R2-3,A-8,R5-3,R3-2),(nm-3,R2-3,A-9,R5-1,R3-1),(nm-3,R2-3,A-9,R5-1,R3-2),(nm-3,R2-3,A-9,R5-2,R3-1),(nm-3,R2-3,A-9,R5-2,R3-2),(nm-3,R2-3,A-9,R5-3,R3-1),(nm-3,R2-3,A-9,R5-3,R3-2),(nm-3,R2-3,A-10,R5-1,R3-1),(nm-3,R2-3,A-10,R5-1,R3-2),(nm-3,R2-3,A-10,R5-2,R3-1),(nm-3,R2-3,A-10,R5-2,R3-2),(nm-3,R2-3,A-10,R5-3,R3-1),(nm-3,R2-3,A-10,R5-3,R3-2),(nm-3,R2-3,A-11,R5-1,R3-1),(nm-3,R2-3,A-11,R5-1,R3-2),(nm-3,R2-3,A-11,R5-2,R3-1),(nm-3,R2-3,A-11,R5-2,R3-2),(nm-3,R2-3,A-11,R5-3,R3-1),(nm-3,R2-3,A-11,R5-3,R3-2),(nm-3,R2-3,A-12,R5-1,R3-1),(nm-3,R2-3,A-12,R5-1,R3-2),(nm-3,R2-3,A-12,R5-2,R3-1),(nm-3,R2-3,A-12,R5-2,R3-2),(nm-3,R2-3,A-12,R5-3,R3-1),(nm-3,R2-3,A-12,R5-3,R3-2),(nm-3,R2-3,A-13,R5-1,R3-1),(nm-3,R2-3,A-13,R5-1,R3-2),(nm-3,R2-3,A-13,R5-2,R3-1),(nm-3,R2-3,A-13,R5-2,R3-2),(nm-3,R2-3,A-13,R5-3,R3-1),(nm-3,R2-3,A-13,R5-3,R3-2),(nm-3,R2-3,A-14,R5-1,R3-1),(nm-3,R2-3,A-14,R5-1,R3-2),(nm-3,R2-3,A-14,R5-2,R3-1),(nm-3,R2-3,A-14,R5-2,R3-2),(nm-3,R2-3,A-14,R5-3,R3-1),(nm-3,R2-3,A-14,R5-3,R3-2),(nm-3,R2-4,A-1,R5-1,R3-1),(nm-3,R2-4,A-1,R5-1,R3-2),(nm-3,R2-4,A-1,R5-2,R3-1),(nm-3,R2-4,A-1,R5-2,R3-2),(nm-3,R2-4,A-1,R5-3,R3-1),(nm-3,R2-4,A-1,R5-3,R3-2),(nm-3,R2-4,A-2,R5-1,R3-1),(nm-3,R2-4,A-2,R5-1,R3-2),(nm-3,R2-4,A-2,R5-2,R3-1),(nm-3,R2-4,A-2,R5-2,R3-2),(nm-3,R2-4,A-2,R5-3,R3-1),(nm-3,R2-4,A-2,R5-3,R3-2),(nm-3,R2-4,A-3,R5-1,R3-1),(nm-3,R2-4,A-3,R5-1,R3-2),(nm-3,R2-4,A-3,R5-2,R3-1),(nm-3,R2-4,A-3,R5-2,R3-2),(nm-3,R2-4,A-3,R5-3,R3-1),(nm-3,R2-4,A-3,R5-3,R3-2),(nm-3,R2-4,A-4,R5-1,R3-1),(nm-3,R2-4,A-4,R5-1,R3-2),(nm-3,R2-4,A-4,R5-2,R3-1),(nm-3,R2-4,A-4,R5-2,R3-2),(nm-3,R2-4,A-4,R5-3,R3-1),(nm-3,R2-4,A-4,R5-3,R3-2),(nm-3,R2-4,A-5,R5-1,R3-1),(nm-3,R2-4,A-5,R5-1,R3-2),(nm-3,R2-4,A-5,R5-2,R3-1),(nm-3,R2-4,A-5,R5-2,R3-2),(nm-3,R2-4,A-5,R5-3,R3-1),(nm-3,R2-4,A-5,R5-3,R3-2),(nm-3,R2-4,A-6,R5-1,R3-1),(nm-3,R2-4,A-6,R5-1,R3-2),(nm-3,R2-4,A-6,R5-2,R3-1),(nm-3,R2-4,A-6,R5-2,R3-2),(nm-3,R2-4,A-6,R5-3,R3-1),(nm-3,R2-4,A-6,R5-3,R3-2),(nm-3,R2-4,A-7,R5-1,R3-1),(nm-3,R2-4,A-7,R5-1,R3-2),(nm-3,R2-4,A-7,R5-2,R3-1),(nm-3,R2-4,A-7,R5-2,R3-2),(nm-3,R2-4,A-7,R5-3,R3-1),(nm-3,R2-4,A-7,R5-3,R3-2),(nm-3,R2-4,A-8,R5-1,R3-1),(nm-3,R2-4,A-8,R5-1,R3-2),(nm-3,R2-4,A-8,R5-2,R3-1),(nm-3,R2-4,A-8,R5-2,R3-2),(nm-3,R2-4,A-8,R5-3,R3-1),(nm-3,R2-4,A-8,R5-3,R3-2),(nm-3,R2-4,A-9,R5-1,R3-1),(nm-3,R2-4,A-9,R5-1,R3-2),(nm-3,R2-4,A-9,R5-2,R3-1),(nm-3,R2-4,A-9,R5-2,R3-2),(nm-3,R2-4,A-9,R5-3,R3-1),(nm-3,R2-4,A-9,R5-3,R3-2),(nm-3,R2-4,A-10,R5-1,R3-1),(nm-3,R2-4,A-10,R5-1,R3-2),(nm-3,R2-4,A-10,R5-2,R3-1),(nm-3,R2-4,A-10,R5-2,R3-2),(nm-3,R2-4,A-10,R5-3,R3-1),(nm-3,R2-4,A-10,R5-3,R3-2),(nm-3,R2-4,A-11,R5-1,R3-1),(nm-3,R2-4,A-11,R5-1,R3-2),(nm-3,R2-4,A-11,R5-2,R3-1),(nm-3,R2-4,A-11,R5-2,R3-2),(nm-3,R2-4,A-11,R5-3,R3-1),(nm-3,R2-4,A-11,R5-3,R3-2),(nm-3,R2-4,A-12,R5-1,R3-1),(nm-3,R2-4,A-12,R5-1,R3-2),(nm-3,R2-4,A-12,R5-2,R3-1),(nm-3,R2-4,A-12,R5-2,R3-2),(nm-3,R2-4,A-12,R5-3,R3-1),(nm-3,R2-4,A-12,R5-3,R3-2),(nm-3,R2-4,A-13,R5-1,R3-1),(nm-3,R2-4,A-13,R5-1,R3-2),(nm-3,R2-4,A-13,R5-2,R3-1),(nm-3,R2-4,A-13,R5-2,R3-2),(nm-3,R2-4,A-13,R5-3,R3-1),(nm-3,R2-4,A-13,R5-3,R3-2),(nm-3,R2-4,A-14,R5-1,R3-1),(nm-3,R2-4,A-14,R5-1,R3-2),(nm-3,R2-4,A-14,R5-2,R3-1),(nm-3,R2-4,A-14,R5-2,R3-2),(nm-3,R2-4,A-14,R5-3,R3-1),(nm-3,R2-4,A-14,R5-3,R3-2),(nm-3,R2-4,A-14,R5-3,R3-3)。
式(I’)中,n、m、R2a、R2b、环A、R5、R3a和R3b的组合(nm、R2、A、R5、R3)为上述任一组合、E为单键的化合物。
本发明的化合物对由淀粉状β蛋白的产生、分泌或沉积所诱发的疾病有用,例如对阿尔茨海默型痴呆(阿尔茨海默病、阿尔茨海默型老年痴呆等)、唐氏综合征、记忆障碍、朊毒病(早老痴呆症等)、轻度认知障碍(MCI)、荷兰型遗传性淀粉状脑出血、脑淀粉状血管障碍、其他变性痴呆、血管性变性混合型痴呆、帕金森病所伴随的痴呆、进行性核上麻痹所伴随的痴呆、皮质基底核变性症所伴随的痴呆、弥漫性路易小体型阿尔茨海默病、老年黄斑病变、帕金森病、淀粉状血管病等的治疗和/或予防、症状改善有效。
给予本发明化合物时,可以和其他药物(例如乙酰胆碱酯酶等其他阿尔茨海默病治疗药等)结合使用。例如可以和盐酸多奈培齐、他可林、加兰他敏、利凡斯的明、扎那培齐(Zanapezil)、美金刚、长春西汀等抗痴呆药等结合使用。
对人给予本发明化合物时,可以作为散剂、颗粒剂、片剂、胶囊剂、丸剂、溶液剂等进行口服给药;或者作为注射剂、栓剂、经皮吸收剂、吸入剂等进行非口服给药。还可以根据需要向有效量的本化合物中混合适合该剂型的赋形剂、粘合剂、润湿剂、崩解剂、润滑剂等药用添加剂制成药物制剂。
给药量根据疾病的状态、给药途径、患者的年龄或体重而异,对成人口服给药时,通常为0.1μg~1g/天,优选为0.01~200mg/天;非口服给药时,通常为1μg~10g/天,优选为0.1~2g/天。
以下例举出实施例和试验例来进一步详细说明本发明,但本发明并不受限于此。
实施例中各缩写的意思如下。
Me:甲基
Et:乙基
iPr、Pri:异丙基
Ph:苯基
Bn:苄基
Boc:叔丁氧基羰基
TBDPS:叔丁基二苯基甲硅烷基
[实施例1]
化合物588的合成
[化学式48]
步骤一
在氮气环境下,将7.98g化合物(1-1)溶解在330ml二乙基醚-36ml四氢呋喃的混合溶剂中,边用干冰-丙酮浴冷却边加入44.8ml(1.32mol/L)的乙烯基氯化镁的四氢呋喃溶液,搅拌20分钟。之后,将反应液在冰冷下搅拌30分钟、在室温下搅拌35分钟。加入饱和氯化铵水溶液,用乙酸乙酯进行提取,有机层经饱和氯化铵水溶液、饱和碳酸氢钠水溶液、饱和食盐水依次洗涤,之后用无水硫酸镁干燥,减压下馏去溶剂。残余物用中压硅胶柱层析进行纯化,得到6.00g化合物(1-2)。
1H-NMR(CDCl3):1.63(3H,s),2.08(1H,br),5.20(1H,dd,J=10.6,1.6Hz),5.31(1H,dd,J=17.1,1.6Hz),6.09(1H,m),7.46(1H,m),7.52(1H,dd,J=3.4,2.6Hz),7.80(1H,dd,J=3.9,2.6Hz),8.06(1H,br).
步骤二
将6.36g化合物(1-2)溶解在30ml乙酸中,加入1.50g硫脲、20.7ml(1mol/L)的盐酸乙酸溶液,在室温下搅拌3小时、在40℃下搅拌3小时,进一步在室温下搅拌66小时、在40℃下搅拌19小时。追加0.450g硫脲、7.53ml(1mol/L)的盐酸乙酸溶液,在40℃下搅拌23小时。确认化合物(1-2)消失后,减压下馏去溶剂,使残余物从甲醇/二乙基醚中结晶,得到5.23g为晶体的化合物(1-3)。另外,将母液在减压下浓缩干固,得到3.00g作为固体粗产物的化合物(1-3)。
1H-NMR(DMSO-d6):2.09(3H,s),4.10(2H,d,J=7.3Hz),5.94(1H,t,J=7.7Hz),7.50(1H,s),7.75(1H,s),7.87(1H,s),9.17(3H,br),11.46(1H,s).
步骤三
将5.23g化合物(1-3)溶解在25ml三氟乙酸中,冰冷下边搅拌边滴加2.14ml三氟甲磺酸。滴加结束后,将反应液升温至室温,搅拌3.5小时,确认化合物(1-3)消失后,减压下馏去溶剂。向所得残余物中加入水和碳酸钠,用乙酸乙酯提取。有机层经饱和碳酸氢钠水溶液洗涤后,用无水硫酸镁干燥,减压下浓缩干固,得到4.90g作为粗产物的化合物(1-4)。
1H-NMR(CDCl3):1.53(3H,s),1.90(1H,m),2.09(1H,m),2.74(1H,m),2.97(1H,m),4.32(2H,br),7.34(1H,t,J=1.6Hz),7.37(1H,t,J=1.8Hz),7.86(1H,t,J=1.8Hz).
步骤四
在氮气环境下,将4.90g化合物(1-4)溶解在30ml四氢呋喃中,冰冷下边搅拌边加入2.97g二碳酸二叔丁酯、1.89ml三乙胺,搅拌2小时。将反应液升温至室温,进一步搅拌3小时后加入水,用乙酸乙酯提取。有机层用水洗涤,并用无水硫酸镁干燥,之后减压下馏去溶剂。使所得残余物从乙酸乙酯/二乙基醚中结晶,得到4.62g化合物(1-5)。
1H-NMR(CDCl3):1.36(9H,s),1.72(3H,s),2.10(1H,m),2.41(1H,m),2.62(1H,m),2.75(1H,m),7.22(1H,s),7.48(1H,s),8.29(1H,s).
步骤五
将1.00g化合物(1-5)溶解在8.7ml四氢呋喃中,加入4.43ml(1mol/L)的氢氧化锂水溶液,在50℃下搅拌4小时。向反应液中加入水,用乙酸乙酯提取,有机层用水、饱和食盐水依次洗涤,并用无水硫酸镁干燥,之后减压下馏去溶剂。将所得残余物进行中压硅胶柱层析,得到0.668g化合物(1-6)。
1H-NMR(CDCl3):1.51(9H,s),1.63(3H,s),2.06(1H,m),2.40(1H,m),2.68-2.74(2H,m),3.83(2H,br),6.51(1H,t,J=1.8Hz),6.72-6.74(2H,m).
步骤六
将20.0mg化合物(1-6)溶解在4mol/L盐酸-1,4-二噁烷溶液中,搅拌16小时。减压浓缩反应液,使所得残余物从甲醇/二乙基醚中结晶,得到14.7mg化合物(588)。
1H-NMR(DMSO-d6):1.59(3H,s),2.09-2.76(4H,m),6.44(1H,t,J=1.6Hz),6.60(1H,t J=1.9Hz),6.71(1H,t,J=2.0Hz),10.4(1H,s).
[实施例2]
化合物835的合成
[化学式49]
步骤一
将2020mg化合物(2-1)溶解在20ml氯仿中,室温下边搅拌边加入4ml水、1470mg硫氰酸钠,之后在冰冷下滴加1.94ml硫酸。滴加结束后将反应液升温至室温,搅拌345分钟,之后在60℃下搅拌一夜。为了利用TLC来确认化合物(2-1)的残留,将反应液冷却至室温,之后依次加入1470mg硫氰酸钠、5ml水、1.94ml硫酸。将反应液升温至60℃后搅拌1天。冰冷下加入饱和碳酸氢钠水溶液使反应液呈碱性,之后用乙酸乙酯提取。有机层经饱和食盐水洗涤后用硫酸镁干燥。减压馏去溶剂,将所得残余物通过硅胶柱层析进行纯化,得到968mg化合物(2-2)。
1H-NMR(CDCl3,270MHz):1.99(3H,s),3.55(1H,d,J=16.1Hz),3.69(1H,d,J=16.1Hz),7.12-7.64(8H,m),7.82-7.95(2H,m).
步骤二
将842mg化合物(2-2)溶解在8.4ml乙醇中,冰冷下边搅拌边依次加入1600mg磷酸二氢钠、113.2mg硼氢化钠的2.8ml水溶液,之后在相同温度下搅拌30分钟。通过TLC确认化合物(2-2)消失后,在冰冷下加入乙酸乙酯和水,搅拌数分钟,之后用乙酸乙酯提取。有机层经水、饱和食盐水依次洗涤后用硫酸镁干燥。减压馏去溶剂,得到904.8mg作为粗产物的化合物(2-3)。
步骤三
将900mg化合物(2-3)溶解在10ml甲苯中,冰冷下边搅拌边加入0.7ml亚硫酰氯的5ml甲苯溶液,之后在相同温度下搅拌1小时。通过TLC确认化合物(2-3)消失后,在减压下浓缩反应液,得到1076.8mg作为粗产物的化合物(2-4)。
步骤四
在室温下将1070mg化合物(2-4)溶解在约7mol/L的氨的20ml甲醇溶液中,在相同温度下搅拌1天。经TLC确认化合物(2-4)消失后,减压下浓缩反应液,得到2633mg作为粗产物的化合物(835)。
[实施例3]
化合物561的合成
[化学式50]
步骤一
冰冷搅拌下向30ml四氢呋喃中少量多次加入0.63g氢化锂铝,之后滴加1.94g化合物(3-1)的40ml四氢呋喃溶液。在室温下反应20分钟、在加热回流下反应3小时后,冰冷搅拌下少量多次加入冰,在室温下搅拌一昼夜。过滤反应液,之后减压下馏去滤液,残余物通过硅胶柱层析进行纯化,得到0.90g化合物(3-2)。
1H-NMR(CDCl3):1.22(3H,s),3.08(1H,d,J=12.5Hz),3.34(1H,d,J=12.5Hz),3.85(1H,d,J=11.0Hz),4.11(1H,d,J=11.0Hz),7.21-7.25(1H,m),7.34-7.40(2H,m),7.46-7.50(2H,m).
步骤二
将0.90g化合物(3-2)溶解在15ml四氢呋喃中,冰冷搅拌下加入0.69g叔丁基异硫氰酸酯的5ml四氢呋喃溶液。在室温下搅拌3天,之后加入水,用二氯甲烷提取,有机层用无水硫酸钠进行干燥,减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到1.33g化合物(3-3)。
1H-NMR(CDCl3):1.12(9H,s),1.34(3H,s),3.15(1H,br),3.76(1H,d,J=11.2Hz),3.87(1H,dd,J=14.2,4.6Hz),4.13(1H,d,J=11.2Hz),4.23(1H,dd,J=14.2,6.6Hz),5.18(1H,br),6.01(1H,br),7.23-7.28(1H,m),7.34-7.41(4H,m).
步骤三
将315mg化合物(3-3)溶解在3ml乙腈中,冰冷搅拌下加入440mg三苯基膦和520mg四氯化碳的3ml乙腈溶液。在室温下搅拌1小时,之后在冰冷搅拌下加入460mg碳酸钾,在室温下搅拌2天后加入水,用二氯甲烷提取,有机层用无水硫酸钠进行干燥,减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到0.23g化合物(3-4)。
1H-NMR(CDCl3):1.30(9H,s),1.36(3H,s),3.13(1H,d,J=12.2Hz),3.24(1H,dd,J=12.2,2.3Hz),3.51(1H,br),3.53(1H,d,J=15.2Hz),3.99(1H,dd,J=15.2,2.3Hz),7.20-7.25(1H,m),7.30-7.36(2H,m),7.39-7.43(2H,m).
步骤四
向0.22g化合物(3-4)中加入4.5ml浓盐酸,加热回流下搅拌2小时,之后减压下馏去反应液。残余物用甲醇/二乙基醚进行结晶,得到0.16g化合物561。
1H-NMR(DMSO-d6):1.33(3H,s),3.33-3.49(2H,m),3.65-3.96(2H,m),7.29(1H,t.J=7.6Hz),7.40(2H,t.J=7.6Hz),7.48(2H,t.J=7.6Hz).
[实施例4]
化合物534的合成
[化学式51]
步骤一
将0.72g化合物(4-1)溶解在15ml N,N-二甲基甲酰胺中,加入0.31g叠氮化钠。在100℃下搅拌13小时,之后加入水,用二乙基醚提取,有机层用无水硫酸钠进行干燥,减压下馏去溶剂,得到0.71g作为粗产物的化合物(4-2)。
步骤二
冰冷搅拌下向0.71g化合物(4-2)的10ml四氢呋喃溶液中少量多次加入0.14g氢化锂铝,之后在室温下搅拌2小时。反应结束后,在冰冷搅拌下少量多次加入冰,室温下搅拌18小时。过滤反应液,之后在减压下馏去滤液,得到0.89g作为粗产物的化合物(4-3)。
步骤三
将0.89g化合物(4-3)溶解在10ml四氢呋喃中,冰冷搅拌下加入0.56g叔丁基异硫氰酸酯的5ml四氢呋喃溶液。室温下搅拌4小时,之后加入水,用二氯甲烷提取,有机层用无水硫酸钠进行干燥,减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到0.72g化合物(4-4)。
1H-NMR(CDCl3):1.39(9H,s),2.08(3H,s),2.09-2.15(2H,m),3.37-3.44(1H,m),3.80-3.87(1H,m),5.97(1H,br.),6.86(1H,br.),7.28-7.43(5H,m).
步骤四
将120mg化合物(4-4)溶解在2ml乙腈中,冰冷搅拌下加入170mg三苯基膦和200mg四氯化碳的1ml乙腈溶液。室温下搅拌5小时,之后在冰冷搅拌下加入177mg碳酸钾,在室温下搅拌5天,之后加入水,用二氯甲烷提取,有机层用无水硫酸钠进行干燥,并减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到0.06g化合物(4-5)。
1H-NMR(CDCl3):1.35(9H,s),1.59(3H,s),1.91(1H,ddd,J=13.5,8.8,5.0Hz),2.06(1H,dt,J=13.5,5.0Hz),3.00(1H,ddd,J=15.1,8.8,5.0Hz),3.30(1H,dt,J=15.1,5.0Hz),7.24-7.38(5H,m).
步骤五
向0.06g化合物(4-5)中加入3ml浓盐酸,加热回流下搅拌1小时,之后减压下馏去反应液。残余物用甲醇/水进行结晶,得到0.02g化合物534。
1H-NMR(DMSO-d6):1.43(3H,s),1.77(1H,dt.J=8.4,3.4Hz),2.11(1H,d.J=9.2Hz),2.48-2.50(1H,m),2.83-2.99(1H,m),6.12(1H,br),6.65(1H,br),7.21-7.24(1H,m),7.31-7.37(4H,m).
[实施例5]
化合物1008的合成
[化学式52]
步骤一
将3.00g化合物(5-1)溶解在30ml乙醇中,加入1.13g硫脲,加热回流26小时,之后减压下馏去反应液。残余物用乙酸乙酯/己烷进行结晶,得到4.03g化合物(5-2)。
1H-NMR(DMSO-d6):1.95(2H,quint,J=6.8Hz),3.13(2H,t,J=6.8Hz),3.21(2H,t,J=6.8Hz),3.85(3H,s),7.06(2H,d,J=8.8Hz),7.95(2H,d,J=8.8Hz),9.18(4H,br).
步骤二
将1.00g化合物(5-2)溶解在25ml四氢呋喃中,加入1.74g二碳酸二叔丁酯和0.88g三乙胺,室温下搅拌3小时,之后加入水,用二氯甲烷提取,有机层用无水硫酸钠干燥,并减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到1.24g化合物(5-3)。
1H-NMR(CDCl3):1.50(9H,s),2.07-2.17(2H,m),2.98(2H,t,J=7.8Hz),3.09(2H,t,J=6.3Hz),6.95(2H,d,J=8.9Hz),7.95(2H,d,J=8.9Hz).
步骤三
将1.18g化合物(5-3)溶解在12ml四氢呋喃中,用乙腈/干冰浴进行冷却,搅拌下加入10.1ml(0.9mol/L)的甲基溴化镁/四氢呋喃溶液,搅拌1小时,之后在室温下搅拌30分钟。反应后在冰冷搅拌下加入饱和氯化铵水溶液,用二乙基醚进行提取,有机层用无水硫酸钠干燥,并减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到0.39g化合物(5-4)。
1H-NMR(CDCl3):1.51(9H,s),1.63(3H,s),1.55-1.65(2H,m),1.87-1.91(2H,m),2.96-3.12(2H,m),6.86(2H,d,J=8.9Hz),7.36(2H,d,J=8.9Hz).
步骤四
将0.24g化合物(5-4)溶解在6ml三氟乙酸中,室温下搅拌20小时,之后减压下馏去反应液。向残余物中加入水和饱和碳酸氢钠水溶液,用二氯甲烷进行提取,有机层用无水硫酸钠干燥,并减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到0.06g化合物1008。
1H-NMR(CDCl3):1.54(3H,s),1.77-1.87(1H,m),1.90-1.97(1H,m),2.20-2.36(2H,m),2.67-2.79(2H,m),3.81(3H,s),5.30(2H,br),6.87(2H,d,J=9.0Hz),7.33(2H,d,J=9.0Hz).
[实施例6]
化合物783的合成
[化学式53]
步骤一
将0.55g化合物(6-1)溶解在7ml甲醇中,室温搅拌下加入0.36g甲基碘。在室温下搅拌18小时,之后减压下馏去反应液,得到0.92g作为粗产物的化合物(6-2)。
步骤二
将0.92g化合物(6-2)溶解在7ml四氢呋喃中,加入0.24g三乙胺和1.1g氧化银。室温下搅拌3天后滤除不溶物,减压下浓缩滤液,之后残余物通过硅胶柱层析进行纯化,得到0.31g化合物(6-3)。
1H-NMR(CDCl3):1.35(9H,s),1.60(3H,s),1.92(1H,ddd,J=9.2,5.8,3.4Hz),2.07(1H,dt,J=9.2,3.4Hz),3.00(1H,ddd,J=9.2,5.8,3.4Hz),3.30(1H,dt,J=9.2,3.4Hz),7.24-7.38(5H,m).
步骤三
向0.29g化合物(6-3)中加入3ml浓盐酸,加热回流下搅拌1小时,之后减压下馏去反应液。向残余物中加入水进行结晶,得到0.13g化合物783。
1H-NMR(DMSO-d6):1.44(3H,s),1.78(1H,dt.J=12.4,4.2Hz),2.12(1H,d.J=8.9Hz),2.51-2.52(1H,m),2.96(1H,d.J=4.2Hz),6.12(1H,br),6.66(1H,br),7.21-7.24(1H,m),7.32-7.37(4H,m).
[实施例7]
化合物69的合成
[化学式54]
步骤一
将1.93g化合物(7-1)、1.60g叠氮化磷酸二苯酯、0.59g三乙胺的20ml甲苯溶液在80℃下搅拌3小时,之后加入水,用二乙基醚进行提取,有机层用无水硫酸钠干燥,减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到1.69g化合物(7-2)。
1H-NMR(CDCl3):1.00(9H,s),1.72(3H,s),2.17-2.22(2H,m),3.49-3.58(1H,m),3.70-3.80(1H,m),7.20-7.42(10H,m),7.58-7.63(5H,m).
步骤二
将1.68g化合物(7-2)溶解在9ml甲苯中,加入0.79g 3,4-二甲氧基苄醇,加热回流8天,之后加入水,用二氯甲烷进行提取,有机层用无水硫酸钠干燥,并减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到2.09g化合物(7-3)。
1H-NMR(CDCl3):1.03(9H,s),1.87(3H,s),2.04(2H,m),3.48(1H,m),3.51(1H,m),3.62(3H,s),3.65(3H,s),4.95(1H,d,J=12.2Hz),5.03(1H,d,J=12.2Hz),6.80-7.09(3H,m),7.22-7.42(10H,m),7.56-7.64(5H,m).
步骤三
将2.09g化合物(7-3)溶解在15ml 1,4-二噁烷中,加入15ml4mol/L-盐酸/1,4-二噁烷溶液,室温下搅拌24小时,之后加入水和1mol/L-氢氧化钠溶液,用二氯甲烷进行提取,有机层用无水硫酸钠干燥,减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到0.45g化合物(7-4)。
1H-NMR(CDCl3):1.57(3H,s),1.07-1.98(2H,m),3.48-3.56(1H,m),3.72-3.86(1H,m),7.23-7.45(15H,m).
步骤四
将0.44g化合物(7-4)溶解在15ml四氢呋喃中,加入0.41g叔丁基异硫氰酸酯和0.46g二异丙基乙胺。室温下搅拌3天,之后加入水,用二氯甲烷进行提取,有机层用无水硫酸钠干燥,减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到0.17g化合物(7-5)。
1H-NMR(CDCl3):1.79(3H,s),1.82-2.20(2H,m),3.71-3.81(2H,m),5.09(1H,br),7.30-7.52(5H,m).
步骤五
将0.17g化合物(7-5)溶解在3.4ml四氢呋喃中,室温搅拌下加入0.11g甲基碘。室温下搅拌23小时,之后减压下馏去反应液,得到0.28g作为粗产物的化合物(7-6)。
步骤六
将0.28g化合物(7-6)溶解在5ml四氢呋喃中,加入74mg三乙胺和0.34g氧化银。室温下搅拌20小时后滤除不溶物,减压下浓缩滤液,之后残余物通过硅胶柱层析进行纯化,得到0.14g化合物(7-7)。
1H-NMR(CDCl3):1.36(9H,s),1.49(3H,s),1.96-2.09(2H,m),2.77-3.83(1H,m),4.05-4.10(1H,m),7.19(1H,t,J=7.3Hz),7.31(2H,t,J=7.3Hz),7.44(2H,d,J=7.3Hz).
步骤七
向0.12g化合物(7-7)中加入9ml浓盐酸,加热回流下搅拌1小时,之后减压下馏去反应液。残余物用甲醇/水进行结晶,得到0.10g化合物69。
1H-NMR(DMSO-d6):1.65(3H,s),2.28-2.35(1H,m),2.39-2.44(1H,m),3.97(1H,dt,J=7.8,3.0Hz),4.53(1H,dt,J=7.8,3.0Hz),7.32-7.44(5H,m),8.44(2H,br),10.33(1H,s).
[实施例8]
化合物256的合成
[化学式55]
步骤一
将4890mg化合物(8-1)溶解在100ml二甲基甲酰胺中,室温下边搅拌边加入5720mg叠氮化钠,之后将反应液升温至80℃,搅拌12小时。经TLC确认化合物(8-1)消失后,将反应液冷却至室温,加入二乙基醚和水,用二乙基醚进行提取。有机层经饱和食盐水洗涤后用硫酸镁干燥。减压馏去溶剂,得到4940mg作为粗产物的化合物(8-2)。
步骤二
在氮气环境下、冰冷下向1080mg氢化锂铝的90ml四氢呋喃悬浮液中加入4940mg化合物(8-2)的15ml四氢呋喃溶液,之后在相同温度下搅拌30分钟。经TLC确认化合物(8-2)消失后,在冰冷下加入1mol/L的氢氧化钠水溶液,并搅拌片刻。滤除生成的凝胶,母液用二乙基醚进行提取。有机层经饱和食盐水依次洗涤后用硫酸镁干燥。减压馏去溶剂,得到4219.1mg作为粗产物的化合物(8-3)。
步骤三
将800mg化合物(8-3)溶解在16ml乙腈中,室温下边搅拌边加入1840mg化合物(8-4),之后在相同温度下搅拌13小时。经TLC确认化合物(8-3)消失后,减压下浓缩反应液,所得残余物通过硅胶柱层析进行纯化,得到1550.7mg化合物(8-5)。
8-5-(Z):1H-NMR(CDCl3,270MHz):1.49(18H,s),2.06(3H,d,J=1.4Hz),3.91-4.00(2H,m),5.54(1H,td,J=7.1,1,4Hz),7.12-7.41(5H,m),8.17-8.25(1H,m),11.47(1H,s).
8-5-(E):1H-NMR(CDCl3,270MHz):1.49(9H,s),1.52(9H,s),2.09(3H,d,J=1.5Hz),4.24(2H,dd,J=6.6,5.3Hz),5.80(1H,td,J=6.6,1,5Hz),7.21-7.48(5H,m),8.28-8.38(1H,m),11.51(1H,s).
步骤四
冰冷下将474.1mg化合物(8-5)溶解在4.5ml三氟乙酸中,升温至室温后搅拌4小时。经NMR确认化合物(8-5)消失后,将反应液注入到漂浮有冰的1mol/L氢氧化钠水溶液中进行中和,用乙酸乙酯进行提取。有机层经饱和食盐水洗涤后用硫酸镁干燥。减压馏去溶剂,得到326.4mg作为粗产物的化合物(8-6)。
步骤五
将326.4mg化合物(8-6)溶解在2.4ml 1,4-二噁烷中,室温下边搅拌边依次加入195mg氢氧化钠、1.2ml水,之后在冰冷下加入0.84ml二碳酸二叔丁酯。升温至室温并搅拌15小时,之后通过LC-MS确认化合物(8-6)的消失。加入水后用乙酸乙酯提取反应液。有机层经饱和食盐水洗涤后用硫酸镁干燥。减压馏去溶剂,所得残余物通过硅胶柱层析进行纯化,得到113.6mg化合物(8-7)。
1H-NMR(CDCl3,400MHz):1.46(9H,s),1.51(9H,s),1.64(3H,s),2.06(1H,ddd,J=13.4,11.4,5.0Hz),2.27(1H,dt,J=13.4,4.6Hz),3.15(1H,ddd,J=12.9,11.3,4.6Hz),3.70(1H,dt,J=12.9,4.7Hz),7.23-7.29(1H,m),7.33-7.38(4H,m).
步骤六
冰冷下将110mg化合物(8-7)溶解在1ml(4mol/L)的氯化氢的1,4-二噁烷溶液中,升温至室温后搅拌2天。经LC-MS确认化合物(8-7)消失后,室温下向反应液中加入二乙基醚和水。分离二乙基醚层,之后减压下浓缩水层。向所得残余物中加入甲醇,滤除生成的晶体。通过减压馏去母液的甲醇,得到69mg化合物(256)。
1H-NMR(DMSO-d6,400MHz):1.57(3H,s),1.87-1.96(1H,m),2.30(1H,dt,J=13.6,3.8Hz),2.60(1H,td,J=12.0,3.7Hz),3.25(1H,ddd,J=12.8,8.2,4.4Hz),6.93(2H,s),7.27-7.44(5H,m),7.94(1H,s),8.63(1H,s).
[实施例9]
化合物24的合成
[化学式56]
步骤一
将0.39g化合物(9-1)溶解在20ml氯仿中,室温搅拌下加入1.53g碘、1.25g硫氰酸钾、催化剂量的四丁基氯化铵和1ml水,搅拌15小时。反应后加入10%硫代硫酸钠水溶液和水,用二氯甲烷进行提取,有机层用无水硫酸钠干燥,减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到0.56g化合物(9-2)。
1H-NMR(CDCl3):1.95(3H,s),3.62(2H,s),7.30-7.40(4H,m).
步骤二
向0.56g化合物(9-2)的10ml四氢呋喃溶液中加入0.24g叔丁胺,室温下搅拌18小时,之后减压下馏去反应液,残余物通过硅胶柱层析进行纯化,得到190mg化合物(9-3)。
1H-NMR(CDCl3):1.43(9H,s),1.56(3H,s),3.27(1H,d,J=10.6Hz),3.36(1H,d,J=10.6Hz),7.28(2H,d,J=8.2Hz),7.43(2H,d,J=8.2Hz).
步骤三
向190mg化合物(9-3)中加入3ml浓盐酸,在100℃下搅拌7小时,之后在冰冷搅拌下加入6mol/L-氢氧化钠水溶液进行中和,用二氯甲烷进行提取,之后有机层用无水硫酸钠干燥,减压下馏去溶剂。残余物通过硅胶柱层析进行纯化后,用二氯甲烷/正己烷进行结晶,得到110mg化合物24。
1H-NMR(CDCl3):1.62(3H,s),3.47(1H,d,J=10.6Hz),3.52(1H,d,J=10.6Hz),4.59(2H,br),7.29(2H,d,J=8.6Hz),7.39(2H,d,J=8.6Hz).
[实施例10]
化合物48的合成
[化学式57]
步骤一
将79.6mg化合物(10-1)和120mg(10-2)溶解在3ml二甲基甲酰胺中,室温下边搅拌边加入54.6mg 1-羟基苯并三唑和0.063ml N,N’-二异丙基碳二亚胺。之后,将反应液在室温下搅拌一夜,确认化合物(10-1)消失后加入水,用乙酸乙酯进行提取,有机层经饱和食盐水洗涤后用无水硫酸镁干燥,减压下馏去溶剂。残余物用硅胶柱层析进行纯化,得到110.2mg作为非对映体的混合物的化合物(10-3)。
1H-NMR(CDCl3):0.78-1.00(6H,m,),1.14(9/2H,s),1.16(9/2H,s)1.52(3/2H,s),1.54(3/2H,s)1.86-2.28(3H,m),2.56-2.89(2H,m),3.80(3/2H,s),3.81(3/2H,s)4.04-4.14(1H,m),6.80-6.91(2H,m),7.08-7.22(2H,m),7.30-7.51(6H,m),7.61-7.76(4H,m).
步骤二
在氮气流下将100mg化合物(10-3)溶解在3ml四氢呋喃中,0℃下边搅拌边加入0.18ml四丁基氟化铵的1mol/L的四氢呋喃溶液。之后将反应液在0℃下搅拌5分钟,确认化合物(10-3)消失后加入水,用乙酸乙酯进行提取,有机层经饱和食盐水洗涤后用无水硫酸镁干燥,减压下馏去溶剂。残余物用硅胶柱层析进行纯化,得到40.7mg作为非对映体的混合物的化合物48。
1H-NMR(CDCl3):0.80-0.90(3H,m,)1.01-1.12(3H,m)1.70(3H,m),2.02-2.31(2H,m)2.39--2.55(1H,m),2.61-2.90(2H,m)3.53-3.70(1H,m)3.81(3H,m),3.96-4.08(1H,m)6.87-6.96(2H,m),7.13-7.22(2H,m).
[实施例11]
化合物707的合成
[化学式58]
步骤一
将150mg化合物(11-1)溶解在5ml乙腈中,室温下边搅拌边加入219.6mg化合物(11-2),之后将反应液升温至60℃,搅拌25小时。通过TLC确认化合物(11-1)的残留。减压下浓缩反应液,所得残余物通过硅胶柱层析进行纯化,得到211.4mg化合物(11-3)。
1H-NMR(CDCl3,400MHz):1.46(9H,s),1.50(9H,s),1.57(3H,s),1.90(1H,ddd,J=13.7,10.0,3.8Hz)2.11(1H,ddd,J=13.7,6.5,3.7Hz)2.68-2.76(1H,m),2.86-2.93(1H,m),3.88(3H,s),6.91(1H,t,J=8.6Hz)6.99-7.03(1H,m),7.06(1H,dd,J=13.0,2.2Hz),10.14(1H,s),13.93(1H,s).
步骤二
冰冷下将210mg化合物(11-3)溶解在4mol/L的氯化氢的4ml1,4-二噁烷溶液中,升温至室温后搅拌67小时。通过LC-MS确认化合物(11-3)消失后,减压下浓缩反应液。所得残余物用甲醇-二乙基醚进行结晶,之后过滤收集晶体,用二乙基醚洗涤,得到140.2mg化合物(707)。
1H-NMR(DMSO-d6,400MHz):1.56(3H,s),1.90-2.01(1H,m),2.43-2.62(2H,m),2.95-3.03(1H,m),3.84(3H,s),7.10-7.27(3H,m),7.76(3H,br s),8.26(1H,br s),9.42(1H,s).
[实施例12]
化合物845的合成
[化学式59]
步骤一
将50mg化合物(12-1)和17.9mg哌啶溶解在2ml二甲基甲酰胺中,室温下边搅拌边加入79.8mg邻(7-氮杂苯并三唑-1-基)-1,1,3,3-四甲基脲六氟磷酸酯。之后,将反应液在室温下搅拌40小时,确认化合物(12-1)消失后,加热减压下馏去溶剂。向残余物中加入饱和碳酸氢钠水溶液,用乙酸乙酯提取,有机层经饱和食盐水洗涤后用无水硫酸镁干燥,减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到30.7mg化合物845。
1H-NMR(CDCl3):1.60(3H,s),1.51-1.82(6H,m),1.87-1.98(1H,m),2.09-2.19(1H,m),2.91-2.97(2H,m),3.64-3.68(4H,m),6.73(1H,d,J=4.05Hz),7.14(1H,d,J=4.05Hz).
[实施例13]
化合物1262的合成
[化学式60]
步骤一
在氮气环境下将50.0mg化合物(13-1)溶解在1ml四氢呋喃中,冰冷下加入19μl三乙胺、30.1mg 4-溴苯甲酰氯,搅拌40分钟。减压下浓缩反应液,所得残余物溶解在乙酸乙酯中,用饱和碳酸氢钠水溶液洗涤,并用无水硫酸镁干燥后减压浓缩。过滤收集析出的晶体,得到57.2mg化合物(13-2)。
1H-NMR(CDCl3):1.48(9H,s),1.68(3H,s),2.08(1H,m),2.44(1H,m),2.65(1H,m),2.76(1H,m),7.18(1H,s),7.32(1H,s),7.64(2H,d,J=8.2Hz),7.78(2H,d,J=8.2Hz),8.15(1H,s),8.25(1H,br).
步骤二
将62.3mg化合物(13-2)溶解在4mol/L的盐酸1,4-二噁烷溶液中,搅拌24小时。减压浓缩反应液,所得残余物从甲醇/二乙基醚中结晶,得到44.7mg化合物(1262)。
1H-NMR(DMSO-d6):1.67(3H,s),2.10(1H,m),2.50-2.61(3H,m),7.33(1H,s),7.74(1H,s),7.77(2H,d,J=8.6Hz),7.91(2H,d,J=8.6Hz),8.08(1H,s),10.6(1H,s).
[实施例14]
化合物753的合成
[化学式61]
步骤一
将46mg化合物(14-1)溶解在2ml二氯甲烷中,加入20mg 4-氯苯甲醛和17mg乙酸,室温下搅拌20分钟,之后在冰冷下边搅拌边加入45mg三乙酰氧基硼氢化钠。室温下搅拌14小时后加入水,用二氯甲烷进行提取,有机层用无水硫酸钠干燥,减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到52mg化合物(14-2)。
1H-NMR(CDCl3):1.50(9H,s),1.64(3H,s),2.02-2.10(1H,m),2.40(1H,dt,J=14.0,4.1Hz),2.62-2.74(2H,m),4.30(2H,s),6.49(1H,ddd,J=,7.8,2.0,0.8Hz),6.52(1H,t,J=2.0Hz),6.60(1H,ddd,J=,7.8,2.0,0.8Hz),7.16(1H,t,J=7.8Hz),7.18-7.33(4H,m).
步骤二
向52mg化合物(14-2)中加入4ml 4mol/L-盐酸/1,4-二噁烷溶液,室温下搅拌4天,之后减压下馏去反应液。残余物用甲醇/二乙基醚进行结晶,得到42mg化合物753。
1H-NMR(DMSO-d6):1.58(3H,s),2.00(1H,ddd,J=,14.3,11.3,3.3Hz),2.49-2.57(2H,m),3.07(1H,dt,J=12.7,3.3Hz),4.27(2H,s),6.47(1H,d,J=8.2Hz),6.51-6.53(2H,m),7.08(1H,t,J=8.2Hz),7.37(4H,s),8.80(2H,br).
[实施例15]
化合物1135的合成
[化学式62]
步骤一
向101mg化合物(15-1)、56μl 2-丙醇、189mg三苯基膦的2ml四氢呋喃溶液中滴加328μl偶氮二羧酸二乙酯的2.2mol/L的甲苯溶液。滴加结束后,在室温下搅拌1小时,确认化合物(15-1)消失,之后减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到280mg作为三苯基氧化膦和肼二羧酸二乙酯的混合物的化合物(15-2)。
步骤二
向47mg 5-氯吡啶-2-羧酸的1ml甲苯悬浮液中加入1滴二甲基甲酰胺和91μl亚硫酰氯,在100℃下搅拌1小时。减压下馏去溶剂,将残余物溶解在1ml四氢呋喃中,在0℃下滴加280mg化合物(15-2)的混合物和194μl吡啶的0.5ml四氢呋喃溶液。室温下搅拌10分钟,确认化合物(15-2)消失后加入水,用乙酸乙酯进行提取。有机层用水洗涤,之后减压下馏去溶剂。所得残余物通过硅胶柱层析进行纯化,得到68mg作为与肼二羧酸二乙酯的混合物的化合物(15-3)。
步骤三
向作为与肼二羧酸二乙酯的混合物的68mg化合物(15-3)中加入1ml 4mol/L-盐酸/1,4-二噁烷溶液,室温下搅拌16小时,确认化合物(44)消失,之后减压下馏去反应液。残余物用2-丙醇/乙醚进行结晶,得到36mg化合物1135。
1H-NMR(DMSO-d6):1.30(3H,d,J=6.4Hz),1.31(3H,d,J=6.4Hz),1.65(3H,s),2.04-2.11(1H,m),2.50-2.64(2H,m),3.12-3.16(1H,m),4.61(1H,sep,J=6.4Hz),6.66(1H,t,J=2.0Hz),7.48(1H,t,J=2.0Hz),7.60(1H,t,J=2.0Hz),8.16(1H,dd,J=8.4,0.8Hz),8.22(1H,dd,J=8.4,2.4Hz),8.79(1H,dd,J=2.4,0.8Hz),10.33(1H,s),10.72(1H,s).
[实施例16]
化合物161的合成
[化学式63]
步骤一
在氮气环境下将200mg化合物(16-1)、4.7mg乙酸钯、12.5mg三邻甲硅烷基膦溶解在2ml二甲基甲酰胺中,室温下边搅拌边加入0.196ml正丁胺、0.074ml对氯苯乙烯,之后将反应液升温至80℃,搅拌3小时。经TLC确认化合物(16-1)消失后冷却至室温,加入饱和氯化铵水溶液。用乙酸乙酯进行提取,有机层经水、饱和食盐水洗涤后用硫酸镁干燥。减压馏去溶剂,所得残余物通过硅胶柱层析进行纯化,得到213.1mg化合物(16-2)。
1H-NMR(CDCl3,400MHz):1.54(18H,s),1.64(3H,s),1.96(1H,ddd,J=13.7,9.1,4.0Hz)2.10(1H,ddd,J=13.7,8.1,3.4Hz)2.86(1H,ddd,J=12.3,9.1,3.4Hz),3.03(1H,ddd,J=12.3,8.1,4.0Hz),7.08(1H,d,J=16.4Hz)7.15(1H,d,J=16.4Hz),7.27-7.40(5H,m)7.44(2H,d,J=8.8Hz),7.58(1H,s).
步骤二
冰冷下将213mg化合物(16-2)溶解在4mol/L的氯化氢的5ml1,4-二噁烷溶液中,升温至室温后搅拌63小时。经LC-MS确认化合物(16-2)消失后,用二乙醚稀释反应液。过滤收集析出的晶体,用二乙基醚洗涤,得到108.6mg化合物(161)。
1H-NMR(DMSO-d6,400MHz):1.69(3H,s),2.08-2.18(1H,m),2.56-2.70(2H,m),3.13-3.20(1H,m),7.23(1H,d,J=8.0Hz),7.31(1H,d,J=17.0Hz),7.35(1H,d,J=17.0Hz),7.45(2H,d,J=8.6Hz),7.46(1H,t,7.6Hz),7.59(1H,d,J=2.0Hz),7.61-7.64(1H,m),7.64(2H,d,J=8.6Hz),8.53-9.50(2H,br),10.67(1H,br s).
[实施例17]
化合物597的合成
[化学式64]
步骤一
将135mg化合物(17-1)、39mg盐酸甲氧基胺、27mg乙酸钾的3ml甲醇溶液在室温下搅拌16小时,之后加入水,用二氯甲烷进行提取,有机层用无水硫酸钠干燥,减压下馏去溶剂。残余物通过硅胶柱层析进行纯化,得到110mg化合物(17-2)。
1H-NMR(CDCl3):1.51(9H,s),1.70(3H,s),2.14(1H,ddd,J=14.4,11.4,3.4Hz),2.22(3H,s),2.48(1H,m),2.65(1H,dt,J=12.6,11.4Hz),2.78(1H,ddd,J=12.6,5.6,3.4Hz),4.00(3H,s),7.30(1H,d,J=7.8Hz),7.38(1H,d,J=7.8Hz),7.54-7.57(2H,m).
步骤二
向110mg化合物(17-2)中加入4.5ml 4mol/L-盐酸/1,4-二噁烷溶液,在室温下搅拌4天,之后减压下馏去反应液。残余物用甲醇/二乙基醚进行结晶,得到65mg化合物597。
1H-NMR(DMSO-d6):1.67(3H,s),2.08-2.15(1H,m),2.20(3H,s),2.56-2.64(2H,m),3.14-3.17(1H,m),3.92(3H,s),7.37(1H,d,J=8.0Hz),7.48(1H,d,J=8.0Hz),7.56(1H,s),7.62(1H,d,J=8.0Hz).
同样操作来合成其他化合物。以下显示结构式和物理常数。
[表1]
[表2]
[表3]
[表4]
[表5]
[表6]
[表7]
[表8]
[表9]
[表10]
[表11]
[表12]
[表13]
[表14]
[表15]
[表16]
[表17]
[表18]
[表19]
[表20]
[表21]
[表22]
[表23]
[表24]
[表25]
[表26]
[表27]
[表28]
[表29]
[表30]
[表31]
[表32]
[表33]
[表34]
[表35]
[表36]
[表37]
[表38]
[表39]
[表40]
[表41]
[表42]
[表43]
[表44]
[表45]
[表46]
[表47]
[表48]
[表49]
[表50]
[表51]
[表52]
[表53]
[表54]
[表55]
[表56]
[表57]
[表58]
[表59]
[表60]
[表61]
[表62]
[表63]
[表64]
[表65]
[表66]
[表67]
[表68]
[表69]
[表70]
[表71]
[表72]
[表73]
[表74]
[表75]
[表76]
[表77]
[表78]
[表79]
[表80]
[表81]
[表82]
[表83]
[表84]
[表85]
[表86]
[表87]
[表88]
[表89]
[表90]
[表91]
[表92]
[表93]
[表94]
[表95]
[表96]
[表97]
[表98]
[表99]
[表100]
[表101]
[表102]
[表103]
[表104]
[表105]
[表106]
[表107]
[表108]
[表109]
[表110]
[表111]
[表112]
[表113]
[表114]
[表115]
[表116]
[表117]
[表118]
[表119]
[表120]
[表121]
[表122]
[表123]
[表124]
[表125]
[表126]
[表127]
[表128]
[表129]
[表130]
[表131]
[表132]
[表133]
[表134]
[表135]
[化学式65]
[表136]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
1 | 213.4305.3 | |||
3 | 285(dec.) | |||
4 | 无定形 | 219 | ||
5 | 215,262 | |||
6 | 147-148 | |||
8 | 214-217 | |||
9 | oil | 220 | ||
18 | 181-183 | |||
23 | 213.4272.2305.3 | |||
24 | 116-117 | |||
26 | 182-184 | |||
30 | 267.4 | |||
33 | 253.3305.3 | |||
37 | 无定形 | 219,275 | ||
38 | 240-244(dec.) | |||
39 | 285.2 | |||
42 | 187-188 | |||
43 | 218.1275.7 | |||
48 | 230275 | |||
57 | 197-198 | |||
58 | 234-240 | |||
62 | 198-201 | |||
69 | 194-195 | |||
71 | 216.9268.6 | |||
73 | 266-269 | |||
77 | δin d20-DMSO:1.67(3H,s),2.13-2.06(1H,m),2.63-2.55(2H,m),3.16-3.13(4H,m),3.65-3.63(2H,m),4.76-4.73(2H,m),7.15-7.08(2H,m),7.30(1H,t,J=8.0Hz),7.35(1H,s),7.42(1H,t,J=8.0Hz),7.60(1H,d,J=8.0Hz),7.69(1H,d,J=8.0Hz),7.73(1H,brs),7.86(1H,d,J=8.0Hz),10.52(1H,s) | 422.543 | ||
78 | 1H-NMR(CDCl3)δ:1.76(3H,s),2.02(1H,s),2.58(1H,d,J=14.1Hz),2.78(2H,d,J=6.9Hz),3.80(3H,d,J=13.1Hz),4.54(2H,s),6.45(1H,s),6.55-6.57(2H,m),6.66(1H,d,J=8.7Hz),7.10(1H,t,J=7.0Hz),7.22(2H,td,J=7.7,1.4Hz),7.34(1H,d,J=9.1Hz),7.56(1H,d,J=7.7Hz). | 365[M+1] | ||
80 | 220.4280.4 |
[表137]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
85 | 147-148 | 1.54(3H,s),1.75-1.86(1H,m),2.08-2.18(1H,m),2.33(3H,s),2.63-2.74(1H,m),2.81-2.90(1H,m),4.36(2H,br),7.13(2H,d,J=8.6Hz),7.20(2H,d,J=8.6Hz)(溶剂:CDCl3) | ||
86 | 141-142 | |||
91 | 372[M+1]296 | 201206216 | ||
96 | 309 | |||
97 | δin d13-DMSO:1.64(3H,s),2.03-1.97(1H,m),2.63-2.57(2H,m),3.28-3.25(1H,m),7.22(1H,q,J=12.4,9.0Hz),7.82-7.77(2H,m),8.60(1H,s),8.79(1H,s),10.37(1H,s) | |||
99 | 221-224 | |||
101 | 264-265 | |||
104 | 无定形 | 229,280 | ||
113 | 1.58(s,3H),1.88(ddd,J=14.1,10.9,3.7Hz,1H),2.24(ddd,J=14.1,5.9,3.5Hz,1H),2.73(ddd,J=12.3,10.9,3.5Hz,1H),2.88(ddd,J=12.3,5.9,3.7Hz,1H),3.83(d,J=15.4Hz,1H),3.87(d,J=15.4Hz,1H),7.02-7.04(m,1H),7.25-7.31(m,2H),7.36(d,J=2.0Hz,1H),7.45-7.50(m,2H),8.52(d,J=5.2Hz,1H),9.43(s,1H)(溶剂:CDCl3) | |||
114 | 214.5306.5 | |||
115 | δin d6-DMSO:1.47(3H,s),1.80-1.74(1H,m,2.22-2.18(1H,m),2.60-2.55(1H,m),2.96-2.93(1H,m),6.14(1H,s),6.93(1H,s),7.09-7.04(2H,m),7.63-7.61(1H,m),7.68-7.66(1H,m),9.85(1H,s),11.63(1H,brs) | |||
120 | 无定形 | 213 | ||
121 | 166-167 | |||
125 | >300 | |||
126 | 无定形 | 229,271 | ||
127 | 280-285 | |||
128 | 159-163 | |||
129 | 219-222 | |||
130 | 128-131 | 1.56(3H,s),1.83-1.93(1H,m),2.16(1H,dq,J=13.85,3.41Hz),2.29(3H,s),2.72-2.77(1H,m),2.90-2.94(1H,m),4.13(3H,s),6.42(1H,s),7.10-7.14(1H,m),7.32(1H,d,J=7.91Hz),7.37-7.38(1H,m),7.60-7.63(1H,m).(溶剂:CDCl3) | 344[M+1] | |
132 | 147-150 | |||
134 | 228.5 |
[表138]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
139 | 287-290 | 1.77(s,3H),2.10(ddd,J=14.0,10.8,3.6Hz,1H),2.64-2.70(4H,m),2.76(td,J=12.8,3.6Hz,1H),2.90(dt,J=12.8,3.6Hz,1H),7.05(ddd,J=8.0,2.0,0.8Hz,1H),7.41(t,J=8.0Hz,1H),7.69-7.72(m,2H),8.32(dd,J=8.0,0.8Hz,1H),8.40(dd,J=8.0,2.0Hz,1H),9.14(dd,J=2.0,0.8Hz,1H)(溶剂:CDCl3+CD3OD) | ||
141 | δin d17-DMSO:1.41(3H,s),1.75-1.70(1H,m),2.03-1.99(1H,m),2.62-2.56(1H,m),2.94-2.89(1H,m),3.89(3H,s),6.88(1H,d,J=8.8Hz),7.05(1H,d,J=7.6Hz),7.24(1H,t,J=8.0Hz),7.66-7.63(3H,m),8.45-8.44(1H,m),9.90(1H,s) | |||
148 | 362[M+1]286 | 200208212218262 | ||
149 | 143-145 | |||
157 | δin d6-DMSO:1.20(6H,d,J=6.6Hz),1.41(3H,s),1.65-1.77(1H,m),1.96-2.07(1H,m),2.55-2.63(1H,m),2.85-2.95(1H,m),4.04-4.16(1H,m),5.79(2H,bs),7.07(1H,d,J=8.1Hz),7.25(1H,t,J=8.1Hz),7.72-7.78(3H,m),7.93(1H,s),8.64(1H,s),9.96(1H,s). | |||
159 | 无定形 | 285 | ||
161 | 247-251 | |||
163 | 无定形 | |||
164 | 91-96 | 1.68(s,3H),2.07-2.15(m,1H),3.13-3.20(m,1H),7.12(d,J=7.6Hz,1H),7.46(t,J=7.6Hz,1H),7.90-7.94(m,2H),8.83(br s,1H),8.96(br s,1H),9.31(br s,1H),10.36(s,1H),10.86(s,1H) | ||
165 | 246-248 | |||
166 | 无定形 | 220,275 | ||
176 | 无定形 | 217,278 | ||
178 | 224-225 | |||
181 | 261.5 | |||
189 | 259 | |||
193 | 266-268 | |||
196 | 212 | |||
202 | 117-118 | 0.85(3H,t,J=7.3Hz),1.02-1.19(1H,m),1.34-1.54(1H,m),1.72-1.89(3H,m),2.04-2.15(1H,m),2.61-2.82(2H,m),3.80(3H,s),4.32(2H,br),6.85(2H,d,J=8.9Hz),7.18(2H,d,J=8.9Hz)(溶剂:CDCl3) |
[表139]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
204 | 205-208 | 1.64(d,J=1.2Hz,3H),1.95(ddd,J=14.0,10.8,3.6Hz,1H),2.45(ddd,J=14.0,6.4,3.6Hz,1H),2.75(ddd,J=12.4,10.8,3.6Hz,1H),2.99(ddd,J=12.4,6.4,3.6Hz,1H),7.09(dd,J=11.6,8.8Hz,1H),7.47(dd,J=7.2,2.8Hz,1H),8.03(ddd,J=8.8,4.4,2.8Hz,1H),8.89(s,2H),9.75(s,1H)(溶剂:CDCl3) | ||
213 | 油 | 216,272 | ||
214 | 212.2292.3356.5 | |||
216 | 242.7 | |||
220 | 191-193 | 363[M+3]361[M+1]287285 | ||
224 | 油 | 1.58(3H,s),1.87(1H,ddd,J=13.9,10.5,3.7),2.13(1H,ddd,J=13.9,6.3,3.7),2.25(3H,s),2.68(1H,ddd,J=12.1,10.5,6.2),2.89(1H,ddd,J=12.1,6.3,3.7),5.23(2H,s),7.28-7.48(4H,m),7.60(1H,s),7.75(1H,d,J=8.0),8.56(1H,dd,J=5.0,1.4),8.70(1H,d,J=1.4)(溶剂:CDCl3) | 222 | |
227 | 213 | |||
232 | 1H-NMR(CDCl3)δ:1.59(3H,s),1.83-1.90(1H,m),2.35-2.47(4H,m),2.60-2.67(1H,m),2.87-2.92(1H,m),4.70(2H,br s),6.87-6.98(2H,m),7.16(1H,d,J=6.6Hz),7.27(2H,d,J=7.8Hz),7.61(2H,d,J=8.1Hz). | 378[M+1] | ||
233 | 油 | 224,272 | ||
235 | 196-200 | |||
238 | 1H-NMR(CDCl3)δ:1.68(3H,s),1.97-2.00(1H,m),2.53(1H,dt,J=14.4,3.7Hz),2.63-2.79(2H,m),4.52(2H,s),6.56-6.66(3H,m),7.17(1H,t,J=8.0Hz),7.43-7.52(3H,m),7.81(4H,dd,J=11.6,5.7Hz). | 362[M+1] | ||
241 | 187-190 | 1H-NMR(DMSO-d6)δ:1.49(3H,s),1.78-1.86(1H,m),2.13-2.21(1H,m),2.59-2.67(1H,m),2.96-3.02(1H,m),7.11(1H,t,J=10.7Hz),7.29(1H,t,J=7.8Hz),7.45(1H,t,J=7.5Hz),7.66(1H,d,J=8.8Hz),7.74-7.78(1H,m),7.80-7.83(1H,m),8.21(1H,d,J=8.6Hz),10.25(1H,s). | ||
243 | 182-184 | 1.46(s,3H),1.75-1.83(m,1H),2.08-2.16(m,1H),2.55-2.63(m,1H),2.92-2.98(m,1H),4.02(s,3H),7.11(d,J=8.0Hz,1H),7.31(t,J=8.0Hz,1H),7.77(d,J=8.0Hz,1H),7.82(br s,1H),8.41(d,J=1.2Hz,1H),8.90(d,J=1.2Hz,1H),10.38(s,1H)(溶剂:CDCl3) |
[表140]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
244 | 222-224 | |||
251 | 351[M+1]311275 | 200204215285 | ||
255 | 238-239 | |||
256 | 油 | 215,257 | ||
259 | 无定形 | 1.58(3H,s),2.01(1H,ddd,J=15.2,12.2,3.4),2.46-2.56(2H,m),3.07(1H,ddd,J=13.3,5.7,3.5),4.24(2H,s),6.53(1H,d,J=7.6),6.59-6.61(2H,m),7.09-7.12(1H,m),7.11(2H,d,J=7.6),7.24(2H,d,J=7.6),8.82(2H,br)(溶剂:DMSO-d6) | 229298 | |
263 | 363[M+1]287 | 200284 | ||
267 | 114-115 | |||
268 | 214.5298.2 | |||
271 | 油 | 229,276 | ||
275 | (CDCl3)1.66(3H,d,J=1.2Hz),1.98(1H,ddd,J=14.0,10.4,3.7Hz),2.47(1H,ddd,J=14.0,6.7,3.5Hz),2.79(1H,ddd,J=12.0,10.4,3.5Hz),3.02(1H,ddd,J=12,0,6.7,3.7Hz),4.45(2H,br),6.16(2H,br),7.04-7.11(2H,m),7.38(1H,dd,J=7.2,2.9Hz),7.88(1H,d,J=2.0Hz),7.96(1H,ddd,J=8.9,4.2,2.9Hz),9.88(1H,s) | |||
277 | 216228281 | |||
279 | 214.5292.3 | |||
281 | 无定形 | 1.55(3H,s),1.83(1H,ddd,J=13.9,10.6,3.9),2.10(1H,ddd,J=13.9,6.5,3.6),2.67(1H,ddd,J=12.2,10.6,3.6),2.87(1H,ddd,J=12.2,6.5,3.9),4.49(2H,d,J=5.6),4.85(1H,br),6.38(1H,dt,J=8.5,0.9),6.59(1H,ddd,J=7.2,5.2,0.9),7.21-7.24(2H,m),7.28-7.32(2H,m),7.40(1H,ddd,J=8.5,7.2,1.8),8.11(1H,ddd,J=5.2,1.8,0.8)(溶剂:CDCl3) | 233301 | |
282 | 146-147 | |||
284 | 181.5 | |||
293 | 1.57(s,3H),1.78-1.89(m,1H),2.10-2.19(m,1H),2.69(ddd,J=11.9,10.8,3.5Hz,1H),2.83-2.91(m,1H),7.15-7.35(m,5H)(溶剂:CDCl3) | |||
299 | 293.5 |
[表141]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
301 | (CDCl3)1.53(3H,s),1.80(1H,ddd,J=14.0,10,4,3.6Hz),2.12(1H,ddd,J=14.0,6.0,3.6Hz),2.75(1H,ddd,J=12.0,10.4,3.6Hz),2.85(1H,ddd,J=12,0,6.0,3.6Hz),3.64(2H,s),4.32(2H,br),6.55(1H,ddd,J=8.0,2.0,0.8Hz),6.66(1H,t,J=2.0Hz),6.70(1H,ddd,J=8.0,2.0,0.8Hz),7.11(1H,t,J=8.0Hz) | |||
302 | 122-126 | 1.41(s,3H),1.67-1.76(m,1H),1.98-2.06(m,1H),2.55-2.63(m,1H),2.86-2.94(m,1H),3.19(s,6H),5.75(s,2H),7.08(d,J=8.0Hz,1H),7.26(t,J=8.0Hz,1H),7.73(d,J=8.0Hz,1H),7.76(br s,1H),8.16(s,1H),8.73(s,1H),10.00(s,1H)(溶剂:CDCl3) | ||
306 | 231,258,289 | |||
307 | 1.83(ddd,J=13.9,10.3,3.6Hz,1H),2.13(ddd,J=13.6,6.2,3.5Hz,1H),2.53(s,3H),2.66-2.75(m,1H),2.90(ddd,J=12.2,6.3,3.8Hz,1H),7.09(d,J=7.8Hz,1H),7.32(t,J=8.0Hz,1H),7.37(s,1H),7.63(d,J=7.8Hz,1H),8.79(s,1H)(溶剂:CDCl3) | |||
308 | 167-168 | |||
309 | 241-244 | |||
319 | 308.9 | |||
329 | 238-239 | |||
330 | 213.4263.9 | |||
332 | 212.2 | |||
333 | 154-158 | |||
339 | 217-218 | |||
341 | 无定形 | 216249 | ||
342 | 184-187 | |||
344 | (DMSO)1.49(3H,s),1.73-1.85(1H,m),2.15-2.28(1H,m),2.54-2.66(1H,m),2.92-3.04(1H,m),5.86(2H,s),7.03-7.25(3H,m),7.40-7.48(2H,m),7.64-7.78(3H,m),10.31(1H,s),11.74(1H,s) | |||
353 | 279.3364.5 | |||
354 | 102-103 | |||
356 | 无定形 | 1.73(s,3H),2.09-2.17(m,1H),2.40(s,3H),2.65-2.73(m,2H),3.15-3.23(m,1H),3.81(s,3H),7.07(d,J=7.2Hz,2H),7.29(br s,1H),7.36(d,J=8.0Hz,2H),7.61(d,J=8.0Hz,2H),7.78(br s,1H),7.90(d,J=7.2Hz,2H),8.00(br s,1H),10.32(s,1H)(溶剂:DMSO-d6) | 267 | |
357 | 无定形 | 224,298 |
[表142]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
358 | 1.57(3H,s),1.80-1.91(1H,m),2.15-2.18(1H,m),2.70-2.94(2H,m),3.94(3H,s),4.67(2H,s),6.75(1H,s),7.05-7.08(1H,m),7.31(1H,t,J=7.91Hz),7.53(1H,t,J=1.98Hz),7.64-7.67(1H,m),8.64(1H,s).(溶剂:CDCl3) | 360[M+1] | ||
359 | 212-214 | 1.46(s,3H),1.73-1.83(m,1H),2.13-2.20(m,1H),2.54-2.61(m,1H),2.62(s,3H),2.93-3.00(m,1H),5.84(br s,2H),7.12(dd,J=12.0,8.8Hz,1H),7.73-7.78(m,1H),7.81(dd,J=7.2,2.4Hz,1H),8.68(s,1H),9.13(s,1H),10.59(s,1H)(溶剂:CDCl3) | ||
360 | 无定形 | 222 | ||
361 | 280.4 | |||
364 | 油 | 344[M+1] | 227,271 | |
367 | (CDCl3)1.78(3H,s),2.07(1H,ddd,J=14.0,12,4,3.6Hz),2.61(1H,br d,J=14.0Hz),2.84(1H,td,J=12.4,3.2Hz),2.94(1H,td,J=12.4,3.6Hz),4.08(3H,s),7.07(1H,ddd,J=8.0,2.0,0.8Hz),7.40(1H,t,J=8.0Hz),7.63(1H,ddd,J=8.0,2.0,0.8Hz),7.74(1H,t,J=2.0Hz),8.18(1H,d,J=1.2Hz),9.02(1H,d,J=1.2Hz),9.56(1H,s) | |||
375 | 217 | |||
380 | 181-182 | 0.86(t,J=7.2Hz,3H),1.82-1.98(m,3H),2.24(br,1H),2.74(td,J=12.0,3.6Hz,1H),2.84(dt,J=12.0,4.0Hz,1H),7.08(ddd,J=8.0,2.0,0.8Hz,1H),7.37(t,J=8.0Hz,1H),7.58(t,J=2.0Hz,2H),7.76(ddd,J=8.0,2.0,0.8Hz,1H),7.88(dd,J=8.4,2.4Hz,1H),8.25(dd,J=8.4,0.8Hz,1H),8.57(dd,J=2.4,0.8Hz,1H),9.84(s,1H)(溶剂:CDCl3) | ||
383 | 油 | 225,269,288 | ||
389 | 无定形 | 292 | ||
393 | 213.4316.0 | |||
395 | 无定形 | 217,269 | ||
396 | 211-213 | 1.64(s,3H),1.96(ddd,J=14.0,10.4,4.0Hz,1H),2.44(ddd,J=14.0,6.8,3.6Hz,1H),2.75(ddd,J=12.4,10.4,3.6Hz,1H),,2.99(ddd,J=12.4,6.8,4.0Hz,1H),4.50(2H,br),7.08(dd,J=11.6,8.8Hz,1H),7.45(dd,J=6.8,2.8Hz,1H),8.01(ddd,J=8.8,4.4,2.8Hz,1H),8.16(ddd,J=8.0,2.0,0.8Hz,1H),8.43(d,J=8.0Hz,1H),8.89(dd,J=2.0.0.8Hz,1H),9.91(s,1H)(溶剂:CDCl3) | ||
401 | 106-107 |
[表143]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
405 | 192-194 | 1.41(s,3H),1.68-1.77(m,1H),1.96-2.05(m,1H),2.55-2.63(m,1H),2.88-2.95(m,1H),4.15(s,3H),5.74(s,2H),7.13(d,J=8.0Hz,1H),7.29(t,J=8.0Hz,1H),7.44(d,J=8.8Hz,1H),7.75(d,J=8.0Hz,1H),7.86(br s,1H),8.20(d,J=8.8Hz,1H),10.73(s,1H)(溶剂:CDCl3) | ||
406 | 276.9 | |||
408 | 221-224 | 1.74(3H,s),2.28(2H,m),2.67(2H,m),2.91(3H,s),3.82(3H,s),6.90(2H,d,J=9.0),7.19(2H,d,J=9.0)(溶剂:CDCl3) | ||
409 | 油 | 215 | ||
410 | 178-182 | 1.37(d,J=6.0Hz,6H),1.42(s,3H),1.70-1.78(m,1H),2.00-2.08(m,1H),2.53-2.61(m,1H),2.88-2.95(m,1H),5.36(quintet,J=6.0Hz,1H),7.11(d,J=8.0Hz,1H),7.29(t,J=8.0Hz,1H),7.75(d,J=8.0Hz,1H),7.80(br s,1H),8.32(d,J=1.2Hz,1H),8.87(d,J=1.2Hz,1H),10.32(s,1H)(溶剂:CDCl3) | ||
411 | 218,264 | |||
413 | 251-254 | |||
415 | 无定形 | 226,290 | ||
417 | 137-139 | |||
422 | (CDCl3)1.45(3H,s),1.70-1.84(1H,m),1.96-2.04(1H,m),2.88-2.96(1H,m),3.04-3.14(1H,m),6.86(1H,d,J=15.9Hz),6.42(1H,d,J=15.9Hz),7.22-7.41(5H,m) | |||
426 | 211.0312.4 | |||
427 | 216 | |||
429 | 油 | 211259 | ||
430 | (DMSO)1.07(3H,s),1.53-1.66(4H,m),2.50-2.70(2H,m),2.92-3.10(2H,m),5.48(1H,s),7.11-7.21(3H,m),7.23-7.29(2H,m) | |||
432 | 油 | 216.272 | ||
436 | 254-256 | |||
441 | 161-165 | |||
443 | 1H-NMR(CDCl3)δ:1.55(4H,s),1.74-1.80(1H,m),2.13-2.17(1H,m),2.68-2.73(2H,m),4.33(1H,br s),4.48(2H,d,J=4.0Hz),4.76(2H,t,J=20.1Hz),6.52(1H,dd,J=7.9,1.8Hz),6.63-6.65(2H,m),7.13(1H,t,J=7.8Hz),7.45-7.51(2H,m),7.79-7.82(4H,m). | 362[M+1] |
[表144]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
444 | 214-215 | 1.41(s,3H),1.66-1.76(m,1H),1.97-2.05(m,1H),2.53-2.62(m,1H),2.62(s,3H),2.86-2.93(m,1H),5.79(br s,2H),7.12(d,J=8.0Hz,1H),7.28(t,J=8.0Hz,1H),7.74(d,J=8.0Hz,1H),7.81(br s,1H),8.68(s,1H),9.14(s,1H),10.52(s,1H)(溶剂:CDCl3) | ||
445 | 92-93 | |||
446 | 油 | 1.57(3H,s),1.86(1H,ddd,J=13.9,10.4,3.7),2.13(1H,ddd,J=13.9,6.5,3.6),2.25(3H,s),2.35(3H,s),2.70(1H,ddd,J=12.2,10.4,3.6),2.89(1H,ddd,J=12.2,6.5,3.7),4.35(2H,br),5.19(2H,s),7.17(2H,d,J=8.0),7.31-7.34(4H,m),7.50(1H,ddd,J=5.8,3.0,1.8),7.55-7.60(1H,m)(溶剂:CDCl3) | 219252 | |
448 | δin d6-DMSO:1.41(3H,s),1.67-1.75(1H,m),1.98-2.05(1H,m),2.52-2.61(1H,m),2.86-2.94(1H,m),5.79(2H,bs),7.14(1H,d,J=7.8Hz),7.30(1H,t,J=7.8Hz),7.73(1H,bd,J=7.8Hz),7.81(1H,t,J=1.8Hz),8.94(1H,m),9.11(1H,m),10.63(1H,bs). | |||
452 | 132-134 | |||
456 | 147-149 | |||
457 | 153-155 | |||
465 | 194.6 | |||
466 | 211 | |||
470 | 281(dec.) | |||
482 | 1.60(s,3H),1.91(ddd,J=14.0,10.8,4.0Hz,1H),2.23(ddd,J=14.0,6.4,3.6Hz,1H),2.77(ddd,J=12.0,10.8,3.6Hz,1H),2.93(ddd,J=12.0,6.4,4.0Hz,1H),7.16(ddd,J=8.0,2.0,0.8Hz,1H),7.37(t,J=8.0Hz,1H),7.61(t,J=2.0Hz,1H),7.75(ddd,J=8.0,2.0,0.8Hz,1H),8.14(d,J=1.6Hz,1H),8.80(d,J=1.6Hz,1H),9.79(s,1H)(溶剂:CDCl3) | |||
483 | 224-227 | 211,289 | ||
490 | 1.64(3H,s)2.03-2.12(1H,m)2.49-2.62(m)3.12-3.16(1H m)7.22(1H,dd,J=4.2Hz)7.27(1H,bs)7.75(1H bs)7.87(1H,dd,J=4.2Hz)8.04(1H,s)8.12(1H,dd,J=4.2Hz)10.64(1H,s)10.72(1H,s)(溶剂:DMSO-d6) | |||
491 | 1.58(s,3H),1.85-1.96(m,1H),2.15-2.24(m,1H),2.50(s,3H),2.67(s,3H),2.71-2.81(m,1H),2.90-2.98(m,1H),7.13(d,J=6.2Hz,1H),7.35(t,J=8.0Hz,1H),7.40(s,1H),7.55(d,J=7.6Hz,1H)(溶剂:CDCl3) | |||
493 | 216 |
[表145]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
494 | δin d6-DMSO:1.37(3H,s),1.62-1.70(1H,m),2.0-2.12(1H,m),2.40-2.50(1H,m),2.79-2.83(1H,m),3.82(3H,s),4.52(2H,d,J=5.4Hz),6.19(1H,m),6.54(1H,d,J=7.8Hz),6.62(1H,d,J=8.1Hz),6.75(1H,s),7.01(1H,t,J=8.1Hz),7.14-7.25(2H,m),7.51(1H,d,J=8.1Hz),7.60(1H,d,J=7.5Hz). | 366[M+1] | ||
496 | 152-154 | |||
497 | δin d6-DMSO:1.48(3H,s),1.83-1.77(1H,m),2.61-2.56(1H,m),2.99-2.95(1H,m),3.86(3H,s),6.07(1H,s),6.95(1H,s),7.03-7.02(1H,m),7.09-7.06(1H,m),7.58-7.57(1H,m),7.64-7.62(1H,m),9.83(1H,s) | |||
498 | 122-125 | |||
500 | 181-184 | |||
501 | 155-156 | |||
502 | 137-138 | |||
504 | 209-219 | |||
511 | 211-214 | 1.58(s,3H),1.90(ddd,J=14.0,10.0,3.6Hz,1H),2.15(ddd,J=14.0,6.8,3.6Hz,1H),2.77(ddd,J=12.4,10.0,3.6Hz,1H),2.94(ddd,J=12.4,6.8,3.6Hz,1H),4.34(2H,br),7.17(ddd,J=8.0,2.0,0.8Hz,1H),7.38(t,J=8.0Hz,1H),7.50(d,J=2.0Hz,1H),7.56(td,J=2.0Hz,1H),7.70(ddd,J=8.0,2.0,0.8Hz,1H),8.08(d,J=1.6Hz),9.70(s,1H)(溶剂:CDCl3) | ||
515 | 204-206 | 1.61(s,3H),1.90(ddd,J=14.0,10.8,3.6Hz,1H),2.22(ddd,J=14.0,6.0,3.6Hz,1H),2.77(ddd,J=12.4,10.8,3.6Hz,1H),2.93(ddd,J=12.4,6.0,3.6Hz,1H),7.15(ddd,J=8.0,2.0,0.8Hz,1H),7.39(t,J=8.0Hz,1H),7.65(t,J=2.0Hz,1H),7.80(ddd,J=8.0,2.0,0.8Hz,1H),8.89(s,2H),9.77(s,1H)(溶剂:CDCl3) | ||
516 | 292.3 | |||
525 | 105-106 | |||
528 | 173-174 | 1.60(s,3H),1.89(ddd,J=14.0,10.8,3.6Hz,1H),2.22(ddd,J=14.0,6.4,3.2Hz,1H),2.44(s,3H),2.77(ddd,J=12.4,10.8,3.2Hz,1H),2.91(ddd,J=12.4,6.4,3.6Hz,1H),4.50(br,2H),7.11(ddd,J=8.0,2.0,0.8Hz,1H),7.35(t,J=8.0Hz,1H),7.67-7.71(m,2H),7.74(ddd,J=8.0,2.0,0.8Hz,1H),8.18(d,J=8.4Hz,1H),8.44(d,J=1.6Hz,1H),9.98(s,1H)(溶剂:CDCl3) | ||
532 | 305.3 | |||
533 | 180-181 | |||
534 | 201-204 | |||
549 | 100-101 | |||
551 | 139-141 | |||
554 | 216 |
[表146]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
556 | (CDCl3)1.67(3H,d,J=1.2Hz),1.98(1H,ddd,J=14.0,10.4,3.7Hz),2.47(1H,ddd,J=14.0,6.7,3.5Hz),2.79(1H,ddd,J=12.0,10.4,3.5Hz),3.02(1H,ddd,J=12,0,6.7,3.7Hz),4.11(3H,s),4.45(2H,br),7.10(1H,dd,J=11.7,8.8Hz),7.41(1H,dd,J=6.9,2.8Hz),8.04(1H,ddd,J=8.8,4.0,2.8Hz),8.20(1H,d,J=1.4Hz),9.06(1H,d,J=1.4Hz),9.51(1H,s) | |||
558 | 358[M+1]282 | 200 | ||
559 | 224 | |||
560 | δin d10-DMSO:1.72(3H,s),2.12-2.05(1H,m),2.71-2.61(2H,m),3.22-3.19(1H,m),6.52(1H,s),7.26(1H,q,J=11.6,9.2Hz),7.55(1H,s),7.66-7.62(2H,m),7.79-7.77(1H,m),7.90-7.88(1H,m),8.07(1H,s),10.42(1H,s),11.55(1H,s) | |||
561 | 235-240 | |||
567 | 油 | 212 | ||
570 | 186-187 | |||
573 | 112-114 | |||
577 | δin d19-DMSO:2.14-2.07(1H,m),2.88-2.70(3H,m),3.07,3.26(2H,abq,J=12.0Hz),3.73(3H,s),5.40(2H,s),6.51(1H,s),6.85(1H,d,J=12.0Hz),7.34(1H,d,J=8.0Hz) | |||
584 | 152-153 | |||
586 | δin d7-DMSO:1.71(3H,s),2.10-2.04(1H,m),2.69-2.59(2H,m),3.20-3.17(1H,m),4.00(3H,s),7.13(1H,d,J=7.4Hz),7.33-7.23(3H,m),7.55(1H,d,J=8.4Hz),7.72-7.68(1H,m),7.92-7.90(1H,m),10.60(1H,s) | |||
588 | 155-156 | |||
593 | 油 | 226 | ||
595 | 油 | 1.56(3H,s),1.86(1H,ddd,J=13.9,10.1,3.7),2.11(1H,ddd,J=13.9,6.6,3.6),2.32(3H,s),2.70(1H,ddd,J=12.3,10.1,3.6),2.90(1H,ddd,J=12.3,6.6,3.7),5.25(2H,s),7.29-7.35(4H,m),7.47(1H,dt,J=6.8,2.0),7.56-7.58(1H,m),8.59(2H,d,J=6.0)(溶剂:CDCl3) | 220 | |
596 | 215 | |||
597 | 192-194 | |||
600 | 178-180 | |||
601 | 181-192 | 1.59(3H,s),1.85-1.95(1H,m),2.15-2.22(1H,m),2.72-2.78(1H,m),2.88-2.96(1H,m),4.31(3H,s),7.13(1H,d,J=7.25Hz),7.33(1H,t,J=7.91Hz),7.59(1H,s),7.68(1H,d,J=7.91Hz),7.75(1H,s).(溶剂:CDCl3) | 375[M+1] | |
602 | 272-285(dec.) |
[表147]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
605 | 230-233 | 1.63(s,3H),1.94(ddd,J=14.0,10.4,3.6Hz,1H),2.44(ddd,J=14.0,6.4,3.6Hz,1H),2.75(ddd,J=12.4,10.4,3.6Hz,1H),,2.98(ddd,J=12.4,6.4,3.6Hz,1H),4.50(2H,br),7.06(dd,J=11.6,8.8Hz,1H),7.40(dd,J=7.2,2.8Hz,1H),7.59(ddd,J=8.8,8.0,2.8Hz,1H),7.99(ddd,J=8.8,4.4,2.8Hz,1H),8.33(dd,J=8.8,4.4Hz,1H),8.45(d,J=2.8Hz,1H),9.78(s,1H)(溶剂:CDCl3) | ||
608 | 213.4304.1 | |||
611 | 200-202 | |||
613 | 238 | |||
618 | 1.74(s,3H),1.97-2.07(m,1H),2.45-2.55(m,1H),2.77-2.85(m,1H),2.84(s,3H),2.90-2.96(m,1H),7.11(d,J=8.0Hz,1H),7.42(t,J=8.0Hz,1H),7.57(d,J=8.8Hz,1H),7.70(d,J=8.0Hz,1H),7.74(br s,1H),8.29(d,J=8.8Hz,1H),10.12(s,1H)(溶剂:CDCl3) | |||
620 | 212,253 | |||
625 | 07-109 | |||
629 | δin d14-DMSO:1.66(3H,s),2.11-2.05(1H,m),2.37(3H,s),2.63-2.53(2H,m),3.14-3.11(1H,m),7.08-7.04(2H,t,J=7.0Hz),7.43-7.35(4H,m),7.83-7.80(2H,m),10.39(1H,s),11.69(1H,s) | |||
630 | 1.28(3H,t,J=7.7Hz),1.96(1H,ddd,J=3.8,9.9,13.7Hz),2.19(1H,ddd,J=3.5,7.0,13.7Hz),2.74(1H,ddd,J=3.6,9.9,12.2Hz),2.93(1H,ddd,J=3.8,7.0,12.1Hz),4.05-4.49(4H,m),7.40-7.50(3H,m),7.77-7.86(1H,m)(溶剂:CDCl3) | 301[M+1] | ||
634 | (CDCl3)1.67(3H,d,J=1.2Hz),1.98(1H,ddd,J=14.0,10.4,3.7Hz),2.47(1H,ddd,J=14.0,6.7,3.5Hz),2.79(1H,ddd,J=12.0,10.4,3.5Hz),3.02(1H,ddd,J=12,0,6.7,3.7Hz),4.11(3H,s),4.45(2H,br),7.10(1H,dd,J=11.7,8.8Hz),7.41(1H,dd,J=6.9,2.8Hz),8.04(1H,ddd,J=8.8,4.0,2.8Hz),8.20(1H,d,J=1.4Hz),9.06(1H,d,J=1.4Hz),9.51(1H,s) | |||
636 | 118-119 | |||
637 | 229,275 | |||
643 | 55-157 | 1.60(s,3H),1.90(ddd,J=14.0,10.4,3.6Hz,1H),2.20(ddd,J=14.0,6.8,3.6Hz,1H),2.77(ddd,J=12.0,10.4,3.6Hz,1H),,2.93(ddd,J=12.0,6.8,3.6Hz,1H),4.59(brs,1H),7.16(ddd,J=8.0,2.0,0.8Hz,1H),7.37(t,J=8.0Hz,1H),7.67(t,J=2.0Hz,1H),7.71(ddd,J=8.0,2.0,0.8Hz,1H),7.87(dd,J=10.0,1.2Hz,1H),8.73(d,J=1.2Hz,1H),9.74(s,1H)(溶剂:CDCl3) | ||
644 | 201-203 |
[表148]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
645 | 油 | 1.58(3H,s),1.87(1H,ddd,J=14.0,10.4,3.6),2.16(1H,ddd,J=14.0,6.3,3.5),2.34(3H,s),2.70(1H,ddd,J=12.3,10.4,3.5),2.90(1H,ddd,J=12.3,6.3,3.6),5.38(2H,s),7.18-7.33(3H,m),7.43(1H,d,J=8.0),7.49-7.60(2H,m),7.69(1H,dt,J=7.7,1.9),8.59(1H,ddd,J=4.9,1.9,1.1)(溶剂:CDCl3) | 222 | |
649 | 61-162 | |||
651 | 193-196 | 1.59(s,3H),1.90(ddd,J=14.0,10.4,3.6Hz,1H),2.18(ddd,J=14.0,6.4,3.6Hz,1H),2.76(ddd,J=12.4,10.4,3.6Hz,1H),,2.93(ddd,J=12.4,6.4,3.6Hz,1H),4.42(br,2H),7.17(ddd,J=8.0,2.0,0.8Hz,1H),7.38(t,J=8.0Hz,1H),7.64(t,J=2.0Hz,1H),7.77(ddd,J=8.0,2.0,0.8Hz,1H),8.20(dd,J=8.0,2.0Hz,1H),8.44(dd,J=8.0,0.8Hz,1H),8.91(dd,J=2.0,0.8Hz,1H),9.87(s,1H)(溶剂:CDCl3) | ||
652 | δin d21-DMSO:1.67(3H,s),2.14-2.07(1H,m),2.62-2.57(2H,m),3.17-3.14(1H,m),5.74(1H,s),7.14(1H,d,J=8.0Hz),7.44(1H,t,J=8.0Hz),7.85-7.81(2H,m),8.01(1H,d,J=12.0Hz),8.16(1H,d,J=8.0Hz),8.77(1H,s),10.95(1H,s) | |||
653 | 193-194 | |||
654 | 油 | 257 | ||
657 | 199-203 | |||
660 | 无定形 | 223,266 | ||
661 | δin d9-DMSO:1.30(3H,t,J=7.0Hz),1.69(3H,s),2.10-2.04(1H,m),2.20(3H,s),2.67-2.62(2H,m),3.20-3.17(1H,m),4.40(2H,q,J=14.0,7.0Hz),6.83(1H,s),7.25(1H,q,J=12.0,9.0Hz),7.62-7.61(1H,m),7.85-7.83(1H,m),10.42(1H,s) | |||
664 | 无定形 | 225,267 | ||
667 | 无定形 | 226 | ||
673 | 油 | 224 | ||
677 | 无定形 | 216 | ||
680 | 159-160 | 1.63(3H,s),1.65-1.80(1H,m),2.53-2.64(1H,m),2.75-2.88(2H,m),3.83(3H,s),4.32(2H,br),6.87-6.96(2H,m),7.19-7.33(2H,m)(溶剂:CDCl3) | ||
681 | δin d6-DMSO:1.43(3H,s),1.66-1.74(1H,m),2.02-2.07(1H,m),2.56-2.63(1H,m),2.85-2.90(1H,m),5.80(2H,bs),6.91(1H,d,J=7.8Hz),6.96-6.98(2H,m),7.25(1H,t,J=7.8Hz),7.2-7.36(2H,m),7.40(1H,m),7.89-7.92(1H,m),9.42(1H,bs),10.78(1H,bs). | 338[M+1] | ||
683 | 166-168 |
[表149]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
687 | 164-167 | 1.60(3H,s),1.84-1.95(1H,m),2.21-2.26(1H,m),2.73-2.94(2H,m),3.92(3H,s),4.25(3H,s),7.10(1H,d,J=7.58Hz),7.34(1H,t,J=7.91Hz),7.40(1H,s),7.57(1H,br s),7.66(1H,d,J=7.91Hz),8.67(1H,s).(溶剂:CDCl3) | 388[M+1] | |
692 | (CDCl3)1.50(3H,s),1.75-1.88(1H,m),2.00-2.10(1H,m),2.91-2.99(1H,m),3.08-3.18(1H,m),6.21(1H,d,J=15.9Hz),6.59(1H,d,J=15.9Hz),7.42-7.47(3H,m),7.59(1H,dd,J=8.6,2,0Hz),7.74-7.83(4H,m) | |||
698 | 269 | |||
700 | 177-178 | |||
701 | 1.61(s,3H),1.90(m,1H),2.25(m,1H),2.81(m,1H),2.92(m,1H),3.86(s,3H),6.71(t-like,J=1.8Hz,1H),7.12(t-like,J=1.8Hz,1H),7.53(t-like,J=1.8Hz,1H),7.89(dd,J=8.3Hz,2.4Hz,1H),8.24(d,J=8.3Hz,1H),8.58(d,J=2.4Hz,1H),9.85(br,1H)(溶剂:CDCl3) | |||
702 | 1H-NMR(CDCl3)δ:1.65(3H,s),1.91-1.98(1H,m),2.57-2.62(1H,m),2.68-2.75(1H,m),2.92-2.97(1H,m),4.18(3H,s),6.82(1H,br s),7.02-7.08(1H,m),7.28-7.32(1H,m),7.44(1H,s),7.92-7.96(1H,m). | |||
707 | 167-174 | |||
709 | 99-100 | 0.82(3H,t,J=7.3Hz),1.72-1.90(3H,m),2.06-2.15(1H,m),2.61-2.82(2H,m),3.80(3H,s),4.36(2H,br),6.86(2H,d,J=8.9Hz),7.17(2H,d,J=8.9Hz)(溶剂:CDCl3) | ||
717 | 157-162 | 1.58(s,3H),1.90(ddd,J=14.0,10.4,3.6Hz,1H),2.15(ddd,J=14.0,6.8,3.6Hz,1H),2.76(ddd,J=12.4,10.4,3.6Hz,1H),2.94(ddd,J=12.4,6.8,3.6Hz,1H),3.49(1H,S),3.76(2H,br),7.17(ddd,J=8.0,2.0,0.8Hz,1H),7.36(t,J=8.0Hz,1H),7.38(d,J=1.6Hz,1H),7.50(t,J=2.0Hz,1H),7.73(ddd,J=8.0,2.0,0.8Hz,1H),8.22(d,J=2.4Hz),9.26(d,J=2.4Hz,1H),10.12(s,1H)(溶剂:CDCl3) | ||
719 | 油 | 226254 | ||
720 | 133-138 | |||
725 | 无定形 | 1.62(s,3H),1.96-2.03(m,1H),2.38-2.49(m,1H),2.63-2.71(m,1H),3.05-3.12(m,1H),6.73(dd,J=3.2,1.6Hz,2H),7.35(d,J=3.2Hz,1H),7.37(br s,1H),7.57(d,J=8.4Hz,2H),7.67(d,J=8.4Hz,2H),7.77(br s,1H),7.96(br s,1H),8.01(br s,1H),10.35(s,1H)(溶剂:DMSO-d6) | 265 | |
728 | 179-182 | |||
729 | 167-169 |
[表150]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
730 | 211.0289.9 | |||
731 | 91-94 | |||
732 | 无定形 | 211 | ||
735 | 166-168 | |||
737 | 1H-NMR(CDCl3)δ:1.59(3H,s),1.87-1.94(1H,m),2.47-2.53(1H,m),2.67-2.73(1H,m),2.93-2.99(1H,m),4.10(3H,s),6.62(1H,s),7.04(1H,t,J=10.2Hz),7.33(1H,d,J=4.3Hz),7.85(1H,br s). | |||
738 | 181-183 | |||
739 | 285 | |||
740 | 250(dec.) | |||
743 | 148-150 | 1.60(s,3H),179-2.93(m,4H),4.46(2H,br),7.09(d,J=2.0Hz,1H),7.12(ddd,J=7.6,2.0,0.8Hz,1H),7.18(t,J=2.0Hz,1H),7.36(d,J=7.6,2.0,0.8Hz,1H),7.43(t,J=7.6Hz,1H),8.21(d,J=2.0Hz)(溶剂:CDCl3) | ||
744 | δin d8-DMSO:1.47(3H,s),1.82-1.78(1H,m),2.22-2.18(1H,m),2.62-2.56(1H,m),3.00-2.96(1H,m),6.79(1H,s),6.63(1H,s),7.08-7.03(1H,m),7.51(1H,s),7.64-7.57(2H,m),9.57(1H,s),11.25(1H,s) | |||
753 | 无定形 | 225,299 | ||
756 | 110-111 | 1.55(3H,s),1.76-1.87(1H,m),2.08-2.17(1H,m),2.35(3H,s),2.65-2.76(1H,m),2.82-2.92(1H,m),4.35(2H,br),7.01-7.25(4H,m)(溶剂:CDCl3) | ||
758 | 156-157 | |||
766 | 336[M+1]260 | 203212 | ||
767 | 98-100 | |||
768 | 1.60(3H,d,J=1.3Hz),1.89-1.99(1H,m),2.29(3H,s),2.37-2.42(1H,m),2.70-2.75(1H,m),2.96-3.00(1H,m),4.12(3H,s),6.39(1H,s),7.04(1H,dd,J=11.5,8.9Hz),7.18(1H,dd,J=6.9,2.6Hz),7.60(1H,s),7.82-7.86(1H,m).(溶剂:CDCl3) | 362[M+1] | 213263 | |
771 | 417[M+1]341 | 201 | ||
774 | 1H-NMR(CDCl3)δ:1.77(3H,s),2.11-2.21(1H,m),2.71-2.80(1H,m),2.87-2.99(2H,m),6.91(1H,d,J=6.9Hz),7.28(2H,s),7.47(1H,t,J=8.1Hz),7.75(1H,t,J=8.6Hz),8.04(1H,dd,J=8.6,2.3Hz),8.29(1H,d,J=8.2Hz),8.46(1H,d,J=2.2Hz). | 400[M+1] |
[表151]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
781 | 1.63(s,3H),1.92(ddd,J=14.0,10.8,4.0Hz,1H),2.29(m,1H),2.78(ddd,J=12.4,10.8,3.6Hz,1H),,2.91(ddd,J=12.4,6.4,4.0Hz,1H),3.94(3H,s),7.09(ddd,J=8.0,2.0,0.8Hz,1H),7.34(dd,J=8.8,2.8Hz,1H),7.35(t,J=8.0Hz,1H),7.68(t,J=2.0Hz,1H),7.71(ddd,J=8.0,2.0,0.8Hz,1H),8.24(d,J=8.8Hz,1H),8.28(d,J=2.8Hz,1H),9.86(s,1H)(溶剂:CDCl3) | |||
783 | 205-206 | |||
786 | 1.66(3H,s),2.10(1H,m),2.57-2.64(2H,m),3.16(1H,m),6.74(1H,s),7.30(1H,s),7.36(1H,s),7.74(1H,s),7.98(1H,s),8.06(1H,s),10.33(1H,s),10.47(1H,s)(溶剂:DMSO-d6) | |||
790 | 无定形 | 223,290 | ||
791 | δin d18-DMSO:1.41(3H,s),1.76-1.69(1H,m),2.02-1.98(1H,m),2.62-2.55(1H,m),2.92-2.89(1H,m),7.13(1H,d,J=7.6Hz),7.29(1H,t,J=7.6Hz),7.62-7.59(2H,m),8.71(1H,s),9.28(1H,s),10.46(1H,brs) | |||
792 | 299.4 | |||
793 | 269(dec.) | |||
797 | 213.4312.4 | |||
799 | 215.240 | |||
800 | 225.275 | |||
802 | 1.63(s,3H),1.92(ddd,J=14.0,11.2,3.6Hz,1H),2.28(br,1H),2.78(ddd,J=12.4,11.2,3.6Hz,1H),2.81(s,3H),2.92(ddd,J=12.4,6.4,4.0Hz,1H),7.10(ddd,J=8.0,2.0,0.8Hz,1H),7.35(t,J=8.0Hz,1H),7.56(t,J=2.0Hz,1H),7.65(d,J=2.4Hz,1H),7.74(ddd,J=8.0,2.0,0.8Hz,1H),8.41(d,J=2.4Hz,1H),10.03(s,1H)(溶剂:CDCl3) | |||
803 | 271 | |||
804 | 135-136 | |||
810 | 47-48 | |||
811 | 138-139 | |||
813 | 204-205 | 182(s,3H),1.89-1.94(m,1H),2.78(ddd,J=12.4,6.4,3.6Hz,1H),4.50(2H,br),7.06(dd,J=11.6,8.8Hz,1H),7.40(dd,J=7.2,2.8Hz,1H),7.59(ddd,J=8.8,8.0,2.8Hz,1H),7.99(ddd,J=8.8,4.4,2.8Hz,1H),8.33(dd,J=8.8,4.4Hz,1H),8.45(d,J=2.8Hz,1H),9.78(s,1H)(溶剂:CDCl3) | ||
814 | 油 | 218,272 | ||
816 | 214.5 |
[表152]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
820 | (CDCl3)1.66(3H,d,J=1.2Hz),1.98(1H,ddd,J=14.0,10.4,3.7Hz),2.47(1H,ddd,J=14.0,6.7,3.5Hz),2.79(1H,ddd,J=12.0,10.4,3.5Hz),3.02(1H,ddd,J=12,0,6.7,3.7Hz),4.45(2H,br),6.16(2H,br),7.04-7.11(2H,m),7.38(1H,dd,J=7.2,2.9Hz),7.88(1H,d,J=2.0Hz),7.96(1H,ddd,J=8.9,4.2,2.9Hz),9.88(1H,s) | |||
822 | 279 | |||
827 | 134-137 | 214.5284.0 | ||
832 | 212,299 | |||
833 | 油 | 212,273 | ||
834 | 217,267 | |||
835 | 139-140 | |||
836 | 221.6279.3 | |||
840 | 223-225 | |||
848 | 油 | 223,254 | ||
849 | 143-145 | |||
850 | δin d16-DMSO:1.41(3H,s),1.75-1.70(1H,m),2.02-1.99(1H,m),2.61-2.56(1H,m),2.93-2.88(1H,m),7.13(1H,d,J=8.0),7.29(1H,t,J=7.8Hz),7.35(1H,q,J=8.4,2.4Hz),7.66-7.63(2H,m),8.52-8.47(1H,m),8.81(1H,s),10.44(1H,s) | |||
851 | 82-83 | 1.55(3H,s),1.76-1.88(1H,m),2.10-2.18(1H,m),2.66-2.77(1H,m),2.82-2.91(1H,m),3.81(3H,s),6.73-6.78(1H,m),6.88-6.92(2H,m),7.21-7.29(1H,m)(溶剂:CDCl3) | ||
855 | 油 | 219 | ||
859 | 350[M+1]274 | 200208254 | ||
863 | 192-194 | 1.39(t,J=7.2Hz,3H),1.42(s,3H),1.71-1.79(m,1H),2.02-2.10(m,1H),2.55-2.62(m,1H),2.88-2.96(m,1H),4.47(q,J=7.2Hz,2H),5.70-6.20(br s,2H),7.11(d,J=8.0Hz,1H),7.29(t,J=8.0Hz,1H),7.75(d,J=8.0Hz,1H),7.80(br s,1H),8.38(d,J=1.2Hz,1H),8.87(d,J=1.2Hz,1H),10.34(s,1H)(溶剂:CDCl3) | ||
866 | 293.5 | |||
869 | 1.65(s,3H),1.90-2.01(m,3H),2.32(br,1H),2.80(td,J=12.0,3.6Hz,1H),2.85(t,J=8.0Hz,2H),2.92(ddd,J=12.0,5.6,3.6,1H),3.75(t,J=8.0Hz,2H),7.11(ddd,J=8.0,2.0,0.8Hz,1H),7.37(t,J=8.0Hz,1H),7.70(t,J=2.0Hz,1H),7.73-7.76(m,2H),8.22(d,J=7.6Hz,1H),8.48(d,J=2.0Hz,1H),10.00(s,1H)(溶剂:CDCl3) | |||
871 | 212-213 |
[表153]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
875 | 油 | 222,271 | ||
876 | 油 | 222 | ||
878 | 油 | 211 | ||
881 | 141-144 | |||
887 | 262.7 | |||
892 | 251(dec.) | |||
893 | δin d12-DMSO:1.70(3H,s),2.10-2.04(1H,m),2.69-2.59(2H,m),3.20-3.17(1H,m),6.80(1H,brs),7.26-7.20(1H,m),7.88-7.81(3H,m),10.35(1H,s)13.53(1H,brs) | |||
895 | 378[M+1]302 | 202208216221265 | ||
896 | 无定形 | 219,264 | ||
897 | 212-214 | |||
900 | 205-207 | 1.61(s,3H),1.91(ddd,J=14.0,10.8,4.0Hz,1H),2.23(ddd,J=14.0,6.4,3.6Hz,1H),2.77(ddd,J=12.4,10.8,3.6Hz,1H),2.92(ddd,J=12.4,6.4,4.0Hz,1H),7.15(ddd,J=8.0,2.0,0.8Hz,1H),7.38(t,J=8.0Hz,1H),7.65(t,J=2.0Hz,1H),7.79(ddd,J=8.0,2.0,0.8Hz,1H),8.99(s,2H),9.78(s,1H)(溶剂:CDCl3) | ||
906 | 212.2273.4350.5 | |||
908 | δin d15-DMSO:1.66(3H,s),2.11-2.05(1H,m),2.37(3H,s),2.63-2.54(2H,m),3.16-3.11(1H,m),3.16(3H,s),7.08-6.96(3H,m),7.49-7.41(3H,m),7.85-7.81(2H,m),10.52(1H,s)11.69(1H,s) | |||
910 | 油 | 211,276 | ||
916 | 131-132 | |||
926 | 1.89(3H,s),2.15(1H,m),2.71-2.82(2H,m),2.96(1H,m),3.04(3H,d,J=4.9),7.35(1H,dd,J=8.7,1.8),7.50-7.55(2H,m),7.74(1H,s),7.82-7.90(3H,s),10.40(1H,br),11.36(1H,Br)(溶剂:CDCl3) | |||
928 | 1.20(t,J=7.6Hz,3H),1.53(br s,3H),1.82-1.97(m,1H),2.39(s,3H),2.61(q,J=7.6Hz,2H),2.99-3.07(m,1H),6.93(br s,1H),7.33(d,J=8.4Hz,2H),7.54-7.58(m,2H),7.87(d,J=8.4Hz,2H),10.13(s,1H)(溶剂:CDCl3) | |||
930 | 132.1-134.4 | 328[M+1] | ||
931 | 299 | |||
933 | 无定形 | 212.259 |
[表154]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
935 | 161-165 | 1.62(s,3H),1.91(ddd,J=14.0,10.4,4.0Hz,1H),2.24(ddd,J=14.0,6.4,3.6Hz,1H),2.80(ddd,J=12.0,10.4,3.6Hz,1H),2.93(ddd,J=12.0,6.4,4.0Hz,1H),7.15(ddd,J=8.0,2.0,1.2Hz,1H),7.39(t,J=8.0Hz,1H),7.66(ddd,J=8.4,7.2,1.2Hz,1H),7.75(t,J=2.0Hz,1H),7.80-7.84(m,2H),7.93(ddd,J=8.0,2.0,1.2Hz),8.21(d,J=8.4Hz,1H),8.38(d,J=8.0Hz,1H),8.41(d,J=8.0Hz,1H),10.25(s,1H)(溶剂:CDCl3) | ||
936 | 169-170 | |||
939 | δin d6-DMSO:1.72(3H,s),2.11-2.05(1H,m),2.70-2.60(2H,m),3.21-3.18(1H,m),7.20(1H,d,J=9.2Hz),7.28(1H,q,J=11.6,9.2Hz),8.56-7.54(2H,m),7.69(1H,s),7.90-7.85(2H,m),10.69(1H,s),12.17(1H,brs) | |||
941 | 220 | |||
944 | 无定形 | 219,256 | ||
946 | 1.61(s,3H),1.91(ddd,J=14.0,10.8,3.6Hz,1H),2.26(ddd,J=14.0,6.4,3.6Hz,1H),2.77(ddd,J=12.4,10.8,3.6Hz,1H),,2.92(ddd,J=12.4,6.4,3.6Hz,1H),7.13(ddd,J=8.0,2.0,1.2Hz,1H),7.36(t,J=8.0Hz,1H),7.61(t,J=2.0Hz,1H),7.72(ddd,J=8.0,2.0,1.2Hz,1H),7.91(d,J=2.4Hz,1H),8.49(d,J=2.4Hz,1H),9.75(s,1H)(溶剂:CDCl3) | |||
947 | 215.7276.9 | |||
960 | 261.5 | |||
964 | 185-187 | |||
966 | 油 | 216 | ||
968 | 107-109 | |||
970 | 1.57(s,3H),1.78-1.89(m,1H),2.10-2.19(m,1H),2.69(ddd,J=11.9,10.8,3.5Hz,1H),2.83-2.91(m,1H),7.15-7.35(m,5H)(溶剂:CDCl3) | |||
971 | (DMSO)1.49(3H,s),1.73-1.86(1H,m),2.16-2.30(1H,m),2.54-2.65(1H,m),2.92-3.03(1H,m),5.86(2H,s),7.04-7.18(2H,m),7.38-7.50(3H,m),7.66-7.78(2H,m),10.35(1H,s),11.84(1H,s) | |||
972 | 1.51(3H,s)1.91-1.95(1H,m)2.37(3H,s)3.00-3.05(1H,m)7.24(1Hs)7.33(2H,dJ=9.0Hz)7.66(1H,s)7.85(2H,dJ=9.0Hz)8.03(1H,s)10.37(1H,s)(溶剂:DMSO-d6) | |||
974 | 无定形 | 219 | ||
978 | 油 | 222 | ||
984 | 255.7318.4 | |||
990 | 126-129 | |||
994 | 130-131 |
[表155]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
998 | 无定形 | 229,290 | ||
1005 | 191-193 | |||
1006 | 88-90 | 2.42-2.47(2H,m),2.80-2.86(2H,m),7.78(6H,s),6.83(4H,d,J=8.9Hz),7.22(4H,d,J=8.9Hz)(溶剂:CDCl3) | ||
1008 | 25-126 | |||
1010 | 90-91 | |||
1014 | 206-210 | |||
1020 | 216.9245.1 | |||
1028 | 105-106 | |||
1034 | 212.2286.4 | |||
1035 | 247-251(dec.) | |||
1037 | 无定形 | 224,272 | ||
1039 | 无定形 | 217249 | ||
1043 | 277-281 | |||
1044 | (DMSO)1.12(3H,s),1.60(2H,d,J=6.2Hz),1.73(2H,d,J=8.6Hz),2.65-2.90(2H,m),2.93-3.13(2H,m),5.55(1H,s),7.34-7.52(3H,m),7.68(1H,s),7.79-7.90(3H,m) | |||
1052 | 1.75(s,3H),2.12-2.21(m,1H),2.40(s,3H),2.65-2.73(m,2H),3.17-3.23(m,1H),7.37(d,J=8.4Hz,2H),7.40-7.44(m,1H),7.77(br s,1H),7.92-7.99(m,5H),8.47(br s,1H),8.70(d,J=4.8Hz,1H),10.37(s,1H),10.41(s,1H)(溶剂:CDCl3) | |||
1055 | 169-170 | 1.56(3H,s),1.78-1.89(1H,m),2.04-2.15(1H,m),2.68-2.79(1H,m),2.86-2.95(1H,m),4.32(2H,br),6.94-7.02(4H,m),7.05-7.12(1H,m),7.25-7.37(4H,m)(溶剂:CDCl3) | ||
1056 | 219 | |||
1059 | 262-267 | |||
1061 | 216 | |||
1062 | 136-137 | 1.53(3H,s),1.76-1.88(1H,m),2.03-2.13(1H,m),2.63-2.73(1H,m),2.85-2.94(1H,m),4.35(2H,br),7.23-7.32(4H,m)(溶剂:CDCl3) | ||
1064 | 84-85 | 1.52(3H,s),1.73-1.89(1H,m),1.97-2.07(1H,m),2.64-2.81(1H,m),2.82-2.91(1H,m),2.87(3H,s),3.77(3H,s),4.10(1H,brs),6.84(2H,d,J=8.9Hz),7.28(2H,d,J=8.6Hz)(溶剂:CDCl3) | ||
1067 | 162-165 | |||
1068 | 132-134 | 230 | ||
1069 | 194-196 | |||
1074 | 324[M+1]248 | 200207 | ||
1076 | 无定形 | 217 |
[表156]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
1084 | 146-149 | |||
1087 | 311.2 | |||
1088 | 无定形 | 1.55(3H,s),1.83(1H,ddd,J=13.9,10.5,3.7),2.09(1H,ddd,J=13.9,6.6,3.6),2.67(1H,ddd,J=12.3,10.5,3.6),2.88(1H,ddd,J=12.3,6.6,3.7),4.48(2H,d,J=6.0),4.91(1H,br),6.33(1H,dd,J=8.8,0.8),7.19(1H,d,J=7.3,7.23-7.30(2H,m),7.35(1H,dd,J=8.8,2.8),8.05(1H,dd,J=2.8,0.8)(溶剂:CDCl3) | 229318 | |
1094 | 216,322 | |||
1100 | 278(dec.) | |||
1107 | 油 | 1.58(3H,s),1.90(1H,ddd,J=13.9,10.1,3.7),2.14(1H,ddd,J=13.9,6.8,3.6),2.69(1H,ddd,J=12.2,10.1,3.6),2.94(1H,ddd,J=12.2,6.8,3.7),3.81(3H,s),4.62(2H,s),6.90(2H,d,J=8.8),7.30(2H,d,J=8.8),7.43(1H,t,J=7.4),7.57(1H,ddd,J=7.4,1.6,1.2),7.81(1H,ddd,J=7.6,1.6,1.2),7.95(1H,t,J=1.6)(溶剂:CDCl3) | 226284 | |
1109 | 134-140 | |||
1110 | 109-110 | |||
1111 | 118-119 | |||
1114 | 121-124 | |||
1115 | 167-170 | 1.63(s,3H),1.93(ddd,J=14.0,10.4,4.0Hz,1H),2.24(ddd,J=14.0,6.4,3.6Hz,1H),2.81(ddd,J=12.4,10.4,3.6Hz,1H),2.96(ddd,J=12.4,6.4,4.0Hz,1H),4.49(br,2H),7.19(ddd,J=8.0,2.0,0.8Hz,1H),7.42(t,J=8.0Hz,1H),7.74(t,J=2.0Hz,1H),7.84(ddd,J=8.0,2.0,0.8Hz,1H),7.88-7.95(m,2H),8.22-8.26(m,2H),9.80(s,1H),9.89(s,1H)(溶剂:CDCl3) | ||
1116 | 油 | 220,255,307 | ||
1119 | 153-157 | |||
1120 | 213-214 | |||
1124 | 169-172 | 225 | ||
1125 | 195-198 | 222256289 | ||
1131 | 189-191 | |||
1132 | 175-180(dec) | |||
1133 | 无定形 | 219,292 | ||
1135 | 255-260(dec.) | |||
1139 | 140-141 | |||
1140 | 油 | 218 | ||
1142 | 182-186(dec.) |
[表157]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
1147 | 214.5275.7 | |||
1150 | 221.6279.3 | |||
1153 | 156-159 | |||
1160 | 1.64(3H,s)2.02-2.12(1H,m)2.54-2.63(1H,m)3.11-3.16(1H,m)7.28(1H,s)7.70(1H,dd J=8.1Hz)7.85(1H,s)8.04-8.17(2H,m)8.28(1H s)8.74(1H d J=5.1Hz)10.81(1H,s)10.96(1H,s)(溶剂:DMSO-d6) | |||
1161 | 192-193 | |||
1166 | 290-295 | 444[M+3]442[M+1]368366 | ||
1172 | 1.55(3H,s)1.94-2.03(1H,m)2.18-2.27(1H,m)2.32(3H,s)3.03-3.07(1H,m)7.05(1H.s)7.09(1H,s)7.14(1H,s)7.37(2H,d J=9.0Hz)7.66(2H,d J=9.0Hz)10.65(1H,s)10.70(1H,s)(溶剂:DMSO-d6) | |||
1181 | 194-195 | 1.60(3H,s),1.81-1.93(1H,m),2.13-2.22(1H,m),2.70-2.81(1H,m),2.86-2.96(1H,m),4.36(2H,br),7.29-7.46(5H,m),7.53-7.61(4H,m)(溶剂:CDCl3) | ||
1184 | 149-150 | |||
1185 | 225.1280.4 | |||
1193 | 182-183 | |||
1194 | 344[M+1]268 | 209214261 | ||
1197 | 250-255(dec.) | |||
1199 | 274-283 | |||
1205 | 油 | E 213,273Z 219,275 | ||
1207 | 106-108 | |||
1211 | 1.77(s,3H),1.98-2.54(m,2H),2.81(s,3H),2.81-2.94(m,2H),3.93(s,3H),7.03(ddd,J=8.0,2.0,0.8Hz,1H),7.08(d,J=2.4Hz,1H),7.36(t,J=8.0Hz,1H),7.63(t,J=2.0Hz,1H),7.69(ddd,J=8.0,2.0,0.8Hz,1H),8.14(d,J=2.4Hz,1H),10.13(s,1H)(溶剂:CDCl3) | |||
1213 | 406[M+1]330 | 20209213 |
[表158]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
1215 | 无定形 | 1.64(s,3H),2.07(ddd,J=14.1,11.5,3.8Hz,1H),2.17(s,3H),2.39(ddd,J=14.1,5.3,3.5Hz,1H),2.72(ddd,J=12.6,11.5,3.5Hz,1H),2.80(ddd,J=12.6,5.3,3.8Hz,1H),3.21(t,J=8.9Hz,2H),4.58(t,J=8.9Hz,2H),6.76(d,J=8.4Hz,1H),6.97-7.02(m,1H),7.08-7.11(m,1H)(溶剂:CDCl3) | ||
1216 | 305.3 | |||
1217 | 263-266 | |||
1221 | 无定形 | 220,253 | ||
1223 | 226.3280.4 | |||
1224 | δin d11-DMSO:1.46(3H,s),1.83-1.77(1H,m),2.18-2.15(1H,m),2.61-2.56(1H,m),2.99-2.95(1H,m),7.08(1H,q,J=12.0,8.4Hz),7.72-7.66(2H,m),7.79(2H,d,J=9.2)9.67(1H,s) | |||
1228 | 油 | 224 | ||
1230 | 232-234 | |||
1240 | 216.9285.2 | |||
1241 | 194-195 | |||
1242 | δin d21-DMSO:1.41(3H,m),1.75-1.68(1H,m),2.04-1.99(1H,m),2.61-2.56(1H,m),2.89(4H,s),5.75(2H,brs),7.07(1H,d,J=4.0Hz),7.25(1H,t,J=8.0Hz),7.72(1H,d,J=8.0Hz),7.75(1H,s),7.83(1H,brs),7.96(1H,s),8.67(1H,s),9.96(1H,s) | |||
1243 | 无定形 | 1.58(3H,s),2.00(1H,ddd,J=14.3,11.5,3.1),2.53(1H,m),2.56(1H,m),3.07(1H,dt,J=12.5,3.1),4.26(2H,s),6.47-6.56(3H,m),7.07-7.15(1H,m),7.12(2H,t,J=8.8),7.39(2H,dd,J=8.8,5.6),8.76(2H,br)(溶剂:DMSO-d6) | 223299 | |
1244 | 268-288 | 1.68(s,3H),2.11(ddd,J=15.2,12.0,4.0Hz,1H),2.57-2.64(m,2H),3.16(dt,J=12.0,4.0Hz,1H),7.13(ddd,J=8.0,2.0,0.8Hz,1H),7.46(t,J=8.0Hz,1H),7.89(t,J=2.0Hz,1H),7.97(ddd,J=8.0,2.0,0.8Hz,1H),8.35(d,J=8.0Hz,1H),8.52(dd,J=8.0,2.4Hz,1H),9.12(d,J=2.4Hz,1H),10.68(s,1H),10.92(s,1H)(溶剂:DMSO-d6) | 219288 | |
1245 | 油 | 286 | ||
1247 | 211 | |||
1255 | 242.7 | |||
1257 | 无定形 | 211 | ||
1258 | 352[M+1] | 228276301 | ||
1261 | 179-180 | |||
1262 | 278-281 |
[表159]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
1263 | 1H-NMR(δin d6-DMSO):1.41(3H,s),1.65-1.77(1H,m),1.95-2.07(1H,m),2.54-2.63(1H,m),2.84-2.94(1H,m),3.39-3.46(2H,m),3.53-3.61(2H,m),4.83(1H,t,J=5.4Hz),5.79(2H,bs),7.07(1H,d,J=7.5Hz),7.25(1H,t,J=7.8Hz),7.73(1H,d,J=7.8Hz),7.76(1H,m),7.87-7.93(1H,m),8.02(1H,d,J=1.2Hz),8.63(1H,d,J=1.2Hz),9.97(1H,s). | 387[M+1] | ||
1264 | 1H-NMR(δin d6-DMSO):1.41(3H,s),1.65-1.77(1H,m),1.95-2.07(1H,m),2.53-2.63(1H,m),2.84-2.95(1H,m),3.73(8H,s),5.79(2H,bs),7.09(1H,d,J=7.8Hz),7.26(1H,t,J=7.8Hz),7.72(1H,d,J=7.8Hz),7.75-7.78(1H,m),8.34(1H,d,J=1.2Hz),8.76(1H,d,J=1.2Hz),10.08(1H,bs). | 413[M+1] | ||
1265 | 1H-NMR(DMSO-d6)δ:1.42(3H,s),1.70-1.76(1H,m),2.02-2.05(1H,m),2.56-2.59(1H,m),2.87-2.93(2H,m),7.07(1H,d,J=7.6Hz),7.23-7.26(3H,m),7.72-7.74(2H,m),7.93(1H,s),8.60(1H,s),9.99(1H,s). | |||
1266 | 1H-NMR(δin d6-DMSO):1.43(3H,s),1.70-1.81(1H,m),1.97-2.10(1H,m),2.55-2.64(1H,m),2.89-2.95(1H,m),5.84(2H,bs),7.17(1H,d,J=7.8Hz),7.33(1H,t,J=7.8Hz),9.98(1H,d,J=1.2Hz),10.01(1H,d,J=1.2Hz),10.74(1H,bs). | 369[M+1] | ||
1267 | 1H-NMR(CDCl3)δ:1.82-1.91(1H,m),2.04(3H,s),2.22(1H,ddd,J=13.8,5.2,3.6Hz),2.67(1H,dt,J=16.7,5.8Hz),2.80(1H,dt,J=12.4,4.7Hz),6.95(2H,d,J=8.1Hz),7.06(2H,td,J=7.8,1.2Hz),7.18(1H,td,J=7.6,1.1Hz),7.27(1H,d,J=1.7Hz),7.32(1H,d,J=7.9Hz),7.42-7.44(2H,m),7.80(1H,dd,J=8.0,1.9Hz). | 338[M+1] | ||
1268 | 1H-NMR(CDCl3)δ:1.62(3H,s),1.89(1H,t,J=12.3Hz),2.27-2.30(1H,m),2.69-2.76(1H,m),2.85-2.88(1H,m),7.11(1H,dd,J=11.4,7.7Hz),7.30-7.53(2H,m),7.63(1H,s),7.71(1H,d,J=6.9Hz). | 327[M+1] | ||
1269 | 1H-NMR(DMSO-d6)δ:1.40(3H,s),1.70-1.73(1H,m),1.99-2.02(1H,m),2.57-2.60(1H,m),2.88-2.90(1H,m),3.29(3H,s),3.52(4H,s),5.75(2H,br s),7.07(1H,d,J=7.6Hz),7.25(1H,t,J=7.7Hz),7.72(1H,d,J=8.3Hz),7.75(1H,s),7.92(1H,br s),8.03(1H,s),8.64(1H,s),9.96(1H,s). | |||
1271 | 1H-NMR(δin d6-DMSO):1.41(3H,s),1.65-1.75(1H,m),1.99-2.06(5H,m),2.52-2.61(1H,m),2.85-2.93(1H,m),3.55(4H,t,J=6.6Hz),5.79(2H,bs),7.05(1H,d,J=7.8Hz),7.25(1H,t,J=7.8Hz),7.70-7.75(1H,m),7.73-7.77(1H,m),7.97(1H,d,J=1.2Hz),8.72(1H,d,J=1.2Hz),10.00(1H,s). | 397[M+1] |
[表160]
化合物编号 | 熔点(℃) | 1H-NMR(δ) | MS(m/z) | UV(λmax:nm) |
1272 | (CDCl3)1.61(3H,s),1.85-1.96(1H,m),2.17-2.27(1H,m),2.69-2.79(1H,m),2.87-2.97(1H,m),7.17(1H,d,J=8.1Hz),7.38(1H,t,J=8.1Hz),7.48-7.74(5H,m),8.40(2H,d,J=7.5Hz) | |||
1273 | 1H-NMR(CDCl3)δ:1.58(3H,s),1.89(1H,t,J=11.2Hz),2.27(1H,s),2.75-2.82(2H,m),6.61(1H,dd,J=20.3,8.4Hz),7.10(1H,d,J=7.2Hz),7.37(1H,dd,J=15.0,8.8Hz),7.90(1H,d,J=7.6Hz),8.10(1H,d,J=3.2Hz),9.37(1H,d,J=4.9Hz),9.69(1H,s). | 395[M+1] | ||
1274 | 1H-NMR(CDCl3)δ:1.61(3H,s),1.84-1.93(1H,m),2.30(1H,t,J=13.1Hz),2.77-2.86(2H,m),6.64(1H,dd,J=20.6,8.6Hz),7.13(1H,d,J=7.9Hz),7.38-7.43(1H,m),7.93(1H,d,J=8.1Hz),8.13(1H,s),9.40(1H,d,J=4.9Hz),9.72(1H,s). | 327[M+1] | ||
1275 | 1H-NMR(DMSO-d6)δ:1.40(3H,s),1.70-1.72(1H,m),2.01-2.04(1H,m),2.18(6H,s),2.44(2H,t,J=6.3Hz),2.56-2.59(1H,m),2.86-2.92(1H,m),7.06(1H,d,J=7.6Hz),7.25(1H,t,J=7.7Hz),7.71-7.73(3H,m),8.02(1H,s),8.64(1H,s),9.95(1H,s). | |||
1276 | 1H-NMR(DMSO-d6)δ:1.70-1.73(1H,m),1.99-2.02(1H,m),2.57-2.60(1H,m),2.88-2.91(1H,m),3.04(3H,s),3.43(3H,t,J=6.3Hz),3.79-3.81(2H,m),5.75(3H,brs),7.08(1H,d,J=7.3Hz),7.26(1H,t,J=7.8Hz),7.72(1H,d,J=7.8Hz),7.76(1H,s),8.04(1H,s),8.09(1H,brs),8.70(1H,s),10.01(1H,s). | |||
1279 | 1H-NMR(CDCl3)δ:1.73(3H,s),2.04(1H,dt,J=18.2,6.5Hz),2.45(1H,d,J=13.6Hz),2.78(2H,t,J=11.8Hz),2.89(2H,t,J=11.5Hz),6.60(1H,s),6.99(1H,d,J=8.2Hz),7.34(1H,t,J=8.0Hz),7.48(1H,s),7.70(1H,d,J=8.2Hz). | 328[M+1] | ||
1280 | 1H-NMR(δin d6-DMSO):1.42(3H,s),1.68-1.82(1H,m),2.02-2.09(1H,m),2.23(3H,s),2.43(4H,t,J=5.1Hz),2.53-2.61(1H,m),2.87-2.95(1H,m),3.73(4H,t,J=5.1Hz),6.01(2H,bs),7.07(1H,d,J=7.8Hz),7.26(1H,t,J=7.8Hz),7.73(1H,d,J=7.8Hz),7.73-7.78(1H,m),8.33(1H,d,J=1.2Hz),8.72(1H,d,J=1.2Hz),10.06(1H,s). | 426[M+1] | ||
1281 | 1H-NMR(δin d6-DMSO):1.40(3H,s),1.30-1.50(2H,m),1.69-1.76(1H,m),1.82-1.88(2H,m),2.01-2.07(1H,m),2.52-2.61(1H,m),2.86-2.94(1H,m),3.76-3.83(1H,m),4.10-4.18(2H,m),4.82(1H,d,J=4.2Hz),5.91(2H,bs),7.07(1H,d,J=7.8Hz),7.26(1H,t,J=7.8Hz),7.70-7.77(2H,m),8.33(1H,d,J=1.2Hz),8.70(1H,d,J=1.2Hz),10.02(1H,s). | 427[M+1] |
[表161]
化合物编号 | MS(m/z) |
2 | 336[M+1] |
7 | 394[M+1] |
10 | 431[M+3]429[M+1] |
11 | 356[M+1] |
12 | 354.M+1] |
13 | 363[M+3]361[M+1] |
14 | 394[M+1] |
15 | 409[M+1] |
16 | 425[M+1] |
17 | 374[M+1] |
19 | 362[M+3]360[M+1] |
20 | 438[M+1] |
21 | 380[M+3]378[M+1] |
22 | 380[M+3]378[M+1] |
25 | 354[M+1] |
27 | 338[M+1] |
28 | 356[M+1] |
29 | 372[M+1] |
31 | 378[M+1] |
32 | 417[M+1] |
34 | 358[M+1] |
35 | 398[M+3]396[M+1] |
36 | 370[M+1] |
40 | 416[M+1]340 |
41 | 414[M+1] |
44 | 362[M+3]360[M+1] |
45 | 365[M+1] |
46 | 362[M+1] |
47 | 416[M+3]414[M+1] |
49 | 394[M+3]392[M+1] |
50 | 292[M+1] |
51 | 388[M+1] |
52 | 360[M+1]284 |
53 | 380[M+1] |
54 | 332[M+1] |
55 | 412[M+3]410[M+1] |
56 | 397[M+1]395[M+1] |
59 | 412[M+1] |
60 | 422[M+1]420[M+1] |
61 | 394[M+1] |
63 | 366[M+1] |
64 | 441[M+1]365 |
65 | 384[M+1] |
66 | 398[M+1] |
67 | 386[M+1]310 |
68 | 376[M+1] |
70 | 372[M+1] |
72 | 330[M+1] |
74 | 322[M+1] |
75 | 412[M+1] |
76 | 363[M+3]361[M+1] |
79 | 310[M+1] |
81 | 386[M+1] |
82 | 306[M+1] |
83 | 336[M+1] |
84 | 380[M+1] |
87 | 415[M+1] |
88 | 426[M+1] |
89 | 370[M+1] |
90 | 354[M+1] |
92 | 417[M+1] |
93 | 407[M+1] |
94 | 350[M+1] |
95 | 406[M+3]404[M+1] |
98 | 398[M+3]396[M+1] |
100 | 332[M+1] |
102 | 424[M+3]422[M+1] |
103 | 444[M+1] |
105 | 424[M+1]348 |
106 | 490[M+1]414 |
107 | 414[M+3]412[M+1] |
108 | 332[M+1] |
109 | 412[M+1] |
110 | 404[M+1] |
111 | 469[M+1]393 |
112 | 377[M+1] |
116 | 408[M+1] |
117 | 413[M+1] |
118 | 372[M+1] |
119 | 424[M+1] |
122 | 338[M+1] |
124 | 471[M+1] |
131 | 412[M+3]410[M+1] |
133 | 404[M+1] |
135 | 416[M+1] |
136 | 380[M+1] |
137 | 327[M+1] |
138 | 394[M+1] |
140 | 456[M+1] |
142 | 446[M+1] |
143 | 399[M+1] |
144 | 432[M+1] |
145 | 394[M+3]392[M+1] |
146 | 433[M+3]431[M+1] |
147 | 324[M+1] |
150 | 418[M+1] |
151 | 458[M+3]456[M+1] |
152 | 371[M+1] |
153 | 398[M+1] |
154 | 401[M+1] |
155 | 322[M+1] |
156 | 332[M+3]330[M+1] |
158 | 394[M+1] |
[表162]
160 | 427[M+1] |
162 | 416[M+3]414[M+1] |
167 | 392[M+3]390[M+1] |
168 | 380[M+3]378[M+1] |
169 | 346[M+1] |
170 | 356[M+1] |
171 | 334[M+1] |
172 | 376[M+3]374[M+1] |
173 | 424[M+3]422[M+1] |
174 | 369[M+1] |
175 | 410[M+1] |
177 | 357[M+1] |
179 | 334[M+1] |
180 | 426[M+1] |
182 | 396[M+3]394[M+1] |
183 | 372[M+1] |
184 | 346[M+1] |
185 | 330[M+1] |
186 | 393[M+3]391[M+1] |
187 | 374[M+1] |
188 | 423[M+1] |
190 | 278[M+1] |
191 | 448[M+1] |
192 | 436[M+3]434[M+1] |
194 | 384[M+1] |
195 | 369[M+1] |
197 | 382[M+1] |
198 | 355[M+1] |
199 | 361[M+1] |
200 | 356[M+1]280 |
201 | 452[M+1] |
203 | 397[M+1] |
205 | 427[M+1] |
206 | 386[M+1]310 |
207 | 384[M+1] |
208 | 386[M+3]384[M+1] |
209 | 371[M+1] |
210 | 366[M+1] |
211 | 442[M+1]366 |
212 | 345[M+1] |
215 | 425[M+3]423[M+1] |
217 | 362[M+1] |
218 | 322[M+1] |
219 | 347[M+1] |
221 | 444[M+1] |
222 | 329[M+1] |
223 | 413[M+1] |
225 | 402[M+1] |
226 | 390[M+1] |
228 | 383[M+1] |
229 | 366[M+1] |
230 | 368[M+1] |
231 | 336[M+1] |
234 | 376[M+1] |
236 | 392[M+1] |
237 | 348[M+1] |
239 | 384[M+1] |
240 | 341[M+1] |
242 | 446[M+1] |
245 | 374[M+1] |
246 | 390[M+1]314 |
247 | 374[M+1] |
248 | 370[M+1] |
249 | 336[M+1] |
250 | 366[M+1] |
252 | 401[M+1] |
253 | 397[M+1] |
254 | 434[M+1] |
257 | 321[M+1] |
258 | 398[M+1] |
260 | 440[M+1] |
261 | 308[M+1] |
262 | 466[M+3]464[M+1] |
264 | 336[M+1] |
265 | 435[M+1] |
266 | 432[M+3]430[M+1] |
269 | 372[M+1]296 |
270 | 338[M+1] |
272 | 349[M+1] |
273 | 406[M+3]404[M+1] |
274 | 380[M+1 |
276 | 398[M+3]396[M+1] |
278 | 404[M+1] |
280 | 433[M+3]431[M+1] |
283 | 322[M+1] |
285 | 340[M+1] |
286 | 433[M+3]431[M+1] |
287 | 440[M+1] |
288 | 354[M+1] |
289 | 341[M+1] |
290 | 363[M+3]361[M+1] |
291 | 317[M+1] |
292 | 426[M+1] |
294 | 424[M+3]422[M+1] |
295 | 394[M+3]392[M+1] |
296 | 389[M+1] |
297 | 448[M+3]446[M+1] |
298 | 363[M+3]361[M+1] |
300 | 356[M+1] |
303 | 366[M+1] |
304 | 402[M+1] |
305 | 407[M+3]405[M+1] |
310 | 411[M+1] |
[表163]
311 | 388[M+1] |
312 | 428[M+1] |
313 | 453[M+1] |
314 | 368[M+1] |
315 | 322[M+1] |
316 | 386[M+1] |
317 | 328[M+1] |
318 | 362[M+1] |
320 | 327[M+1] |
321 | 392[M+1] |
322 | 404[M+1]328 |
323 | 394[M+1] |
324 | 384[M+1] |
325 | 399[M+1] |
326 | 440[M+1]364 |
327 | 314[M+1] |
328 | 384[M+1] |
331 | 360[M+1] |
334 | 412[M+1] |
335 | 316[M+1] |
336 | 356[M+1] |
337 | 428[M+1] |
338 | 466[M+3]464[M+1] |
340 | 344[M+1] |
343 | 399[M+1] |
345 | 412[M+1] |
346 | 384[M+1] |
347 | 430[M+1] |
348 | 341[M+1] |
349 | 335[M+1] |
350 | 412[M+1] |
351 | 322[M+1] |
352 | 327[M+1] |
355 | 397[M+1] |
362 | 366[M+1] |
363 | 376[M+3]374[M+1] |
365 | 366[M+1] |
366 | 409[M+1] |
368 | 384[M+1] |
369 | 396[M+3]394[M+1] |
371 | 398[M+3]396[M+1] |
372 | 348[M+1] |
373 | 358[M+1] |
374 | 364[M+1] |
376 | 412[M+1] |
377 | 425[M+1] |
378 | 380[M+3]378[M+1] |
379 | 377[M+1] |
381 | 409[M+1] |
382 | 340[M+1] |
384 | 388[M+1] |
385 | 384[M+1] |
386 | 352[M+1] |
387 | 376[M+1] |
388 | 440[M+1] |
390 | 407[M+1]331 |
391 | 362[M+1] |
392 | 390[M+1] |
394 | 363[M+3]361[M+1] |
397 | 460[M+3]458[M+1] |
398 | 408[M+1] |
399 | 372[M+1] |
400 | 374[M+1] |
402 | 372[M+1]296 |
403 | 436[M+1] |
404 | 376[M+3]374[M+1] |
407 | 449[M+3]447[M+1] |
412 | 410[M+1] |
414 | 331[M+1] |
416 | 282[M+1] |
418 | 322[M+1] |
419 | 420[M+3]418[M+1] |
420 | 332[M+1] |
421 | 388[M+3]386[M+1] |
423 | 412[M+3]410[M+1] |
424 | 370[M+1] |
425 | 380[M+3]378[M+1] |
428 | 350[M+1] |
431 | 391[M+1] |
433 | 454[M+3]452[M+1] |
434 | 448[M+3]446[M+1] |
435 | 431[M+3]429[M+1] |
437 | 382[M+1] |
438 | 400[M+1]324 |
439 | 380[M+1] |
440 | 358[M+1] |
442 | 394[M+1]318 |
447 | 370[M+1] |
449 | 336[M+1] |
450 | 455[M+1] |
451 | 390[M+3]388[M+1] |
453 | 358[M+1] |
454 | 407[M+1]331 |
455 | 296[M+1] |
458 | 382[M+1] |
459 | 392[M+1] |
460 | 431[M+1] |
461 | 369[M+1] |
462 | 381[M+3]379[M+1] |
463 | 440[M+3]438[M+1] |
464 | 338[M+1]262 |
467 | 387[M+1] |
468 | 439[M+1]363 |
469 | 360[M+1] |
471 | 363[M+3]361[M+1] |
[表164]
472 | 376[M+1] |
473 | 414[M+1] |
474 | 334[M+1] |
475 | 317[M+1] |
476 | 324[M+1] |
477 | 437[M+1] |
478 | 379[M+1] |
479 | 394[M+1] |
480 | 370[M+1] |
481 | 431[M+1] |
484 | 314[M+3]312[M+1] |
485 | 448[M+1] |
486 | 350[M+1] |
487 | 338[M+1] |
488 | 306[M+1] |
489 | 335[M+1] |
492 | 380[M+1] |
495 | 334[M+1] |
499 | 370[M+1] |
503 | 412[M+1] |
505 | 363[M+3]361[M+1] |
506 | 386[M+1] |
507 | 400[M+1] |
508 | 372[M+1] |
509 | 414[M+1]338 |
510 | 374[M+1] |
512 | 320[M+1] |
513 | 420[M+3]418[M+1] |
514 | 372[M+1] |
517 | 369[M+1] |
518 | 376[M+1] |
519 | 411[M+1] |
520 | 395[M+1] |
521 | 372[M+1] |
522 | 390[M+1] |
523 | 414[M+1] |
524 | 341[M+1] |
526 | 426[M+1] |
527 | 381[M+3]379[M+1] |
529 | 320[M+1] |
530 | 390[M+3]388[M+1] |
531 | 410[M+1] |
535 | 356[M+1] |
536 | 372[M+1] |
537 | 377[M+1] |
538 | 406[M+1] |
539 | 411[M+1] |
540 | 354[M+1] |
541 | 342[M+1] |
542 | 361[M+1] |
543 | 344[M+1] |
544 | 412[M+1] |
545 | 366[M+1] |
546 | 383[M+1] |
547 | 430[M+1]428[M+1] |
548 | 427[M+1] |
550 | 340[M+1] |
552 | 400[M+1] |
553 | 304[M+1] |
555 | 383[M+1] |
557 | 304[M+1] |
562 | 374[M+1] |
563 | 366[M+1] |
564 | 395[M+1] |
565 | 336[M+1] |
566 | 427[M+1]351 |
568 | 362[M+3]360[M+1] |
569 | 356[M+1] |
571 | 356[M+1] |
572 | 473[M+3]471[M+1] |
574 | 381[M+3]379[M+1] |
575 | 360[M+1] |
576 | 384[M+1] |
578 | 344[M+1] |
579 | 370[M+1] |
580 | 347[M+1] |
581 | 409[M+1] |
582 | 334[M+1] |
583 | 392[M+1] |
585 | 358[M+1] |
587 | 348[M+1] |
589 | 407[M+3]405[M+1] |
590 | 410[M+3]408[M+1] |
591 | 460[M+1]384 |
592 | 380[M+3]378[M+1] |
594 | 390[M+1] |
598 | 394[M+1] |
599 | 377[M+1] |
603 | 398[M+3]396[M+1] |
604 | 395[M+1] |
606 | 358[M+1] |
607 | 362[M+1] |
609 | 413[M+1] |
610 | 409[M+1] |
612 | 385[M+1] |
614 | 322[M+1] |
615 | 441[M+1] |
616 | 346[M+3]344[M+1]270268 |
617 | 406[M+3]404[M+1] |
619 | 404[M+1] |
621 | 366[M+1] |
623 | 422[M+1]346 |
624 | 370[M+1] |
626 | 402[M+1] |
627 | 398[M+3]396[M+1] |
628 | 413[M+1] |
631 | 370[M+1] |
632 | 414[M+3]412[M+1] |
[表165]
633 | 322[M+1] |
635 | 420[M+1] |
638 | 408[M+1] |
639 | 386[M+1]310 |
640 | 370[M+1] |
641 | 437[M+1] |
642 | 380[M+1] |
646 | 395[M+1] |
647 | 334[M+1] |
648 | 403[M+1] |
650 | 370[M+1] |
655 | 362[M+1] |
656 | 308[M+1] |
658 | 430[M+1] |
659 | 340[M+3]388[M+1] |
662 | 330[M+1] |
663 | 334[M+1] |
665 | 316[M+1] |
666 | 345[M+1] |
668 | 430[M+1] |
669 | 377[M+1] |
670 | 368[M+3]366[M+1] |
671 | 334[M+1] |
672 | 442[M+1] |
674 | 340[M+1] |
675 | 306[M+1] |
676 | 392[M+1] |
678 | 386[M+1] |
679 | 426[M+1] |
682 | 414[M+3]412[M+1] |
684 | 384[M+1] |
685 | 389[M+1] |
686 | 446[M+1] |
688 | 414[M+1] |
689 | 306[M+1] |
690 | 348[M+1] |
691 | 452[M+1] |
693 | 371[M+1] |
694 | 448[M+1] |
695 | 364[M+1] |
696 | 392[M+3]390[M+1] |
697 | 358[M+1] |
699 | 426[M+1] |
703 | 451[M+3]449[M+1] |
704 | 342[M+1] |
705 | 372[M+1] |
706 | 368[M+1] |
708 | 383[M+1] |
710 | 396[M+3]394[M+1] |
711 | 351[M+1] |
712 | 376[M+1] |
713 | 398[M+3]396[M+1] |
714 | 366[M+1] |
715 | 454[M+1] |
716 | 381[M+3]379[M+1] |
718 | 386[M+1] |
721 | 322[M+1] |
722 | 377[M+1] |
723 | 440[M+1]364 |
724 | 457[M+3]455[M+1] |
726 | 362[M+1] |
727 | 366[M+1] |
734 | 370[M+1] |
736 | 338[M+1] |
741 | 404[M+1] |
742 | 351[M+1] |
745 | 386[M+1] |
746 | 370[M+1]294 |
747 | 336[M+1] |
748 | 381[M+3]379[M+1] |
749 | 416[M+1]340 |
750 | 437[M+1] |
751 | 362[M+1] |
752 | 352[M+3]350[M+1] |
754 | 366[M+1] |
755 | 354[M+1] |
757 | 425[M+1] |
759 | 346[M+1] |
760 | 344[M+1] |
76 | 402[M+1] |
762 | 251[M+1] |
763 | 355[M+1] |
764 | 362[M+3]360[M+1] |
765 | 392[M+3]390[M+1] |
769 | 366[M+1] |
770 | 372[M+1] |
772 | 292[M+1] |
773 | 424[M+1] |
775 | 396[M+3]394[M+1] |
776 | 388[M+1] |
777 | 383[M+1] |
778 | 404[M+1] |
779 | 398[M+1] |
780 | 368[M+1] |
782 | 368[M+1] |
784 | 369[M+1] |
785 | 431[M+3]429[M+1] |
787 | 473[M+1]397 |
788 | 375[M+1] |
789 | 467[M+1] |
794 | 327[M+1] |
795 | 384[M+1] |
796 | 370[M+1] |
798 | 370[M+1] |
801 | 404[M+3]402[M+1] |
805 | 376[M+1] |
806 | 411[M+1] |
807 | 356[M+1] |
[表166]
808 | 354[M+1] |
809 | 400[M+1]324 |
812 | 425[M+1] |
815 | 386[M+1] |
817 | 377[M+1] |
818 | 398[M+1] |
819 | 352[M+1] |
821 | 336[M+1] |
823 | 362[M+1] |
824 | 363[M+1]287 |
825 | 420[M+1] |
826 | 430[M+1] |
828 | 377[M+1] |
829 | 437[M+1] |
830 | 370[M+1] |
831 | 327[M+1] |
837 | 324[M+1]248 |
838 | 377[M+1] |
839 | 376[M+3]374[M+1] |
841 | 363[M+3]361[M+1] |
842 | 386[M+1] |
843 | 466[M+3]464[M+1] |
844 | 381[M+1] |
845 | 324[M+1]248 |
846 | 358[M+1] |
847 | 373[M+1] |
852 | 489[M+1] |
853 | 376[M+1] |
854 | 448[M+1] |
856 | 420[M+1]344 |
857 | 341[M+1] |
858 | 383[M+1] |
860 | 370[M+1] |
861 | 334[M+3]332[M+1] |
862 | 358[M+1] |
864 | 392[M+1] |
865 | 398[M+3]396[M+1] |
867 | 399[M+1] |
868 | 430[M+1] |
870 | 362[M+3]360[M+1] |
872 | 428[M+1] |
873 | 351[M+1] |
874 | 341[M+1] |
877 | 399[M+1]323 |
879 | 332[M+1] |
880 | 363[M+3]361[M+1] |
882 | 426[M+1] |
883 | 360[M+1] |
884 | 320[M+1] |
885 | 361[M+1] |
886 | 380[M+1] |
888 | 292[M+1] |
889 | 451[M+1]449[M+1] |
890 | 400[M+1] |
891 | 292[M+1] |
894 | 347[M+1] |
898 | 412[M+3]410[M+1] |
899 | 397[M+1] |
901 | 411[M+1] |
902 | 377[M+1] |
903 | 370[M+1] |
904 | 422[M+1] |
905 | 392[M+1] |
907 | 308[M+1] |
909 | 393[M+1] |
911 | 415[M+1] |
912 | 383[M+1] |
913 | 413[M+1] |
914 | 400[M+1] |
915 | 389[M+1]313 |
917 | 358[M+1] |
918 | 433[M+3]431[M+1] |
919 | 354[M+1] |
920 | 381[M+3]379[M+1] |
921 | 389[M+1] |
922 | 413[M+1]337 |
923 | 437[M+1] |
924 | 376[M+1] |
925 | 390[M+1] |
927 | 355[M+1] |
929 | 370[M+1] |
932 | 380[M+3]378[M+1] |
934 | 507[M+1] |
937 | 388[M+1] |
938 | 366[M+1] |
940 | 388[M+1] |
942 | 378[M+1] |
943 | 413[M+1] |
945 | 372[M+1] |
948 | 462[M+1] |
949 | 363[M+1] |
950 | 368[M+1] |
951 | 412[M+1] |
952 | 378[M+1] |
953 | 318[M+1] |
954 | 363[M+3]361[M+1] |
955 | 406[M+3]404[M+1] |
956 | 292[M+1] |
957 | 398[M+3]396[M+1] |
958 | 310[M+1] |
959 | 406[M+3]404[M+1] |
961 | 362[M+3]360[M+1] |
962 | 327[M+1] |
963 | 392[M+1] |
[表167]
965 | 438[M+3]436[M+1] |
967 | 425[M+3]423[M+1] |
969 | 413[M+1] |
973 | 386[M+1] |
975 | 407[M+3]405[M+1] |
976 | 358[M+1] |
977 | 369[M+1] |
979 | 395[M+1] |
980 | 402[M+1] |
981 | 392[M+3]390[M+1] |
982 | 366[M+1] |
983 | 379[M+1] |
985 | 408[M+1] |
986 | 440[M+3]438[M+1] |
987 | 358[M+1] |
988 | 294[M+1] |
989 | 332[M+1] |
991 | 356[M+1] |
992 | 477[M+1] |
993 | 416[M+3]414[M+1] |
995 | 425[M+3]423[M+1] |
996 | 416[M+3]414[M+1] |
997 | 363[M+3]361[M+1] |
999 | 336[M+1] |
1000 | 388[M+1]312 |
1001 | 374[M+1] |
1002 | 400[M+1] |
1003 | 394[M+1] |
1004 | 397[M+1] |
1007 | 448[M+1]372 |
1009 | 366[M+1] |
1011 | 419[M+1] |
1012 | 316[M+1] |
1013 | 431[M+1] |
1015 | 372[M+1] |
1016 | 470[M+1] |
1017 | 413[M+1] |
1018 | 386[M+1] |
1019 | 433[M+3]431[M+1] |
1021 | 464[M+1] |
1022 | 384[M+1] |
1023 | 407[M+3]405[M+1] |
1024 | 346[M+1] |
1025 | 455[M+3]453[M+1] |
1026 | 425[M+1] |
1027 | 444[M+1] |
1029 | 410[M+1] |
1030 | 413[M+1] |
1031 | 404[M+1] |
1032 | 472[M+1]396 |
1033 | 377[M+1] |
1036 | 350[M+1] |
1038 | 364[M+1] |
1040 | 317[M+1] |
1041 | 407[M+1] |
1042 | 382[M+1] |
1045 | 425[M+3]423[M+1] |
1046 | 366[M+1] |
1047 | 390[M+1] |
1048 | 440[M+1] |
1049 | 396[M+1] |
1050 | 400[M+1] |
1051 | 315[M+1] |
1053 | 363[M+3]361[M+1] |
1054 | 360[M+1] |
1057 | 427[M+1] |
1058 | 360[M+1] |
1060 | 381[M+3]379[M+1] |
1063 | 395[M+1] |
1065 | 451[M+1]449[M+1] |
1066 | 485[M+1] |
1070 | 380[M+3]378[M+1] |
1071 | 345[M+1] |
1072 | 381[M+3]379[M+1] |
1073 | 397[M+1] |
1075 | 342[M+1] |
1077 | 344[M+1] |
1078 | 370[M+1] |
1079 | 387[M+1] |
1080 | 370[M+1]294 |
1081 | 355[M+1] |
1082 | 398[M+3]396[M+1] |
1083 | 318[M+1] |
1085 | 439[M+3]437[M+1] |
1086 | 428[M+1] |
1089 | 399[M+1] |
1090 | 398[M+1] |
1091 | 434[M+3]432[M+1] |
1092 | 398[M+3]396[M+1] |
1093 | 401[M+1] |
1095 | 400[M+1] |
1096 | 409[M+1] |
1097 | 384[M+1] |
1098 | 395[M+1] |
1099 | 511[M+4]510[M+3]509[M+2]508[M+1] |
1101 | 350[M+1] |
1102 | 442[M+1] |
1103 | 397[M+1] |
1105 | 372[M+1] |
1106 | 346[M+1] |
1108 | 383[M+1] |
1112 | 445[M+1] |
[表168]
1113 | 358[M+1] |
1117 | 394[M+1] |
1118 | 336[M+1]260 |
1121 | 392[M+3]390[M+1] |
1122 | 322[M+1] |
1123 | 316[M+1] |
1126 | 386[M+1] |
1127 | 368[M+1] |
1128 | 416[M+3]414[M+1] |
1129 | 341[M+1] |
1130 | 432[M+1] |
1134 | 396[M+1] |
1136 | 396[M+3]394[M+1] |
1137 | 292[M+1] |
1138 | 413[M+1] |
1141 | 344[M+1] |
1143 | 384[M+1] |
1144 | 446[M+1] |
1145 | 390[M+1]314 |
1146 | 405[M+1] |
1148 | 380[M+1]304 |
1149 | 364[M+1] |
1151 | 442[M+1] |
1152 | 365[M+1] |
1154 | 318[M+1] |
1155 | 427[M+1] |
1156 | 368[M+1] |
1157 | 366[M+1] |
1158 | 415[M+3]413[M+1] |
1159 | 414[M+3]412[M+1] |
1162 | 370[M+1]294 |
1163 | 416[M+3]414[M+1] |
1164 | 396[M+1]320 |
1165 | 361[M+1] |
1167 | 424[M+1]348 |
1168 | 428[M+1] |
1169 | 422[M+1] |
1170 | 411[M+1] |
1171 | 390[M+3]388[M+1] |
1173 | 361[M+1] |
1174 | 342[M+1] |
1175 | 430[M+1] |
1176 | 345[M+1] |
1177 | 376[M+3]374[M+1] |
1178 | 351[M+1] |
1179 | 344[M+1] |
1180 | 398[M+3]396[M+1] |
1182 | 426[M+1] |
1183 | 376[M+3]374[M+1] |
1186 | 374[M+1]298 |
1187 | 427[M+1] |
1188 | 350[M+1] |
1189 | 408[M+3]406[M+1] |
1190 | 386[M+1] |
1191 | 377[M+1] |
1192 | 335[M+1] |
1195 | 412[M+3]410[M+1] |
1196 | 380[M+1] |
1198 | 398[M+1]322 |
1200 | 352[M+1] |
1201 | 424[M+3]422[M+1] |
1202 | 369[M+1] |
1203 | 420[M+1] |
1204 | 398[M+3]396[M+1] |
1206 | 416[M+1] |
1208 | 344[M+1] |
1209 | 422[M+1] |
1210 | 408[M+1] |
1212 | 391[M+1] |
1214 | 360[M+1] |
1218 | 372[M+1] |
1219 | 470[M+1] |
1220 | 264[M+1] |
1222 | 362[M+3]360[M+1] |
1225 | 413[M+1] |
1226 | 374[M+1] |
1227 | 425[M+1] |
1229 | 455[M+3]453[M+1] |
1231 | 413[M+1] |
1232 | 340[M+1] |
1233 | 394[M+1] |
1234 | 416[M+3]414[M+1] |
1235 | 427[M+1] |
1236 | 348[M+1]272 |
1237 | 353[M+1] |
1238 | 419[M+1] |
1239 | 416[M+3]414[M+1] |
1246 | 474[M+1] |
1248 | 414[M+1] |
1249 | 336[M+1] |
1250 | 352[M+1] |
1251 | 393[M+1] |
1252 | 357[M+1] |
1253 | 430[M+1] |
1254 | 412[M+1] |
1256 | 333[M+1] |
1259 | 356[M+1] |
1260 | 348[M+1] |
1270 | 374[M+1] |
1282 | 362[M+1] |
[化学式66]
上述式(Ia)~(Ih)中,NR2aR2b、R3c、R3d、R5和G的组合(NR2aR2b、R3c、R3d、R5、G)为以下组合的化合物。
(NHMe,H,H,Me,CONHPh),(NHMe,H,H,Me,CONH-3-吡啶基),(NHMe,H,H,Me,NHCOPh),(NHMe,H,H,Me,NHCO-2-呋喃基),(NH Me,H,H,Me,NHCONHPh),(NHMe,H,H,Me,NHCOCONHPh),(NHMe,H,H,Et,CONHPh),(NHMe,H,H,Et,CONH-3-吡啶基),(NHMe,H,H,Et,NHC OPh),(NHMe,H,H,Et,NHCO-2-呋喃基),(NHMe,H,H,Et,NHCONHPh),(NHMe,H,H,Et,NHCOCONHPh),(NHMe,H,H,CH2OH,CONHPh),(NHMe,H,H,CH2OH,CONH-3-吡啶基),(NHMe,H,H,CH2OH,NHCOPh),(NH Me,H,H,CH2OH,NHCO-2-呋喃基),(NHMe,H,H,CH2OH,NHCONHPh),(NHMe,H,H,CH2OH,NHCOCONHPh),(NHMe,H,Me,Me,CONHPh),(NHMe,H,Me,Me,CONH-3-吡啶基),(NHMe,H,Me,Me,NHCOPh),(NHMe,H,Me,Me,NHCO-2-呋喃基),(NHMe,H,Me,Me,NHCONHPh),(NHMe,H,Me,Me,NHCOCONHPh),(NHMe,H,Me,Et,CONHPh),(NHMe,H,Me,Et,CONH-3-吡啶基),(NHMe,H,Me,Et,NHCOPh),(NHMe,H,Me,Et,NHCO-2-呋喃基),(NHMe,H,Me,Et,NHCONHPh),(NHMe,H,Me,Et,NHCOCONHPh),(NHMe,H,Me,CH2OH,CONHPh),(NHMe,H,Me,CH2OH,CONH-3-吡啶基),(NHMe,H,Me,CH2OH,NHCOPh),(NHMe,H,Me,CH2OH,NHCO-2-呋喃基),(NHMe,H,Me,CH2OH,NHCONHPh),(NHMe,H,Me,CH2OH,NHCOCONHPh),(NHMe,H,Ph,Me,CONHPh),(NHMe,H,Ph,Me,CONH-3-吡啶基),(NHMe,H,Ph,Me,NHCOPh),(NHMe,H,Ph,Me,NHCO-2-呋喃基),(NHMe,H,Ph,Me,NHCONHPh),(NHMe,H,Ph,Me,NHCOCONHPh),(NHMe,H,Ph,Et,CONHPh),(NHMe,H,Ph,Et,CONH-3-吡啶基),(NHMe,H,Ph,Et,NHCOPh),(NHMe,H,Ph,Et,NHCO-2-呋喃基),(NHMe,H,Ph,Et,NHCONHPh),(NHMe,H,Ph,Et,NHCOCONHPh),(NHMe,H,Ph,CH2OH,CONHPh),(NHMe,H,Ph,CH2OH,CONH-3-吡啶基),(NHMe,H,Ph,CH2OH,NHCOPh),(NHMe,H,Ph,CH2OH,NHCO-2-呋喃基),(NHMe,H,Ph,CH2OH,NHCONHPh),(NHMe,H,Ph,CH2OH,NHCOCONHPh),(NHMe,H,OH,Me,CONHPh),(NHMe,H,OH,Me,CONH-3-吡啶基),(NHMe,H,OH,Me,NHCOPh),(NHMe,H,OH,Me,NHCO-2-呋喃基),(NHMe,H,OH,Me,NHCONHPh),(NHMe,H,OH,Me,NHCOCONHPh),(NHMe,H,OH,Et,CONHPh),(NHMe,H,OH,Et,CONH-3-吡啶基),(NHMe,H,OH,Et,NHCOPh),(NHMe,H,OH,Et,NHCO-2-呋喃基),(NHMe,H,OH,Et,NHCONHPh),(NHMe,H,OH,Et,NHCOCONHPh),(NHMe,H,OH,CH2OH,CONHPh),(NHMe,H,OH,CH2OH,CONH-3-吡啶基),(NHMe,H,OH,CH2OH,NHCOPh),(NHMe,H,OH,CH2OH,NHCO-2-呋喃基),(NHMe,H,OH,CH2OH,NHCONHPh),(NHMe,H,OH,CH2OH,NHCOCONHPh),(NHMe,Me,H,Me,CONHPh),(NHMe,Me,H,Me,CONH-3-吡啶基),(NHMe,Me,H,Me,NHCOPh),(NHMe,Me,H,Me,NHCO-2-呋喃基),(NHMe,Me,H,Me,NHCONHPh),(NHMe,Me,H,Me,NHCOCONHPh),(NHMe,Me,H,Et,CONHPh),(NHMe,Me,H,Et,CONH-3-吡啶基),(NHMe,Me,H,Et,NHCOPh),(NHMe,Me,H,Et,NHCO-2-呋喃基),(NHMe,Me,H,Et,NHCONHPh),(NHMe,Me,H,Et,NHCOCONHPh),(NHMe,Me,H,CH2OH,CONHPh),(NHMe,Me,H,CH2OH,CONH-3-吡啶基),(NHMe,Me,H,CH2OH,NHCOPh),(NHMe,Me,H,CH2OH,NHCO-2-呋喃基),(NHMe,Me,H,CH2OH,NHCONHPh),(NHMe,Me,H,CH2OH,NHCOCONHPh),(NHMe,Me,Me,Me,CONHPh),(NHMe,Me,Me,Me,CONH-3-吡啶基),(NHMe,Me,Me,Me,NHCOPh),(NHMe,Me,Me,Me,NHCO-2-呋喃基),(NHMe,Me,Me,Me,NHCONHPh),(NHMe,Me,Me,Me,NHCOCONHPh),(NHMe,Me,Me,Et,CONHPh),(NHMe,Me,Me,Et,CONH-3-吡啶基),(NHMe,Me,Me,Et,NHCOPh),(NHMe,Me,Me,Et,NHCO-2-呋喃基),(NHMe,Me,Me,Et,NHCONHPh),(NHMe,Me,Me,Et,NHCOCONHPh),(NHMe,Me,Me,CH2OH,CONHPh),(NHMe,Me,Me,CH2OH,CONH-3-吡啶基),(NHMe,Me,Me,CH2OH,NHCOPh),(NHMe,Me,Me,CH2OH,NHCO-2-呋喃基),(NHMe,Me,Me,CH2OH,NHCONHPh),(NHMe,Me,Me,CH2OH,NHCOCONHPh),(NHMe,Me,Ph,Me,CONHPh),(NHMe,Me,Ph,Me,CONH-3-吡啶基),(NHMe,Me,Ph,Me,NHCOPh),(NHMe,Me,Ph,Me,NHCO-2-呋喃基),(NHMe,Me,Ph,Me,NHCONHPh),(NHMe,Me,Ph,Me,NHCOCONHPh),(NHMe,Me,Ph,Et,CONHPh),(NHMe,Me,Ph,Et,CONH-3-吡啶基),(NHMe,Me,Ph,Et,NHCOPh),(NHMe,Me,Ph,Et,NHCO-2-呋喃基),(NHMe,Me,Ph,Et,NHCONHPh),(NHMe,Me,Ph,Et,NHCOCONHPh),(NHMe,Me,Ph,CH2OH,CONHPh),(NHMe,Me,Ph,CH2OH,CONH-3-吡啶基),(NHMe,Me,Ph,CH2OH,NHCOPh),(NHMe,Me,Ph,CH2OH,NHCO-2-呋喃基),(NHMe,Me,Ph,CH2OH,NHCONHPh),(NHMe,Me,Ph,CH2OH,NHCOCONHPh),(NHMe,Me,OH,Me,CONHPh),(NHMe,Me,OH,Me,CONH-3-吡啶基),(NHMe,Me,OH,Me,NHCOPh),(NHMe,Me,OH,Me,NHCO-2-呋喃基),(NHMe,Me,OH,Me,NHCONHPh),(NHMe,Me,OH,Me,NHCOCONHPh),(NHMe,Me,OH,Et,CONHPh),(NHMe,Me,OH,Et,CONH-3-吡啶基),(NHMe,Me,OH,Et,NHCOPh),(NHMe,Me,OH,Et,NHCO-2-呋喃基),(NHMe,Me,OH,Et,NHCONHPh),(NHMe,Me,OH,Et,NHCOCONHPh),(NHMe,Me,OH,CH2OH,CONHPh),(NHMe,Me,OH,CH2OH,CONH-3-吡啶基),(NHMe,Me,OH,CH2OH,NHCOPh),(NHMe,Me,OH,CH2OH,NHCO-2-呋喃基),(NHMe,Me,OH,CH2OH,NHCONHPh),(NHMe,Me,OH,CH2OH,NHCOCONHPh),(NHMe,Ph,H,Me,CONHPh),(NHMe,Ph,H,Me,CONH-3-吡啶基),(NHMe,Ph,H,Me,NHCOPh),(NHMe,Ph,H,Me,NHCO-2-呋喃基),(NHMe,Ph,H,Me,NHCONHPh),(NHMe,Ph,H,Me,NHCOCONHPh),(NHMe,Ph,H,Et,CONHPh),(NHMe,Ph,H,Et,CONH-3-吡啶基),(NHMe,Ph,H,Et,NHCOPh),(NHMe,Ph,H,Et,NHCO-2-呋喃基),(NHMe,Ph,H,Et,NHCONHPh),(NHMe,Ph,H,Et,NHCOCONHPh),(NHMe,Ph,H,CH2OH,CONHPh),(NHMe,Ph,H,CH2OH,CONH-3-吡啶基),(NHMe,Ph,H,CH2OH,NHCOPh),(NHMe,Ph,H,CH2OH,NHCO-2-呋喃基),(NHMe,Ph,H,CH2OH,NHCONHPh),(NHMe,Ph,H,CH2OH,NHCOCONHPh),(NHMe,Ph,Me,Me,CONHPh),(NHMe,Ph,Me,Me,CONH-3-吡啶基),(NHMe,Ph,Me,Me,NHCOPh),(NHMe,Ph,Me,Me,NHCO-2-呋喃基),(NHMe,Ph,Me,Me,NHCONHPh),(NHMe,Ph,Me,Me,NHCOCONHPh),(NHMe,Ph,Me,Et,CONHPh),(NHMe,Ph,Me,Et,CONH-3-吡啶基),(NHMe,Ph,Me,Et,NHCOPh),(NHMe,Ph,Me,Et,NHCO-2-呋喃基),(NHMe,Ph,Me,Et,NHCONHPh),(NHMe,Ph,Me,Et,NHCOCONHPh),(NHMe,Ph,Me,CH2OH,CONHPh),(NHMe,Ph,Me,CH2OH,CONH-3-吡啶基),(NHMe,Ph,Me,CH2OH,NHCOPh),(NHMe,Ph,Me,CH2OH,NHCO-2-呋喃基),(NHMe,Ph,Me,CH2OH,NHCONHPh),(NHMe,Ph,Me,CH2OH,NHCOCONHPh),(NHMe,Ph,Ph,Me,CONHPh),(NHMe,Ph,Ph,Me,CONH-3-吡啶基),(NHMe,Ph,Ph,Me,NHCOPh),(NHMe,Ph,Ph,Me,NHCO-2-呋喃基),(NHMe,Ph,Ph,Me,NHCONHPh),(NHMe,Ph,Ph,Me,NHCOCONHPh),(NHMe,Ph,Ph,Et,CONHPh),(NHMe,Ph,Ph,Et,CONH-3-吡啶基),(NHMe,Ph,Ph,Et,NHCOPh),(NHMe,Ph,Ph,Et,NHCO-2-呋喃基),(NHMe,Ph,Ph,Et,NHCONHPh),(NHMe,Ph,Ph,Et,NHCOCONHPh),(NHMe,Ph,Ph,CH2OH,CONHPh),(NHMe,Ph,Ph,CH2OH,CONH-3-吡啶基),(NHMe,Ph,Ph,CH2OH,NHCOPh),(NHMe,Ph,Ph,CH2OH,NHCO-2-呋喃基),(NHMe,Ph,Ph,CH2OH,NHCONHPh),(NHMe,Ph,Ph,CH2OH,NHCOCONHPh),(NHMe,Ph,OH,Me,CONHPh),(NHMe,Ph,OH,Me,CONH-3-吡啶基),(NHMe,Ph,OH,Me,NHCOPh),(NHMe,Ph,OH,Me,NHCO-2-呋喃基),(NHMe,Ph,OH,Me,NHCONHPh),(NHMe,Ph,OH,Me,NHCOCONHPh),(NHMe,Ph,OH,Et,CONHPh),(NHMe,Ph,OH,Et,CONH-3-吡啶基),(NHMe,Ph,OH,Et,NHCOPh),(NHMe,Ph,OH,Et,NHCO-2-呋喃基),(NHMe,Ph,OH,Et,NHCONHPh),(NHMe,Ph,OH,Et,NHCOCONHPh),(NHMe,Ph,OH,CH2OH,CONHPh),(NHMe,Ph,OH,CH2OH,CONH-3-吡啶基),(NHMe,Ph,OH,CH2OH,NHCOPh),(NHMe,Ph,OH,CH2OH,NHCO-2-呋喃基),(NHMe,Ph,OH,CH2OH,NHCONHPh),(NHMe,Ph,OH,CH2OH,NHCOCONHPh),(NHCH2CH2OH,H,H,Me,CONHPh),(NHCH2CH2OH,H,H,Me,CONH-3-吡啶基),(NHCH2CH2OH,H,H,Me,NHCOPh),(NHCH2CH2OH,H,H,Me,NHCO-2-呋喃基),(NHCH2CH2OH,H,H,Me,NHCONHPh),(NHCH2CH2OH,H,H,Me,NHCOCONHPh),(NHCH2CH2OH,H,H,Et,CONHPh),(NHCH2CH2OH,H,H,Et,CONH-3-吡啶基),(NHCH2CH2OH,H,H,Et,NHCOPh),(NHCH2CH2OH,H,H,Et,NHCO-2-呋喃基),(NHCH2CH2OH,H,H,Et,NHCONHPh),(NHCH2CH2OH,H,H,Et,NHCOCONHPh),(NHCH2CH2OH,H,H,CH2OH,CONHPh),(NHCH2CH2OH,H,H,CH2OH,CONH-3-吡啶基),(NHCH2CH2OH,H,H,CH2OH,NHCOPh),(NHCH2CH2OH,H,H,CH2OH,NHCO-2-呋喃基),(NHCH2CH2OH,H,H,CH2OH,NHCONHPh),(NHCH2CH2OH,H,H,CH2OH,NHCOCONHPh),(NHCH2CH2OH,H,Me,Me,CONHPh),(NHCH2CH2OH,H,Me,Me,CONH-3-吡啶基),(NHCH2CH2OH,H,Me,Me,NHCOPh),(NHCH2CH2OH,H,Me,Me,NHCO-2-呋喃基),(NHCH2CH2OH,H,Me,Me,NHCONHPh),(NHCH2CH2OH,H,Me,Me,NHCOCONHPh),(NHCH2CH2OH,H,Me,Et,CONHPh),(NHCH2CH2OH,H,Me,Et,CONH-3-吡啶基),(NHCH2CH2OH,H,Me,Et,NHCOPh),(NHCH2CH2OH,H,Me,Et,NHCO-2-呋喃基),(NHCH2CH2OH,H,Me,Et,NHCONHPh),(NHCH2CH2OH,H,Me,Et,NHCOCONHPh),(NHCH2CH2OH,H,Me,CH2OH,CONHPh),(NHCH2CH2OH,H,Me,CH2OH,CONH-3-吡啶基),(NHCH2CH2OH,H,Me,CH2OH,NHCOPh),(NHCH2CH2OH,H,Me,CH2OH,NHCO-2-呋喃基),(NHCH2CH2OH,H,Me,CH2OH,NHCONHPh),(NHCH2CH2OH,H,Me,CH2OH,NHCOCONHPh),(NHCH2CH2OH,H,Ph,Me,CONHPh),(NHCH2CH2OH,H,Ph,Me,CONH-3-吡啶基),(NHCH2CH2OH,H,Ph,Me,NHCOPh),(NHCH2CH2OH,H,Ph,Me,NHCO-2-呋喃基),(NHCH2CH2OH,H,Ph,Me,NHCONHPh),(NHCH2CH2OH,H,Ph,Me,NHCOCONHPh),(NHCH2CH2OH,H,Ph,Et,CONHPh),(NHCH2CH2OH,H,Ph,Et,CONH-3-吡啶基),(NHCH2CH2OH,H,Ph,Et,NHCOPh),(NHCH2CH2OH,H,Ph,Et,NHCO-2-呋喃基),(NHCH2CH2OH,H,Ph,Et,NHCONHPh),(NHCH2CH2OH,H,Ph,Et,NHCOCONHPh),(NHCH2CH2OH,H,Ph,CH2OH,CONHPh),(NHCH2CH2OH,H,Ph,CH2OH,CONH-3-吡啶基),(NHCH2CH2OH,H,Ph,CH2OH,NHCOPh),(NHCH2CH2OH,H,Ph,CH2OH,NHCO-2-呋喃基),(NHCH2CH2OH,H,Ph,CH2OH,NHCONHPh),(NHCH2CH2OH,H,Ph,CH2OH,NHCOCONHPh),(NHCH2CH2OH,H,OH,Me,CONHPh),(NHCH2CH2OH,H,OH,Me,CONH-3-吡啶基),(NHCH2CH2OH,H,OH,Me,NHCOPh),(NHCH2CH2OH,H,OH,Me,NHCO-2-呋喃基),(NHCH2CH2OH,H,OH,Me,NHCONHPh),(NHCH2CH2OH,H,OH,Me,NHCOCONHPh),(NHCH2CH2OH,H,OH,Et,CONHPh),(NHCH2CH2OH,H,OH,Et,CONH-3-吡啶基),(NHCH2CH2OH,H,OH,Et,NHCOPh),(NHCH2CH2OH,H,OH,Et,NHCO-2-呋喃基),(NHCH2CH2OH,H,OH,Et,NHCONHPh),(NHCH2CH2OH,H,OH,Et,NHCOCONHPh),(NHCH2CH2OH,H,OH,CH2OH,CONHPh),(NHCH2CH2OH,H,OH,CH2OH,CONH-3-吡啶基),(NHCH2CH2OH,H,OH,CH2OH,NHCOPh),(NHCH2CH2OH,H,OH,CH2OH,NHCO-2-呋喃基),(NHCH2CH2OH,H,OH,CH2OH,NHCONHPh),(NHCH2CH2OH,H,OH,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Me,H,Me,CONHPh),(NHCH2CH2OH,Me,H,Me,CONH-3-吡啶基),(NHCH2CH2OH,Me,H,Me,NHCOPh),(NHCH2CH2OH,Me,H,Me,NHCO-2-呋喃基),(NHCH2CH2OH,Me,H,Me,NHCONHPh),(NHCH2CH2OH,Me,H,Me,NHCOCONHPh),(NHCH2CH2OH,Me,H,Et,CONHPh),(NHCH2CH2OH,Me,H,Et,CONH-3-吡啶基),(NHCH2CH2OH,Me,H,Et,NHCOPh),(NHCH2CH2OH,Me,H,Et,NHCO-2-呋喃基),(NHCH2CH2OH,Me,H,Et,NHCONHPh),(NHCH2CH2OH,Me,H,Et,NHCOCONHPh),(NHCH2CH2OH,Me,H,CH2OH,CONHPh),(NHCH2CH2OH,Me,H,CH2OH,CONH-3-吡啶基),(NHCH2CH2OH,Me,H,CH2OH,NHCOPh),(NHCH2CH2OH,Me,H,CH2OH,NHCO-2-呋喃基),(NHCH2CH2OH,Me,H,CH2OH,NHCONHPh),(NHCH2CH2OH,Me,H,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Me,Me,Me,CONHPh),(NHCH2CH2OH,Me,Me,Me,CONH-3-吡啶基),(NHCH2CH2OH,Me,Me,Me,NHCOPh),(NHCH2CH2OH,Me,Me,Me,NHCO-2-呋喃基),(NHCH2CH2OH,Me,Me,Me,NHCONHPh),(NHCH2CH2OH,Me,Me,Me,NHCOCONHPh),(NHCH2CH2OH,Me,Me,Et,CONHPh),(NHCH2CH2OH,Me,Me,Et,CONH-3-吡啶基),(NHCH2CH2OH,Me,Me,Et,NHCOPh),(NHCH2CH2OH,Me,Me,Et,NHCO-2-呋喃基),(NHCH2CH2OH,Me,Me,Et,NHCONHPh),(NHCH2CH2OH,Me,Me,Et,NHCOCONHPh),(NHCH2CH2OH,Me,Me,CH2OH,CONHPh),(NHCH2CH2OH,Me,Me,CH2OH,CONH-3-吡啶基),(NHCH2CH2OH,Me,Me,CH2OH,NHCOPh),(NHCH2CH2OH,Me,Me,CH2OH,NHCO-2-呋喃基),(NHCH2CH2OH,Me,Me,CH2OH,NHCONHPh),(NHCH2CH2OH,Me,Me,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Me,Ph,Me,CONHPh),(NHCH2CH2OH,Me,Ph,Me,CONH-3-吡啶基),(NHCH2CH2OH,Me,Ph,Me,NHCOPh),(NHCH2CH2OH,Me,Ph,Me,NHCO-2-呋喃基),(NHCH2CH2OH,Me,Ph,Me,NHCONHPh),(NHCH2CH2OH,Me,Ph,Me,NHCOCONHPh),(NHCH2CH2OH,Me,Ph,Et,CONHPh),(NHCH2CH2OH,Me,Ph,Et,CONH-3-吡啶基),(NHCH2CH2OH,Me,Ph,Et,NHCOPh),(NHCH2CH2OH,Me,Ph,Et,NHCO-2-呋喃基),(NHCH2CH2OH,Me,Ph,Et,NHCONHPh),(NHCH2CH2OH,Me,Ph,Et,NHCOCONHPh),(NHCH2CH2OH,Me,Ph,CH2OH,CONHPh),(NHCH2CH2OH,Me,Ph,CH2OH,CONH-3-吡啶基),(NHCH2CH2OH,Me,Ph,CH2OH,NHCOPh),(NHCH2CH2OH,Me,Ph,CH2OH,NHCO-2-呋喃基),(NHCH2CH2OH,Me,Ph,CH2OH,NHCONHPh),(NHCH2CH2OH,Me,Ph,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Me,OH,Me,CONHPh),(NHCH2CH2OH,Me,OH,Me,CONH-3-吡啶基),(NHCH2CH2OH,Me,OH,Me,NHCOPh),(NHCH2CH2OH,Me,OH,Me,NHCO-2-呋喃基),(NHCH2CH2OH,Me,OH,Me,NHCONHPh),(NHCH2CH2OH,Me,OH,Me,NHCOCONHPh),(NHCH2CH2OH,Me,OH,Et,CONHPh),(NHCH2CH2OH,Me,OH,Et,CONH-3-吡啶基),(NHCH2CH2OH,Me,OH,Et,NHCOPh),(NHCH2CH2OH,Me,OH,Et,NHCO-2-呋喃基),(NHCH2CH2OH,Me,OH,Et,NHCONHPh),(NHCH2CH2OH,Me,OH,Et,NHCOCONHPh),(NHCH2CH2OH,Me,OH,CH2OH,CONHPh),(NHCH2CH2OH,Me,OH,CH2OH,CONH-3-吡啶基),(NHCH2CH2OH,Me,OH,CH2OH,NHCOPh),(NHCH2CH2OH,Me,OH,CH2OH,NHCO-2-呋喃基),(NHCH2CH2OH,Me,OH,CH2OH,NHCONHPh),(NHCH2CH2OH,Me,OH,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Ph,H,Me,CONHPh),(NHCH2CH2OH,Ph,H,Me,CONH-3-吡啶基),(NHCH2CH2OH,Ph,H,Me,NHCOPh),(NHCH2CH2OH,Ph,H,Me,NHCO-2-呋喃基),(NHCH2CH2OH,Ph,H,Me,NHCONHPh),(NHCH2CH2OH,Ph,H,Me,NHCOCONHPh),(NHCH2CH2OH,Ph,H,Et,CONHPh),(NHCH2CH2OH,Ph,H,Et,CONH-3-吡啶基),(NHCH2CH2OH,Ph,H,Et,NHCOPh),(NHCH2CH2OH,Ph,H,Et,NHCO-2-呋喃基),(NHCH2CH2OH,Ph,H,Et,NHCONHPh),(NHCH2CH2OH,Ph,H,Et,NHCOCONHPh),(NHCH2CH2OH,Ph,H,CH2OH,CONHPh),(NHCH2CH2OH,Ph,H,CH2OH,CONH-3-吡啶基),(NHCH2CH2OH,Ph,H,CH2OH,NHCOPh),(NHCH2CH2OH,Ph,H,CH2OH,NHCO-2-呋喃基),(NHCH2CH2OH,Ph,H,CH2OH,NHCONHPh),(NHCH2CH2OH,Ph,H,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Ph,Me,Me,CONHPh),(NHCH2CH2OH,Ph,Me,Me,CONH-3-吡啶基),(NHCH2CH2OH,Ph,Me,Me,NHCOPh),(NHCH2CH2OH,Ph,Me,Me,NHCO-2-呋喃基),(NHCH2CH2OH,Ph,Me,Me,NHCONHPh),(NHCH2CH2OH,Ph,Me,Me,NHCOCONHPh),(NHCH2CH2OH,Ph,Me,Et,CONHPh),(NHCH2CH2OH,Ph,Me,Et,CONH-3-吡啶基),(NHCH2CH2OH,Ph,Me,Et,NHCOPh),(NHCH2CH2OH,Ph,Me,Et,NHCO-2-呋喃基),(NHCH2CH2OH,Ph,Me,Et,NHCONHPh),(NHCH2CH2OH,Ph,Me,Et,NHCOCONHPh),(NHCH2CH2OH,Ph,Me,CH2OH,CONHPh),(NHCH2CH2OH,Ph,Me,CH2OH,CONH-3-吡啶基),(NHCH2CH2OH,Ph,Me,CH2OH,NHCOPh),(NHCH2CH2OH,Ph,Me,CH2OH,NHCO-2-呋喃基),(NHCH2CH2OH,Ph,Me,CH2OH,NHCONHPh),(NHCH2CH2OH,Ph,Me,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Ph,Ph,Me,CONHPh),(NHCH2CH2OH,Ph,Ph,Me,CONH-3-吡啶基),(NHCH2CH2OH,Ph,Ph,Me,NHCOPh),(NHCH2CH2OH,Ph,Ph,Me,NHCO-2-呋喃基),(NHCH2CH2OH,Ph,Ph,Me,NHCONHPh),(NHCH2CH2OH,Ph,Ph,Me,NHCOCONHPh),(NHCH2CH2OH,Ph,Ph,Et,CONHPh),(NHCH2CH2OH,Ph,Ph,Et,CONH-3-吡啶基),(NHCH2CH2OH,Ph,Ph,Et,NHCOPh),(NHCH2CH2OH,Ph,Ph,Et,NHCO-2-呋喃基),(NHCH2CH2OH,Ph,Ph,Et,NHCONHPh),(NHCH2CH2OH,Ph,Ph,Et,NHCOCONHPh),(NHCH2CH2OH,Ph,Ph,CH2OH,CONHPh),(NHCH2CH2OH,Ph,Ph,CH2OH,CONH-3-吡啶基),(NHCH2CH2OH,Ph,Ph,CH2OH,NHCOPh),(NHCH2CH2OH,Ph,Ph,CH2OH,NHCO-2-呋喃基),(NHCH2CH2OH,Ph,Ph,CH2OH,NHCONHPh),(NHCH2CH2OH,Ph,Ph,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Ph,OH,Me,CONHPh),(NHCH2CH2OH,Ph,OH,Me,CONH-3-吡啶基),(NHCH2CH2OH,Ph,OH,Me,NHCOPh),(NHCH2CH2OH,Ph,OH,Me,NHCO-2-呋喃基),(NHCH2CH2OH,Ph,OH,Me,NHCONHPh),(NHCH2CH2OH,Ph,OH,Me,NHCOCONHPh),(NHCH2CH2OH,Ph,OH,Et,CONHPh),(NHCH2CH2OH,Ph,OH,Et,CONH-3-吡啶基),(NHCH2CH2OH,Ph,OH,Et,NHCOPh),(NHCH2CH2OH,Ph,OH,Et,NHCO-2-呋喃基),(NHCH2CH2OH,Ph,OH,Et,NHCONHPh),(NHCH2CH2OH,Ph,OH,Et,NHCOCONHPh),(NHCH2CH2OH,Ph,OH,CH2OH,CONHPh),(NHCH2CH2OH,Ph,OH,CH2OH,CONH-3-吡啶基),(NHCH2CH2OH,Ph,OH,CH2OH,NHCOPh),(NHCH2CH2OH,Ph,OH,CH2OH,NHCO-2-呋喃基),(NHCH2CH2OH,Ph,OH,CH2OH,NHCONHPh),(NHCH2CH2OH,Ph,OH,CH2OH,NHCOCONHPh),(NHCH2CONH2,H,H,Me,CONHPh),(NHCH2CONH2,H,H,Me,CONH-3-吡啶基),(NHCH2CONH2,H,H,Me,NHCOPh),(NHCH2CONH2,H,H,Me,NHCO-2-呋喃基),(NHCH2CONH2,H,H,Me,NHCONHPh),(NHCH2CONH2,H,H,Me,NHCOCONHPh),(NHCH2CONH2,H,H,Et,CONHPh),(NHCH2CONH2,H,H,Et,CONH-3-吡啶基),(NHCH2CONH2,H,H,Et,NHCOPh),(NHCH2CONH2,H,H,Et,NHCO-2-呋喃基),(NHCH2CONH2,H,H,Et,NHCONHPh),(NHCH2CONH2,H,H,Et,NHCOCONHPh),(NHCH2CONH2,H,H,CH2OH,CONHPh),(NHCH2CONH2,H,H,CH2OH,CONH-3-吡啶基),(NHCH2CONH2,H,H,CH2OH,NHCOPh),(NHCH2CONH2,H,H,CH2OH,NHCO-2-呋喃基),(NHCH2CONH2,H,H,CH2OH,NHCONHPh),(NHCH2CONH2,H,H,CH2OH,NHCOCONHPh),(NHCH2CONH2,H,Me,Me,CONHPh),(NHCH2CONH2,H,Me,Me,CONH-3-吡啶基),(NHCH2CONH2,H,Me,Me,NHCOPh),(NHCH2CONH2,H,Me,Me,NHCO-2-呋喃基),(NHCH2CONH2,H,Me,Me,NHCONHPh),(NHCH2CONH2,H,Me,Me,NHCOCONHPh),(NHCH2CONH2,H,Me,Et,CONHPh),(NHCH2CONH2,H,Me,Et,CONH-3-吡啶基),(NHCH2CONH2,H,Me,Et,NHCOPh),(NHCH2CONH2,H,Me,Et,NHCO-2-呋喃基),(NHCH2CONH2,H,Me,Et,NHCONHPh),(NHCH2CONH2,H,Me,Et,NHCOCONHPh),(NHCH2CONH2,H,Me,CH2OH,CONHPh),(NHCH2CONH2,H,Me,CH2OH,CONH-3-吡啶基),(NHCH2CONH2,H,Me,CH2OH,NHCOPh),(NHCH2CONH2,H,Me,CH2OH,NHCO-2-呋喃基),(NHCH2CONH2,H,Me,CH2OH,NHCONHPh),(NHCH2CONH2,H,Me,CH2OH,NHCOCONHPh),(NHCH2CONH2,H,Ph,Me,CONHPh),(NHCH2CONH2,H,Ph,Me,CONH-3-吡啶基),(NHCH2CONH2,H,Ph,Me,NHCOPh),(NHCH2CONH2,H,Ph,Me,NHCO-2-呋喃基),(NHCH2CONH2,H,Ph,Me,NHCONHPh),(NHCH2CONH2,H,Ph,Me,NHCOCONHPh),(NHCH2CONH2,H,Ph,Et,CONHPh),(NHCH2CONH2,H,Ph,Et,CONH-3-吡啶基),(NHCH2CONH2,H,Ph,Et,NHCOPh),(NHCH2CONH2,H,Ph,Et,NHCO-2-呋喃基),(NHCH2CONH2,H,Ph,Et,NHCONHPh),(NHCH2CONH2,H,Ph,Et,NHCOCONHPh),(NHCH2CONH2,H,Ph,CH2OH,CONHPh),(NHCH2CONH2,H,Ph,CH2OH,CONH-3-吡啶基),(NHCH2CONH2,H,Ph,CH2OH,NHCOPh),(NHCH2CONH2,H,Ph,CH2OH,NHCO-2-呋喃基),(NHCH2CONH2,H,Ph,CH2OH,NHCONHPh),(NHCH2CONH2,H,Ph,CH2OH,NHCOCONHPh),(NHCH2CONH2,H,OH,Me,CONHPh),(NHCH2CONH2,H,OH,Me,CONH-3-吡啶基),(NHCH2CONH2,H,OH,Me,NHCOPh),(NHCH2CONH2,H,OH,Me,NHCO-2-呋喃基),(NHCH2CONH2,H,OH,Me,NHCONHPh),(NHCH2CONH2,H,OH,Me,NHCOCONHPh),(NHCH2CONH2,H,OH,Et,CONHPh),(NHCH2CONH2,H,OH,Et,CONH-3-吡啶基),(NHCH2CONH2,H,OH,Et,NHCOPh),(NHCH2CONH2,H,OH,Et,NHCO-2-呋喃基),(NHCH2CONH2,H,OH,Et,NHCONHPh),(NHCH2CONH2,H,OH,Et,NHCOCONHPh),(NHCH2CONH2,H,OH,CH2OH,CONHPh),(NHCH2CONH2,H,OH,CH2OH,CONH-3-吡啶基),(HCH2CONH2,H,OH,CH2OH,NHCOPh),(NHCH2CONH2,H,OH,CH2OH,NHCO-2-呋喃基),(NHCH2CONH2,H,OH,CH2OH,NHCONHPh),(NHCH2CONH2,H,OH,CH2OH,NHCOCONHPh),(NHCH2CONH2,Me,H,Me,CONHPh),(NHCH2CONH2,Me,H,Me,CONH-3-吡啶基),(NHCH2CONH2,Me,H,Me,NHCOPh),(NHCH2CONH2,Me,H,Me,NHCO-2-呋喃基),(NHCH2CONH2,Me,H,Me,NHCONHPh),(NHCH2CONH2,Me,H,Me,NHCOCONHPh),(NHCH2CONH2,Me,H,Et,CONHPh),(NHCH2CONH2,Me,H,Et,CONH-3-吡啶基),(NHCH2CONH2,Me,H,Et,NHCOPh),(NHCH2CONH2,Me,H,Et,NHCO-2-呋喃基),(NHCH2CONH2,Me,H,Et,NHCONHPh),(NHCH2CONH2,Me,H,Et,NHCOCONHPh),(NHCH2CONH2,Me,H,CH2OH,CONHPh),(NHCH2CONH2,Me,H,CH2OH,CONH-3-吡啶基),(NHCH2CONH2,Me,H,CH2OH,NHCOPh),(NHCH2CONH2,Me,H,CH2OH,NHCO-2-呋喃基),(NHCH2CONH2,Me,H,CH2OH,NHCONHPh),(NHCH2CONH2,Me,H,CH2OH,NHCOCONHPh),(NHCH2CONH2,Me,Me,Me,CONHPh),(NHCH2CONH2,Me,Me,Me,CONH-3-吡啶基),(NHCH2CONH2,Me,Me,Me,NHCOPh),(NHCH2CONH2,Me,Me,Me,NHCO-2-呋喃基),(NHCH2CONH2,Me,Me,Me,NHCONHPh),(NHCH2CONH2,Me,Me,Me,NHCOCONHPh),(NHCH2CONH2,Me,Me,Et,CONHPh),(NHCH2CONH2,Me,Me,Et,CONH-3-吡啶基),(NHCH2CONH2,Me,Me,Et,NHCOPh),(NHCH2CONH2,Me,Me,Et,NHCO-2-呋喃基),(NHCH2CONH2,Me,Me,Et,NHCONHPh),(NHCH2CONH2,Me,Me,Et,NHCOCONHPh),(NHCH2CONH2,Me,Me,CH2OH,CONHPh),(NHCH2CONH2,Me,Me,CH2OH,CONH-3-吡啶基),(NHCH2CONH2,Me,Me,CH2OH,NHCOPh),(NHCH2CONH2,Me,Me,CH2OH,NHCO-2-呋喃基),(NHCH2CONH2,Me,Me,CH2OH,NHCONHPh),(NHCH2CONH2,Me,Me,CH2OH,NHCOCONHPh),(NHCH2CONH2,Me,Ph,Me,CONHPh),(NHCH2CONH2,Me,Ph,Me,CONH-3-吡啶基),(NHCH2CONH2,Me,Ph,Me,NHCOPh),(NHCH2CONH2,Me,Ph,Me,NHCO-2-呋喃基),(NHCH2CONH2,Me,Ph,Me,NHCONHPh),(NHCH2CONH2,Me,Ph,Me,NHCOCONHPh),(NHCH2CONH2,Me,Ph,Et,CONHPh),(NHCH2CONH2,Me,Ph,Et,CONH-3-吡啶基),(NHCH2CONH2,Me,Ph,Et,NHCOPh),(NHCH2CONH2,Me,Ph,Et,NHCO-2-呋喃基),(NHCH2CONH2,Me,Ph,Et,NHCONHPh),(NHCH2CONH2,Me,Ph,Et,NHCOCONHPh),(NHCH2CONH2,Me,Ph,CH2OH,CONHPh),(NHCH2CONH2,Me,Ph,CH2OH,CONH-3-吡啶基),(NHCH2CONH2,Me,Ph,CH2OH,NHCOPh),(NHCH2CONH2,Me,Ph,CH2OH,NHCO-2-呋喃基),(NHCH2CONH2,Me,Ph,CH2OH,NHCONHPh),(NHCH2CONH2,Me,Ph,CH2OH,NHCOCONHPh),(NHCH2CONH2,Me,OH,Me,CONHPh),(NHCH2CONH2,Me,OH,Me,CONH-3-吡啶基),(NHCH2CONH2,Me,OH,Me,NHCOPh),(NHCH2CONH2,Me,OH,Me,NHCO-2-呋喃基),(NHCH2CONH2,Me,OH,Me,NHCONHPh),(NHCH2CONH2,Me,OH,Me,NHCOCONHPh),(NHCH2CONH2,Me,OH,Et,CONHPh),(NHCH2CONH2,Me,OH,Et,CONH-3-吡啶基),(NHCH2CONH2,Me,OH,Et,NHCOPh),(NHCH2CONH2,Me,OH,Et,NHCO-2-呋喃基),(NHCH2CONH2,Me,OH,Et,NHCONHPh),(NHCH2CONH2,Me,OH,Et,NHCOCONHPh),(NHCH2CONH2,Me,OH,CH2OH,CONHPh),(NHCH2CONH2,Me,OH,CH2OH,CONH-3-吡啶基),(NHCH2CONH2,Me,OH,CH2OH,NHCOPh),(NHCH2CONH2,Me,OH,CH2OH,NHCO-2-呋喃基),(NHCH2CONH2,Me,OH,CH2OH,NHCONHPh),(NHCH2CONH2,Me,OH,CH2OH,NHCOCONHPh),(NHCH2CONH2,Ph,H,Me,CONHPh),(NHCH2CONH2,Ph,H,Me,CONH-3-吡啶基),(NHCH2CONH2,Ph,H,Me,NHCOPh),(NHCH2CONH2,Ph,H,Me,NHCO-2-呋喃基),(NHCH2CONH2,Ph,H,Me,NHCONHPh),(NHCH2CONH2,Ph,H,Me,NHCOCONHPh),(NHCH2CONH2,Ph,H,Et,CONHPh),(NHCH2CONH2,Ph,H,Et,CONH-3-吡啶基),(NHCH2CONH2,Ph,H,Et,NHCOPh),(NHCH2CONH2,Ph,H,Et,NHCO-2-呋喃基),(NHCH2CONH2,Ph,H,Et,NHCONHPh),(NHCH2CONH2,Ph,H,Et,NHCOCONHPh),(NHCH2CONH2,Ph,H,CH2OH,CONHPh),(NHCH2CONH2,Ph,H,CH2OH,CONH-3-吡啶基),(NHCH2CONH2,Ph,H,CH2OH,NHCOPh),(NHCH2CONH2,Ph,H,CH2OH,NHCO-2-呋喃基),(NHCH2CONH2,Ph,H,CH2OH,NHCONHPh),(NHCH2CONH2,Ph,H,CH2OH,NHCOCONHPh),(NHCH2CONH2,Ph,Me,Me,CONHPh),(NHCH2CONH2,Ph,Me,Me,CONH-3-吡啶基),(NHCH2CONH2,Ph,Me,Me,NHCOPh),(NHCH2CONH2,Ph,Me,Me,NHCO-2-呋喃基),(NHCH2CONH2,Ph,Me,Me,NHCONHPh),(NHCH2CONH2,Ph,Me,Me,NHCOCONHPh),(NHCH2CONH2,Ph,Me,Et,CONHPh),(NHCH2CONH2,Ph,Me,Et,CONH-3-吡啶基),(NHCH2CONH2,Ph,Me,Et,NHCOPh),(NHCH2CONH2,Ph,Me,Et,NHCO-2-呋喃基),(NHCH2CONH2,Ph,Me,Et,NHCONHPh),(NHCH2CONH2,Ph,Me,Et,NHCOCONHPh),(NHCH2CONH2,Ph,Me,CH2OH,CONHPh),(NHCH2CONH2,Ph,Me,CH2OH,CONH-3-吡啶基),(NHCH2CONH2,Ph,Me,CH2OH,NHCOPh),(NHCH2CONH2,Ph,Me,CH2OH,NHCO-2-呋喃基),(NHCH2CONH2,Ph,Me,CH2OH,NHCONHPh),(NHCH2CONH2,Ph,Me,CH2OH,NHCOCONHPh),(NHCH2CONH2,Ph,Ph,Me,CONHPh),(NHCH2CONH2,Ph,Ph,Me,CONH-3-吡啶基),(NHCH2CONH2,Ph,Ph,Me,NHCOPh),(NHCH2CONH2,Ph,Ph,Me,NHCO-2-呋喃基),(NHCH2CONH2,Ph,Ph,Me,NHCONHPh),(NHCH2CONH2,Ph,Ph,Me,NHCOCONHPh),(NHCH2CONH2,Ph,Ph,Et,CONHPh),(NHCH2CONH2,Ph,Ph,Et,CONH-3-吡啶基),(NHCH2CONH2,Ph,Ph,Et,NHCOPh),(NHCH2CONH2,Ph,Ph,Et,NHCO-2-呋喃基),(NHCH2CONH2,Ph,Ph,Et,NHCONHPh),(NHCH2CONH2,Ph,Ph,Et,NHCOCONHPh),(NHCH2CONH2,Ph,Ph,CH2OH,CONHPh),(NHCH2CONH2,Ph,Ph,CH2OH,CONH-3-吡啶基),(NHCH2CONH2,Ph,Ph,CH2OH,NHCOPh),(NHCH2CONH2,Ph,Ph,CH2OH,NHCO-2-呋喃基),(NHCH2CONH2,Ph,Ph,CH2OH,NHCONHPh),(NHCH2CONH2,Ph,Ph,CH2OH,NHCOCONHPh),(NHCH2CONH2,Ph,OH,Me,CONHPh),(NHCH2CONH2,Ph,OH,Me,CONH-3-吡啶基),(NHCH2CONH2,Ph,OH,Me,NHCOPh),(NHCH2CONH2,Ph,OH,Me,NHCO-2-呋喃基),(NHCH2CONH2,Ph,OH,Me,NHCONHPh),(NHCH2CONH2,Ph,OH,Me,NHCOCONHPh),(NHCH2CONH2,Ph,OH,Et,CONHPh),(NHCH2CONH2,Ph,OH,Et,CONH-3-吡啶基),(NHCH2CONH2,Ph,OH,Et,NHCOPh),(NHCH2CONH2,Ph,OH,Et,NHCO-2-呋喃基),(NHCH2CONH2,Ph,OH,Et,NHCONHPh),(NHCH2CONH2,Ph,OH,Et,NHCOCONHPh),(NHCH2CONH2,Ph,OH,CH2OH,CONHPh),(NHCH2CONH2,Ph,OH,CH2OH,CONH-3-吡啶基),(NHCH2CONH2,Ph,OH,CH2OH,NHCOPh),(NHCH2CONH2,Ph,OH,CH2OH,NHCO-2-呋喃基),(NHCH2CONH2,Ph,OH,CH2OH,NHCONHPh),(NHCH2CONH2,Ph,OH,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,H,H,Me,CONHPh),(NHCH(Bn)CONH2,H,H,Me,CONH-3-吡啶基),(NHCH(Bn)CONH2,H,H,Me,NHCOPh),(NHCH(Bn)CONH2,H,H,Me,NHCO-2-呋喃基),(NHCH(Bn)CONH2,H,H,Me,NHCONHPh),(NHCH(Bn)CONH2,H,H,Me,NHCOCONHPh),(NHCH(Bn)CONH2,H,H,Et,CONHPh),(NHCH(Bn)CONH2,H,H,Et,CONH-3-吡啶基),(NHCH(Bn)CONH2,H,H,Et,NHCOPh),(NHCH(Bn)CONH2,H,H,Et,NHCO-2-呋喃基),(NHCH(Bn)CONH2,H,H,Et,NHCONHPh),(NHCH(Bn)CONH2,H,H,Et,NHCOCONHPh),(NHCH(Bn)CONH2,H,H,CH2OH,CONHPh),(NHCH(Bn)CONH2,H,H,CH2OH,CONH-3-吡啶基),(NHCH(Bn)CONH2,H,H,CH2OH,NHCOPh),(NHCH(Bn)CONH2,H,H,CH2OH,NHCO-2-呋喃基),(NHCH(Bn)CONH2,H,H,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,H,H,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,H,Me,Me,CONHPh),(NHCH(Bn)CONH2,H,Me,Me,CONH-3-吡啶基),(NHCH(Bn)CONH2,H,Me,Me,NHCOPh),(NHCH(Bn)CONH2,H,Me,Me,NHCO-2-呋喃基),(NHCH(Bn)CONH2,H,Me,Me,NHCONHPh),(NHCH(Bn)CONH2,H,Me,Me,NHCOCONHPh),(NHCH(Bn)CONH2,H,Me,Et,CONHPh),(NHCH(Bn)CONH2,H,Me,Et,CONH-3-吡啶基),(NHCH(Bn)CONH2,H,Me,Et,NHCOPh),(NHCH(Bn)CONH2,H,Me,Et,NHCO-2-呋喃基),(NHCH(Bn)CONH2,H,Me,Et,NHCONHPh),(NHCH(Bn)CONH2,H,Me,Et,NHCOCONHPh),(NHCH(Bn)CONH2,H,Me,CH2OH,CONHPh),(NHCH(Bn)CONH2,H,Me,CH2OH,CONH-3-吡啶基),(NHCH(Bn)CONH2,H,Me,CH2OH,NHCOPh),(NHCH(Bn)CONH2,H,Me,CH2OH,NHCO-2-呋喃基),(NHCH(Bn)CONH2,H,Me,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,H,Me,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,H,Ph,Me,CONHPh),(NHCH(Bn)CONH2,H,Ph,Me,CONH-3-吡啶基),(NHCH(Bn)CONH2,H,Ph,Me,NHCOPh),(NHCH(Bn)CONH2,H,Ph,Me,NHCO-2-呋喃基),(NHCH(Bn)CONH2,H,Ph,Me,NHCONHPh),(NHCH(Bn)CONH2,H,Ph,Me,NHCOCONHPh),(NHCH(Bn)CONH2,H,Ph,Et,CONHPh),(NHCH(Bn)CONH2,H,Ph,Et,CONH-3-吡啶基),(NHCH(Bn)CONH2,H,Ph,Et,NHCOPh),(NHCH(Bn)CONH2,H,Ph,Et,NHCO-2-呋喃基),(NHCH(Bn)CONH2,H,Ph,Et,NHCONHPh),(NHCH(Bn)CONH2,H,Ph,Et,NHCOCONHPh),(NHCH(Bn)CONH2,H,Ph,CH2OH,CONHPh),(NHCH(Bn)CONH2,H,Ph,CH2OH,CONH-3-吡啶基),(NHCH(Bn)CONH2,H,Ph,CH2OH,NHCOPh),(NHCH(Bn)CONH2,H,Ph,CH2OH,NHCO-2-呋喃基),(NHCH(Bn)CONH2,H,Ph,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,H,Ph,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,H,OH,Me,CONHPh),(NHCH(Bn)CONH2,H,OH,Me,CONH-3-吡啶基),(NHCH(Bn)CONH2,H,OH,Me,NHCOPh),(NHCH(Bn)CONH2,H,OH,Me,NHCO-2-呋喃基),(NHCH(Bn)CONH2,H,OH,Me,NHCONHPh),(NHCH(Bn)CONH2,H,OH,Me,NHCOCONHPh),(NHCH(Bn)CONH2,H,OH,Et,CONHPh),(NHCH(Bn)CONH2,H,OH,Et,CONH-3-吡啶基),(NHCH(Bn)CONH2,H,OH,Et,NHCOPh),(NHCH(Bn)CONH2,H,OH,Et,NHCO-2-呋喃基),(NHCH(Bn)CONH2,H,OH,Et,NHCONHPh),(NHCH(Bn)CONH2,H,OH,Et,NHCOCONHPh),(NHCH(Bn)CONH2,H,OH,CH2OH,CONHPh),(NHCH(Bn)CONH2,H,OH,CH2OH,CONH-3-吡啶基),(NHCH(Bn)CONH2,H,OH,CH2OH,NHCOPh),(NHCH(Bn)CONH2,H,OH,CH2OH,NHCO-2-呋喃基),(NHCH(Bn)CONH2,H,OH,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,H,OH,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Me,H,Me,CONHPh),(NHCH(Bn)CONH2,Me,H,Me,CONH-3-吡啶基),(NHCH(Bn)CONH2,Me,H,Me,NHCOPh),(NHCH(Bn)CONH2,Me,H,Me,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Me,H,Me,NHCONHPh),(NHCH(Bn)CONH2,Me,H,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Me,H,Et,CONHPh),(NHCH(Bn)CONH2,Me,H,Et,CONH-3-吡啶基),(NHCH(Bn)CONH2,Me,H,Et,NHCOPh),(NHCH(Bn)CONH2,Me,H,Et,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Me,H,Et,NHCONHPh),(NHCH(Bn)CONH2,Me,H,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Me,H,CH2OH,CONHPh),(NHCH(Bn)CONH2,Me,H,CH2OH,CONH-3-吡啶基),(NHCH(Bn)CONH2,Me,H,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Me,H,CH2OH,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Me,H,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Me,H,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Me,Me,Me,CONHPh),(NHCH(Bn)CONH2,Me,Me,Me,CONH-3-吡啶基),(NHCH(Bn)CONH2,Me,Me,Me,NHCOPh),(NHCH(Bn)CONH2,Me,Me,Me,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Me,Me,Me,NHCONHPh),(NHCH(Bn)CONH2,Me,Me,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Me,Me,Et,CONHPh),(NHCH(Bn)CONH2,Me,Me,Et,CONH-3-吡啶基),(NHCH(Bn)CONH2,Me,Me,Et,NHCOPh),(NHCH(Bn)CONH2,Me,Me,Et,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Me,Me,Et,NHCONHPh),(NHCH(Bn)CONH2,Me,Me,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Me,Me,CH2OH,CONHPh),(NHCH(Bn)CONH2,Me,Me,CH2OH,CONH-3-吡啶基),(NHCH(Bn)CONH2,Me,Me,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Me,Me,CH2OH,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Me,Me,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Me,Me,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Me,Ph,Me,CONHPh),(NHCH(Bn)CONH2,Me,Ph,Me,CONH-3-吡啶基),(NHCH(Bn)CONH2,Me,Ph,Me,NHCOPh),(NHCH(Bn)CONH2,Me,Ph,Me,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Me,Ph,Me,NHCONHPh),(NHCH(Bn)CONH2,Me,Ph,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Me,Ph,Et,CONHPh),(NHCH(Bn)CONH2,Me,Ph,Et,CONH-3-吡啶基),(NHCH(Bn)CONH2,Me,Ph,Et,NHCOPh),(NHCH(Bn)CONH2,Me,Ph,Et,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Me,Ph,Et,NHCONHPh),(NHCH(Bn)CONH2,Me,Ph,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Me,Ph,CH2OH,CONHPh),(NHCH(Bn)CONH2,Me,Ph,CH2OH,CONH-3-吡啶基),(NHCH(Bn)CONH2,Me,Ph,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Me,Ph,CH2OH,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Me,Ph,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Me,Ph,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Me,OH,Me,CONHPh),(NHCH(Bn)CONH2,Me,OH,Me,CONH-3-吡啶基),(NHCH(Bn)CONH2,Me,OH,Me,NHCOPh),(NHCH(Bn)CONH2,Me,OH,Me,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Me,OH,Me,NHCONHPh),(NHCH(Bn)CONH2,Me,OH,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Me,OH,Et,CONHPh),(NHCH(Bn)CONH2,Me,OH,Et,CONH-3-吡啶基),(NHCH(Bn)CONH2,Me,OH,Et,NHCOPh),(NHCH(Bn)CONH2,Me,OH,Et,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Me,OH,Et,NHCONHPh),(NHCH(Bn)CONH2,Me,OH,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Me,OH,CH2OH,CONHPh),(NHCH(Bn)CONH2,Me,OH,CH2OH,CONH-3-吡啶基),(NHCH(Bn)CONH2,Me,OH,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Me,OH,CH2OH,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Me,OH,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Me,OH,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,H,Me,CONHPh),(NHCH(Bn)CONH2,Ph,H,Me,CONH-3-吡啶基),(NHCH(Bn)CONH2,Ph,H,Me,NHCOPh),(NHCH(Bn)CONH2,Ph,H,Me,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Ph,H,Me,NHCONHPh),(NHCH(Bn)CONH2,Ph,H,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,H,Et,CONHPh),(NHCH(Bn)CONH2,Ph,H,Et,CONH-3-吡啶基),(NHCH(Bn)CONH2,Ph,H,Et,NHCOPh),(NHCH(Bn)CONH2,Ph,H,Et,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Ph,H,Et,NHCONHPh),(NHCH(Bn)CONH2,Ph,H,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,H,CH2OH,CONHPh),(NHCH(Bn)CONH2,Ph,H,CH2OH,CONH-3-吡啶基),(NHCH(Bn)CONH2,Ph,H,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Ph,H,CH2OH,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Ph,H,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Ph,H,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,Me,Me,CONHPh),(NHCH(Bn)CONH2,Ph,Me,Me,CONH-3-吡啶基),(NHCH(Bn)CONH2,Ph,Me,Me,NHCOPh),(NHCH(Bn)CONH2,Ph,Me,Me,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Ph,Me,Me,NHCONHPh),(NHCH(Bn)CONH2,Ph,Me,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,Me,Et,CONHPh),(NHCH(Bn)CONH2,Ph,Me,Et,CONH-3-吡啶基),(NHCH(Bn)CONH2,Ph,Me,Et,NHCOPh),(NHCH(Bn)CONH2,Ph,Me,Et,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Ph,Me,Et,NHCONHPh),(NHCH(Bn)CONH2,Ph,Me,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,Me,CH2OH,CONHPh),(NHCH(Bn)CONH2,Ph,Me,CH2OH,CONH-3-吡啶基),(NHCH(Bn)CONH2,Ph,Me,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Ph,Me,CH2OH,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Ph,Me,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Ph,Me,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,Ph,Me,CONHPh),(NHCH(Bn)CONH2,Ph,Ph,Me,CONH-3-吡啶基),(NHCH(Bn)CONH2,Ph,Ph,Me,NHCOPh),(NHCH(Bn)CONH2,Ph,Ph,Me,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Ph,Ph,Me,NHCONHPh),(NHCH(Bn)CONH2,Ph,Ph,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,Ph,Et,CONHPh),(NHCH(Bn)CONH2,Ph,Ph,Et,CONH-3-吡啶基),(NHCH(Bn)CONH2,Ph,Ph,Et,NHCOPh),(NHCH(Bn)CONH2,Ph,Ph,Et,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Ph,Ph,Et,NHCONHPh),(NHCH(Bn)CONH2,Ph,Ph,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,Ph,CH2OH,CONHPh),(NHCH(Bn)CONH2,Ph,Ph,CH2OH,CONH-3-吡啶基),(NHCH(Bn)CONH2,Ph,Ph,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Ph,Ph,CH2OH,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Ph,Ph,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Ph,Ph,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,OH,Me,CONHPh),(NHCH(Bn)CONH2,Ph,OH,Me,CONH-3-吡啶基),(NHCH(Bn)CONH2,Ph,OH,Me,NHCOPh),(NHCH(Bn)CONH2,Ph,OH,Me,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Ph,OH,Me,NHCONHPh),(NHCH(Bn)CONH2,Ph,OH,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,OH,Et,CONHPh),(NHCH(Bn)CONH2,Ph,OH,Et,CONH-3-吡啶基),(NHCH(Bn)CONH2,Ph,OH,Et,NHCOPh),(NHCH(Bn)CONH2,Ph,OH,Et,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Ph,OH,Et,NHCONHPh),(NHCH(Bn)CONH2,Ph,OH,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,OH,CH2OH,CONHPh),(NHCH(Bn)CONH2,Ph,OH,CH2OH,CONH-3-吡啶基),(NHCH(Bn)CONH2,Ph,OH,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Ph,OH,CH2OH,NHCO-2-呋喃基),(NHCH(Bn)CONH2,Ph,OH,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Ph,OH,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,H,H,Me,CONHPh),(NHCH(Me)CH2OH,H,H,Me,CONH-3-吡啶基),(NHCH(Me)CH2OH,H,H,Me,NHCOPh),(NHCH(Me)CH2OH,H,H,Me,NHCO-2-呋喃基),(NHCH(Me)CH2OH,H,H,Me,NHCONHPh),(NHCH(Me)CH2OH,H,H,Me,NHCOCONHPh),(NHCH(Me)CH2OH,H,H,Et,CONHPh),(NHCH(Me)CH2OH,H,H,Et,CONH-3-吡啶基),(NHCH(Me)CH2OH,H,H,Et,NHCOPh),(NHCH(Me)CH2OH,H,H,Et,NHCO-2-呋喃基),(NHCH(Me)CH2OH,H,H,Et,NHCONHPh),(NHCH(Me)CH2OH,H,H,Et,NHCOCONHPh),(NHCH(Me)CH2OH,H,H,CH2OH,CONHPh),(NHCH(Me)CH2OH,H,H,CH2OH,CONH-3-吡啶基),(NHCH(Me)CH2OH,H,H,CH2OH,NHCOPh),(NHCH(Me)CH2OH,H,H,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CH2OH,H,H,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,H,H,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,H,Me,Me,CONHPh),(NHCH(Me)CH2OH,H,Me,Me,CONH-3-吡啶基),(NHCH(Me)CH2OH,H,Me,Me,NHCOPh),(NHCH(Me)CH2OH,H,Me,Me,NHCO-2-呋喃基),(NHCH(Me)CH2OH,H,Me,Me,NHCONHPh),(NHCH(Me)CH2OH,H,Me,Me,NHCOCONHPh),(NHCH(Me)CH2OH,H,Me,Et,CONHPh),(NHCH(Me)CH2OH,H,Me,Et,CONH-3-吡啶基),(NHCH(Me)CH2OH,H,Me,Et,NHCOPh),(NHCH(Me)CH2OH,H,Me,Et,NHCO-2-呋喃基),(NHCH(Me)CH2OH,H,Me,Et,NHCONHPh),(NHCH(Me)CH2OH,H,Me,Et,NHCOCONHPh),(NHCH(Me)CH2OH,H,Me,CH2OH,CONHPh),(NHCH(Me)CH2OH,H,Me,CH2OH,CONH-3-吡啶基),(NHCH(Me)CH2OH,H,Me,CH2OH,NHCOPh),(NHCH(Me)CH2OH,H,Me,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CH2OH,H,Me,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,H,Me,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,H,Ph,Me,CONHPh),(NHCH(Me)CH2OH,H,Ph,Me,CONH-3-吡啶基),(NHCH(Me)CH2OH,H,Ph,Me,NHCOPh),(NHCH(Me)CH2OH,H,Ph,Me,NHCO-2-呋喃基),(NHCH(Me)CH2OH,H,Ph,Me,NHCONHPh),(NHCH(Me)CH2OH,H,Ph,Me,NHCOCONHPh),(NHCH(Me)CH2OH,H,Ph,Et,CONHPh),(NHCH(Me)CH2OH,H,Ph,Et,CONH-3-吡啶基),(NHCH(Me)CH2OH,H,Ph,Et,NHCOPh),(NHCH(Me)CH2OH,H,Ph,Et,NHCO-2-呋喃基),(NHCH(Me)CH2OH,H,Ph,Et,NHCONHPh),(NHCH(Me)CH2OH,H,Ph,Et,NHCOCONHPh),(NHCH(Me)CH2OH,H,Ph,CH2OH,CONHPh),(NHCH(Me)CH2OH,H,Ph,CH2OH,CONH-3-吡啶基),(NHCH(Me)CH2OH,H,Ph,CH2OH,NHCOPh),(NHCH(Me)CH2OH,H,Ph,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CH2OH,H,Ph,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,H,Ph,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,H,OH,Me,CONHPh),(NHCH(Me)CH2OH,H,OH,Me,CONH-3-吡啶基),(NHCH(Me)CH2OH,H,OH,Me,NHCOPh),(NHCH(Me)CH2OH,H,OH,Me,NHCO-2-呋喃基),(NHCH(Me)CH2OH,H,OH,Me,NHCONHPh),(NHCH(Me)CH2OH,H,OH,Me,NHCOCONHPh),(NHCH(Me)CH2OH,H,OH,Et,CONHPh),(NHCH(Me)CH2OH,H,OH,Et,CONH-3-吡啶基),(NHCH(Me)CH2OH,H,OH,Et,NHCOPh),(NHCH(Me)CH2OH,H,OH,Et,NHCO-2-呋喃基),(NHCH(Me)CH2OH,H,OH,Et,NHCONHPh),(NHCH(Me)CH2OH,H,OH,Et,NHCOCONHPh),(NHCH(Me)CH2OH,H,OH,CH2OH,CONHPh),(NHCH(Me)CH2OH,H,OH,CH2OH,CONH-3-吡啶基),(NHCH(Me)CH2OH,H,OH,CH2OH,NHCOPh),(NHCH(Me)CH2OH,H,OH,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CH2OH,H,OH,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,H,OH,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Me,H,Me,CONHPh),(NHCH(Me)CH2OH,Me,H,Me,CONH-3-吡啶基),(NHCH(Me)CH2OH,Me,H,Me,NHCOPh),(NHCH(Me)CH2OH,Me,H,Me,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Me,H,Me,NHCONHPh),(NHCH(Me)CH2OH,Me,H,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Me,H,Et,CONHPh),(NHCH(Me)CH2OH,Me,H,Et,CONH-3-吡啶基),(NHCH(Me)CH2OH,Me,H,Et,NHCOPh),(NHCH(Me)CH2OH,Me,H,Et,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Me,H,Et,NHCONHPh),(NHCH(Me)CH2OH,Me,H,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Me,H,CH2OH,CONHPh),(NHCH(Me)CH2OH,Me,H,CH2OH,CONH-3-吡啶基),(NHCH(Me)CH2OH,Me,H,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Me,H,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Me,H,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Me,H,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Me,Me,Me,CONHPh),(NHCH(Me)CH2OH,Me,Me,Me,CONH-3-吡啶基),(NHCH(Me)CH2OH,Me,Me,Me,NHCOPh),(NHCH(Me)CH2OH,Me,Me,Me,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Me,Me,Me,NHCONHPh),(NHCH(Me)CH2OH,Me,Me,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Me,Me,Et,CONHPh),(NHCH(Me)CH2OH,Me,Me,Et,CONH-3-吡啶基),(NHCH(Me)CH2OH,Me,Me,Et,NHCOPh),(NHCH(Me)CH2OH,Me,Me,Et,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Me,Me,Et,NHCONHPh),(NHCH(Me)CH2OH,Me,Me,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Me,Me,CH2OH,CONHPh),(NHCH(Me)CH2OH,Me,Me,CH2OH,CONH-3-吡啶基),(NHCH(Me)CH2OH,Me,Me,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Me,Me,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Me,Me,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Me,Me,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Me,Ph,Me,CONHPh),(NHCH(Me)CH2OH,Me,Ph,Me,CONH-3-吡啶基),(NHCH(Me)CH2OH,Me,Ph,Me,NHCOPh),(NHCH(Me)CH2OH,Me,Ph,Me,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Me,Ph,Me,NHCONHPh),(NHCH(Me)CH2OH,Me,Ph,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Me,Ph,Et,CONHPh),(NHCH(Me)CH2OH,Me,Ph,Et,CONH-3-吡啶基),(NHCH(Me)CH2OH,Me,Ph,Et,NHCOPh),(NHCH(Me)CH2OH,Me,Ph,Et,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Me,Ph,Et,NHCONHPh),(NHCH(Me)CH2OH,Me,Ph,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Me,Ph,CH2OH,CONHPh),(NHCH(Me)CH2OH,Me,Ph,CH2OH,CONH-3-吡啶基),(NHCH(Me)CH2OH,Me,Ph,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Me,Ph,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Me,Ph,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Me,Ph,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Me,OH,Me,CONHPh),(NHCH(Me)CH2OH,Me,OH,Me,CONH-3-吡啶基),(NHCH(Me)CH2OH,Me,OH,Me,NHCOPh),(NHCH(Me)CH2OH,Me,OH,Me,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Me,OH,Me,NHCONHPh),(NHCH(Me)CH2OH,Me,OH,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Me,OH,Et,CONHPh),(NHCH(Me)CH2OH,Me,OH,Et,CONH-3-吡啶基),(NHCH(Me)CH2OH,Me,OH,Et,NHCOPh),(NHCH(Me)CH2OH,Me,OH,Et,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Me,OH,Et,NHCONHPh),(NHCH(Me)CH2OH,Me,OH,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Me,OH,CH2OH,CONHPh),(NHCH(Me)CH2OH,Me,OH,CH2OH,CONH-3-吡啶基),(NHCH(Me)CH2OH,Me,OH,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Me,OH,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Me,OH,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Me,OH,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,H,Me,CONHPh),(NHCH(Me)CH2OH,Ph,H,Me,CONH-3-吡啶基),(NHCH(Me)CH2OH,Ph,H,Me,NHCOPh),(NHCH(Me)CH2OH,Ph,H,Me,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Ph,H,Me,NHCONHPh),(NHCH(Me)CH2OH,Ph,H,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,H,Et,CONHPh),(NHCH(Me)CH2OH,Ph,H,Et,CONH-3-吡啶基),(NHCH(Me)CH2OH,Ph,H,Et,NHCOPh),(NHCH(Me)CH2OH,Ph,H,Et,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Ph,H,Et,NHCONHPh),(NHCH(Me)CH2OH,Ph,H,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,H,CH2OH,CONHPh),(NHCH(Me)CH2OH,Ph,H,CH2OH,CONH-3-吡啶基),(NHCH(Me)CH2OH,Ph,H,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Ph,H,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Ph,H,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Ph,H,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,Me,Me,CONHPh),(NHCH(Me)CH2OH,Ph,Me,Me,CONH-3-吡啶基),(NHCH(Me)CH2OH,Ph,Me,Me,NHCOPh),(NHCH(Me)CH2OH,Ph,Me,Me,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Ph,Me,Me,NHCONHPh),(NHCH(Me)CH2OH,Ph,Me,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,Me,Et,CONHPh),(NHCH(Me)CH2OH,Ph,Me,Et,CONH-3-吡啶基),(NHCH(Me)CH2OH,Ph,Me,Et,NHCOPh),(NHCH(Me)CH2OH,Ph,Me,Et,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Ph,Me,Et,NHCONHPh),(NHCH(Me)CH2OH,Ph,Me,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,Me,CH2OH,CONHPh),(NHCH(Me)CH2OH,Ph,Me,CH2OH,CONH-3-吡啶基),(NHCH(Me)CH2OH,Ph,Me,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Ph,Me,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Ph,Me,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Ph,Me,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,Ph,Me,CONHPh),(NHCH(Me)CH2OH,Ph,Ph,Me,CONH-3-吡啶基),(NHCH(Me)CH2OH,Ph,Ph,Me,NHCOPh),(NHCH(Me)CH2OH,Ph,Ph,Me,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Ph,Ph,Me,NHCONHPh),(NHCH(Me)CH2OH,Ph,Ph,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,Ph,Et,CONHPh),(NHCH(Me)CH2OH,Ph,Ph,Et,CONH-3-吡啶基),(NHCH(Me)CH2OH,Ph,Ph,Et,NHCOPh),(NHCH(Me)CH2OH,Ph,Ph,Et,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Ph,Ph,Et,NHCONHPh),(NHCH(Me)CH2OH,Ph,Ph,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,Ph,CH2OH,CONHPh),(NHCH(Me)CH2OH,Ph,Ph,CH2OH,CONH-3-吡啶基),(NHCH(Me)CH2OH,Ph,Ph,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Ph,Ph,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Ph,Ph,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Ph,Ph,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,OH,Me,CONHPh),(NHCH(Me)CH2OH,Ph,OH,Me,CONH-3-吡啶基),(NHCH(Me)CH2OH,Ph,OH,Me,NHCOPh),(NHCH(Me)CH2OH,Ph,OH,Me,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Ph,OH,Me,NHCONHPh),(NHCH(Me)CH2OH,Ph,OH,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,OH,Et,CONHPh),(NHCH(Me)CH2OH,Ph,OH,Et,CONH-3-吡啶基),(NHCH(Me)CH2OH,Ph,OH,Et,NHCOPh),(NHCH(Me)CH2OH,Ph,OH,Et,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Ph,OH,Et,NHCONHPh),(NHCH(Me)CH2OH,Ph,OH,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,OH,CH2OH,CONHPh),(NHCH(Me)CH2OH,Ph,OH,CH2OH,CONH-3-吡啶基),(NHCH(Me)CH2OH,Ph,OH,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Ph,OH,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CH2OH,Ph,OH,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Ph,OH,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,H,H,Me,CONHPh),(NHCH(Me)CONHMe,H,H,Me,CONH-3-吡啶基),(NHCH(Me)CONHMe,H,H,Me,NHCOPh),(NHCH(Me)CONHMe,H,H,Me,NHCO-2-呋喃基),(NHCH(Me)CONHMe,H,H,Me,NHCONHPh),(NHCH(Me)CONHMe,H,H,Me,NHCOCONHPh),(NHCH(Me)CONHMe,H,H,Et,CONHPh),(NHCH(Me)CONHMe,H,H,Et,CONH-3-吡啶基),(NHCH(Me)CONHMe,H,H,Et,NHCOPh),(NHCH(Me)CONHMe,H,H,Et,NHCO-2-呋喃基),(NHCH(Me)CONHMe,H,H,Et,NHCONHPh),(NHCH(Me)CONHMe,H,H,Et,NHCOCONHPh),(NHCH(Me)CONHMe,H,H,CH2OH,CONHPh),(NHCH(Me)CONHMe,H,H,CH2OH,CONH-3-吡啶基),(NHCH(Me)CONHMe,H,H,CH2OH,NHCOPh),(NHCH(Me)CONHMe,H,H,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CONHMe,H,H,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,H,H,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,H,Me,Me,CONHPh),(NHCH(Me)CONHMe,H,Me,Me,CONH-3-吡啶基),(NHCH(Me)CONHMe,H,Me,Me,NHCOPh),(NHCH(Me)CONHMe,H,Me,Me,NHCO-2-呋喃基),(NHCH(Me)CONHMe,H,Me,Me,NHCONHPh),(NHCH(Me)CONHMe,H,Me,Me,NHCOCONHPh),(NHCH(Me)CONHMe,H,Me,Et,CONHPh),(NHCH(Me)CONHMe,H,Me,Et,CONH-3-吡啶基),(NHCH(Me)CONHMe,H,Me,Et,NHCOPh),(NHCH(Me)CONHMe,H,Me,Et,NHCO-2-呋喃基),(NHCH(Me)CONHMe,H,Me,Et,NHCONHPh),(NHCH(Me)CONHMe,H,Me,Et,NHCOCONHPh),(NHCH(Me)CONHMe,H,Me,CH2OH,CONHPh),(NHCH(Me)CONHMe,H,Me,CH2OH,CONH-3-吡啶基),(NHCH(Me)CONHMe,H,Me,CH2OH,NHCOPh),(NHCH(Me)CONHMe,H,Me,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CONHMe,H,Me,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,H,Me,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,H,Ph,Me,CONHPh),(NHCH(Me)CONHMe,H,Ph,Me,CONH-3-吡啶基),(NHCH(Me)CONHMe,H,Ph,Me,NHCOPh),(NHCH(Me)CONHMe,H,Ph,Me,NHCO-2-呋喃基),(NHCH(Me)CONHMe,H,Ph,Me,NHCONHPh),(NHCH(Me)CONHMe,H,Ph,Me,NHCOCONHPh),(NHCH(Me)CONHMe,H,Ph,Et,CONHPh),(NHCH(Me)CONHMe,H,Ph,Et,CONH-3-吡啶基),(NHCH(Me)CONHMe,H,Ph,Et,NHCOPh),(NHCH(Me)CONHMe,H,Ph,Et,NHCO-2-呋喃基),(NHCH(Me)CONHMe,H,Ph,Et,NHCONHPh),(NHCH(Me)CONHMe,H,Ph,Et,NHCOCONHPh),(NHCH(Me)CONHMe,H,Ph,CH2OH,CONHPh),(NHCH(Me)CONHMe,H,Ph,CH2OH,CONH-3-吡啶基),(NHCH(Me)CONHMe,H,Ph,CH2OH,NHCOPh),(NHCH(Me)CONHMe,H,Ph,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CONHMe,H,Ph,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,H,Ph,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,H,OH,Me,CONHPh),(NHCH(Me)CONHMe,H,OH,Me,CONH-3-吡啶基),(NHCH(Me)CONHMe,H,OH,Me,NHCOPh),(NHCH(Me)CONHMe,H,OH,Me,NHCO-2-呋喃基),(NHCH(Me)CONHMe,H,OH,Me,NHCONHPh),(NHCH(Me)CONHMe,H,OH,Me,NHCOCONHPh),(NHCH(Me)CONHMe,H,OH,Et,CONHPh),(NHCH(Me)CONHMe,H,OH,Et,CONH-3-吡啶基),(NHCH(Me)CONHMe,H,OH,Et,NHCOPh),(NHCH(Me)CONHMe,H,OH,Et,NHCO-2-呋喃基),(NHCH(Me)CONHMe,H,OH,Et,NHCONHPh),(NHCH(Me)CONHMe,H,OH,Et,NHCOCONHPh),(NHCH(Me)CONHMe,H,OH,CH2OH,CONHPh),(NHCH(Me)CONHMe,H,OH,CH2OH,CONH-3-吡啶基),(NHCH(Me)CONHMe,H,OH,CH2OH,NHCOPh),(NHCH(Me)CONHMe,H,OH,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CONHMe,H,OH,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,H,OH,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Me,H,Me,CONHPh),(NHCH(Me)CONHMe,Me,H,Me,CONH-3-吡啶基),(NHCH(Me)CONHMe,Me,H,Me,NHCOPh),(NHCH(Me)CONHMe,Me,H,Me,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Me,H,Me,NHCONHPh),(NHCH(Me)CONHMe,Me,H,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Me,H,Et,CONHPh),(NHCH(Me)CONHMe,Me,H,Et,CONH-3-吡啶基),(NHCH(Me)CONHMe,Me,H,Et,NHCOPh),(NHCH(Me)CONHMe,Me,H,Et,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Me,H,Et,NHCONHPh),(NHCH(Me)CONHMe,Me,H,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Me,H,CH2OH,CONHPh),(NHCH(Me)CONHMe,Me,H,CH2OH,CONH-3-吡啶基),(NHCH(Me)CONHMe,Me,H,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Me,H,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Me,H,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Me,H,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Me,Me,Me,CONHPh),(NHCH(Me)CONHMe,Me,Me,Me,CONH-3-吡啶基),(NHCH(Me)CONHMe,Me,Me,Me,NHCOPh),(NHCH(Me)CONHMe,Me,Me,Me,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Me,Me,Me,NHCONHPh),(NHCH(Me)CONHMe,Me,Me,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Me,Me,Et,CONHPh),(NHCH(Me)CONHMe,Me,Me,Et,CONH-3-吡啶基),(NHCH(Me)CONHMe,Me,Me,Et,NHCOPh),(NHCH(Me)CONHMe,Me,Me,Et,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Me,Me,Et,NHCONHPh),(NHCH(Me)CONHMe,Me,Me,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Me,Me,CH2OH,CONHPh),(NHCH(Me)CONHMe,Me,Me,CH2OH,CONH-3-吡啶基),(NHCH(Me)CONHMe,Me,Me,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Me,Me,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Me,Me,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Me,Me,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Me,Ph,Me,CONHPh),(NHCH(Me)CONHMe,Me,Ph,Me,CONH-3-吡啶基),(NHCH(Me)CONHMe,Me,Ph,Me,NHCOPh),(NHCH(Me)CONHMe,Me,Ph,Me,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Me,Ph,Me,NHCONHPh),(NHCH(Me)CONHMe,Me,Ph,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Me,Ph,Et,CONHPh),(NHCH(Me)CONHMe,Me,Ph,Et,CONH-3-吡啶基),(NHCH(Me)CONHMe,Me,Ph,Et,NHCOPh),(NHCH(Me)CONHMe,Me,Ph,Et,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Me,Ph,Et,NHCONHPh),(NHCH(Me)CONHMe,Me,Ph,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Me,Ph,CH2OH,CONHPh),(NHCH(Me)CONHMe,Me,Ph,CH2OH,CONH-3-吡啶基),(NHCH(Me)CONHMe,Me,Ph,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Me,Ph,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Me,Ph,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Me,Ph,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Me,OH,Me,CONHPh),(NHCH(Me)CONHMe,Me,OH,Me,CONH-3-吡啶基),(NHCH(Me)CONHMe,Me,OH,Me,NHCOPh),(NHCH(Me)CONHMe,Me,OH,Me,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Me,OH,Me,NHCONHPh),(NHCH(Me)CONHMe,Me,OH,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Me,OH,Et,CONHPh),(NHCH(Me)CONHMe,Me,OH,Et,CONH-3-吡啶基),(NHCH(Me)CONHMe,Me,OH,Et,NHCOPh),(NHCH(Me)CONHMe,Me,OH,Et,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Me,OH,Et,NHCONHPh),(NHCH(Me)CONHMe,Me,OH,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Me,OH,CH2OH,CONHPh),(NHCH(Me)CONHMe,Me,OH,CH2OH,CONH-3-吡啶基),(NHCH(Me)CONHMe,Me,OH,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Me,OH,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Me,OH,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Me,OH,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,H,Me,CONHPh),(NHCH(Me)CONHMe,Ph,H,Me,CONH-3-吡啶基),(NHCH(Me)CONHMe,Ph,H,Me,NHCOPh),(NHCH(Me)CONHMe,Ph,H,Me,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Ph,H,Me,NHCONHPh),(NHCH(Me)CONHMe,Ph,H,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,H,Et,CONHPh),(NHCH(Me)CONHMe,Ph,H,Et,CONH-3-吡啶基),(NHCH(Me)CONHMe,Ph,H,Et,NHCOPh),(NHCH(Me)CONHMe,Ph,H,Et,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Ph,H,Et,NHCONHPh),(NHCH(Me)CONHMe,Ph,H,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,H,CH2OH,CONHPh),(NHCH(Me)CONHMe,Ph,H,CH2OH,CONH-3-吡啶基),(NHCH(Me)CONHMe,Ph,H,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Ph,H,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Ph,H,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Ph,H,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,Me,Me,CONHPh),(NHCH(Me)CONHMe,Ph,Me,Me,CONH-3-吡啶基),(NHCH(Me)CONHMe,Ph,Me,Me,NHCOPh),(NHCH(Me)CONHMe,Ph,Me,Me,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Ph,Me,Me,NHCONHPh),(NHCH(Me)CONHMe,Ph,Me,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,Me,Et,CONHPh),(NHCH(Me)CONHMe,Ph,Me,Et,CONH-3-吡啶基),(NHCH(Me)CONHMe,Ph,Me,Et,NHCOPh),(NHCH(Me)CONHMe,Ph,Me,Et,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Ph,Me,Et,NHCONHPh),(NHCH(Me)CONHMe,Ph,Me,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,Me,CH2OH,CONHPh),(NHCH(Me)CONHMe,Ph,Me,CH2OH,CONH-3-吡啶基),(NHCH(Me)CONHMe,Ph,Me,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Ph,Me,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Ph,Me,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Ph,Me,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,Ph,Me,CONHPh),(NHCH(Me)CONHMe,Ph,Ph,Me,CONH-3-吡啶基),(NHCH(Me)CONHMe,Ph,Ph,Me,NHCOPh),(NHCH(Me)CONHMe,Ph,Ph,Me,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Ph,Ph,Me,NHCONHPh),(NHCH(Me)CONHMe,Ph,Ph,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,Ph,Et,CONHPh),(NHCH(Me)CONHMe,Ph,Ph,Et,CONH-3-吡啶基),(NHCH(Me)CONHMe,Ph,Ph,Et,NHCOPh),(NHCH(Me)CONHMe,Ph,Ph,Et,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Ph,Ph,Et,NHCONHPh),(NHCH(Me)CONHMe,Ph,Ph,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,Ph,CH2OH,CONHPh),(NHCH(Me)CONHMe,Ph,Ph,CH2OH,CONH-3-吡啶基),(NHCH(Me)CONHMe,Ph,Ph,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Ph,Ph,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Ph,Ph,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Ph,Ph,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,OH,Me,CONHPh),(NHCH(Me)CONHMe,Ph,OH,Me,CONH-3-吡啶基),(NHCH(Me)CONHMe,Ph,OH,Me,NHCOPh),(NHCH(Me)CONHMe,Ph,OH,Me,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Ph,OH,Me,NHCONHPh),(NHCH(Me)CONHMe,Ph,OH,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,OH,Et,CONHPh),(NHCH(Me)CONHMe,Ph,OH,Et,CONH-3-吡啶基),(NHCH(Me)CONHMe,Ph,OH,Et,NHCOPh),(NHCH(Me)CONHMe,Ph,OH,Et,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Ph,OH,Et,NHCONHPh),(NHCH(Me)CONHMe,Ph,OH,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,OH,CH2OH,CONHPh),(NHCH(Me)CONHMe,Ph,OH,CH2OH,CONH-3-吡啶基),(NHCH(Me)CONHMe,Ph,OH,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Ph,OH,CH2OH,NHCO-2-呋喃基),(NHCH(Me)CONHMe,Ph,OH,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Ph,OH,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,H,H,Me,CONHPh),(NHCOCH(iPr)OH,H,H,Me,CONH-3-吡啶基),(NHCOCH(iPr)OH,H,H,Me,NHCOPh),(NHCOCH(iPr)OH,H,H,Me,NHCO-2-呋喃基),(NHCOCH(iPr)OH,H,H,Me,NHCONHPh),(NHCOCH(iPr)OH,H,H,Me,NHCOCONHPh),(NHCOCH(iPr)OH,H,H,Et,CONHPh),(NHCOCH(iPr)OH,H,H,Et,CONH-3-吡啶基),(NHCOCH(iPr)OH,H,H,Et,NHCOPh),(NHCOCH(iPr)OH,H,H,Et,NHCO-2-呋喃基),(NHCOCH(iPr)OH,H,H,Et,NHCONHPh),(NHCOCH(iPr)OH,H,H,Et,NHCOCONHPh),(NHCOCH(iPr)OH,H,H,CH2OH,CONHPh),(NHCOCH(iPr)OH,H,H,CH2OH,CONH-3-吡啶基),(NHCOCH(iPr)OH,H,H,CH2OH,NHCOPh),(NHCOCH(iPr)OH,H,H,CH2OH,NHCO-2-呋喃基),(NHCOCH(iPr)OH,H,H,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,H,H,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,H,Me,Me,CONHPh),(NHCOCH(iPr)OH,H,Me,Me,CONH-3-吡啶基),(NHCOCH(iPr)OH,H,Me,Me,NHCOPh),(NHCOCH(iPr)OH,H,Me,Me,NHCO-2-呋喃基),(NHCOCH(iPr)OH,H,Me,Me,NHCONHPh),(NHCOCH(iPr)OH,H,Me,Me,NHCOCONHPh),(NHCOCH(iPr)OH,H,Me,Et,CONHPh),(NHCOCH(iPr)OH,H,Me,Et,CONH-3-吡啶基),(NHCOCH(iPr)OH,H,Me,Et,NHCOPh),(NHCOCH(iPr)OH,H,Me,Et,NHCO-2-呋喃基),(NHCOCH(iPr)OH,H,Me,Et,NHCONHPh),(NHCOCH(iPr)OH,H,Me,Et,NHCOCONHPh),(NHCOCH(iPr)OH,H,Me,CH2OH,CONHPh),(NHCOCH(iPr)OH,H,Me,CH2OH,CONH-3-吡啶基),(NHCOCH(iPr)OH,H,Me,CH2OH,NHCOPh),(NHCOCH(iPr)OH,H,Me,CH2OH,NHCO-2-呋喃基),(NHCOCH(iPr)OH,H,Me,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,H,Me,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,H,Ph,Me,CONHPh),(NHCOCH(iPr)OH,H,Ph,Me,CONH-3-吡啶基),(NHCOCH(iPr)OH,H,Ph,Me,NHCOPh),(NHCOCH(iPr)OH,H,Ph,Me,NHCO-2-呋喃基),(NHCOCH(iPr)OH,H,Ph,Me,NHCONHPh),(NHCOCH(iPr)OH,H,Ph,Me,NHCOCONHPh),(NHCOCH(iPr)OH,H,Ph,Et,CONHPh),(NHCOCH(iPr)OH,H,Ph,Et,CONH-3-吡啶基),(NHCOCH(iPr)OH,H,Ph,Et,NHCOPh),(NHCOCH(iPr)OH,H,Ph,Et,NHCO-2-呋喃基),(NHCOCH(iPr)OH,H,Ph,Et,NHCONHPh),(NHCOCH(iPr)OH,H,Ph,Et,NHCOCONHPh),(NHCOCH(iPr)OH,H,Ph,CH2OH,CONHPh),(NHCOCH(iPr)OH,H,Ph,CH2OH,CONH-3-吡啶基),(NHCOCH(iPr)OH,H,Ph,CH2OH,NHCOPh),(NHCOCH(iPr)OH,H,Ph,CH2OH,NHCO-2-呋喃基),(NHCOCH(iPr)OH,H,Ph,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,H,Ph,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,H,OH,Me,CONHPh),(NHCOCH(iPr)OH,H,OH,Me,CONH-3-吡啶基),(NHCOCH(iPr)OH,H,OH,Me,NHCOPh),(NHCOCH(iPr)OH,H,OH,Me,NHCO-2-呋喃基),(NHCOCH(iPr)OH,H,OH,Me,NHCONHPh),(NHCOCH(iPr)OH,H,OH,Me,NHCOCONHPh),(NHCOCH(iPr)OH,H,OH,Et,CONHPh),(NHCOCH(iPr)OH,H,OH,Et,CONH-3-吡啶基),(NHCOCH(iPr)OH,H,OH,Et,NHCOPh),(NHCOCH(iPr)OH,H,OH,Et,NHCO-2-呋喃基),(NHCOCH(iPr)OH,H,OH,Et,NHCONHPh),(NHCOCH(iPr)OH,H,OH,Et,NHCOCONHPh),(NHCOCH(iPr)OH,H,OH,CH2OH,CONHPh),(NHCOCH(iPr)OH,H,OH,CH2OH,CONH-3-吡啶基),(NHCOCH(iPr)OH,H,OH,CH2OH,NHCOPh),(NHCOCH(iPr)OH,H,OH,CH2OH,NHCO-2-呋喃基),(NHCOCH(iPr)OH,H,OH,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,H,OH,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Me,H,Me,CONHPh),(NHCOCH(iPr)OH,Me,H,Me,CONH-3-吡啶基),(NHCOCH(iPr)OH,Me,H,Me,NHCOPh),(NHCOCH(iPr)OH,Me,H,Me,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Me,H,Me,NHCONHPh),(NHCOCH(iPr)OH,Me,H,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Me,H,Et,CONHPh),(NHCOCH(iPr)OH,Me,H,Et,CONH-3-吡啶基),(NHCOCH(iPr)OH,Me,H,Et,NHCOPh),(NHCOCH(iPr)OH,Me,H,Et,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Me,H,Et,NHCONHPh),(NHCOCH(iPr)OH,Me,H,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Me,H,CH2OH,CONHPh),(NHCOCH(iPr)OH,Me,H,CH2OH,CONH-3-吡啶基),(NHCOCH(iPr)OH,Me,H,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Me,H,CH2OH,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Me,H,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,Me,H,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Me,Me,Me,CONHPh),(NHCOCH(iPr)OH,Me,Me,Me,CONH-3-吡啶基),(NHCOCH(iPr)OH,Me,Me,Me,NHCOPh),(NHCOCH(iPr)OH,Me,Me,Me,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Me,Me,Me,NHCONHPh),(NHCOCH(iPr)OH,Me,Me,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Me,Me,Et,CONHPh),(NHCOCH(iPr)OH,Me,Me,Et,CONH-3-吡啶基),(NHCOCH(iPr)OH,Me,Me,Et,NHCOPh),(NHCOCH(iPr)OH,Me,Me,Et,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Me,Me,Et,NHCONHPh),(NHCOCH(iPr)OH,Me,Me,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Me,Me,CH2OH,CONHPh),(NHCOCH(iPr)OH,Me,Me,CH2OH,CONH-3-吡啶基),(NHCOCH(iPr)OH,Me,Me,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Me,Me,CH2OH,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Me,Me,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,Me,Me,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Me,Ph,Me,CONHPh),(NHCOCH(iPr)OH,Me,Ph,Me,CONH-3-吡啶基),(NHCOCH(iPr)OH,Me,Ph,Me,NHCOPh),(NHCOCH(iPr)OH,Me,Ph,Me,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Me,Ph,Me,NHCONHPh),(NHCOCH(iPr)OH,Me,Ph,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Me,Ph,Et,CONHPh),(NHCOCH(iPr)OH,Me,Ph,Et,CONH-3-吡啶基),(NHCOCH(iPr)OH,Me,Ph,Et,NHCOPh),(NHCOCH(iPr)OH,Me,Ph,Et,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Me,Ph,Et,NHCONHPh),(NHCOCH(iPr)OH,Me,Ph,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Me,Ph,CH2OH,CONHPh),(NHCOCH(iPr)OH,Me,Ph,CH2OH,CONH-3-吡啶基),(NHCOCH(iPr)OH,Me,Ph,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Me,Ph,CH2OH,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Me,Ph,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,Me,Ph,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Me,OH,Me,CONHPh),(NHCOCH(iPr)OH,Me,OH,Me,CONH-3-吡啶基),(NHCOCH(iPr)OH,Me,OH,Me,NHCOPh),(NHCOCH(iPr)OH,Me,OH,Me,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Me,OH,Me,NHCONHPh),(NHCOCH(iPr)OH,Me,OH,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Me,OH,Et,CONHPh),(NHCOCH(iPr)OH,Me,OH,Et,CONH-3-吡啶基),(NHCOCH(iPr)OH,Me,OH,Et,NHCOPh),(NHCOCH(iPr)OH,Me,OH,Et,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Me,OH,Et,NHCONHPh),(NHCOCH(iPr)OH,Me,OH,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Me,OH,CH2OH,CONHPh),(NHCOCH(iPr)OH,Me,OH,CH2OH,CONH-3-吡啶基),(NHCOCH(iPr)OH,Me,OH,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Me,OH,CH2OH,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Me,OH,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,Me,OH,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,H,Me,CONHPh),(NHCOCH(iPr)OH,Ph,H,Me,CONH-3-吡啶基),(NHCOCH(iPr)OH,Ph,H,Me,NHCOPh),(NHCOCH(iPr)OH,Ph,H,Me,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Ph,H,Me,NHCONHPh),(NHCOCH(iPr)OH,Ph,H,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,H,Et,CONHPh),(NHCOCH(iPr)OH,Ph,H,Et,CONH-3-吡啶基),(NHCOCH(iPr)OH,Ph,H,Et,NHCOPh),(NHCOCH(iPr)OH,Ph,H,Et,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Ph,H,Et,NHCONHPh),(NHCOCH(iPr)OH,Ph,H,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,H,CH2OH,CONHPh),(NHCOCH(iPr)OH,Ph,H,CH2OH,CONH-3-吡啶基),(NHCOCH(iPr)OH,Ph,H,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Ph,H,CH2OH,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Ph,H,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,Ph,H,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,Me,Me,CONHPh),(NHCOCH(iPr)OH,Ph,Me,Me,CONH-3-吡啶基),(NHCOCH(iPr)OH,Ph,Me,Me,NHCOPh),(NHCOCH(iPr)OH,Ph,Me,Me,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Ph,Me,Me,NHCONHPh),(NHCOCH(iPr)OH,Ph,Me,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,Me,Et,CONHPh),(NHCOCH(iPr)OH,Ph,Me,Et,CONH-3-吡啶基),(NHCOCH(iPr)OH,Ph,Me,Et,NHCOPh),(NHCOCH(iPr)OH,Ph,Me,Et,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Ph,Me,Et,NHCONHPh),(NHCOCH(iPr)OH,Ph,Me,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,Me,CH2OH,CONHPh),(NHCOCH(iPr)OH,Ph,Me,CH2OH,CONH-3-吡啶基),(NHCOCH(iPr)OH,Ph,Me,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Ph,Me,CH2OH,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Ph,Me,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,Ph,Me,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,Ph,Me,CONHPh),(NHCOCH(iPr)OH,Ph,Ph,Me,CONH-3-吡啶基),(NHCOCH(iPr)OH,Ph,Ph,Me,NHCOPh),(NHCOCH(iPr)OH,Ph,Ph,Me,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Ph,Ph,Me,NHCONPh),(NHCOCH(iPr)OH,Ph,Ph,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,Ph,Et,CONHPh),(NHCOCH(iPr)OH,Ph,Ph,Et,CONH-3-吡啶基),(NHCOCH(iPr)OH,Ph,Ph,Et,NHCOPh),(NHCOCH(iPr)OH,Ph,Ph,Et,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Ph,Ph,Et,NHCONHPh),(NHCOCH(iPr)OH,Ph,Ph,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,Ph,CH2OH,CONHPh),(NHCOCH(iPr)OH,Ph,Ph,CH2OH,CONH-3-吡啶基),(NHCOCH(iPr)OH,Ph,Ph,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Ph,Ph,CH2OH,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Ph,Ph,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,Ph,Ph,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,OH,Me,CONHPh),(NHCOCH(iPr)OH,Ph,OH,Me,CONH-3-吡啶基),(NHCOCH(iPr)OH,Ph,OH,Me,NHCOPh),(NHCOCH(iPr)OH,Ph,OH,Me,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Ph,OH,Me,NHCONHPh),(NHCOCH(iPr)OH,Ph,OH,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,OH,Et,CONHPh),(NHCOCH(iPr)OH,Ph,OH,Et,CONH-3-吡啶基),(NHCOCH(iPr)OH,Ph,OH,Et,NHCOPh),(NHCOCH(iPr)OH,Ph,OH,Et,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Ph,OH,Et,NHCONHPh),(NHCOCH(iPr)OH,Ph,OH,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,OH,CH2OH,CONHPh),(NHCOCH(iPr)OH,Ph,OH,CH2OH,CONH-3-吡啶基),(NHCOCH(iPr)OH,Ph,OH,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Ph,OH,CH2OH,NHCO-2-呋喃基),(NHCOCH(iPr)OH,Ph,OH,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,Ph,OH,CH2OH,NHCOCONHPh),(NHSO2Me,H,H,Me,CONHPh),(NHSO2Me,H,H,Me,CONH-3-吡啶基),(NHSO2Me,H,H,Me,NHCOPh),(NHSO2Me,H,H,Me,NHCO-2-呋喃基),(NHSO2Me,H,H,Me,NHCONHPh),(NHSO2Me,H,H,Me,NHCOCONHPh),(NHSO2Me,H,H,Et,CONHPh),(NHSO2Me,H,H,Et,CONH-3-吡啶基),(NHSO2Me,H,H,Et,NHCOPh),(NHSO2Me,H,H,Et,NHCO-2-呋喃基),(NHSO2Me,H,H,Et,NHCONHPh),(NHSO2Me,H,H,Et,NHCOCONHPh),(NHSO2Me,H,H,CH2OH,CONHPh),(NHSO2Me,H,H,CH2OH,CONH-3-吡啶基),(NHSO2Me,H,H,CH2OH,NHCOPh),(NHSO2Me,H,H,CH2OH,NHCO-2-呋喃基),(NHSO2Me,H,H,CH2OH,NHCONHPh),(NHSO2Me,H,H,CH2OH,NHCOCONHPh),(NHSO2Me,H,Me,Me,CONHPh),(NHSO2Me,H,Me,Me,CONH-3-吡啶基),(NHSO2Me,H,Me,Me,NHCOPh),(NHSO2Me,H,Me,Me,NHCO-2-呋喃基),(NHSO2Me,H,Me,Me,NHCONHPh),(NHSO2Me,H,Me,Me,NHCOCONHPh),(NHSO2Me,H,Me,Et,CONHPh),(NHSO2Me,H,Me,Et,CONH-3-吡啶基),(NHSO2Me,H,Me,Et,NHCOPh),(NHSO2Me,H,Me,Et,NHCO-2-呋喃基),(NHSO2Me,H,Me,Et,NHCONHPh),(NHSO2Me,H,Me,Et,NHCOCONHPh),(NHSO2Me,H,Me,CH2OH,CONHPh),(NHSO2Me,H,Me,CH2OH,CONH-3-吡啶基),(NHSO2Me,H,Me,CH2OH,NHCOPh),(NHSO2Me,H,Me,CH2OH,NHCO-2-呋喃基),(NHSO2Me,H,Me,CH2OH,NHCONHPh),(NHSO2Me,H,Me,CH2OH,NHCOCONHPh),(NHSO2Me,H,Ph,Me,CONHPh),(NHSO2Me,H,Ph,Me,CONH-3-吡啶基),(NHSO2Me,H,Ph,Me,NHCOPh),(NHSO2Me,H,Ph,Me,NHCO-2-呋喃基),(NHSO2Me,H,Ph,Me,NHCONHPh),(NHSO2Me,H,Ph,Me,NHCOCONHPh),(NHSO2Me,H,Ph,Et,CONHPh),(NHSO2Me,H,Ph,Et,CONH-3-吡啶基),(NHSO2Me,H,Ph,Et,NHCOPh),(NHSO2Me,H,Ph,Et,NHCO-2-呋喃基),(NHSO2Me,H,Ph,Et,NHCONHPh),(NHSO2Me,H,Ph,Et,NHCOCONHPh),(NHSO2Me,H,Ph,CH2OH,CONHPh),(NHSO2Me,H,Ph,CH2OH,CONH-3-吡啶基),(NHSO2Me,H,Ph,CH2OH,NHCOPh),(NHSO2Me,H,Ph,CH2OH,NHCO-2-呋喃基),(NHSO2Me,H,Ph,CH2OH,NHCONHPh),(NHSO2Me,H,Ph,CH2OH,NHCOCONHPh),(NHSO2Me,H,OH,Me,CONHPh),(NHSO2Me,H,OH,Me,CONH-3-吡啶基),(NHSO2Me,H,OH,Me,NHCOPh),(NHSO2Me,H,OH,Me,NHCO-2-呋喃基),(NHSO2Me,H,OH,Me,NHCONHPh),(NHSO2Me,H,OH,Me,NHCOCONHPh),(NHSO2Me,H,OH,Et,CONHPh),(NHSO2Me,H,OH,Et,CONH-3-吡啶基),(NHSO2Me,H,OH,Et,NHCOPh),(NHSO2Me,H,OH,Et,NHCO-2-呋喃基),(NHSO2Me,H,OH,Et,NHCONHPh),(NHSO2Me,H,OH,Et,NHCOCONHPh),(NHSO2Me,H,OH,CH2OH,CONHPh),(NHSO2Me,H,OH,CH2OH,CONH-3-吡啶基),(NHSO2Me,H,OH,CH2OH,NHCOPh),(NHSO2Me,H,OH,CH2OH,NHCO-2-呋喃基),(NHSO2Me,H,OH,CH2OH,NHCONHPh),(NHSO2Me,H,OH,CH2OH,NHCOCONHPh),(NHSO2Me,Me,H,Me,CONHPh),(NHSO2Me,Me,H,Me,CONH-3-吡啶基),(NHSO2Me,Me,H,Me,NHCOPh),(NHSO2Me,Me,H,Me,NHCO-2-呋喃基),(NHSO2Me,Me,H,Me,NHCONHPh),(NHSO2Me,Me,H,Me,NHCOCONHPh),(NHSO2Me,Me,H,Et,CONHPh),(NHSO2Me,Me,H,Et,CONH-3-吡啶基),(NHSO2Me,Me,H,Et,NHCOPh),(NHSO2Me,Me,H,Et,NHCO-2-呋喃基),(NHSO2Me,Me,H,Et,NHCONHPh),(NHSO2Me,Me,H,Et,NHCOCONHPh),(NHSO2Me,Me,H,CH2OH,CONHPh),(NHSO2Me,Me,H,CH2OH,CONH-3-吡啶基),(NHSO2Me,Me,H,CH2OH,NHCOPh),(NHSO2Me,Me,H,CH2OH,NHCO-2-呋喃基),(NHSO2Me,Me,H,CH2OH,NHCONHPh),(NHSO2Me,Me,H,CH2OH,NHCOCONHPh),(NHSO2Me,Me,Me,Me,CONHPh),(NHSO2Me,Me,Me,Me,CONH-3-吡啶基),(NHSO2Me,Me,Me,Me,NHCOPh),(NHSO2Me,Me,Me,Me,NHCO-2-呋喃基),(NHSO2Me,Me,Me,Me,NHCONHPh),(NHSO2Me,Me,Me,Me,NHCOCONHPh),(NHSO2Me,Me,Me,Et,CONHPh),(NHSO2Me,Me,Me,Et,CONH-3-吡啶基),(NHSO2Me,Me,Me,Et,NHCOPh),(NHSO2Me,Me,Me,Et,NHCO-2-呋喃基),(NHSO2Me,Me,Me,Et,NHCONHPh),(NHSO2Me,Me,Me,Et,NHCOCONHPh),(NHSO2Me,Me,Me,CH2OH,CONHPh),(NHSO2Me,Me,Me,CH2OH,CONH-3-吡啶基),(NHSO2Me,Me,Me,CH2OH,NHCOPh),(NHSO2Me,Me,Me,CH2OH,NHCO-2-呋喃基),(NHSO2Me,Me,Me,CH2OH,NHCONHPh),(NHSO2Me,Me,Me,CH2OH,NHCOCONHPh),(NHSO2Me,Me,Ph,Me,CONHPh),(NHSO2Me,Me,Ph,Me,CONH-3-吡啶基),(NHSO2Me,Me,Ph,Me,NHCOPh),(NHSO2Me,Me,Ph,Me,NHCO-2-呋喃基),(NHSO2Me,Me,Ph,Me,NHCONHPh),(NHSO2Me,Me,Ph,Me,NHCOCONHPh),(NHSO2Me,Me,Ph,Et,CONHPh),(NHSO2Me,Me,Ph,Et,CONH-3-吡啶基),(NHSO2Me,Me,Ph,Et,NHCOPh),(NHSO2Me,Me,Ph,Et,NHCO-2-呋喃基),(NHSO2Me,Me,Ph,Et,NHCONHPh),(NHSO2Me,Me,Ph,Et,NHCOCONHPh),(NHSO2Me,Me,Ph,CH2OH,CONHPh),(NHSO2Me,Me,Ph,CH2OH,CONH-3-吡啶基),(NHSO2Me,Me,Ph,CH2OH,NHCOPh),(NHSO2Me,Me,Ph,CH2OH,NHCO-2-呋喃基),(NHSO2Me,Me,Ph,CH2OH,NHCONHPh),(NHSO2Me,Me,Ph,CH2OH,NHCOCONHPh),(NHSO2Me,Me,OH,Me,CONHPh),(NHSO2Me,Me,OH,Me,CONH-3-吡啶基),(NHSO2Me,Me,OH,Me,NHCOPh),(NHSO2Me,Me,OH,Me,NHCO-2-呋喃基),(NHSO2Me,Me,OH,Me,NHCONHPh),(NHSO2Me,Me,OH,Me,NHCOCONHPh),(NHSO2Me,Me,OH,Et,CONHPh),(NHSO2Me,Me,OH,Et,CONH-3-吡啶基),(NHSO2Me,Me,OH,Et,NHCOPh),(NHSO2Me,Me,OH,Et,NHCO-2-呋喃基),(NHSO2Me,Me,OH,Et,NHCONHPh),(NHSO2Me,Me,OH,Et,NHCOCONHPh),(NHSO2Me,Me,OH,CH2OH,CONHPh),(NHSO2Me,Me,OH,CH2OH,CONH-3-吡啶基),(NHSO2Me,Me,OH,CH2OH,NHCOPh),(NHSO2Me,Me,OH,CH2OH,NHCO-2-呋喃基),(NHSO2Me,Me,OH,CH2OH,NHCONHPh),(NHSO2Me,Me,OH,CH2OH,NHCOCONHPh),(NHSO2Me,Ph,H,Me,CONHPh),(NHSO2Me,Ph,H,Me,CONH-3-吡啶基),(NHSO2Me,Ph,H,Me,NHCOPh),(NHSO2Me,Ph,H,Me,NHCO-2-呋喃基),(NHSO2Me,Ph,H,Me,NHCONHPh),(NHSO2Me,Ph,H,Me,NHCOCONHPh),(NHSO2Me,Ph,H,Et,CONHPh),(NHSO2Me,Ph,H,Et,CONH-3-吡啶基),(NHSO2Me,Ph,H,Et,NHCOPh),(NHSO2Me,Ph,H,Et,NHCO-2-呋喃基),(NHSO2Me,Ph,H,Et,NHCONHPh),(NHSO2Me,Ph,H,Et,NHCOCONHPh),(NHSO2Me,Ph,H,CH2OH,CONHPh),(NHSO2Me,Ph,H,CH2OH,CONH-3-吡啶基),(NHSO2Me,Ph,H,CH2OH,NHCOPh),(NHSO2Me,Ph,H,CH2OH,NHCO-2-呋喃基),(NHSO2Me,Ph,H,CH2OH,NHCONHPh),(NHSO2Me,Ph,H,CH2OH,NHCOCONHPh),(NHSO2Me,Ph,Me,Me,CONHPh),(NHSO2Me,Ph,Me,Me,CONH-3-吡啶基),(NHSO2Me,Ph,Me,Me,NHCOPh),(NHSO2Me,Ph,Me,Me,NHCO-2-呋喃基),(NHSO2Me,Ph,Me,Me,NHCONHPh),(NHSO2Me,Ph,Me,Me,NHCOCONHPh),(NHSO2Me,Ph,Me,Et,CONHPh),(NHSO2Me,Ph,Me,Et,CONH-3-吡啶基),(NHSO2Me,Ph,Me,Et,NHCOPh),(NHSO2Me,Ph,Me,Et,NHCO-2-呋喃基),(NHSO2Me,Ph,Me,Et,NHCONHPh),(NHSO2Me,Ph,Me,Et,NHCOCONHPh),(NHSO2Me,Ph,Me,CH2OH,CONHPh),(NHSO2Me,Ph,Me,CH2OH,CONH-3-吡啶基),(NHSO2Me,Ph,Me,CH2OH,NHCOPh),(NHSO2Me,Ph,Me,CH2OH,NHCO-2-呋喃基),(NHSO2Me,Ph,Me,CH2OH,NHCONHPh),(NHSO2Me,Ph,Me,CH2OH,NHCOCONHPh),(NHSO2Me,Ph,Ph,Me,CONHPh),(NHSO2Me,Ph,Ph,Me,CONH-3-吡啶基),(NHSO2Me,Ph,Ph,Me,NHCOPh),(NHSO2Me,Ph,Ph,Me,NHCO-2-呋喃基),(NHSO2Me,Ph,Ph,Me,NHCONHPh),(NHSO2Me,Ph,Ph,Me,NHCOCONHPh),(NHSO2Me,Ph,Ph,Et,CONHPh),(NHSO2Me,Ph,Ph,Et,CONH-3-吡啶基),(NHSO2Me,Ph,Ph,Et,NHCOPh),(NHSO2Me,Ph,Ph,Et,NHCO-2-呋喃基),(NHSO2Me,Ph,Ph,Et,NHCONHPh),(NHSO2Me,Ph,Ph,Et,NHCOCONHPh),(NHSO2Me,Ph,Ph,CH2OH,CONHPh),(NHSO2Me,Ph,Ph,CH2OH,CONH-3-吡啶基),(NHSO2Me,Ph,Ph,CH2OH,NHCOPh),(NHSO2Me,Ph,Ph,CH2OH,NHCO-2-呋喃基),(NHSO2Me,Ph,Ph,CH2OH,NHCONHPh),(NHSO2Me,Ph,Ph,CH2OH,NHCOCONHPh),(NHSO2Me,Ph,OH,Me,CONHPh),(NHSO2Me,Ph,OH,Me,CONH-3-吡啶基),(NHSO2Me,Ph,OH,Me,NHCOPh),(NHSO2Me,Ph,OH,Me,NHCO-2-呋喃基),(NHSO2Me,Ph,OH,Me,NHCONHPh),(NHSO2Me,Ph,OH,Me,NHCOCONHPh),(NHSO2Me,Ph,OH,Et,CONHPh),(NHSO2Me,Ph,OH,Et,CONH-3-吡啶基),(NHSO2Me,Ph,OH,Et,NHCOPh),(NHSO2Me,Ph,OH,Et,NHCO-2-呋喃基),(NHSO2Me,Ph,OH,Et,NHCONHPh),(NHSO2Me,Ph,OH,Et,NHCOCONHPh),(NHSO2Me,Ph,OH,CH2OH,CONHPh),(NHSO2Me,Ph,OH,CH2OH,CONH-3-吡啶基),(NHSO2Me,Ph,OH,CH2OH,NHCOPh),(NHSO2Me,Ph,OH,CH2OH,NHCO-2-呋喃基),(NHSO2Me,Ph,OH,CH2OH,NHCONHPh),(NHSO2Me,Ph,OH,CH2OH,NHCOCONHPh),(NH2,H,H,Me,CONHPh),(NH2,H,H,Me,CONH-3-吡啶基),(NH2,H,H,Me,NHCOPh),(NH2,H,H,Me,NHCO-2-呋喃基),(NH2,H,H,Me,NHCONHPh),(NH2,H,H,Me,NHCOCONHPh),(NH2,H,H,Et,CONHPh),(NH2,H,H,Et,CONH-3-吡啶基),(NH2,H,H,Et,NHCOPh),(NH2,H,H,Et,NHCO-2-呋喃基),(NH2,H,H,Et,NHCONHPh),(NH2,H,H,Et,NHCOCONHPh),(NH2,H,H,CH2OH,CONHPh),(NH2,H,H,CH2OH,CONH-3-吡啶基),(NH2,H,H,CH2OH,NHCONHPh),(NH2,H,H,CH2OH,NHCOCONHPh),(NH2,H,Me,Me,CONHPh),(NH2,H,Me,Me,CONH-3-吡啶基),(NH2,H,Me,Me,NHCONHPh),(NH2,H,Me,Me,NHCOCONHPh),(NH2,H,Me,Et,CONHPh),(NH2,H,Me,Et,CONH-3-吡啶基),(NH2,H,Me,Et,NHCOPh),(NH2,H,Me,Et,NHCO-2-呋喃基),(NH2,H,Me,Et,NHCONHPh),(NH2,H,Me,Et,NHCOCONHPh),(NH2,H,Me,CH2OH,CONHPh),(NH2,H,Me,CH2OH,CONH-3-吡啶基),(NH2,H,Me,CH2OH,NHCONHPh),(NH2,H,Me,CH2OH,NHCOCONHPh),(NH2,H,Ph,Me,CONHPh),(NH2,H,Ph,Me,CONH-3-吡啶基),(NH2,H,Ph,Me,NHCONHPh),(NH2,H,Ph,Me,NHCOCONHPh),(NH2,H,Ph,Et,CONHPh),(NH2,H,Ph,Et,CONH-3-吡啶基),(NH2,H,Ph,Et,NHCOPh),(NH2,H,Ph,Et,NHCO-2-呋喃基),(NH2,H,Ph,Et,NHCONHPh),(NH2,H,Ph,Et,NHCOCONHPh),(NH2,H,Ph,CH2OH,CONHPh),(NH2,H,Ph,CH2OH,CONH-3-吡啶基),(NH2,H,Ph,CH2OH,NHCONHPh),(NH2,H,Ph,CH2OH,NHCOCONHPh),(NH2,H,OH,Me,CONHPh),(NH2,H,OH,Me,CONH-3-吡啶基),(NH2,H,OH,Me,NHCONHPh),(NH2,H,OH,Me,NHCOCONHPh),(NH2,H,OH,Et,CONHPh),(NH2,H,OH,Et,CONH-3-吡啶基),(NH2,H,OH,Et,NHCOPh),(NH2,H,OH,Et,NHCO-2-呋喃基),(NH2,H,OH,Et,NHCONHPh),(NH2,H,OH,Et,NHCOCONHPh),(NH2,H,OH,CH2OH,CONHPh),(NH2,H,OH,CH2OH,CONH-3-吡啶基),(NH2,H,OH,CH2OH,NHCONHPh),(NH2,H,OH,CH2OH,NHCOCONHPh),(NH2,Me,H,Me,CONHPh),(NH2,Me,H,Me,CONH-3-吡啶基),(NH2,Me,H,Me,NHCONHPh),(NH2,Me,H,Me,NHCOCONHPh),(NH2,Me,H,Et,CONHPh),(NH2,Me,H,Et,CONH-3-吡啶基),(NH2,Me,H,Et,NHCOPh),(NH2,Me,H,Et,NHCO-2-呋喃基),(NH2,Me,H,Et,NHCONHPh),(NH2,Me,H,Et,NHCOCONHPh),(NH2,Me,H,CH2OH,CONHPh),(NH2,Me,H,CH2OH,CONH-3-吡啶基),(NH2,Me,H,CH2OH,NHCONHPh),(NH2,Me,H,CH2OH,NHCOCONHPh),(NH2,Me,Me,Me,CONHPh),(NH2,Me,Me,Me,CONH-3-吡啶基),(NH2,Me,Me,Me,NHCONHPh),(NH2,Me,Me,Me,NHCOCONHPh),(NH2,Me,Me,Et,CONHPh),(NH2,Me,Me,Et,CONH-3-吡啶基),(NH2,Me,Me,Et,NHCOPh),(NH2,Me,Me,Et,NHCO-2-呋喃基),(NH2,Me,Me,Et,NHCONHPh),(NH2,Me,Me,Et,NHCOCONHPh),(NH2,Me,Me,CH2OH,CONHPh),(NH2,Me,Me,CH2OH,CONH-3-吡啶基),(NH2,Me,Me,CH2OH,NHCONHPh),(NH2,Me,Me,CH2OH,NHCOCONHPh),(NH2,Me,Ph,Me,CONHPh),(NH2,Me,Ph,Me,CONH-3-吡啶基),(NH2,Me,Ph,Me,NHCOPh),(NH2,Me,Ph,Me,NHCO-2-呋喃基),(NH2,Me,Ph,Me,NHCONHPh),(NH2,Me,Ph,Me,NHCOCONHPh),(NH2,Me,Ph,Et,CONHPh),(NH2,Me,Ph,Et,CONH-3-吡啶基),(NH2,Me,Ph,Et,NHCOPh),(NH2,Me,Ph,Et,NHCO-2-呋喃基),(NH2,Me,Ph,Et,NHCONHPh),(NH2,Me,Ph,Et,NHCOCONHPh),(NH2,Me,Ph,CH2OH,CONHPh),(NH2,Me,Ph,CH2OH,CONH-3-吡啶基),(NH2,Me,Ph,CH2OH,NHCONHPh),(NH2,Me,Ph,CH2OH,NHCOCONHPh),(NH2,Me,OH,Me,CONHPh),(NH2,Me,OH,Me,CONH-3-吡啶基),(NH2,Me,OH,Me,NHCONHPh),(NH2,Me,OH,Me,NHCOCONHPh),(NH2,Me,OH,Et,CONHPh),(NH2,Me,OH,Et,CONH-3-吡啶基),(NH2,Me,OH,Et,NHCOPh),(NH2,Me,OH,Et,NHCO-2-呋喃基),(NH2,Me,OH,Et,NHCONHPh),(NH2,Me,OH,Et,NHCOCONHPh),(NH2,Me,OH,CH2OH,CONHPh),(NH2,Me,OH,CH2OH,CONH-3-吡啶基),,(NH2,Me,OH,CH2OH,NHCONHPh),(NH2,Me,OH,CH2OH,NHCOCONHPh),(NH2,Ph,H,Me,CONHPh),(NH2,Ph,H,Me,CONH-3-吡啶基),(NH2,Ph,H,Me,NHCONHPh),(NH2,Ph,H,Me,NHCOCONHPh),(NH2,Ph,H,Et,CONHPh),(NH2,Ph,H,Et,CONH-3-吡啶基),(NH2,Ph,H,Et,NHCOPh),(NH2,Ph,H,Et,NHCO-2-呋喃基),(NH2,Ph,H,Et,NHCONHPh),(NH2,Ph,H,Et,NHCOCONHPh),(NH2,Ph,H,CH2OH,CONHPh),(NH2,Ph,H,CH2OH,CONH-3-吡啶基),(NH2,Ph,H,CH2OH,NHCONHPh),(NH2,Ph,H,CH2OH,NHCOCONHPh),(NH2,Ph,Me,Me,CONHPh),(NH2,Ph,Me,Me,CONH-3-吡啶基),(NH2,Ph,Me,Me,NHCONHPh),(NH2,Ph,Me,Me,NHCOCONHPh),(NH2,Ph,Me,Et,CONHPh),(NH2,Ph,Me,Et,CONH-3-吡啶基),(NH2,Ph,Me,Et,NHCOPh),(NH2,Ph,Me,Et,NHCO-2-呋喃基),(NH2,Ph,Me,Et,NHCONHPh),(NH2,Ph,Me,Et,NHCOCONHPh),(NH2,Ph,Me,CH2OH,CONHPh),(NH2,Ph,Me,CH2OH,CONH-3-吡啶基),(NH2,Ph,Me,CH2OH,NHCONHPh),(NH2,Ph,Me,CH2OH,NHCOCONHPh),(NH2,Ph,Ph,Me,CONHPh),(NH2,Ph,Ph,Me,CONH-3-吡啶基),(NH2,Ph,Ph,Me,NHCOPh),(NH2,Ph,Ph,Me,NHCO-2-呋喃基),(NH2,Ph,Ph,Me,NHCONHPh),(NH2,Ph,Ph,Me,NHCOCONHPh),(NH2,Ph,Ph,Et,CONHPh),(NH2,Ph,Ph,Et,CONH-3-吡啶基),(NH2,Ph,Ph,Et,NHCOPh),(NH2,Ph,Ph,Et,NHCO-2-呋喃基),(NH2,Ph,Ph,Et,NHCONHPh),(NH2,Ph,Ph,Et,NHCOCONHPh),(NH2,Ph,Ph,CH2OH,CONHPh),(NH2,Ph,Ph,CH2OH,CONH-3-吡啶基),(NH2,Ph,Ph,CH2OH,NHCOPh),(NH2,Ph,Ph,CH2OH,NHCO-2-呋喃基),(NH2,Ph,Ph,CH2OH,NHCONHPh),(NH2,Ph,Ph,CH2OH,NHCOCONHPh),(NH2,Ph,OH,Me,CONHPh),(NH2,Ph,OH,Me,CONH-3-吡啶基),(NH2,Ph,OH,Me,NHCONHPh),(NH2,Ph,OH,Me,NHCOCONHPh),(NH2,Ph,OH,Et,CONHPh),(NH2,Ph,OH,Et,CONH-3-吡啶基),(NH2,Ph,OH,Et,NHCOPh),(NH2,Ph,OH,Et,NHCO-2-呋喃基),(NH2,Ph,OH,Et,NHCONHPh),(NH2,Ph,OH,Et,NHCOCONHPh),(NH2,Ph,OH,CH2OH,CONHPh),(NH2,Ph,OH,CH2OH,CONH-3-吡啶基),(NH2,Ph,OH,CH2OH,NHCOPh),(NH2,Ph,OH,CH2OH,NHCO-2-呋喃基),(NH2,Ph,OH,CH2OH,NHCONHPh),(NH2,Ph,OH,CH2OH,NHCOCONHPh),(NHCH2CH(OH)CH2OH,H,H,Me,CONHPh),(NHCH2CH(OH)CH2OH,H,H,Me,CONH-3-吡啶基),(NHCH2CH(OH)CH2OH,H,H,Me,NHCOPh),(NHCH2CH(OH)CH2OH,H,H,Me,NHCO-2-呋喃基),(NHCH2CH(OH)CH2OH,H,H,Me,NHCONHPh),(NHCH2CH(OH)CH2OH,H,H,Me,NHCOCONHPh),(NHCH2CH(OH)CH2OMe,H,H,Me,CONHPh),(NHCH2CH(OH)CH2OMe,H,H,Me,CONH-3-吡啶基),(NHCH2CH(OH)CH2OMe,H,H,Me,NHCOPh),(NHCH2CH(OH)CH2OMe,H,H,Me,NHCO-2-呋喃基),(NHCH2CH(OH)CH2OMe,H,H,Me,NHCONHPh),(NHCH2CH(OH)CH2OMe,H,H,Me,NHCOCONHPh),(NHCH2CH(OH)CH2NH2,H,H,Me,CONHPh),(NHCH2CH(OH)CH2NH2,H,H,Me,CONH-3-吡啶基),(NHCH2CH(OH)CH2NH2,H,H,Me,NHCOPh),(NHCH2CH(OH)CH2NH2,H,H,Me,NHCO-2-呋喃基),(NHCH2CH(OH)CH2NH2,H,H,Me,NHCONHPh),(NHCH2CH(OH)CH2NH2,H,H,Me,NHCOCONHPh),(NHCH2CH(OH)CH2NHMe,H,H,Me,CONHPh),(NHCH2CH(OH)CH2NHMe,H,H,Me,CONH-3-吡啶基),(NHCH2CH(OH)CH2NHMe,H,H,Me,NHCOPh),(NHCH2CH(OH)CH2NHMe,H,H,Me,NHCO-2-呋喃基),(NHCH2CH(OH)CH2NHMe,H,H,Me,NHCONHPh),(NHCH2CH(OH)CH2NHMe,H,H,Me,NHCOCONHPh),(NHCH2CH(OH)CH2NHCOMe,H,H,Me,CONHPh),(NHCH2CH(OH)CH2NHCOMe,H,H,Me,CONH-3-吡啶基),(NHCH2CH(OH)CH2NHCOMe,H,H,Me,NHCOPh),(NHCH2CH(OH)CH2NHCOMe,H,H,Me,NHCO-2-呋喃基),(NHCH2CH(OH)CH2NHCOMe,H,H,Me,NHCONHPh),(NHCH2CH(OH)CH2NHCOMe,H,H,Me,NHCOCONHPh),(NHCH2CH(OH)CH2N(Me)Me,H,H,Me,CONHPh),(NHCH2CH(OH)CH2N(Me)Me,H,H,Me,CONH-3-吡啶基),(NHCH2CH(OH)CH2N(Me)Me,H,H,Me,NHCOPh),(NHCH2CH(OH)CH2N(Me)Me,H,H,Me,NHCO-2-呋喃基),(NHCH2CH(OH)CH2N(Me)Me,H,H,Me,NHCONHPh),(NHCH2CH(OH)CH2N(Me)Me,H,H,Me,NHCOCONHPh),(NHC(O)C(O)NH2,H,H,Me,CONHPh),(NHC(O)C(O)NH2,H,H,Me,CONH-3-吡啶基),(NHC(O)C(O)NH2,H,H,Me,NHCOPh),(NHC(O)C(O)NH2,H,H,Me,NHCO-2-呋喃基),(NHC(O)C(O)NH2,H,H,Me,NHCONHPh),(NHC(O)C(O)NH2,H,H,Me,NHCOCONHPh),(NHC(O)C(O)NHMe,H,H,Me,CONHPh),(NHC(O)C(O)NHMe,H,H,Me,CONH-3-吡啶基),(NHC(O)C(O)NHMe,H,H,Me,NHCOPh),(NHC(O)C(O)NHMe,H,H,Me,NHCO-2-呋喃基),(NHC(O)C(O)NHMe,H,H,Me,NHCONHPh),(NHC(O)C(O)NHMe,H,H,Me,NHCOCONHPh),(NHC(O)C(O)N(Me)Me,H,H,Me,CONHPh),(NHC(O)C(O)N(Me)Me,H,H,Me,CONH-3-吡啶基),(NHC(O)C(O)N(Me)Me,H,H,Me,NHCOPh),(NHC(O)C(O)N(Me)Me,H,H,Me,NHCO-2-呋喃基),(NHC(O)C(O)N(Me)Me,H,H,Me,NHCONHPh),(NHC(O)C(O)N(Me)Me,H,H,Me,NHCOCONHPh)。
[化学式67]
上述式(Ii)或(Ij)中,B、接头、A、R5的组合(B、接头、A、R5为以下组合的化合物。
[表169]
(B、接头、A、R5)=
(B1,L1,A1,R51),(B1,L1,A1,R52),(B1,L1,A1,R53),(B1,L1,A1,R54),(B1,L1,A1,R55),(B1,L1,A1,R56),(B1,L1,A2,R51),(B1,L1,A2,R52),(B1,L1,A2,R53),(B1,L1,A2,R54),(B1,L1,A2,R55),(B1,L1,A2,R56),(B1,L1,A3,R51),(B1,L1,A3,R52),(B1,L1,A3,R53),(B1,L1,A3,R54),(B1,L1,A3,R55),(B1,L1,A3,R56),(B1,L1,A4,R51),(B1,L1,A4,R52),(B1,L1,A4,R53),(B1,L1,A4,R54),(B1,L1,A4,R55),(B1,L1,A4,R56),(B1,L1,A5,R51),(B1,L1,A5,R52),(B1,L1,A5,R53),(B1,L1,A5,R54),(B1,L1,A5,R55),(B1,L1,A5,R56),(B1,L2,A1,R51),(B1,L2,A1,R52),(B1,L2,A1,R53),(B1,L2,A1,R54),(B1,L2,A1,R55),(B1,L2,A1,R56),(B1,L2,A2,R51),(B1,L2,A2,R52),(B1,L2,A2,R53),(B1,L2,A2,R54),(B1,L2,A2,R55),(B1,L2,A2,R56),(B1,L2,A3,R51),(B1,L2,A3,R52),(B1,L2,A3,R53),(B1,L2,A3,R54),(B1,L2,A3,R55),(B1,L2,A3,R56),(B1,L2,A4,R51),(B1,L2,A4,R52),(B1,L2,A4,R53),(B1,L2,A4,R54),(B1,L2,A4,R55),(B1,L2,A4,R56),(B1,L2,A5,R51),(B1,L2,A5,R52),(B1,L2,A5,R53),(B1,L2,A5,R54),(B1,L2,A5,R55),(B1,L2,A5,R56),(B1,L3,A1,R51),(B1,L3,A1,R52),(B1,L3,A1,R53),(B1,L3,A1,R54),(B1,L3,A1,R55),(B1,L3,A1,R56),(B1,L3,A2,R51),(B1,L3,A2,R52),(B1,L3,A2,R53),(B1,L3,A2,R54),(B1,L3,A2,R55),(B1,L3,A2,R56),(B1,L3,A3,R51),(B1,L3,A3,R52),(B1,L3,A3,R53),(B1,L3,A3,R54),(B1,L3,A3,R55),(B1,L3,A3,R56),(B1,L3,A4,R51),(B1,L3,A4,R52),(B1,L3,A4,R53),(B1,L3,A4,R54),(B1,L3,A4,R55),(B1,L3,A4,R56),(B1,L3,A5,R51),(B1,L3,A5,R52),(B1,L3,A5,R53),(B1,L3,A5,R54),(B1,L3,A5,R55),(B1,L3,A5,R56),(B1,L4,A1,R51),(B1,L4,A1,R52),(B1,L4,A1,R53),(B1,L4,A1,R54),(B1,L4,A1,R55),(B1,L4,A1,R56),(B1,L4,A2,R51),(B1,L4,A2,R52),(B1,L4,A2,R53),(B1,L4,A2,R54),(B1,L4,A2,R55),(B1,L4,A2,R56),(B1,L4,A3,R51),(B1,L4,A3,R52),(B1,L4,A3,R53),(B1,L4,A3,R54),(B1,L4,A3,R55),(B1,L4,A3,R56),(B1,L4,A4,R51),(B1,L4,A4,R52),(B1,L4,A4,R53),(B1,L4,A4,R54),(B1,L4,A4,R55),(B1,L4,A4,R56),(B1,L4,A5,R51),(B1,L4,A5,R52),(B1,L4,A5,R53),(B1,L4,A5,R54),(B1,L4,A5,R55),(B1,L4,A5,R56),(B1,L5,A1,R51),(B1,L5,A1,R52),(B1,L5,A1,R53),(B1,L5,A1,R54),(B1,L5,A1,R55),(B1,L5,A1,R56),(B1,L5,A2,R51),(B1,L5,A2,R52),(B1,L5,A2,R53),(B1,L5,A2,R54),(B1,L5,A2,R55),(B1,L5,A2,R56),(B1,L5,A3,R51),(B1,L5,A3,R52),(B1,L5,A3,R53),(B1,L5,A3,R54),(B1,L5,A3,R55),(B1,L5,A3,R56),(B1,L5,A4,R51),(B1,L5,A4,R52),(B1,L5,A4,R53),(B1,L5,A4,R54),(B1,L5,A4,R55),(B1,L5,A4,R56),(B1,L5,A5,R51),(B1,L5,A5,R52),(B1,L5,A5,R53),(B1,L5,A5,R54),(B1,L5,A5,R55),(B1,L5,A5,R56),(B2,L1,A1,R51),(B2,L1,A1,R52),(B2,L1,A1,R53),(B2,L1,A1,R54),(B2,L1,A1,R55),(B2,L1,A1,R56),(B2,L1,A2,R51),(B2,L1,A2,R52),(B2,L1,A2,R53),(B2,L1,A2,R54),(B2,L1,A2,R55),(B2,L1,A2,R56),(B2,L1,A3,R51),(B2,L1,A3,R52),(B2,L1,A3,R53),(B2,L1,A3,R54),(B2,L1,A3,R55),(B2,L1,A3,R56),(B2,L1,A4,R51),(B2,L1,A4,R52),(B2,L1,A4,R53),(B2,L1,A4,R54),(B2,L1,A4,R55),(B2,L1,A4,R56),(B2,L1,A5,R51),(B2,L1,A5,R52),(B2,L1,A5,R53),(B2,L1,A5,R54),(B2,L1,A5,R55),(B2,L1,A5,R56),(B2,L2,A1,R51),(B2,L2,A1,R52),(B2,L2,A1,R53),(B2,L2,A1,R54),(B2,L2,A1,R55),(B2,L2,A1,R56),(B2,L2,A2,R51),(B2,L2,A2,R52),(B2,L2,A2,R53),(B2,L2,A2,R54),(B2,L2,A2,R55),(B2,L2,A2,R56),(B2,L2,A3,R51),(B2,L2,A3,R52),(B2,L2,A3,R53),(B2,L2,A3,R54),(B2,L2,A3,R55),(B2,L2,A3,R56),(B2,L2,A4,R51),(B2,L2,A4,R52),(B2,L2,A4,R53),(B2,L2,A4,R54),(B2,L2,A4,R55),(B2,L2,A4,R56),(B2,L2,A5,R51),(B2,L2,A5,R52),(B2,L2,A5,R53),(B2,L2,A5,R54),(B2,L2,A5,R55),(B2,L2,A5,R56),(B2,L3,A1,R51),(B2,L3,A1,R52),(B2,L3,A1,R53),(B2,L3,A1,R54),(B2,L3,A1,R55),(B2,L3,A1,R56),(B2,L3,A2,R51),(B2,L3,A2,R52),(B2,L3,A2,R53),(B2,L3,A2,R54),(B2,L3,A2,R55),(B2,L3,A2,R56),(B2,L3,A3,R51),(B2,L3,A3,R52),(B2,L3,A3,R53),(B2,L3,A3,R54),(B2,L3,A3,R55),(B2,L3,A3,R56),(B2,L3,A4,R51),(B2,L3,A4,R52),(B2,L3,A4,R53),(B2,L3,A4,R54),(B2,L3,A4,R55),(B2,L3,A4,R56),(B2,L3,A5,R51),(B2,L3,A5,R52),(B2,L3,A5,R53),(B2,L3,A5,R54),(B2,L3,A5,R55),(B2,L3,A5,R56),(B2,L4,A1,R51),(B2,L4,A1,R52),(B2,L4,A1,R53),(B2,L4,A1,R54),(B2,L4,A1,R55),(B2,L4,A1,R56),(B2,L4,A2,R51),(B2,L4,A2,R52),(B2,L4,A2,R53),(B2,L4,A2,R54),(B2,L4,A2,R55),(B2,L4,A2,R56),(B2,L4,A3,R51),(B2,L4,A3,R52),(B2,L4,A3,R53),(B2,L4,A3,R54),(B2,L4,A3,R55),(B2,L4,A3,R56),(B2,L4,A4,R51),(B2,L4,A4,R52),(B2,L4,A4,R53),(B2,L4,A4,R54),(B2,L4,A4,R55),(B2,L4,A4,R56),(B2,L4,A5,R51),(B2,L4,A5,R52),(B2,L4,A5,R53),(B2,L4,A5,R54),(B2,L4,A5,R55),(B2,L4,A5,R56),(B2,L5,A1,R51),(B2,L5,A1,R52),(B2,L5,A1,R53),(B2,L5,A1,R54),(B2,L5,A1,R55),(B2,L5,A1,R56),(B2,L5,A2,R51),(B2,L5,A2,R52),(B2,L5,A2,R53),(B2,L5,A2,R54),(B2,L5,A2,R55),(B2,L5,A2,R56),(B2,L5,A3,R51),(B2,L5,A3,R52),(B2,L5,A3,R53),(B2,L5,A3,R54),(B2,L5,A3,R55),(B2,L5,A3,R56),(B2,L5,A4,R51),(B2,L5,A4,R52),(B2,L5,A4,R53),(B2,L5,A4,R54),(B2,L5,A4,R55),(B2,L5,A4,R56),(B2,L5,A5,R51),(B2,L5,A5,R52),(B2,L5,A5,R53),(B2,L5,A5,R54),(B2,L5,A5,R55),(B2,L5,A5,R56),(B3,L1,A1,R51),(B3,L1,A1,R52),(B3,L1,A1,R53),(B3,L1,A1,R54),(B3,L1,A1,R55),(B3,L1,A1,R56),(B3,L1,A2,R51),(B3,L1,A2,R52),(B3,L1,A2,R53),(B3,L1,A2,R54),(B3,L1,A2,R55),(B3,L1,A2,R56),(B3,L1,A3,R51),(B3,L1,A3,R52),(B3,L1,A3,R53),(B3,L1,A3,R54),(B3,L1,A3,R55),(B3,L1,A3,R56),(B3,L1,A4,R51),(B3,L1,A4,R52),(B3,L1,A4,R53),(B3,L1,A4,R54),(B3,L1,A4,R55),(B3,L1,A4,R56),(B3,L1,A5,R51),(B3,L1,A5,R52),(B3,L1,A5,R53),(B3,L1,A5,R54),(B3,L1,A5,R55),(B3,L1,A5,R56),(B3,L2,A1,R51),(B3,L2,A1,R52),(B3,L2,A1,R53),(B3,L2,A1,R54),(B3,L2,A1,R55),(B3,L2,A1,R56),(B3,L2,A2,R51),(B3,L2,A2,R52),(B3,L2,A2,R53),(B3,L2,A2,R54),(B3,L2,A2,R55),(B3,L2,A2,R56),(B3,L2,A3,R51),(B3,L2,A3,R52),(B3,L2,A3,R53),(B3,L2,A3,R54),(B3,L2,A3,R55),(B3,L2,A3,R56),(B3,L2,A4,R51),(B3,L2,A4,R52),(B3,L2,A4,R53),(B3,L2,A4,R54),(B3,L2,A4,R55),(B3,L2,A4,R56),(B3,L2,A5,R51),(B3,L2,A5,R52),(B3,L2,A5,R53),(B3,L2,A5,R54),(B3,L2,A5,R55),(B3,L2,A5,R56),(B3,L3,A1,R51),(B3,L3,A1,R52),(B3,L3,A1,R53),(B3,L3,A1,R54),(B3,L3,A1,R55),(B3,L3,A1,R56),(B3,L3,A2,R51),(B3,L3,A2,R52),(B3,L3,A2,R53),(B3,L3,A2,R54),(B3,L3,A2,R55),(B3,L3,A2,R56),(B3,L3,A3,R51),(B3,L3,A3,R52),(B3,L3,A3,R53),(B3,L3,A3,R54),(B3,L3,A3,R55),(B3,L3,A3,R56),(B3,L3,A4,R51),(B3,L3,A4,R52),(B3,L3,A4,R53),(B3,L3,A4,R54),(B3,L3,A4,R55),(B3,L3,A4,R56),(B3,L3,A5,R51),(B3,L3,A5,R52),(B3,L3,A5,R53),(B3,L3,A5,R54),(B3,L3,A5,R55),(B3,L3,A5,R56),(B3,L4,A1,R51),(B3,L4,A1,R52),(B3,L4,A1,R53),(B3,L4,A1,R54),(B3,L4,A1,R55),(B3,L4,A1,R56),(B3,L4,A2,R51),(B3,L4,A2,R52),(B3,L4,A2,R53),(B3,L4,A2,R54),(B3,L4,A2,R55),(B3,L4,A2,R56),(B3,L4,A3,R51),(B3,L4,A3,R52),(B3,L4,A3,R53),(B3,L4,A3,R54),(B3,L4,A3,R55),(B3,L4,A3,R56),(B3,L4,A4,R51),(B3,L4,A4,R52),(B3,L4,A4,R53),(B3,L4,A4,R54),(B3,L4,A4,R55),(B3,L4,A4,R56),(B3,L4,A5,R51),(B3,L4,A5,R52),(B3,L4,A5,R53),(B3,L4,A5,R54),(B3,L4,A5,R55),(B3,L4,A5,R56),(B3,L5,A1,R51),(B3,L5,A1,R52),(B3,L5,A1,R53),(B3,L5,A1,R54),(B3,L5,A1,R55),(B3,L5,A1,R56),(B3,L5,A2,R51),(B3,L5,A2,R52),(B3,L5,A2,R53),(B3,L5,A2,R54),(B3,L5,A2,R55),(B3,L5,A2,R56),(B3,L5,A3,R51),(B3,L5,A3,R52),(B3,L5,A3,R53),(B3,L5,A3,R54),(B3,L5,A3,R55),(B3,L5,A3,R56),(B3,L5,A4,R51),(B3,L5,A4,R52),(B3,L5,A4,R53),(B3,L5,A4,R54),(B3,L5,A4,R55),(B3,L5,A4,R56),(B3,L5,A5,R51),(B3,L5,A5,R52),(B3,L5,A5,R53),(B3,L5,A5,R54),(B3,L5,A5,R55),(B3,L5,A5,R56),(B4,L1,A1,R51),(B4,L1,A1,R52),(B4,L1,A1,R53),(B4,L1,A1,R54),(B4,L1,A1,R55),(B4,L1,A1,R56),(B4,L1,A2,R51),(B4,L1,A2,R52),(B4,L1,A2,R53),(B4,L1,A2,R54),(B4,L1,A2,R55),(B4,L1,A2,R56),(B4,L1,A3,R51),(B4,L1,A3,R52),(B4,L1,A3,R53),(B4,L1,A3,R54),(B4,L1,A3,R55),(B4,L1,A3,R56),(B4,L1,A4,R51),(B4,L1,A4,R52),(B4,L1,A4,R53),(B4,L1,A4,R54),(B4,L1,A4,R55),(B4,L1,A4,R56),(B4,L1,A5,R51),(B4,L1,A5,R52),(B4,L1,A5,R53),(B4,L1,A5,R54),(B4,L1,A5,R55),(B4,L1,A5,R56),(B4,L2,A1,R51),(B4,L2,A1,R52),(B4,L2,A1,R53),(B4,L2,A1,R54),(B4,L2,A1,R55),(B4,L2,A1,R56),(B4,L2,A2,R51),(B4,L2,A2,R52),(B4,L2,A2,R53),(B4,L2,A2,R54),(B4,L2,A2,R55),(B4,L2,A2,R56),(B4,L2,A3,R51),(B4,L2,A3,R52),(B4,L2,A3,R53),(B4,L2,A3,R54),(B4,L2,A3,R55),(B4,L2,A3,R56),(B4,L2,A4,R51),(B4,L2,A4,R52),(B4,L2,A4,R53),(B4,L2,A4,R54),(B4,L2,A4,R55),(B4,L2,A4,R56),(B4,L2,A5,R51),(B4,L2,A5,R52),(B4,L2,A5,R53),(B4,L2,A5,R54),(B4,L2,A5,R55),(B4,L2,A5,R56),(B4,L3,A1,R51),(B4,L3,A1,R52),(B4,L3,A1,R53),(B4,L3,A1,R54),(B4,L3,A1,R55),(B4,L3,A1,R56),(B4,L3,A2,R51),(B4,L3,A2,R52),(B4,L3,A2,R53),(B4,L3,A2,R54),(B4,L3,A2,R55),(B4,L3,A2,R56),(B4,L3,A3,R51),(B4,L3,A3,R52),(B4,L3,A3,R53),(B4,L3,A3,R54),(B4,L3,A3,R55),(B4,L3,A3,R56),(B4,L3,A4,R51),(B4,L3,A4,R52),(B4,L3,A4,R53),(B4,L3,A4,R54),(B4,L3,A4,R55),(B4,L3,A4,R56),(B4,L3,A5,R51),(B4,L3,A5,R52),(B4,L3,A5,R53),(B4,L3,A5,R54),(B4,L3,A5,R55),(B4,L3,A5,R56),(B4,L4,A1,R51),(B4,L4,A1,R52),(B4,L4,A1,R53),(B4,L4,A1,R54),(B4,L4,A1,R55),(B4,L4,A1,R56),(B4,L4,A2,R51),(B4,L4,A2,R52),(B4,L4,A2,R53),(B4,L4,A2,R54),(B4,L4,A2,R55),(B4,L4,A2,R56),(B4,L4,A3,R51),(B4,L4,A3,R52),(B4,L4,A3,R53),(B4,L4,A3,R54),(B4,L4,A3,R55),(B4,L4,A3,R56),(B4,L4,A4,R51),(B4,L4,A4,R52),(B4,L4,A4,R53),(B4,L4,A4,R54),(B4,L4,A4,R55),(B4,L4,A4,R56),(B4,L4,A5,R51),(B4,L4,A5,R52),(B4,L4,A5,R53),(B4,L4,A5,R54),(B4,L4,A5,R55),(B4,L4,A5,R56),(B4,L5,A1,R51),(B4,L5,A1,R52),(B4,L5,A1,R53),(B4,L5,A1,R54),(B4,L5,A1,R55),(B4,L5,A1,R56),(B4,L5,A2,R51),(B4,L5,A2,R52),(B4,L5,A2,R53),(B4,L5,A2,R54),(B4,L5,A2,R55),(B4,L5,A2,R56),(B4,L5,A3,R51),(B4,L5,A3,R52),(B4,L5,A3,R53),(B4,L5,A3,R54),(B4,L5,A3,R55),(B4,L5,A3,R56),(B4,L5,A4,R51),(B4,L5,A4,R52),(B4,L5,A4,R53),(B4,L5,A4,R54),(B4,L5,A4,R55),(B4,L5,A4,R56),(B4,L5,A5,R51),(B4,L5,A5,R52),(B4,L5,A5,R53),(B4,L5,A5,R54),(B4,L5,A5,R55),(B4,L5,A5,R56),(B5,L1,A1,R51),(B5,L1,A1,R52),(B5,L1,A1,R53),(B5,L1,A1,R54),(B5,L1,A1,R55),(B5,L1,A1,R56),(B5,L1,A2,R51),(B5,L1,A2,R52),(B5,L1,A2,R53),(B5,L1,A2,R54),(B5,L1,A2,R55),(B5,L1,A2,R56),(B5,L1,A3,R51),(B5,L1,A3,R52),(B5,L1,A3,R53),(B5,L1,A3,R54),(B5,L1,A3,R55),(B5,L1,A3,R56),(B5,L1,A4,R51),(B5,L1,A4,R52),(B5,L1,A4,R53),(B5,L1,A4,R54),(B5,L1,A4,R55),(B5,L1,A4,R56),(B5,L1,A5,R51),(B5,L1,A5,R52),(B5,L1,A5,R53),(B5,L1,A5,R54),(B5,L1,A5,R55),(B5,L1,A5,R56),(B5,L2,A1,R51),(B5,L2,A1,R52),(B5,L2,A1,R53),(B5,L2,A1,R54),(B5,L2,A1,R55),(B5,L2,A1,R56),(B5,L2,A2,R51),(B5,L2,A2,R52),(B5,L2,A2,R53),(B5,L2,A2,R54),(B5,L2,A2,R55),(B5,L2,A2,R56),(B5,L2,A3,R51),(B5,L2,A3,R52),(B5,L2,A3,R53),(B5,L2,A3,R54),(B5,L2,A3,R55),(B5,L2,A3,R56),(B5,L2,A4,R51),(B5,L2,A4,R52),(B5,L2,A4,R53),(B5,L2,A4,R54),(B5,L2,A4,R55),(B5,L2,A4,R56),(B5,L2,A5,R51),(B5,L2,A5,R52),(B5,L2,A5,R53),(B5,L2,A5,R54),(B5,L2,A5,R55),(B5,L2,A5,R56),(B5,L3,A1,R51),(B5,L3,A1,R52),(B5,L3,A1,R53),(B5,L3,A1,R54),(B5,L3,A1,R55),(B5,L3,A1,R56),(B5,L3,A2,R51),(B5,L3,A2,R52),(B5,L3,A2,R53),(B5,L3,A2,R54),(B5,L3,A2,R55),(B5,L3,A2,R56),(B5,L3,A3,R51),(B5,L3,A3,R52),(B5,L3,A3,R53),(B5,L3,A3,R54),(B5,L3,A3,R55),(B5,L3,A3,R56),(B5,L3,A4,R51),(B5,L3,A4,R52),(B5,L3,A4,R53),(B5,L3,A4,R54),(B5,L3,A4,R55),(B5,L3,A4,R56),(B5,L3,A5,R51),(B5,L3,A5,R52),(B5,L3,A5,R53),(B5,L3,A5,R54),(B5,L3,A5,R55),(B5,L3,A5,R56),(B5,L4,A1,R51),(B5,L4,A1,R52),(B5,L4,A1,R53),(B5,L4,A1,R54),(B5,L4,A1,R55),(B5,L4,A1,R56),(B5,L4,A2,R51),(B5,L4,A2,R52),(B5,L4,A2,R53),(B5,L4,A2,R54),(B5,L4,A2,R55),(B5,L4,A2,R56),(B5,L4,A3,R51),(B5,L4,A3,R52),(B5,L4,A3,R53),(B5,L4,A3,R54),(B5,L4,A3,R55),(B5,L4,A3,R56),(B5,L4,A4,R51),(B5,L4,A4,R52),(B5,L4,A4,R53),(B5,L4,A4,R54),(B5,L4,A4,R55),(B5,L4,A4,R56),(B5,L4,A5,R51),(B5,L4,A5,R52),(B5,L4,A5,R53),(B5,L4,A5,R54),(B5,L4,A5,R55),(B5,L4,A5,R56),(B5,L5,A1,R51),(B5,L5,A1,R52),(B5,L5,A1,R53),(B5,L5,A1,R54),(B5,L5,A1,R55),(B5,L5,A1,R56),(B5,L5,A2,R51),(B5,L5,A2,R52),(B5,L5,A2,R53),(B5,L5,A2,R54),(B5,L5,A2,R55),(B5,L5,A2,R56),(B5,L5,A3,R51),(B5,L5,A3,R52),(B5,L5,A3,R53),(B5,L5,A3,R54),(B5,L5,A3,R55),(B5,L5,A3,R56),(B5,L5,A4,R51),(B5,L5,A4,R52),(B5,L5,A4,R53),(B5,L5,A4,R54),(B5,L5,A4,R55),(B5,L5,A4,R56),(B5,L5,A5,R51),(B5,L5,A5,R52),(B5,L5,A5,R53),(B5,L5,A5,R54),(B5,L5,A5,R55),(B5,L5,A5,R56)。
试验例β分泌酶抑制作用的测定
向96孔half-area平板(黑色平板,Costar公司制)的各孔中加入48.5μl底物肽(Biotin-XSEVNLDAEFRHDSGC-Eu:X=ε-氨基正己酸、Eu=铕穴合物(Europium cryptate))溶液,分别添加0.5μl受试化合物(N,N’-二甲基甲醛溶液)和1μl重组人BACE-1(R&D systems公司制),之后在30℃下反应3小时。底物肽通过使Cryptate TBPCOOH mono SMP(CIS bio international公司制)与Biotin-XSEVNLDAEFRHDSGC(Peptide研究所制)反应来合成。底物肽的最终浓度为18nM、重组人BACE-1的最终浓度为7.4nM,反应缓冲液使用乙酸钠缓冲液(50mM乙酸钠pH5.0、0.008%Triton X-100)。反应结束后,向各孔中添加50μl溶解在磷酸缓冲液(150mM K2HPO4-KH2PO4 pH7.0、0.008%TritonX-100、0.8M KF)中的8.0μg/ml的Streptavidin-XL665(CIS biointernational公司制),在30℃下静置1小时。之后,使用Wallac 1420多标计数仪(Perkin Elmer life sciences公司制)测定荧光强度(激发波长320nm、测定波长620nm和665nm)。酶活性由各测定波长的计数率(10000×计数665/计数620)求出,算出50%抑制酶活性的用量(IC50)。受试物质的IC50值如表170所示。
[表170]
通过相同的试验,以下化合物的IC50值也显示100μM以下。
3,4,6,8,12,17,18,30,31,35,36,38,39,42,43,57,61,67,67,71,77,78,80,85,97,99,105,106,113,114,115,117,120,121,125,128,129,130,134,139,144,154,157,159,164,172,175,178,181,182,186,189,200,200,201,204,207,209,211,214,215,216,228,232,240,241,243,243,243,251,255,259,267,,273,275,278,279,281,282,,293,298,299,300,302,303,307,314,319,321,322,326,328,330,333,335,339,341,344,345,346,348,352,353,357,358,359,359,359,360,361,363,369,370,373,378,380,383,389,390,393,396,397,402,405,406,409,410,413,415,426,442,443,444,451,452,454,456,463,467,469,472,472,479,480,482,482,483,491,493,497,500,501,502,509,511,515,516,517,527,528,532,542,544,549,550,551,558,560,568,569,575,578,584,586,588,591,600,607,608,611,613,618,620,629,634,634,637,643,646,652,657,661,671,677,681,687,691,708,711,719,720,723,725,728,729,730,732,735,743,746,756,758,761,770,775,781,787,788,790,791,792,796,797,802,803,804,808,809,813,816,819,820,824,833,835,836,847,850,861,865,866,871,876,887,893,894,900,905,906,908,910,919,922,928,932,933,935,936,939,941,943,944,946,947,949,959,966,971,984,986,988,990,1004,1005,1007,1009,1013,1020,1028,1034,1039,1046,1055,1062,1063,1069,1074,1077,1084,1089,1096,1099,1108,1109,1114,1124,1125,1131,1140,1142,1145,1147,1148,1150,1164,1165,1172,1174,1184,1185,1193,1211,1217,1221,1237,1241,1243,1255,1256,1257,1258,1261,1263,1264,1265,1266,1268,1269,1270,1271,1272,1274等。
制剂例1
制备含有以下成分的颗粒剂。
成分 式(I)所示的化合物 10mg
乳糖 700mg
玉米淀粉 274mg
HPC-L 16mg
1000mg
将式(I)所示的化合物和乳糖过60目的筛。将玉米淀粉过120目的筛。用V型混合机混合上述成分。向混合粉末中添加HPC-L(低粘度羟丙基纤维素)水溶液,进行混合、制粒(挤出制粒,孔径0.5~1mm)、干燥步骤。将所得干燥颗粒用振动筛(12/60目)过筛,得到颗粒剂。
制剂例2
制备含有以下成分的胶囊填充用颗粒剂。
成分 式(I)所示的化合物 15mg
乳糖 90mg
玉米淀粉 42mg
HPC-L 3mg
150mg
将式(I)所示的化合物、乳糖过60目的筛。将玉米淀粉过120目的筛。混合上述成分,向混合粉末中添加HPC-L溶液,进行混合、制粒、干燥。所得干燥颗粒整粒后,将该150mg填充到4号硬明胶胶囊中。
制剂例3
制备含有以下成分的片剂。
成分 式(I)所示的化合物 10mg
乳糖 90mg
微晶纤维素 30mg
CMC-Na 15mg
硬脂酸镁 5mg
150mg
将式(I)所示的化合物、乳糖、微晶纤维素、CMC-Na(羧甲基纤维素钠盐)过60目的筛,进行混合。向混合粉末中混合硬脂酸镁,得到制片用混合粉末。将该混合粉末直接压片,得到150mg的片剂。
制剂例4
将以下成分加热混合,然后灭菌,制备注射剂。
成分 式(I)所示的化合物 3mg
非离子表面活性剂 15mg
注射用纯净水 1ml
产业实用性
本发明化合物作为由淀粉状β蛋白的产生、分泌和/或沉积所诱发的疾病的治疗药是有用的药物。
Claims (21)
1.BACE1抑制剂,该抑制剂以式(I)所示的化合物或其药学上可接受的盐或它们的溶剂合物作为有效成分,
[化学式1]
式中,环A为可具有取代基的碳环式基团或可具有取代基的杂环式基团;
[化学式2]
AlK1为低级亚烷基或低级亚烯基;
R0为氢、低级烷基或酰基;
X为S、O或NR1;
R1为氢或低级烷基;
R2a和R2b各自独立表示氢、羟基、可具有取代基的低级烷基、可具有取代基的低级烯基、可具有取代基的氨基、可具有取代基的脒基、可具有取代基的酰基、可具有取代基的氨基甲酰基、可具有取代基的氨基甲酰基羰基、可具有取代基的低级烷基磺酰基、可具有取代基的芳基磺酰基、可具有取代基的碳环式基团或可具有取代基的杂环式基团;
R3a、R3b、R4a和R4b各自独立表示氢、卤素、羟基、可具有取代基的低级烷基、可具有取代基的低级烯基、可具有取代基的酰基、羧基、可具有取代基的低级烷氧基羰基、可具有取代基的氨基、可具有取代基的氨基甲酰基、可具有取代基的碳环式基团或可具有取代基的杂环式基团;
n和m各自独立表示0~3的整数,且n+m为1~3;
各R3a、各R3b、各R4a、各R4b可以不同;
R5表示氢、可具有取代基的低级烷基、可具有取代基的低级烯基、可具有取代基的低级炔基、可具有取代基的碳环式基团或可具有取代基的杂环式基团;
[化学式3]
式中,R5a和R5b各自独立表示氢或低级烷基;
s为1~4的整数;
各R5a、各R5b可以不同;
其中,n+m为2、R5为氢、环A为未取代的苯基的化合物除外。
2.权利要求1的BACE1抑制剂,其中X为S。
3.权利要求1的BACE1抑制剂,其中n为2、m为0。
4.权利要求1的BACE1抑制剂,其中E为单键。
5.式(I)所示的化合物或其药学上可接受的盐或它们的溶剂合物,
[化学式4]
式中,各记号与权利要求1定义相同,但以下化合物除外:
i)n+m为2、R5为氢、环A为未取代的苯基的化合物;
ii)n为2、m为0、R2a为氢、R2b为氢或乙酰基、R5为甲基、环A为苯基或4-甲氧基苯基的化合物;
iii)n为2、m为0、R2a为氢、R2b为氢或乙酰基、R5为乙基、环A为3,4-二甲氧基苯基的化合物;
iv)n为2、m为0、R2a为氢、R2b为氢或乙酰基、R5和环A为苯基的化合物;
v)n为2、m为0、R2a和R2b为氢、R5和环A一起形成:
[化学式5]
vi)n+m为2、R5为氢、环A为只被选自羟基、卤素、低级烷基、低级烷氧基、硝基、氨基、低级烷基羰基氨基、巯基、低级烷硫基和氨基甲酰基的1~2个取代基取代的苯基、未取代的苯基或未取代的萘基的化合物。
6.权利要求5的化合物或其药学上可接受的盐或它们的溶剂合物,其中X为S。
7.权利要求5或6的化合物或其药学上可接受的盐或它们的溶剂合物,其中n为2、m为0。
8.权利要求5~7中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中R5为可具有取代基的低级烷基、可具有取代基的低级烯基、可具有取代基的低级炔基、可具有取代基的碳环式基团或可具有取代基的杂环式基团。
9.权利要求5~8中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中R2a为氢,R2b为氢、可具有取代基的低级烷基、可具有取代基的酰基、可具有取代基的低级烷基磺酰基、可具有取代基的脒基。
11.权利要求5~10中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中环A为被取代的苯基。
12.权利要求5~10中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中环A为:
[化学式7]
式中,R9、R10和R11为氢或G;
G为卤素、羟基、氰基、硝基、巯基、可具有取代基的低级烷基、可具有取代基的低级烷氧基、可具有取代基的低级烯基、可具有取代基的低级炔基、可具有取代基的酰基、可具有取代基的酰氧基、羧基、可具有取代基的低级烷氧基羰基、可具有取代基的低级烷氧基羰基氧基、可具有取代基的芳氧基羰基氧基、可具有取代基的氨基、可具有取代基的氨基甲酰基、可具有取代基的氨基甲酰氧基、可具有取代基的低级烷硫基、可具有取代基的芳硫基、可具有取代基的低级烷基磺酰基、可具有取代基的芳基磺酰基、可具有取代基的低级烷基亚硫酰基、可具有取代基的芳基亚硫酰基、可具有取代基的低级烷基磺酰氧基、可具有取代基的芳基磺酰氧基、可具有取代基的氨磺酰基、可具有取代基的碳环式基团、可具有取代基的碳环氧基、可具有取代基的杂环式基团或可具有取代基的杂环氧基;
各G可以不同。
14.权利要求13的化合物或其药学上可接受的盐或它们的溶剂合物,其中环B为可以被选自卤素、羟基、可具有取代基的低级烷基、可具有取代基的低级烷氧基、可具有取代基的酰基、可具有取代基的氨基、氰基、可具有取代基的氨基甲酰基、可具有取代基的碳环式基团、可具有取代基的碳环氧基或可具有取代基的杂环式基团的一个以上基团分别取代的芳基或杂芳基。
16.权利要求5~15中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中R5为C1~C3烷基。
17.权利要求5~15中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中R5为甲基。
18.权利要求5~17中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中R3a和R3b各自独立表示氢、卤素、羟基、可具有取代基的低级烷基、可具有取代基的低级烷氧基或可具有取代基的芳基。
19.权利要求5~17中任一项的化合物或其药学上可接受的盐或它们的溶剂合物,其中R3a和R3b全部为氢。
20.药物组合物,其特征在于:以权利要求5~19中任一项的化合物或其药学上可接受的盐或它们的溶剂合物作为有效成分。
21.BACE1抑制剂,其特征在于:以权利要求5~19中任一项的化合物或其药学上可接受的盐或它们的溶剂合物作为有效成分。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005309642 | 2005-10-25 | ||
JP309642/2005 | 2005-10-25 | ||
JP2006076636 | 2006-03-20 | ||
JP076636/2006 | 2006-03-20 | ||
PCT/JP2006/321015 WO2007049532A1 (ja) | 2005-10-25 | 2006-10-23 | アミノジヒドロチアジン誘導体 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410074667.6A Division CN103936690B (zh) | 2005-10-25 | 2006-10-23 | 氨基二氢噻嗪衍生物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101346357A true CN101346357A (zh) | 2009-01-14 |
CN101346357B CN101346357B (zh) | 2014-04-02 |
Family
ID=37967644
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410074667.6A Expired - Fee Related CN103936690B (zh) | 2005-10-25 | 2006-10-23 | 氨基二氢噻嗪衍生物 |
CN200680048810.8A Expired - Fee Related CN101346357B (zh) | 2005-10-25 | 2006-10-23 | 氨基二氢噻嗪衍生物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410074667.6A Expired - Fee Related CN103936690B (zh) | 2005-10-25 | 2006-10-23 | 氨基二氢噻嗪衍生物 |
Country Status (12)
Country | Link |
---|---|
US (6) | US8173642B2 (zh) |
EP (3) | EP2597087B1 (zh) |
JP (2) | JP5281794B2 (zh) |
KR (1) | KR101052122B1 (zh) |
CN (2) | CN103936690B (zh) |
AU (1) | AU2006307314C1 (zh) |
BR (1) | BRPI0617852A2 (zh) |
CA (1) | CA2628074C (zh) |
ES (3) | ES2537898T3 (zh) |
RU (2) | RU2416603C9 (zh) |
TW (2) | TWI535705B (zh) |
WO (1) | WO2007049532A1 (zh) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102471296A (zh) * | 2009-07-09 | 2012-05-23 | 伊莱利利公司 | Bace抑制剂 |
CN102482268A (zh) * | 2009-09-11 | 2012-05-30 | 霍夫曼-拉罗奇有限公司 | 作为用于糖尿病治疗的bace2抑制剂的2-氨基二氢[1,3]噻嗪 |
CN102639516A (zh) * | 2009-08-19 | 2012-08-15 | 霍夫曼-拉罗奇有限公司 | 3-氨基-5-苯基-5,6-二氢-2h-[1,4]*嗪衍生物 |
CN102666507A (zh) * | 2010-07-13 | 2012-09-12 | 诺瓦提斯公司 | 噁嗪衍生物及其在治疗神经病症中的用途 |
CN102686584A (zh) * | 2009-11-13 | 2012-09-19 | 盐野义制药株式会社 | 具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物 |
CN102712621A (zh) * | 2009-12-31 | 2012-10-03 | 诺瓦提斯公司 | 吡嗪衍生物及其在治疗神经学障碍中的用途 |
CN102834384A (zh) * | 2009-12-11 | 2012-12-19 | 盐野义制药株式会社 | *嗪衍生物 |
CN102933564A (zh) * | 2010-06-09 | 2013-02-13 | 詹森药业有限公司 | 用作β-分泌酶(BACE)抑制剂的5,6-二氢-2H-[1,4]噁嗪-3-基-胺衍生物 |
CN102958922A (zh) * | 2010-05-07 | 2013-03-06 | 霍夫曼-拉罗奇有限公司 | 2,5,6,7-四氢-[1,4]氧氮杂*-3-基胺或2,3,6,7-四氢-[1,4]氧氮杂*-5-基胺化合物 |
CN103261199A (zh) * | 2010-10-29 | 2013-08-21 | 盐野义制药株式会社 | 萘啶衍生物 |
CN103339117A (zh) * | 2011-02-02 | 2013-10-02 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,4 噁嗪类 |
CN103403001A (zh) * | 2011-01-13 | 2013-11-20 | 诺瓦提斯公司 | 新的杂环衍生物及其在神经性疾病治疗中的应用 |
CN103429589A (zh) * | 2011-01-12 | 2013-12-04 | 诺瓦提斯公司 | 噁嗪衍生物及其在治疗神经障碍中的用途 |
CN103429588A (zh) * | 2011-01-12 | 2013-12-04 | 诺瓦提斯公司 | 晶态噁嗪衍生物及其作为bace抑制剂的用途 |
CN103429590A (zh) * | 2011-03-04 | 2013-12-04 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,4硫氮杂*/砜 |
CN103459401A (zh) * | 2011-01-21 | 2013-12-18 | 卫材R&D管理有限公司 | 稠合的氨基二氢噻嗪衍生物 |
CN103476760A (zh) * | 2011-02-18 | 2013-12-25 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,4-氧氮杂* |
CN103502227A (zh) * | 2011-04-11 | 2014-01-08 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,3噁嗪类 |
CN103517901A (zh) * | 2011-04-04 | 2014-01-15 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,4-氧氮杂* |
CN103534243A (zh) * | 2011-05-16 | 2014-01-22 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,3-噁嗪类 |
CN103596939A (zh) * | 2011-04-13 | 2014-02-19 | 默沙东公司 | 作为bace抑制剂的5-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其应用 |
CN103596961A (zh) * | 2011-05-27 | 2014-02-19 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的螺-[1,3]-*嗪和螺-[1,4]-氧氮杂* |
CN103608344A (zh) * | 2011-06-07 | 2014-02-26 | 霍夫曼-拉罗奇有限公司 | [1,3]噁嗪类 |
CN103608345A (zh) * | 2011-04-26 | 2014-02-26 | 盐野义制药株式会社 | 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂 |
CN103649083A (zh) * | 2011-07-06 | 2014-03-19 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的环丙基-稠合-1,3-硫氮杂*类 |
CN103987710A (zh) * | 2011-10-13 | 2014-08-13 | 诺华股份有限公司 | 新的*嗪衍生物及它们在治疗疾病中的应用 |
CN106414431A (zh) * | 2014-04-11 | 2017-02-15 | 盐野义制药株式会社 | 具有bace1抑制作用的二氢噻嗪和二氢噁嗪衍生物 |
CN107257795A (zh) * | 2015-03-19 | 2017-10-17 | 伊莱利利公司 | 选择性bace1抑制剂 |
CN107613771A (zh) * | 2015-04-21 | 2018-01-19 | 新源生物科技股份有限公司 | 化合物及其作为β‑分泌酶1抑制剂的用途 |
CN108430982A (zh) * | 2015-12-25 | 2018-08-21 | 盐野义制药株式会社 | 用于制备噻嗪衍生物的方法和中间体 |
CN109180671A (zh) * | 2018-09-21 | 2019-01-11 | 广东东阳光药业有限公司 | 亚氨基噻二嗪二氧化物衍生物及其用途 |
Families Citing this family (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US8722708B2 (en) | 2005-06-14 | 2014-05-13 | Merck Sharp & Dohme Inc. | Substituted isoindolines as aspartyl protease inhibitors |
SG162790A1 (en) | 2005-06-14 | 2010-07-29 | Schering Corp | Aspartyl protease inhibitors |
EP2597087B1 (en) | 2005-10-25 | 2016-03-30 | Shionogi&Co., Ltd. | Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors |
KR20090004976A (ko) | 2006-04-19 | 2009-01-12 | 아스테라스 세이야쿠 가부시키가이샤 | 아졸카르복사미드 유도체 |
RU2009100074A (ru) | 2006-06-12 | 2010-07-20 | Шеринг Корпорейшн (US) | Гетероциклические ингибиторы аспартильной протеазы |
TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
EP2064191B1 (en) | 2006-12-12 | 2014-06-25 | Merck Sharp & Dohme Corp. | Aspartyl protease inhibitors |
JP5383483B2 (ja) * | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
WO2008133274A1 (ja) * | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | 環式基で置換されたアミノジヒドロチアジン誘導体 |
TW200902499A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
TW200911768A (en) * | 2007-05-17 | 2009-03-16 | Cortex Pharma Inc | Di-substituted amides for enhancing glutamatergic synaptic responses |
BRPI0812347A2 (pt) * | 2007-06-08 | 2016-08-02 | Helicon Therapeutics Inc | composto, composição farmacêutica e métodos de modulação de um ou mais subtipos de gabaa, de aumento da função cognitiva e de tratamento de deficiência orgânica cognitiva em animal e usos do composto |
TW200918521A (en) * | 2007-08-31 | 2009-05-01 | Astrazeneca Ab | Heterocyclic amides and methods of use thereof |
JP2009079037A (ja) * | 2007-09-06 | 2009-04-16 | Sumitomo Chemical Co Ltd | アミロイドβタンパク質の蓄積を抑制するための医薬組成物 |
SI2206707T1 (sl) | 2007-10-24 | 2014-11-28 | Astellas Pharma Inc. | Azolkarboksamidna spojina ali njena sol |
CN101910143B (zh) * | 2008-01-18 | 2013-08-21 | 卫材R&D管理有限公司 | 稠合的氨基二氢噻嗪衍生物 |
AR072952A1 (es) | 2008-04-22 | 2010-10-06 | Schering Corp | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso |
TWI431004B (zh) * | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Bace抑制劑 |
WO2009151098A1 (ja) * | 2008-06-13 | 2009-12-17 | 塩野義製薬株式会社 | βセクレターゼ阻害作用を有する含硫黄複素環誘導体 |
CN102105475B (zh) * | 2008-07-28 | 2014-04-09 | 卫材R&D管理有限公司 | 螺氨基二氢噻嗪衍生物 |
WO2010013302A1 (ja) * | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
JP5444240B2 (ja) * | 2008-07-28 | 2014-03-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
US8450308B2 (en) | 2008-08-19 | 2013-05-28 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
EA201100461A1 (ru) * | 2008-09-11 | 2011-10-31 | Амген Инк. | Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования |
CN102171221B (zh) * | 2008-09-30 | 2013-11-06 | 卫材R&D管理有限公司 | 新的稠合的氨基二氢噻嗪衍生物 |
CN102186841A (zh) * | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
WO2010056195A1 (en) * | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | New compounds 575 |
US20100125081A1 (en) * | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | New compounds 574 |
TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
KR101908255B1 (ko) | 2009-03-13 | 2018-10-15 | 비타이 파마슈티컬즈, 인코포레이티드 | 베타세크리타아제 저해제 |
US20120015961A1 (en) | 2009-03-31 | 2012-01-19 | Shionogi & Co., Ltd. | Isothiourea derivatives or isourea derivatives having bace1 inhibitory activity |
US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
GB0912777D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydropyrimidone derivatives |
AR077328A1 (es) | 2009-07-24 | 2011-08-17 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos |
EP2281824A1 (en) | 2009-08-07 | 2011-02-09 | Noscira, S.A. | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
EP2485590B1 (en) | 2009-10-08 | 2015-01-07 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
US8552197B2 (en) | 2009-11-12 | 2013-10-08 | Ranbaxy Laboratories Limited | Sorafenib ethylsulfonate salt, process for preparation and use |
WO2011071057A1 (ja) * | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
WO2011070781A1 (ja) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 置換アミノチアジン誘導体 |
US7964594B1 (en) * | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
UA103272C2 (uk) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
JPWO2011071109A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | アミノ基を有する縮合ヘテロ環化合物 |
US20120258961A1 (en) * | 2009-12-24 | 2012-10-11 | Shionogi & Co., Ltd. | 4-amino-1,3-thiazine or oxazine derivative |
CN102812005B (zh) | 2010-02-24 | 2014-12-10 | 生命医药公司 | β-分泌酶抑制剂 |
US8497264B2 (en) | 2010-03-15 | 2013-07-30 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US8883782B2 (en) | 2010-03-15 | 2014-11-11 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use |
CN104860907A (zh) | 2010-06-07 | 2015-08-26 | 诺沃梅迪科斯有限公司 | 呋喃基化合物及其用途 |
US8921363B2 (en) | 2010-08-05 | 2014-12-30 | Amgen Inc. | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors |
US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
EP2643299B1 (en) | 2010-11-22 | 2016-06-22 | Noscira, S.A. | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions |
US8957083B2 (en) | 2010-11-23 | 2015-02-17 | Amgen Inc. | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use |
WO2012085038A1 (en) | 2010-12-22 | 2012-06-28 | Janssen Pharmaceutica Nv | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
SG191710A1 (en) | 2011-01-21 | 2013-08-30 | Eisai R&D Man Co Ltd | Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives |
GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
US9346827B2 (en) | 2011-02-07 | 2016-05-24 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use |
US8404680B2 (en) * | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
EP2675810A1 (en) | 2011-02-15 | 2013-12-25 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
CA2824360C (en) | 2011-03-01 | 2020-01-14 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
EP2683721B1 (en) | 2011-03-09 | 2015-01-28 | Janssen Pharmaceutica N.V. | 3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
WO2012139425A1 (en) | 2011-04-13 | 2012-10-18 | Schering Corporation | 5-substituted iminothiazines and their mono-and dioxides as bace inhibitors,compositions,and their use |
CN103649082A (zh) | 2011-04-26 | 2014-03-19 | 盐野义制药株式会社 | 吡啶衍生物和含有该吡啶衍生物的bace1抑制剂 |
US8604024B2 (en) * | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
WO2012162334A1 (en) | 2011-05-24 | 2012-11-29 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
BR112013031098A2 (pt) | 2011-06-07 | 2016-12-06 | Hoffmann La Roche | halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2 |
AU2012298983A1 (en) | 2011-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as BACE inhibitors, compositions and their use |
UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
EP2758406A1 (en) | 2011-09-21 | 2014-07-30 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
UA113538C2 (xx) * | 2012-01-26 | 2017-02-10 | Фторметил-5,6-дигідро-4h-$1,3]оксазини | |
TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β-分泌酶抑制劑 |
US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
WO2013142613A1 (en) | 2012-03-20 | 2013-09-26 | Elan Pharmaceuticals, Inc. | Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof |
WO2013182638A1 (en) * | 2012-06-08 | 2013-12-12 | H. Lundbeck A/S | 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease |
TW201422592A (zh) | 2012-08-27 | 2014-06-16 | Boehringer Ingelheim Int | β-分泌酶抑制劑 |
JP2015532282A (ja) | 2012-09-28 | 2015-11-09 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | β−セクレターゼの阻害剤 |
WO2014059185A1 (en) | 2012-10-12 | 2014-04-17 | Amgen Inc. | Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
EP2908825B1 (en) | 2012-10-17 | 2018-04-18 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US9416129B2 (en) | 2012-10-17 | 2016-08-16 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use |
US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
WO2014078314A1 (en) | 2012-11-15 | 2014-05-22 | Amgen Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
WO2014091352A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
US9447085B2 (en) | 2012-12-14 | 2016-09-20 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use |
US9475784B2 (en) | 2012-12-19 | 2016-10-25 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production |
US9489013B2 (en) | 2012-12-20 | 2016-11-08 | Merck Sharp & Dohme Corp. | C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use |
CA2894919A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | C5,c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors, compositions, and their use |
EP2934534B1 (en) | 2012-12-21 | 2017-12-13 | Merck Sharp & Dohme Corp. | C5-spiro iminothiadiazine dioxides as bace inhibitors |
JP2016507551A (ja) | 2013-02-13 | 2016-03-10 | ファイザー・インク | ヘテロアリール置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
CA2902212C (en) | 2013-03-01 | 2020-10-13 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
AP2015008716A0 (en) | 2013-03-08 | 2015-09-30 | Amgen Inc | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
RU2737434C2 (ru) | 2013-03-13 | 2020-11-30 | Форма Терапьютикс, Инк. | Новые соединения и композиции для ингибирования fasn |
AU2014280122B2 (en) | 2013-06-12 | 2017-12-21 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2H)-one derivatives as inhibitors of beta-secretase (BACE) |
US9580433B2 (en) | 2013-06-12 | 2017-02-28 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE) |
JP6435321B2 (ja) | 2013-06-12 | 2018-12-05 | ヤンセン ファーマシューティカ エヌ.ベー. | β−セクレターゼ(BACE)の阻害剤としての4−アミノ−6−フェニル−6,7−ジヒドロ[1,2,3]トリアゾロ[1,5−A]ピラジン誘導体 |
TWI639607B (zh) | 2013-06-18 | 2018-11-01 | 美國禮來大藥廠 | Bace抑制劑 |
US9096615B2 (en) | 2013-07-30 | 2015-08-04 | Amgen Inc. | Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof |
EP3082823B1 (en) | 2013-12-18 | 2020-04-22 | Merck Sharp & Dohme Corp. | Iminothiadiazepane dioxide compounds as bace inhibitors, compositions, and their use |
WO2015094930A1 (en) * | 2013-12-18 | 2015-06-25 | Merck Sharp & Dohme Corp. | C-6 spirocarbocyclic iminothiadiazine dioxides as bace inhibitors, compositions, and their use |
GB201401886D0 (en) | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
MX2016013329A (es) | 2014-04-10 | 2017-01-26 | Pfizer | 2-amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8h )-il-1,3-tiazol-4-ilamidas. |
MX2017001794A (es) | 2014-08-08 | 2017-06-29 | Amgen Inc | Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso. |
ES2768823T3 (es) | 2014-12-18 | 2020-06-23 | Janssen Pharmaceutica Nv | Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa |
EP3261442B1 (en) * | 2015-01-20 | 2020-04-01 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxides bearing an amine-linked substituent as bace inhibitors, compositions, and their use |
WO2017024180A1 (en) | 2015-08-06 | 2017-02-09 | Amgen Inc. | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
AU2016325665A1 (en) | 2015-09-24 | 2018-03-08 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides |
EP3353182A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
EP3353174A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors |
WO2017061534A1 (en) | 2015-10-08 | 2017-04-13 | Shionogi & Co., Ltd. | Dihydrothiazine derivatives |
ES2928164T3 (es) | 2015-10-19 | 2022-11-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
TWI763641B (zh) | 2015-11-19 | 2022-05-11 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
TW201726623A (zh) * | 2015-12-17 | 2017-08-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
MA55194A (fr) | 2015-12-22 | 2022-05-04 | Incyte Corp | Composés hétérocycliques en tant qu'immunomodulateurs |
WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA45116A (fr) | 2016-05-26 | 2021-06-02 | Incyte Corp | Composés hétérocycliques comme immunomodulateurs |
UA125391C2 (uk) | 2016-06-20 | 2022-03-02 | Інсайт Корпорейшн | Гетероциклічні сполуки як імуномодулятори |
US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
JP2019524825A (ja) | 2016-08-26 | 2019-09-05 | イーライ リリー アンド カンパニー | 選択的bace1阻害剤として有用な1,4−オキサジン |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
EP3555085B1 (en) | 2016-12-15 | 2020-12-02 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
US11021493B2 (en) | 2016-12-15 | 2021-06-01 | Amgen Inc. | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use |
US10947223B2 (en) | 2016-12-15 | 2021-03-16 | Amgen Inc. | Substituted oxazines as beta-secretase inhibitors |
MX2019007102A (es) * | 2016-12-15 | 2019-12-16 | Amgen Inc | Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso. |
EP3555106B1 (en) | 2016-12-15 | 2022-03-09 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
HRP20221216T1 (hr) | 2016-12-22 | 2022-12-23 | Incyte Corporation | Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1 |
US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
ES2934230T3 (es) | 2016-12-22 | 2023-02-20 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores |
SG11202000839TA (en) | 2017-08-14 | 2020-02-27 | Epizyme Inc | Methods of treating cancer by inhibiting setd2 |
PE20211911A1 (es) | 2018-03-30 | 2021-09-28 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
WO2019208693A1 (en) | 2018-04-27 | 2019-10-31 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective bace1 inhibitory activity |
MD3790877T2 (ro) | 2018-05-11 | 2023-08-31 | Incyte Corp | Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1 |
BR112021002633A2 (pt) * | 2018-08-14 | 2021-05-04 | Epizyme, Inc. | composto, composição farmacêutica, método para tratar um sujeito que precisa do mesmo, composto para uso, uso de um composto, kit, método para tratar um sujeito que tem mieloma múltiplo, método para identificar se um sujeito que tem mieloma múltiplo é um candidato para o tratamento com um composto, método para prever o resultado do tratamento em um sujeito que tem mieloma múltiplo e método que compreende administrar uma quantidade terapeuticamente eficaz de um composto |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
WO2020092395A1 (en) | 2018-10-29 | 2020-05-07 | Forma Therapeutics, Inc. | SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE |
WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
KR20220075382A (ko) | 2019-09-30 | 2022-06-08 | 인사이트 코포레이션 | 면역조절제로서의 피리도[3,2-d]피리미딘 화합물 |
AU2020385113A1 (en) | 2019-11-11 | 2022-05-19 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
CN111450857B (zh) * | 2020-05-13 | 2023-06-13 | 江苏帕睿尼新材料科技有限公司 | 一种催化剂及叔丁基异硫氰酸酯的制备工艺 |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
CA3200844A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
WO2023236920A1 (en) * | 2022-06-07 | 2023-12-14 | Sironax Ltd. | Sarm1 modulators, preparations, and uses thereof |
Family Cites Families (195)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3235551A (en) * | 1966-02-15 | Novel derivatives of | ||
US3227713A (en) | 1966-01-04 | Azine derivatives | ||
US2899426A (en) | 1959-08-11 | Synthesis of l | ||
US3115494A (en) * | 1961-10-13 | 1963-12-24 | Mcneilab Inc | 2-amino-5, 6-dihydro-4ii-1, 3-oxazines and a process for their preparation |
BE637923A (zh) * | 1962-09-29 | |||
US3232551A (en) * | 1962-11-19 | 1966-02-01 | Gen Aniline & Film Corp | Automatic follower control for web tensioning |
US3636116A (en) | 1968-09-03 | 1972-01-18 | Dow Chemical Co | 1 2-substituted indene compounds |
SU465792A3 (ru) * | 1968-11-06 | 1975-03-30 | Хиноин Гиогисцер-Ес Вегиесцети Термекек Гиара Рт (Фирма) | Способ получени гетероциклических соединений |
US3577428A (en) * | 1969-04-14 | 1971-05-04 | Colgate Palmolive Co | 2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines |
US3719674A (en) | 1971-02-08 | 1973-03-06 | Dow Chemical Co | 1,2-substituted indene compounds |
DE2426653C3 (de) | 1974-06-01 | 1982-05-06 | Bayer Ag, 5090 Leverkusen | Derivate des 2-Amino-1,3-thiazins |
DD140144A1 (de) | 1978-11-08 | 1980-02-13 | Horst Hartmann | Verfahren zur herstellung von p-aminophenylsubstituierten 2-amino-1,3-thiaziniumsalzen |
US4311840A (en) * | 1980-11-13 | 1982-01-19 | E. R. Squibb & Sons, Inc. | 2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones |
US4696959A (en) | 1983-09-26 | 1987-09-29 | Ppg Industries, Inc. | Modified piperidines as ultraviolet light stabilizers |
JPS62120374A (ja) * | 1985-11-20 | 1987-06-01 | Yoshitomi Pharmaceut Ind Ltd | 1,3−チアジンまたは1,3−オキサジン誘導体 |
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
CA1332151C (en) | 1988-01-28 | 1994-09-27 | Roman Amrein | Use of a benzamide to treat cognitive disorder |
US5236942A (en) | 1990-04-19 | 1993-08-17 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful in the treatment of Altzheimer's dementia |
US5328915A (en) | 1992-09-17 | 1994-07-12 | E. I. Du Pont De Nemours And Company | Arthropodicidal amidrazone ureas |
SI9300616A (en) | 1992-11-27 | 1994-06-30 | Wellcome Found | Enzyme inhibitors |
EP0723438A1 (en) | 1993-10-04 | 1996-07-31 | The Wellcome Foundation Limited | Substituted urea and isothiourea derivatives as no synthase inhibitors |
GB9418912D0 (en) | 1994-09-20 | 1994-11-09 | Fisons Corp | Pharmaceutically active compounds |
AU4149696A (en) | 1994-11-15 | 1996-06-06 | Merck & Co., Inc. | Substituted heterocycles as inhibitors of nitric oxide synthase |
DE4442116A1 (de) * | 1994-11-25 | 1996-05-30 | Cassella Ag | 2-Amino-1,3-thiazine als Hemmstoffe der Stickstoffmonoxid-Synthase |
WO1996018607A1 (fr) | 1994-12-12 | 1996-06-20 | Chugai Seiyaku Kabushiki Kaisha | Derive d'aniline inhibant la synthase du monoxyde d'azote |
JPH08333258A (ja) * | 1994-12-14 | 1996-12-17 | Japan Tobacco Inc | チアジン又はチアゼピン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤 |
DE4444930A1 (de) * | 1994-12-16 | 1996-06-27 | Cassella Ag | 2-Amino-1,3-thiazepine und deren Verwendung als Hemmstoffe der Stickstoffmonoxid-Synthase |
CN1198739A (zh) | 1995-08-11 | 1998-11-11 | 美国辉瑞有限公司 | (1s,2s)-1-(4-羟基苯基)-2-(4-羟基-4-苯基哌啶-1-基)-1-丙醇甲磺酸盐三水合物 |
JPH0967355A (ja) | 1995-08-31 | 1997-03-11 | Tokyo Tanabe Co Ltd | チアジン誘導体、チアゾール誘導体及びそれらの製造方法 |
RU2128165C1 (ru) * | 1995-09-18 | 1999-03-27 | Санкио Компани Лимитед | Производные амидов и композиция, обладающая асат-ингибирующей активностью |
CA2235304A1 (en) | 1995-10-17 | 1997-04-24 | Thomas Mcinally | Pharmaceutically active quinazoline compounds |
CN1221407A (zh) | 1996-04-13 | 1999-06-30 | 英国阿斯特拉药品有限公司 | 氨基异喹啉和氨基噻吩并吡啶衍生物及其作为抗炎剂的用途 |
US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
US5952374A (en) | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
SE9703693D0 (sv) | 1997-10-10 | 1997-10-10 | Astra Pharma Prod | Novel combination |
TW460460B (en) | 1997-11-04 | 2001-10-21 | Chugai Pharmaceutical Co Ltd | Heterocyclic compounds having NOS inhibitory activities |
US6294695B1 (en) * | 1998-03-26 | 2001-09-25 | Mount Sinai School Of Medicine Of The City University Of New York | Aminobenzoic acid derivatives having anti-tumorigenic activity methods of making and using the same |
AUPP285898A0 (en) | 1998-04-07 | 1998-04-30 | Fujisawa Pharmaceutical Co., Ltd. | Amido derivatives |
SE9802333D0 (sv) | 1998-06-29 | 1998-06-29 | Astra Pharma Prod | Novel combination |
US7375125B2 (en) | 1999-08-04 | 2008-05-20 | Ore Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
WO2001019788A2 (en) | 1999-09-17 | 2001-03-22 | Cor Therapeutics, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
JP2003530432A (ja) | 2000-04-12 | 2003-10-14 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | 神経変性疾患の治療 |
AU2001258771A1 (en) | 2000-05-19 | 2001-11-26 | Takeda Chemical Industries Ltd. | -secretase inhibitors |
US6420566B2 (en) * | 2000-06-09 | 2002-07-16 | Aventis Pharma S.A. | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof |
US6713276B2 (en) | 2000-06-28 | 2004-03-30 | Scios, Inc. | Modulation of Aβ levels by β-secretase BACE2 |
WO2002062766A2 (en) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
US20030095958A1 (en) | 2001-04-27 | 2003-05-22 | Bhisetti Govinda R. | Inhibitors of bace |
US6562783B2 (en) | 2001-05-30 | 2003-05-13 | Neurologic, Inc. | Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors |
AP2004003049A0 (en) | 2001-11-08 | 2004-06-30 | Elan Pharm Inc | N,N' -substituted-1,3-diamino -2-hydroxypropane derivatives. |
IL161842A0 (en) | 2001-11-09 | 2005-11-20 | Aventis Pharma Sa | 2-Amino-4-heteroarylethyl-thiazoline derivatives and their use as inhibitors of inducible no-synthase |
ATE446295T1 (de) * | 2001-11-09 | 2009-11-15 | Aventis Pharma Sa | 2-amino-4-pyridylmethyl-thiazolinderivate und ihre verwendung als induzierbare no-synthase inhibitoren |
ATE319693T1 (de) * | 2001-11-09 | 2006-03-15 | Aventis Pharma Sa | 2-amino-thiazolinderivate und ihre verwendung als hemmstoffe der induzierbaren no-synthase |
EP1492784A4 (en) | 2002-03-28 | 2006-03-29 | Merck & Co Inc | SUBSTITUTED 2,3-DIPHENYLPYRIDINES |
CA2487541A1 (en) * | 2002-06-19 | 2003-12-31 | Solvay Pharmaceuticals Gmbh | Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins |
AU2003249983A1 (en) * | 2002-07-18 | 2004-02-09 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
AU2003254844A1 (en) | 2002-08-09 | 2004-02-25 | Takeda Chemical Industries, Ltd. | Substituted amino compounds and use thereof |
TW200502221A (en) * | 2002-10-03 | 2005-01-16 | Astrazeneca Ab | Novel lactams and uses thereof |
JP2004149429A (ja) | 2002-10-29 | 2004-05-27 | Takeda Chem Ind Ltd | インドール化合物およびその用途 |
JP2006096665A (ja) | 2002-10-29 | 2006-04-13 | Ono Pharmaceut Co Ltd | 脊柱管狭窄症治療剤 |
JP4494212B2 (ja) | 2002-11-12 | 2010-06-30 | メルク・シャープ・エンド・ドーム・コーポレイション | アルツハイマー病の治療用フェニルカルボキサミドベータセクレターゼ阻害剤 |
RU2252936C2 (ru) | 2002-12-05 | 2005-05-27 | Институт физиологически активных веществ РАН | S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты) |
US7429603B2 (en) | 2003-04-25 | 2008-09-30 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
GB0324498D0 (en) | 2003-07-21 | 2003-11-26 | Aventis Pharma Inc | Heterocyclic compounds as P2X7 ion channel blockers |
ES2308247T3 (es) * | 2003-08-08 | 2008-12-01 | Schering Corporation | Aminas ciclicas inhibidoras de bace-1 que tienen un sustituyente heterociclico. |
JP2007525482A (ja) | 2003-10-07 | 2007-09-06 | レノビス, インコーポレイテッド | イオンチャネルリガンドとしてのアミド化合物およびその使用 |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
CN102627609B (zh) | 2003-12-15 | 2016-05-04 | 默沙东公司 | 杂环天冬氨酰蛋白酶抑制剂 |
WO2005097767A1 (en) | 2004-03-30 | 2005-10-20 | Merck & Co., Inc. | 2-aminothiazole compounds useful as aspartyl protease inhibitors |
US7459450B2 (en) * | 2004-04-30 | 2008-12-02 | Schering Corporation | Neuropeptide receptor modulators |
ES2321853T3 (es) | 2004-06-16 | 2009-06-12 | Wyeth | Difenilimidazopiridina e -imidazol aminas como inhibidores de b-secretasa". |
NL1026798C2 (nl) | 2004-08-06 | 2006-02-07 | Johannes Antonius Koster | Combinatie van een ondergrond voor een muziekinstrument en ten minste één positioneringselement. |
WO2006023750A2 (en) | 2004-08-23 | 2006-03-02 | Merck & Co., Inc. | Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2006029850A1 (en) | 2004-09-14 | 2006-03-23 | The Genetics Company, Inc. | Hydrazone derivatives and their use as beta secretase inhibitors |
WO2006041405A1 (en) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-pyrimidones and uses thereof |
WO2006041404A1 (en) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-compounds and uses thereof |
EP1831170A4 (en) | 2004-12-14 | 2009-10-14 | Astrazeneca Ab | SUBSTITUTED AMINOPYRIDINES AND THEIR USE |
AU2006211646B2 (en) | 2005-01-07 | 2012-09-20 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
MX2007008555A (es) | 2005-01-14 | 2007-11-21 | Wyeth Corp | Amino-imidazolonas para la inhibicion de (-secretasa. |
JP2008530103A (ja) | 2005-02-14 | 2008-08-07 | ワイス | β−セクレターゼ阻害剤としてのアゾリルアシルグアニジン |
WO2006088694A1 (en) | 2005-02-14 | 2006-08-24 | Wyeth | SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS |
WO2006088705A1 (en) | 2005-02-14 | 2006-08-24 | Wyeth | Terphenyl guanidines as [beta symbol] -secretase inhibitors |
US20060223849A1 (en) | 2005-03-14 | 2006-10-05 | Mjalli Adnan M | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors |
JP2008543844A (ja) | 2005-06-14 | 2008-12-04 | シェーリング コーポレイション | アスパルチルプロテアーゼ阻害剤 |
AU2006259675A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
AU2006259525B2 (en) | 2005-06-14 | 2012-05-24 | Gpcr Therapeutics, Inc | Pyrimidine compounds |
US8722708B2 (en) | 2005-06-14 | 2014-05-13 | Merck Sharp & Dohme Inc. | Substituted isoindolines as aspartyl protease inhibitors |
WO2007002220A2 (en) | 2005-06-21 | 2007-01-04 | Bristol-Myers Squibb Company | Aminoacetamide acyl guanidines as beta-secretase inhibitors |
TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
CA2613435A1 (en) | 2005-06-30 | 2007-01-11 | Wyeth | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for .beta.-secretase modulation |
TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
JP2009509957A (ja) | 2005-09-26 | 2009-03-12 | ワイス | β−セクレターゼ阻害剤としてのアミノ−5−[4−(ジフルオロメトキシ)フェニル]−5−フェニルイミダゾロン化合物 |
EP2597087B1 (en) | 2005-10-25 | 2016-03-30 | Shionogi&Co., Ltd. | Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors |
US20090215801A9 (en) | 2005-11-15 | 2009-08-27 | Astrazeneca Ab, Sodertaije, Swedenastex Thereapeutics Ltd | Novel 2-Aminopyrimidinone Derivatives And Their Use |
WO2007058582A1 (en) | 2005-11-15 | 2007-05-24 | Astrazeneca Ab | Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use |
TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
CN101360716A (zh) | 2005-11-21 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途 |
BRPI0620025A2 (pt) | 2005-12-19 | 2011-10-25 | Wyeth Corp | composto, método para o tratamento de uma doença ou transtorno associado a atividade excessiva de bace, método para modular a atividade de bace, composição farmacêutica e uso do composto |
AR058381A1 (es) | 2005-12-19 | 2008-01-30 | Astrazeneca Ab | Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica |
PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
WO2007092854A2 (en) | 2006-02-06 | 2007-08-16 | Janssen Pharmaceutica N.V. | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
US7776882B2 (en) | 2006-02-06 | 2010-08-17 | Baxter Ellen W | 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
JP2009532464A (ja) | 2006-04-05 | 2009-09-10 | アストラゼネカ・アクチエボラーグ | 2−アミノピリミジン−4−オン及びAβ−関連の病理を治療又は予防するためのその使用 |
TW200808751A (en) | 2006-04-13 | 2008-02-16 | Astrazeneca Ab | New compounds |
DK2021335T3 (da) | 2006-04-20 | 2011-09-05 | Janssen Pharmaceutica Nv | Heterocykliske forbindelser som C-FMS-kinasehæmmere |
RU2009100074A (ru) | 2006-06-12 | 2010-07-20 | Шеринг Корпорейшн (US) | Гетероциклические ингибиторы аспартильной протеазы |
JP2009544625A (ja) | 2006-07-20 | 2009-12-17 | メーメット・カーラマン | Rhoキナーゼのベンゾチオフェン阻害剤 |
TW200817406A (en) | 2006-08-17 | 2008-04-16 | Wyeth Corp | Imidazole amines as inhibitors of β-secretase |
EP2064191B1 (en) | 2006-12-12 | 2014-06-25 | Merck Sharp & Dohme Corp. | Aspartyl protease inhibitors |
AU2007332750A1 (en) | 2006-12-12 | 2008-06-19 | Schering Corporation | Aspartyl protease inhibitors containing a tricyclic ring system |
TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
EP2121641B1 (en) | 2007-02-15 | 2014-09-24 | F. Hoffmann-La Roche AG | 2-aminooxazolines as taar1 ligands |
JP5383483B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
WO2008133274A1 (ja) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | 環式基で置換されたアミノジヒドロチアジン誘導体 |
GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
JP4846769B2 (ja) | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | 医薬組成物 |
US9986911B2 (en) | 2007-10-19 | 2018-06-05 | Smiths Medical Asd, Inc. | Wireless telecommunications system adaptable for patient monitoring |
WO2009064418A1 (en) | 2007-11-14 | 2009-05-22 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
CN101910143B (zh) | 2008-01-18 | 2013-08-21 | 卫材R&D管理有限公司 | 稠合的氨基二氢噻嗪衍生物 |
NZ586831A (en) | 2008-01-28 | 2012-02-24 | Janssen Pharmaceutica Nv | 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace) |
NZ586830A (en) | 2008-01-29 | 2012-02-24 | Janssen Pharmaceutica Nv | 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace) |
EP2252595B1 (en) | 2008-02-01 | 2014-03-26 | Takeda Pharmaceutical Company Limited | Oxim derivatives as hsp90 inhibitors |
CN101952260B (zh) | 2008-02-18 | 2013-02-13 | 弗·哈夫曼-拉罗切有限公司 | 4,5-二氢-*唑-2-基胺衍生物 |
AR072952A1 (es) | 2008-04-22 | 2010-10-06 | Schering Corp | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso |
TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Bace抑制劑 |
WO2009151098A1 (ja) | 2008-06-13 | 2009-12-17 | 塩野義製薬株式会社 | βセクレターゼ阻害作用を有する含硫黄複素環誘導体 |
WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
CN102105475B (zh) | 2008-07-28 | 2014-04-09 | 卫材R&D管理有限公司 | 螺氨基二氢噻嗪衍生物 |
EP2312946A4 (en) | 2008-08-13 | 2012-10-24 | Merck Sharp & Dohme | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
US20110251172A1 (en) | 2008-08-13 | 2011-10-13 | Rivkin Alexey A | Purine derivatives for treatment of alzheimer's disease |
CN102171221B (zh) | 2008-09-30 | 2013-11-06 | 卫材R&D管理有限公司 | 新的稠合的氨基二氢噻嗪衍生物 |
CN102186841A (zh) | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
US20100125081A1 (en) | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | New compounds 574 |
TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
WO2010056195A1 (en) | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | New compounds 575 |
US20120015961A1 (en) | 2009-03-31 | 2012-01-19 | Shionogi & Co., Ltd. | Isothiourea derivatives or isourea derivatives having bace1 inhibitory activity |
KR101123178B1 (ko) | 2009-04-09 | 2012-06-13 | (주)에스메디 | 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 |
EP2459565B1 (en) | 2009-05-07 | 2018-05-02 | The Board of Trustees of The Leland Stanford Junior University | Saxitoxin derivatives, methods and compositions for studying, imaging, and treating pain |
US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
GB0912777D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydropyrimidone derivatives |
GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
AR077328A1 (es) | 2009-07-24 | 2011-08-17 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos |
US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
EP2485590B1 (en) | 2009-10-08 | 2015-01-07 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
CN102686584A (zh) | 2009-11-13 | 2012-09-19 | 盐野义制药株式会社 | 具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物 |
US8435994B2 (en) | 2009-11-16 | 2013-05-07 | Merck Sharp & Dohme Corp. | Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists |
WO2011070781A1 (ja) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 置換アミノチアジン誘導体 |
WO2011071057A1 (ja) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
JPWO2011071109A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | アミノ基を有する縮合ヘテロ環化合物 |
AU2010328975B2 (en) | 2009-12-11 | 2015-01-22 | Shionogi & Co. Ltd. | Oxazine derivative |
UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
US20120258961A1 (en) | 2009-12-24 | 2012-10-11 | Shionogi & Co., Ltd. | 4-amino-1,3-thiazine or oxazine derivative |
EA201200952A1 (ru) | 2009-12-31 | 2013-02-28 | Новартис Аг | Производные пиразина и их применение для лечения неврологических нарушений |
US8673894B2 (en) | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
KR101730937B1 (ko) | 2010-06-09 | 2017-04-27 | 얀센 파마슈티카 엔.브이. | 베타-세크레타아제(bace) 저해제로 유용한 5,6-디하이드로-2h-[1,4]옥사진-3-일-아민 유도체 |
EP2588466B1 (en) | 2010-06-09 | 2014-03-19 | Janssen Pharmaceutica, N.V. | 5-Amino-3,6-dihydro-1H-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (BACE) |
KR20130089231A (ko) | 2010-06-28 | 2013-08-09 | 얀센 파마슈티카 엔.브이. | 알츠하이머병 및 다른 형태의 치매 치료용으로 유용한 3-아미노-5,6-디하이드로-1h-피라진-2-온 유도체 |
PL2483255T3 (pl) | 2010-07-13 | 2014-03-31 | Novartis Ag | Pochodne oksazyny i ich zastosowanie w leczeniu zaburzeń neurologicznych |
US8815881B2 (en) | 2010-08-09 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds |
AU2011306941B2 (en) | 2010-09-22 | 2014-06-12 | Janssen Pharmaceutica Nv | 4,7-dihydro-pyrazolo[1,5-a] pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
WO2012057248A1 (ja) | 2010-10-29 | 2012-05-03 | 塩野義製薬株式会社 | ナフチリジン誘導体 |
US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
WO2012085038A1 (en) | 2010-12-22 | 2012-06-28 | Janssen Pharmaceutica Nv | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
JP2014505689A (ja) | 2011-01-13 | 2014-03-06 | ノバルティス アーゲー | 代謝障害の処置用bace−2阻害剤 |
PT2663561E (pt) | 2011-01-13 | 2016-06-07 | Novartis Ag | Derivados heterocíclicos novos e sua utilização no tratamento de distúrbios neurológicos |
US9242943B2 (en) | 2011-01-18 | 2016-01-26 | Siena Biotech S.P.A. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
US8399459B2 (en) | 2011-02-02 | 2013-03-19 | Hoffmann-La Roche Inc. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
US8404680B2 (en) | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
US8815841B2 (en) | 2011-02-18 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
CA2824360C (en) | 2011-03-01 | 2020-01-14 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
US9067924B2 (en) | 2011-03-04 | 2015-06-30 | Hoffmann-La Roche Inc. | 1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors |
EP2683721B1 (en) | 2011-03-09 | 2015-01-28 | Janssen Pharmaceutica N.V. | 3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
US8748418B2 (en) | 2011-03-18 | 2014-06-10 | Hoffmann-La Roche Inc. | 1,4-oxazepines as BACE1 and/or BACE2 inhibitors |
US8877744B2 (en) | 2011-04-04 | 2014-11-04 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
CN103649082A (zh) | 2011-04-26 | 2014-03-19 | 盐野义制药株式会社 | 吡啶衍生物和含有该吡啶衍生物的bace1抑制剂 |
US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
US8604024B2 (en) | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
WO2012162334A1 (en) | 2011-05-24 | 2012-11-29 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
US9079919B2 (en) | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
WO2012168175A1 (en) | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | [1,3]oxazines |
BR112013031098A2 (pt) | 2011-06-07 | 2016-12-06 | Hoffmann La Roche | halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2 |
-
2006
- 2006-10-23 EP EP13150550.5A patent/EP2597087B1/en not_active Not-in-force
- 2006-10-23 ES ES13150548.9T patent/ES2537898T3/es active Active
- 2006-10-23 JP JP2007542552A patent/JP5281794B2/ja not_active Expired - Fee Related
- 2006-10-23 EP EP20130150548 patent/EP2612854B1/en not_active Not-in-force
- 2006-10-23 BR BRPI0617852-9A patent/BRPI0617852A2/pt not_active Application Discontinuation
- 2006-10-23 WO PCT/JP2006/321015 patent/WO2007049532A1/ja active Application Filing
- 2006-10-23 RU RU2008120601A patent/RU2416603C9/ru not_active IP Right Cessation
- 2006-10-23 ES ES06822035.9T patent/ES2476027T3/es active Active
- 2006-10-23 KR KR1020087012436A patent/KR101052122B1/ko not_active IP Right Cessation
- 2006-10-23 AU AU2006307314A patent/AU2006307314C1/en not_active Ceased
- 2006-10-23 ES ES13150550T patent/ES2572263T3/es active Active
- 2006-10-23 CN CN201410074667.6A patent/CN103936690B/zh not_active Expired - Fee Related
- 2006-10-23 EP EP20060822035 patent/EP1942105B8/en not_active Not-in-force
- 2006-10-23 US US12/089,409 patent/US8173642B2/en not_active Expired - Fee Related
- 2006-10-23 CA CA 2628074 patent/CA2628074C/en not_active Expired - Fee Related
- 2006-10-23 CN CN200680048810.8A patent/CN101346357B/zh not_active Expired - Fee Related
- 2006-10-25 TW TW101124677A patent/TWI535705B/zh not_active IP Right Cessation
- 2006-10-25 TW TW95139276A patent/TWI451869B/zh active
-
2010
- 2010-12-14 RU RU2010151410/04A patent/RU2010151410A/ru not_active Application Discontinuation
-
2011
- 2011-09-23 US US13/243,971 patent/US8546380B2/en not_active Expired - Fee Related
- 2011-09-23 US US13/243,874 patent/US8633188B2/en not_active Expired - Fee Related
-
2013
- 2013-01-23 JP JP2013009901A patent/JP5608250B2/ja not_active Expired - Fee Related
- 2013-02-15 US US13/768,557 patent/US8815851B2/en not_active Expired - Fee Related
- 2013-07-12 US US13/941,082 patent/US9029358B2/en not_active Expired - Fee Related
-
2015
- 2015-04-06 US US14/679,666 patent/US20150210680A1/en not_active Abandoned
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102471296A (zh) * | 2009-07-09 | 2012-05-23 | 伊莱利利公司 | Bace抑制剂 |
CN102639516A (zh) * | 2009-08-19 | 2012-08-15 | 霍夫曼-拉罗奇有限公司 | 3-氨基-5-苯基-5,6-二氢-2h-[1,4]*嗪衍生物 |
CN102482268A (zh) * | 2009-09-11 | 2012-05-30 | 霍夫曼-拉罗奇有限公司 | 作为用于糖尿病治疗的bace2抑制剂的2-氨基二氢[1,3]噻嗪 |
CN102482268B (zh) * | 2009-09-11 | 2014-11-26 | 霍夫曼-拉罗奇有限公司 | 作为用于糖尿病治疗的bace2抑制剂的2-氨基二氢[1,3]噻嗪 |
CN102686584A (zh) * | 2009-11-13 | 2012-09-19 | 盐野义制药株式会社 | 具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物 |
CN102834384A (zh) * | 2009-12-11 | 2012-12-19 | 盐野义制药株式会社 | *嗪衍生物 |
CN102712621A (zh) * | 2009-12-31 | 2012-10-03 | 诺瓦提斯公司 | 吡嗪衍生物及其在治疗神经学障碍中的用途 |
CN102712621B (zh) * | 2009-12-31 | 2015-03-11 | 诺华股份有限公司 | 吡嗪衍生物及其在治疗神经学障碍中的用途 |
CN102958922A (zh) * | 2010-05-07 | 2013-03-06 | 霍夫曼-拉罗奇有限公司 | 2,5,6,7-四氢-[1,4]氧氮杂*-3-基胺或2,3,6,7-四氢-[1,4]氧氮杂*-5-基胺化合物 |
CN102958922B (zh) * | 2010-05-07 | 2015-09-30 | 霍夫曼-拉罗奇有限公司 | 2,5,6,7-四氢-[1,4]氧氮杂*-3-基胺或2,3,6,7-四氢-[1,4]氧氮杂*-5-基胺化合物 |
CN102933564B (zh) * | 2010-06-09 | 2015-07-22 | 詹森药业有限公司 | 用作β-分泌酶(BACE)抑制剂的5,6-二氢-2H-[1,4]噁嗪-3-基-胺衍生物 |
CN102933564A (zh) * | 2010-06-09 | 2013-02-13 | 詹森药业有限公司 | 用作β-分泌酶(BACE)抑制剂的5,6-二氢-2H-[1,4]噁嗪-3-基-胺衍生物 |
CN102666507B (zh) * | 2010-07-13 | 2014-09-17 | 诺华股份有限公司 | 噁嗪衍生物及其在治疗神经病症中的用途 |
CN102666507A (zh) * | 2010-07-13 | 2012-09-12 | 诺瓦提斯公司 | 噁嗪衍生物及其在治疗神经病症中的用途 |
CN103261199A (zh) * | 2010-10-29 | 2013-08-21 | 盐野义制药株式会社 | 萘啶衍生物 |
CN103429589A (zh) * | 2011-01-12 | 2013-12-04 | 诺瓦提斯公司 | 噁嗪衍生物及其在治疗神经障碍中的用途 |
CN103429588A (zh) * | 2011-01-12 | 2013-12-04 | 诺瓦提斯公司 | 晶态噁嗪衍生物及其作为bace抑制剂的用途 |
CN103403001B (zh) * | 2011-01-13 | 2016-08-17 | 诺瓦提斯公司 | 杂环衍生物及其在神经性疾病治疗中的应用 |
CN106117193B (zh) * | 2011-01-13 | 2019-09-13 | 诺华股份有限公司 | 新的杂环衍生物及其在神经性疾病治疗中的应用 |
CN106117193A (zh) * | 2011-01-13 | 2016-11-16 | 诺华股份有限公司 | 新的杂环衍生物及其在神经性疾病治疗中的应用 |
CN103403001A (zh) * | 2011-01-13 | 2013-11-20 | 诺瓦提斯公司 | 新的杂环衍生物及其在神经性疾病治疗中的应用 |
CN103459401A (zh) * | 2011-01-21 | 2013-12-18 | 卫材R&D管理有限公司 | 稠合的氨基二氢噻嗪衍生物 |
CN103339117A (zh) * | 2011-02-02 | 2013-10-02 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,4 噁嗪类 |
CN103339117B (zh) * | 2011-02-02 | 2015-05-27 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,4 噁嗪类 |
CN103476760A (zh) * | 2011-02-18 | 2013-12-25 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,4-氧氮杂* |
CN103476760B (zh) * | 2011-02-18 | 2015-11-25 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,4-氧氮杂* |
CN103429590A (zh) * | 2011-03-04 | 2013-12-04 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,4硫氮杂*/砜 |
CN103429590B (zh) * | 2011-03-04 | 2016-10-26 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,4硫氮杂*/砜 |
CN103517901A (zh) * | 2011-04-04 | 2014-01-15 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,4-氧氮杂* |
CN103502227A (zh) * | 2011-04-11 | 2014-01-08 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,3噁嗪类 |
CN103596939A (zh) * | 2011-04-13 | 2014-02-19 | 默沙东公司 | 作为bace抑制剂的5-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其应用 |
CN103608345A (zh) * | 2011-04-26 | 2014-02-26 | 盐野义制药株式会社 | 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂 |
CN103534243A (zh) * | 2011-05-16 | 2014-01-22 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,3-噁嗪类 |
CN103596961A (zh) * | 2011-05-27 | 2014-02-19 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的螺-[1,3]-*嗪和螺-[1,4]-氧氮杂* |
CN103596961B (zh) * | 2011-05-27 | 2016-09-28 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的螺-[1,3]-*嗪和螺-[1,4]-氧氮杂* |
CN103608344B (zh) * | 2011-06-07 | 2016-11-23 | 霍夫曼-拉罗奇有限公司 | [1,3]噁嗪类 |
CN103608344A (zh) * | 2011-06-07 | 2014-02-26 | 霍夫曼-拉罗奇有限公司 | [1,3]噁嗪类 |
CN103649083A (zh) * | 2011-07-06 | 2014-03-19 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的环丙基-稠合-1,3-硫氮杂*类 |
CN103987710A (zh) * | 2011-10-13 | 2014-08-13 | 诺华股份有限公司 | 新的*嗪衍生物及它们在治疗疾病中的应用 |
CN106414431A (zh) * | 2014-04-11 | 2017-02-15 | 盐野义制药株式会社 | 具有bace1抑制作用的二氢噻嗪和二氢噁嗪衍生物 |
CN107257795A (zh) * | 2015-03-19 | 2017-10-17 | 伊莱利利公司 | 选择性bace1抑制剂 |
CN107613771A (zh) * | 2015-04-21 | 2018-01-19 | 新源生物科技股份有限公司 | 化合物及其作为β‑分泌酶1抑制剂的用途 |
CN107613771B (zh) * | 2015-04-21 | 2020-12-15 | 新源生物科技股份有限公司 | 化合物及其作为β-分泌酶1抑制剂的用途 |
CN108430982A (zh) * | 2015-12-25 | 2018-08-21 | 盐野义制药株式会社 | 用于制备噻嗪衍生物的方法和中间体 |
CN109180671A (zh) * | 2018-09-21 | 2019-01-11 | 广东东阳光药业有限公司 | 亚氨基噻二嗪二氧化物衍生物及其用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101346357B (zh) | 氨基二氢噻嗪衍生物 | |
CA2588761C (en) | 2,4(4,6)pyrimidine derivatives | |
CA2939786C (en) | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use | |
US8653067B2 (en) | Pharmaceutical composition for treating Alzheimer's disease | |
CN101687827B (zh) | 环状基团取代的氨基二氢噻嗪衍生物 | |
JP4592077B2 (ja) | 嘔吐、抑鬱、不安および咳の処置のためのニューロキニン−1(nk−1)アンタゴニストとしての1−アミド−4−フェニル−4−ベンジルオキシメチル−ピペリジン誘導体および関連化合物 | |
JP2019508467A (ja) | 癌治療用の2−シアノイソインドリン誘導体 | |
JP2022547014A (ja) | ヘテロ環式rip1キナーゼ阻害剤 | |
CN112638380A (zh) | 小脑蛋白(crbn)配体 | |
WO2006004200A1 (ja) | ウレア誘導体 | |
CA3129438A1 (en) | Tyk2 pseudokinase ligands | |
AU2021227907A1 (en) | Potent and selective degraders of ALK | |
JP2022548594A (ja) | Usp30阻害剤及びその使用 | |
CA3172589A1 (en) | Piperidine-2,6-diones as small molecule degraders of helios and methods of use | |
CA3106354A1 (en) | Amino-pyridinyl-azetidinyl-carboxamide derivatives and pharmaceutical compositions thereof useful as inhibitors of histone deacetylase | |
CN108341819B (zh) | 磷酸二酯酶抑制剂及其用途 | |
WO2017066742A1 (en) | Bace-2 inhibitory compounds and related methods of use | |
NZ754113A (en) | Indole carboxamide compounds useful as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140402 Termination date: 20181023 |